CA2536041A1 - Medical implants and fibrosis-inducing agents - Google Patents

Medical implants and fibrosis-inducing agents Download PDF

Info

Publication number
CA2536041A1
CA2536041A1 CA002536041A CA2536041A CA2536041A1 CA 2536041 A1 CA2536041 A1 CA 2536041A1 CA 002536041 A CA002536041 A CA 002536041A CA 2536041 A CA2536041 A CA 2536041A CA 2536041 A1 CA2536041 A1 CA 2536041A1
Authority
CA
Canada
Prior art keywords
agent
polymer
delivered
coating
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002536041A
Other languages
French (fr)
Inventor
David M. Gravett
William L. Hunter
Richard T. Liggins
Arpita Maiti
Pierre E. Signore
Philip M. Toleikis
Dechi Guan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiotech International AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2536041A1 publication Critical patent/CA2536041A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/11Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/1214Coils or wires
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12168Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • A61B17/12186Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices liquid materials adapted to be injected
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • A61B17/1219Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices expandable in contact with liquids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/363Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4833Thrombin (3.4.21.5)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/56Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
    • A61B17/58Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
    • A61B17/68Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/38Materials or treatment for tissue regeneration for reconstruction of the spine, vertebrae or intervertebral discs

Abstract

Published without an Abstract

Description

DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter 1e Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:

MEDICAL IMPLANTS AND FIBROSIS-INDUCING AGENTS
BACKGROUND OF THE INVENTION
Field of the Invention The present invention relates generally to pharmaceutical compositions, methods and devices, and more specifically, to compositions and methods for preparing medical implants to make them more adherent to, or, more readily incorporated within a living tissue. The pharmaceutical agents and compositions are utilized to create novel drug-coated implants and medical devices which induce a fibrotic response in the surrounding tissue such that the device is effectively anchored in situ and its performance is enhanced.
Description of the Related Art The clinical performance of numerous medical devices depends upon the device being effectively anchored into the surrounding tissue to provide either structural support or to facilitate scarring and healing.
Effective attachment of the device into the surrounding tissue, however, is not always readily achieved. One reason for ineffective attachment is that implantable medical devices generally are composed of materials that are highly biocompatible and designed to reduce the host tissue response. These materials (e.g., stainless steel, titanium based alloys, fluoropolymers, and ceramics) typically do not provide a good substrate for host tissue attachment and ingrowth during the scarring process. As a result of poor attachment between the device and the host tissue, devices can have a tendency to migrate within the vessel or tissue in which they are implanted. The extent to which a particular type of medical device can move or migrate after implantation depends on a variety of factors including the type and design of the device, the materials) from which the device is formed, the mechanical attributes (e.g., flexibility and ability to conform to the surrounding geometry at the implantation site), the surface properties, and the porosity of the device or device surface.
The tendency of a device to loosen after implantation also depends on the type of tissue and the geometry at the treatment site, where the ability of the tissue to conform around the device generally can help to secure the device in the implantation site. Device migration can result in device failure and, depending on the type and location of the device, can lead to leakage, vessel occlusion, andlor damage to the surrounding tissue.
Numerous methods and device modifications have been proposed to secure implantable medical devices in place in the body. In one approach, the medical device is anchored mechanically to biological tissue.
For example, artificial implants can be anchored to the surrounding tissues by physical and mechanical means (e.g., screws, cements and porous surfaces) or by friction. For example, mechanical attachment of a device to the site can be effected by using a fastener, such as a suture or staple. In another approach, the device includes in its design mechanical means for fastening it into the surrounding tissue. For example, the device may include metallic spikes, anchors, hooks, barbs, pins, clamps, or a flange or lip to affix the device in place (see, e.g., U.S. Patent Nos. 4,523,592; 6,309,416; 6,302,905; and 6,152,937). A disadvantage of mechanical fasteners, however, is that they can damage the tissue or vessel wall when the device is deployed.
Other methods for preventing device migration have focused on mechanically altering the surface characteristics of the device. One such approach involves scoring or abrading the surface of the implant. The roughened surfaces promote cell, bone or tissue adhesion for better affixing of the implants in the body (see, e.g., WO 96/29030A1 ). Medical devices, such as implantable orthopedic devices, may be fixed to host tissue (e.g., bone) with an adhesive, such as a polymethyl methacrylate (PMMA) bone cement or a bone cement made from calcium phosphates and calcium aluminate (see, e.g., U.S.
Patent No. 6,723,334). A drawback of bone cements, however, is that over time the cemented bone-prosthesis interface can degenerate, and/or the cement itself may weaken and fail, resulting in loosening of the implant.
Chemical or biological modifications of the device surface have been used to enhance adhesion between an implantable medical device and the surrounding host tissue. For example, devices have been coated with a substance to enhance the healing process and/or adhesion of the device to the host tissue. In one approach, implantable medical devices have been developed which permit infiltration by specific desirable tissue cells. One type of tissue infiltration involves the process known as "endothelialization", i.e., migration of endothelial cells from adjacent tissue onto or into the device surface. Methods for promoting endothelialization have included applying a porous coating to the device which allows tissue growth into the interstices of
2 the implant surface (see, e.g., WO 96/37165A1 ). Other efforts at improving host tissue ingrowth capability and adhesion of the implant to host tissue include an electrically charged or ionic material (e.g., fluoropolymer) in the tissue-contacting surface of the device (see, e.g., WO 95/19796A1; J.E.
Davies, in Surface Characterization of Biomaterials, B.D. Ratner, ed., pp. 219-234 (1988); and U.S. Patent No. 5,876,743); biocompatible organic polymers (e.g., polymers substituted with carbon, sulfur or phosphorous oxyacid groups) to promote osteogenesis at the host-implant interface (see, e.g., U.S. Patent No.
4,795,475); and coatings made from biological materials (e.g., collagen) to enhance tissue repair, growth and adaptation at the implant-tissue interface (e.g., U.S. Patent No. 5,002,583).
The above-described approaches, however, have failed to provide a satisfactory long-term solution to the problem of device migration. Thus, there is still a need for an effective, long-lasting and biocompatible approach for anchoring implantable medical devices into or onto biological tissue.
BRIEF SUMMARY OF THE INVENTION
Briefly stated, the present invention provides compositions for delivery of selected therapeutic agents via medical implants or implantable medical devices, as well as methods for making and using these implants and devices. Within one aspect of the invention, drug-coated or drug-impregnated implants and medical devices are provided which induce adhesion or fibrosis in the surrounding tissue, or facilitate "anchoring" of the device/implant in situ, thus enhancing the efficacy. Within various embodiments, fibrosis is induced by local or systemic release of specific pharmacological agents that become localized to the adjacent tissue.
The repair of tissues following a mechanical or surgical intervention involves two distinct processes: (1 ) regeneration (the replacement of injured cells by cells of the same type) and (2) fibrosis (the replacement of injured cells by connective tissue). There are four general components to the process of fibrosis (or scarring) including: formation of new blood vessels (angiogenesis), migration and proliferation of fibroblasts, deposition of extracellular matrix (ECM), and remodeling (maturation and organization of the fibrous tissue). As utilized herein, "induces (promotes) fibrosis" should be understood to refer to agents or compositions which increase or accelerate the formation of fibrous tissue (i.e., by inducing or promoting one or more of the
3 processes of angiogenesis, fibroblast migration or proliferation, ECM
production, and/or remodeling). In addition, numerous therapeutic agents described in this invention can have the additional benefit of also promoting tissue regeneration.
Within one embodiment of the invention, an implant or device is adapted to include or to release an agent that induces fibrosis or regeneration through one or more of the mechanisms sited above. Thus, the present invention provides devices that comprise a medical implant and at least one of (i) a fibrosis-inducing agent and (ii) a composition that comprises a fibrosis-inducing agent. The agent is present so as to induce fibrosis formation that may otherwise not occur or increase fibrosis in a statistically significant manner when the implant is placed within an animal. In another aspect the present invention is directed to methods wherein both an implant and at least one of (i) a fibrosis-inducing agent and (ii) a composition that comprises a fibrosis-inducing agent, are placed into an animal, and the agent causes the formation of fibrosis that may otherwise not occur or increase fibrosis in a statistically significant manner. These and other aspects of the invention are summarized below.
Thus, in various independent aspects, the present invention provides the following: a device, comprising an orthopedic implant and a fibrosis-inducing agent or a composition comprising a fibrosis-inducing agent, wherein the agent induces fibrosis; a device, comprising a male or female sterilization implant and a fibrosis-inducing agent or a composition comprising a fibrosis-inducing agent, wherein the agent induces fibrosis; a device, comprising an implant for treating or preventing urinary incontinence device and a fibrosis-inducing agent or a composition comprising a fibrosis-inducing agent, wherein the agent induces fibrosis; a device, comprising an implant for treating or preventing gastroesophageal reflux disease (GERD) and a fibrosis-inducing agent or a composition comprising a fibrosis-inducing agent, wherein the agent induces fibrosis; a device, comprising an implant for treating or preventing obesity and a fibrosis-inducing agent or a composition comprising a fibrosis-inducing agent, wherein the agent induces fibrosis; a device, comprising an implant for treating or preventing fecal incontinence device and a fibrosis-inducing agent or a composition comprising a fibrosis-inducing agent, wherein the agent induces fibrosis; a device, comprising an embolization implant and a fibrosis-inducing agent or a composition comprising a fibrosis-inducing agent,
4 wherein the agent induces fibrosis; a device, comprising a soft palate implant and a fibrosis-inducing agent or a composition comprising a fibrosis-inducing agent, wherein the agent induces fibrosis; a device, comprising a hernia repair mesh implant arid a fibrosis-inducing agent or a composition comprising a fibrosis-inducing agent, wherein the agent induces fibrosis; and a device, comprising a stent graft and a fibrosis-inducing agent or a composition comprising a fibrosis-inducing agent, wherein the agent induces fibrosis.
These and other devices are described in more detail herein.
In each of the aforementioned devices, in separate aspects the present invention provides that the agent is: an arterial vessel wall irritan;
selected from the group consisting of talcum powder, metallic beryllium and oxides thereof, copper, silk, silica, crystalline silicates, talc, quartz dust, and ethanol; a component of extracellular matrix selected from fibronectin, collagen, fibrin, or fibrinogen; a polymer is selected from the group consisting of polylysine, polyethylene-co-vinylacetate), chitosan, N-carboxybutylchitosan, and RGD proteins; vinyl chloride or a polymer of vinyl chloride; an adhesive selected from the group consisting of cyanoacrylates and crosslinked polyethylene glycol) - methylated collagen; an inflammatory cytokine (e.g., TGF(3, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-(3, IL-3, IL-6, and growth hormone); connective tissue growth factor (CTGF); a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7); leptin, and bleomycin or an analogue or derivative thereof.
Optionally, the device may additionally comprise a proliferative agent that stimulates cellular proliferation. Examples of proliferative agents include:
dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof.
In additional aspects, for each of the aforementioned devices combined with each of the aforementioned agents, it is, for each combination, independently disclosed that the agent may be present in a composition along with a polymer. In one embodiment of this aspect, the polymer is biodegradable. In another embodiment of this aspect, the polymer is non-biodegradable. Other features and characteristics of the polymer, which may serve to describe the present invention for every combination of device and agents described above, are set forth in greater detail herein.
5
6 PCT/US2004/037335 In another aspect, the invention provides a composition, comprising a fibrosis-inducing agent and a bulking agent, wherein the fibrosis-inducing agent induces fibrosis. In another aspect, the invention provides a composition, comprising a fibrosis-inducing agent and a sealant, wherein the agent induces fibrosis. Exemplary fibrosis-inducing agents include, without limitation: an~arterial vessel wall irritant selected from the group consisting of talcum powder, metallic beryllium and oxides thereof, copper, silk, silica, crystalline silicates, talc, quartz dust, and ethanol; a component of extracellular matrix selected from fibronectin, collagen, fibrin, or fibrinogen; a polymer selected from polylysine, polyethylene-co-vinylacetate), chitosan, N-carboxybutylchitosan, and RGD proteins; vinyl chloride or a polymer of vinyl chloride; an adhesive selected from the group consisting of cyanoacrylates and crosslinked polyethylene glycol) - methylated collagen; an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-8, IL-6, and growth hormone); CTGF; BMP (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7); and bleomycin or an analogue or derivative thereof.
Optionally, the device may additionally comprise an agent that stimulates cellular proliferation. Examples of proliferative agents include:
dexamethasone, isotretinoin, 17-(3-estradiol, estradiol, diethylstibesterol, cyclosporine A, all-trans retinoic acid (ATRA), and analogues and derivatives thereof. Bulking agents and sealants are described herein.
In addition to devices, the present invention also provides methods. For example, in additional aspects of the present invention, for each of the aforementioned devices, and for each of the aforementioned combinations of the devices with the fibrosis-inducing agents, the present invention provides methods whereby a specified device is implanted into an animal, and a specified agent associated with the device induces fibrosis that may otherwise not occur or increases fibrosis in a statistically significant manner. Each of the devices identified herein may be a "specified device", and each of the fibrosis-inducing agents identified herein may be a "fibrosis-inducing agent", where the present invention provides, in independent embodiments, for each possible combination of the device and the agent.
The agent may be associated with the device prior to the device being placed within the animal. For example, the agent (or composition comprising the agent) may be coated onto an implant, and the resulting device then placed within the animal. In addition, or alternatively, the agent may be independently placed within the animal in the vicinity of where the device is to be, or is being, placed within the animal. For example, the agent may be sprayed or otherwise placed onto the tissue that can be contacting the medical implant or may otherwise undergo scarring. To this end, the present invention provides, in independent aspects: a method for treating or preventing spider veins or varicose veins, comprising injecting into the vein a composition comprising a fibrosis-inducing agent; a method for sterilizing a female patient, comprising injecting into a Fallopian tube a composition comprising a fibrosis-inducing agent; a method for treating or preventing urinary incontinence, comprising injecting into an urethra a composition comprising a fibrosis-inducing agent; a method for treating or preventing GERD, comprising injecting into a lower esophageal sphincter a composition comprising a fibrosis-inducing agent; a method for treating or preventing fecal incontinence, comprising injecting into an anal sphincter a composition comprising a fibrosis-inducing agent; a method for treating or preventing snoring or sleep apnea, comprising injecting into a soft palate a composition comprising a fibrosis-inducing agent; a method for blocking an artery, comprising injecting into the artery a composition comprising a fibrosis-inducing agent; a method for sealing an air leak in a lung, comprising spraying onto the surface of the lung a composition comprising a fibrosis-inducing agent; a method for treating or preventing diverticulitis, comprising delivering into a diverticulum a composition comprising a fibrosis-inducing agent; a method for treating or preventing arthritis, comprising injecting into a damaged joint a composition comprising a fibrosis-inducing agent; a method for repairing a damaged shoulder capsule, comprising spraying onto an anterior capsule a composition comprising a fibrosis-inducing agent; a method for repairing a damaged tendon or ligament, comprising spraying onto the tendon or ligament a composition comprising a fibrosis-inducing agent; a method for treating a damaged spinal disc, comprising injecting into an intervertebral disc space a composition comprising a fibrosis-inducing agent.
In additional aspects, for each of the aforementioned methods used in combination with each of the aforementioned agents, it is, for each combination, independently disclosed that the agent may be present in a composition along with a polymer. In one embodiment of this aspect, the polymer is biodegradable. In another embodiment of this aspect, the polymer is non-biodegradable. Other features and characteristics of the polymer, which may serve to describe the present invention for every combination of device
7 and agents described above, are set forth in greater detail herein. In addition to, or in lieu of the polymer, the composition may contain collagen.
These and other aspects of the present invention can become evident upon reference to the following detailed description. In addition, various references are set forth herein which describe in more detail certain procedures and/or compositions (e.g., polymers), and are therefore incorporated by reference in their entirety.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a graph showing the effect of cyclosporine A on proliferation of human smooth muscle cells.
Figure 2 is a graph showing the effect of dexamethasone on proliferation of human fibroblasts.
Figure 3 is a graph showing the effect of all-trans retinoic acid (ATRA) on proliferation of human smooth muscle cells.
Figure 4 is a graph showing the effect of isotretinoin on proliferation of human smooth muscle cells.
Figure 5 is a graph showing the effect of 17-~i-estradiol on proliferation of human fibroblasts.
Figure 6 is a graph showing the effect of 1 a,25-dihydroxy-vitamin D3 on proliferation of human smooth muscle cells.
Figure 7 is a graph showing the effect of PDGF-BB on smooth muscle cell migration.
Figure 8 is a bar graph showing the area of granulation tissue in carotid arteries exposed to silk coated perivascular polyurethane (PU) films relative to arteries exposed to uncoated PU films.
Figure 9 is a bar graph showing the area of granulation tissue in carotid arteries exposed to silk suture coated perivascular PU films relative to arteries exposed to uncoated PU films.
Figure 10 is a bar graph showing the area of granulation tissue in carotid arteries exposed to natural and purified silk powder and wrapped with perivascular PU film relative to a control group in which arteries are wrapped with perivascular PU film only.
Figure 11 is a bar graph showing the area of granulation tissue (at 1 month and 3 months) in carotid arteries sprinkled with talcum powder and
8 wrapped with perivascular PU film relative to a control group in which arteries are wrapped with perivascular PU film only.
Figure 12 is a bar graph showing indicating the area of perivascular granulation tissue quantified by computer-assisted morphometric analysis in rat carotid arteries treated with control uncoated PU films and with PU films treated with degummed and virgin silk strands. As shown in the figure, both types of silk markedly increased granulation tissue growth around the blood vessel to the same extent.
' Figure 13 shows representative histology sections of rat carotid arteries treated with PU films coated with degummed and virgin silk strands.
As shown in the figure, both types of silk induced a marked tissue reaction around the treated blood vessel. Movat stain, 100X.
Figure 14 shows representative histology sections of rat carotid arteries treated with PU films coated with degummed and virgin silk strands showing the granulation tissue that has grown around the treated vessels. The silk strands have broken down into small particles surrounded by giant cells and macrophages. The granulation tissue is highly vascularized and contains numerous inflammatory cells and fibroblasts. Extracellular matrix deposition is also extensive. H&E stain 200X.
Figure 15 shows the release profile for cyclosporine A from a polyurethane film as analyzed by HPLC.
DETAILED D~'SCRIPTION OF THE INVENTION
The present invention discloses pharmaceutical agents which promote one or more aspects of the production of fibrous (scar) tissue or tissue regeneration. Furthermore, compositions and methods are described for coating medical devices and implants with drug-delivery compositions such that the pharmaceutical agent is delivered in therapeutic levels over a period sufficient for fibrosis and healing to occur. The present invention also describes various compositions and methods for enhancing the production of scar tissue adjacent to or on the surface of the implant are described. Numerous specific implants and devices are described that are capable of producing superior clinical results as a result of being coated with agents that promote scarring and healing, as well as other related advantages.
9 Definitions Prior to setting forth the invention, it may be helpful to an understanding thereof to first set forth definitions of certain terms that is used hereinafter.
"Medical Device " (or "implant," or "medical implant," or implantable medical device") refers to any object placed in the body for the purpose of restoring physiological function, reducing/alleviating symptoms associated with disease, and/or repairing/replacing damaged or diseased organs and tissues. While normally composed of biologically compatible synthetic materials (e.g., medical-grade stainless steel, titanium and other metals, polymers such as polyurethane, silicon, polylactic acid (PLA), polyglycolic acid (PLGA) and other materials), other materials that are exogenous, some medical devices and implants include materials derived from animals (e.g., "xenografts" such as whole animal organs; animal tissues such as heart valves; naturally occurring or chemically-modified molecules such as collagen, hyaluronic acid, proteins, carbohydrates and others), human donors (e.g., "allografts" such as whole organs; tissues such as bone grafts, skin grafts and others), or from the patients themselves (e.g., "autografts" such as saphenous vein grafts, skin grafts, tendonhigament/muscle transplants).
Medical devices of particular utility in the present invention include, but are not restricted to, orthopaedic implants (artificial joints, ligaments and tendons, screws, plates, and other implantable hardware), dental implants, intravascular implants (particularly arterial and venous occlusion devices and implants;
vascular destructive implants), male and female contraceptive or sterilization devices and implants, implantable tissue bulking agents for incontinence (esophageal, urethral, anal), soft palate implants, embolization agents, pulmonary sealants, surgical meshes (e.g., hernia repair meshes, tissue scaffolds), fistula treatments, and spinal implants (e.g., artificial intervertebral discs, spinal fusion devices, etc.).
"Fibrosis," "Scarring," or "Fibrotic Response" refers to the formation of fibrous tissue in response to injury or medical intervention.
Therapeutic agents which promote (also referred to interchangeably herein as "induce," "stimulate," "cause," and the like) fibrosis or scarring are referred to interchangeably herein as "fibrosis-inducing agents," "scarring agents,"
"fibrosing agents," "adhesion-inducing agents," and the like, where these agents do so through one or more mechanisms including: inducing or promoting angiogenesis, stimulating migration or proliferation of connective tissue cells (such as fibroblasts, smooth muscle cells, vascular smooth muscle cells), inducing ECM production, and/or promoting tissue remodeling. In addition, numerous therapeutic agents described in this invention can have the additional benefit of also promoting tissue regeneration (the replacement of injured cells by cells of the same type).
"Sclerosing" refers to a tissue reaction in which an irritant is applied locally to a tissue which results in an inflammatory reaction and is followed by scar tissue formation at the site of irritation. A pharmaceutical agent that induces or promotes sclerosis is referred to as a "sclerosant," or a "sclerosing agent." Representative examples of sclerosants include ethanol, dimethyl sulfoxide, surfactants (e.g., Triton X, sorbitan monolaurate, sorbitan sesquioleate, glycerol monostearate and polyoxyethylene, polyoxyethylene cetyl ether, etc.), sucrose, sodium chloride, dextrose, glycerin, minocycline, tetracycline, doxycycline, polidocanol, sodium tetradecyl sulfate, sodium morrhuate, ethanolamine, phenol, sarapin and sotradecol.
"Release of an agent" refers to any statistically significant presence of the agent, or a subcomponent thereof, which has disassociated from the implant/device.
Any concentration ranges, percentage range, or ratio range recited herein are to be understood to include concentrations, percentages or ratios of any integer within that range and fractions thereof, such as one tenth and one hundredth of an integer, unless otherwise indicated. Also, any number range recited herein relating to any physical feature, such as polymer subunits, size or thicleness, are to be understood to include any integer within the recited range, unless otherwise indicated. It should be understood that the terms "a"
and "an" as used above and elsewhere herein refer to "one or more" of the enumerated components. As used herein, the term "about" means ~ 15%.
As discussed above, the present invention provides compositions, methods and devices relating to medical implants, which greatly increase their ability to scar in place and incorporate into the surrounding tissue.
Described in more detail below are methods for constructing medical implants, compositions and methods for generating medical implants which promote fibrosis, and methods for utilizing such medical implants.

A. Medicallmplants Medical implants of the present invention contain and/or are adapted to release an agent which induces or promotes adhesion between the implant and tissue or a fibrotic reaction. In certain embodiments, the medical implant, when placed in to a tissue, releases an agent that induces or promotes adhesion between the implant and the tissue or a fibrotic reaction. In other embodiments, the medical implant contains or is made of a fibrosing agent, but does not release the fibrosing agent. fn such embodiments, the fibrosing agent contained in the medical implant induces or promotes fibrosis by direct contact of the agent to the tissue where the implant is placed.
Representative examples of medical implants include;
orthopaedic implants (artificial joints, ligaments and tendons, screws, plates, and other implantable hardware), dental implants, intravascular implants (particularly arterial and venous occlusion devices and implants; vascular destructive implants), male and female contraceptive or sterilization devices and implants, implantable tissue bulking agents for incontinence (esophageal, urethral, anal), soft palate implants, embolization agents, pulmonary sealants, surgical meshes (e.g., hernia repair meshes, tissue scaffolds), fistula treatments, and spinal implants (e.g., artificial intervertebral discs, spinal fusion devices, etc.).
B. Therapeutic Agents Briefly, numerous therapeutic agents (also referred to herein as 'therapeutic agents' or 'drugs') have been identified that can be utilized within the context of the present invention. The agent may be formulated with one or more other materials, e.g., a polymeric carrier, where formulations are discussed below. Many suitable therapeutic agents are specifically identified herein, and others may be readily determined based upon in vitro and in vivo (animal) models such as those provided in Examples 13-20; 33-34; and 40.
Therapeutic agents which promote fibrosis can be identified through in vivo models such as the rat carotid artery model (Examples 17-20).
In one aspect, the fibrosis or adhesion-inducing agent is silk. Silk refers to a fibrous protein, and may be obtained from a number of sources, typically spiders and silkworms. Typical silks contain about 75% of actual fiber, referred to as fibroin, and about 35% sericin, which is a gummy protein that holds the filaments together. Silk filaments are generally very fine and long -as much as 300-900 meters long. There are several species of domesticated silkworm that are used in commercial silk production, however, Bombyx mori is the most common, and most silk comes from this source. Other suitable silkworms include Philosamia Cynthia ricini, Antheraea yamamai, Antheraea pernyi, and Antheraea mylitta. Spider silk is relatively more difficult to obtain, however, recombinant techniques hold promise as a means to obtain spider silk at economical prices (see, e.g., U.S. Patent Nos. 6,268,169; 5,994,099;
5,989,894; and 5,728,810, which are exemplary only). Biotechnology has allowed researchers to develop other sources for silk production, including animals (e.g., goats) and vegetables (e.g., potatoes). Silk from any of these sources may be used in the present invention.
A commercially available silk protein is available from Croda, Inc., of Parsippany, N.J., and is sold under the trade names CROSILK LIQUID (silk amino acids), CROSILK 10,000 (hydrolyzed silk), CROSILK POWDER
(powdered silk), and CROSILKQUAT (cocodiammonium hydroxypropyl silk amino acid). Another example of a comrriercially available silk protein is SERICIN, available from Pentapharm, LTD, a division of Kordia, BV, of the Netherlands. Further details of such silk protein mixtures can be found in U.S.
Patent. No. 4,906,460, to Kim, et al., assigned to Sorenco. Silk useful in the present invention includes natural (raw) silk, hydrolyzed silk, and modified silk, i.e., silk that has undergone a chemical, mechanical, or vapor treatment, e.g., acid treatment or acylation (see, e.g., U.S. Patent No. 5,747,015).
Raw silk is typically twisted into a strand sufficiently strong for weaving or knitting. Four different types of silk thread may be produced by this procedure: organzine, crepe, tram and thrown singles. Organzine is a thread made by giving the raw silk a preliminary twist in one direction and then twisting two of these threads together in the opposite direction. Crepe is similar to organzine but is twisted to a much greater extent. Twisting in only one direction two or more raw silk threads makes tram. Thrown singles are individual raw silk threads that are twisted in only one direction. Any of these types of silk threads may be used in the present invention.
The silk used in the present invention may be in any suitable form that allows the silk to be joined with the medical implant, e.g., the silk may be in thread or powder-based forms. The silk can be prepared in the powdered form by several different methods. For example the silk can be milled (e.g., cryomill) into a powdered form. Alternatively the silk can be dissolved in a suitable solvent (e.g., HFIP or 9M Liar) and then sprayed (electrospray, spray dry) or added to a non-solvent to produce a powder. Furthermore, the silk may have any molecular weight, where various molecular weights are typically obtained by the hydrolysis of natural silk, where the extent and harshness of the hydrolysis conditions determines the product molecular weight. For example, the silk may have an average (number or weight) molecular weight of about 200 to 5,000. See, e.g., JP-B-59-29199 (examined Japanese patent publication) for a description of conditions that may be used to hydrolyze silk.
A discussion of silk may be found in the following documents, which are exemplary only: Hinman, M.B., et al. "Synthetic spider silk: a modular fibre" Trends in Biotechnology, 2000, 18(9) 374-379; Vollrath, F. and Knight, D.P. "Liquid crystalline spinning of spider silk" Nature, 2001, 410(6828) 541-548; and Hayashi, C.Y., et al. "Hypotheses that correlate the sequence, structure, and mechanical properties of spider silk proteins" int. J. Biol.
Macromolecules, 1999, 24(2-3), 265-270; and U.S. Patent No. 6,427,933.
Other representative examples of fibrosis and adhesion-inducing agents include irritants (e.g., talc, talcum powder, copper, metallic beryllium (or its oxides), wool (e.g., animal wool, wood wolol, and synthetic woof), quartz dust, silica, crystalline silicates), polymers (e.g., polylysine, polyurethanes, polyethylene terephthalate), polytetrafluoroethylene (PTFE), poly(alkylcyanoacrylates), and poly(ethylene-co-vinylacetate)); vinyl chloride and polymers of vinyl chloride; peptides with high lysine content; growth factors and inflammatory cytokines involved in angiogenesis, fibroblast migration, fibroblast proliferation, ECM synthesis and tissue remodeling, such as epidermal growth factor (EGF) family, transforming growth factor-a (TGF- a), transforming growth factor-~ (TGF-9-1, TGF-9-2, TGF-9-3, platelet-derived growth factor (PDGF), fibroblast growth factor (acidic - aFGF; and basic -bFGF), fibroblast stimulating factor-1, activins, vascular endothelial growth factor (including VEGF-2, VEGF-3, VEGF-A, VEGF-B, VEGF-C, placental growth factor - PIGF), angiopoietins, insulin-like growth factors (IGF), hepatocyte growth factor (HGF), connective tissue growth factor (CTGF), myeloid colony-stimulating factors (CSFs), monocyte chemotactic protein, granulocyte-macrophage colony-stimulating factors (GM-CSF), granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), erythropoietin, interleukins (particularly IL-1, IL-8, and IL-6), tumor necrosis factor-a (TNF9), nerve growth factor (NGF), interferon-a, interferon-~3, histamine, endothelin-1, angiotensin II, growth hormone (GH), and synthetic peptides, analogues or derivatives of these factors are also suitable for release from specific implants and devices to be described later. Other examples include CTGF (connective tissue growth factor); inflammatory microcrystals (e.g., crystalline minerals such as crystalline silicates); bromocriptine, methylsergide, methotrexate, chitosan, N-carboxybutyl chitosan, carbon tetrachloride, thioacetamide, fibrosin, ethanol, bleomycin, naturally occurring or synthetic peptides containing the Arg-Gly-Asp (RGD) sequence, generally at one or both termini (see e.g., U.S. Patent No. 5,997,895), and tissue adhesives, such as cyanoacrylate and crosslinked polyethylene glycol) - methylated collagen compositions, such as described below. Other examples of fibrosis-inducing agents include bone morphogenic proteins (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1 ), BMP-7 (OP-1 ), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Of these, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, and BMP-7 are of particular utility. Bone morphogenic proteins are described, for example, in U.S. Patent Nos.
4,877,864; 5,013,649; 5,661,007; 5,688,678; 6,177,406; 6,432,919; and 6,534,268 and Wozney, J.M., et al. (1988) Science: 242(4885); 1528-1534.
Other representative examples of fibrosis-inducing agent's include crosslinked compositions that comprise amino-functional groups. For example, amino-functionalized polyethylene glycol (e.g., 4-armed tetra-amino PEG [10k]) can be reacted with a 4-armed NHS functionalized PEG (e.g., pentaerythritol polyethylene glycol)ether tetra-succinimidyl glutarate) under basic buffer conditions. In another example a 4-armed thiol functionalized PEG (e.g., pentaerythritol polyethylene glycol)ether tetra-thiol) can be substituted for the 4-arm amino-functionalized PEG such that the amount of amino functional groups in the final composition can be varied. These reagents can be mixed at the time of application to provide an in situ forming crosslinked hydrogel.
These reagents could be premixed to produce the crosslinked material. The material can be made in various forms such as rods, tubes, films, slabs or spheres. The crosslinked material could also be milled to produce a particulate material.
These materials can be dried (e.g., air, vacuum, freeze-dried) and used as a dry powdered material. Alternatively the materials can be hydrated just prior to application. These materials can further comprise one of the fibrosis=inducing agents described herein.

Other representative examples of fibrosis-inducing agents include components of extracellular matrix (e.g., fibronectin, fibrin, fibrinogen, collagen (e.g., bovine collagen), fibrillar and non-fibrillar collagen, adhesive glycoproteins, proteoglycans (e.g., heparin sulfate, chondroitin sulfate, dermatan sulfate), hyaluronan, secreted protein acidic and rich in cysteine (SPARC), thrombospondins, tenacin, and cell adhesion molecules (including integrins, vitronectin, fibronectin, laminin, hyaluronic acid, elastin, bitronectin), proteins found in basement membranes, and fibrosin) and inhibitors of matrix metalloproteinases, such as TIMPs (tissue inhibitors of matrix metalloproteinases) and synthetic TIMPs, e.g., marimistat, batimistat, doxycycline, tetracycline, minocycline, TROCADE, Ro-1130830, CGS 27023A, and BMS-275291.
Within various embodiments of the invention, a device is coated with a first composition that promotes fibrosis (and/or restenosis) and a second composition or compound which acts to have an inhibitory effect on pathological processes in or around the treatment site. Representative examples of agents which can inhibit pathological processes in the treatment site include, but not limited to, the following classes of compounds: anti-inflammatory agents (e.g., dexamethasone, cortisone, fludrocortisone, prednisone, prednisolone, 6a-methylprednisolone, triamcinolone, and betamethasone); Matrix Metalloproteinase (MMP) inhibitors (e.g., marimistat, batimistat, TIMP's representative examples of which are included in U.S.
Patent Nos. 5,665,777; 5,985,911; 6,288,261; 5,952,320; 6,441,189; 6,235,786;
6,294,573; 6,294,539; 6,563,002; 6,071,903; 6,358,980; 5,852,213; 6,124,502;
6,160,132; 6,197,791; 6,172,057; 6,288,086; 6,342,508; 6,228,869; 5,977,408;
5,929,097; 6,498,167; 6,534,491; 6,548,524; 5,962,481; 6,197,795; 6,162,814;
6,441,023; 6,444,704; 6,462,073; 6,162,821; 6,444,639; 6,262,080; 6,486,193;
6,329,550; 6,544,980; 6,352,976; 5,968,795; 5,789,434; 5,932,763; 6,500,847;
5,925,637; 6,225,314; 5,804,581; 5,863,915; 5,859,047; 5,861,428; 5,886,043;
6,288,063; 5,939,583; 6,166,082; 5,874,473; 5,886,022; 5.,932,577; 5,854,277;
5,886,024; 6,495,565; 6,642,255; 6,495,548; 6,479,502; 5,696,082; 5,700,838;
6,444,639; 6,262,080; 6,486,193; 6,329,550; 6,544,980; 6,352,976; 5,968,795;
5,789,434; 5,932,763; 6,500,847; 5,925,637; 6,225,314; 5,804,581; 5,863,915;
5,859,047; 5,861,428; 5,886,043; 6,288,063; 5,939,583; 6,166,082; 5,874,473;
5,886,022; 5,932,577; 5,854,277; 5,886,024; 6,495,565; 6,642,255; 6,495,548;
6,479,502; 5,696,082; 5,700,838; 5,861,436; 5,691,382; 5,763,621; 5,866,717;

5,902,791; 5,962,529; 6,017,889; 6,022,873; 6,022,898; 6,103,739; 6,127,427;
6,258,851; 6,310,084; 6,358,987; 5,872,152; 5,917,090; 6,124,329; 6,329,373;
6,344,457; 5,698,706; 5,872,146; 5,853,623; 6,624,144; 6,462,042; 5,981,491;
5,955,435; 6,090,840; 6,114,372; 6,566,384; 5,994,293; 6,063,786; 6,469,020;
6,118,001; 6,187,924; 6,310,088; 5,994,312; 6,180,611; 6,110,896; 6,380,253;
5,455,262; 5,470,834; 6,147,114; 6,333,324; 6,489,324; 6,362,183; 6,372,758;
6,448,250; 6,492,367; 6,380,258; 6,583,299; 5,239,078; 5,892,112; 5,773,438;
5,696,147; 6,066,662; 6,600,057; 5,990,158; 5,731,293; 6,277,876; 6,521,606;
6,168,807; 6,506,414; 6,620,813; 5,684,152; 6,451,791; 6,476,027; 6,013,649;
6,503,892; 6,420,427; 6,300,514; 6,403,644; 6,177,466; 6,569,899; 5,594,006;
6,417,229; 5,861,510; 6,156,798; 6,387,931; 6,350,907; 6,090,852; 6,458,822;
6,509,337; 6,147,061; 6,114,568; 6,118,016; 5,804,593; 5,847,153; 5,859,061;
6,194,451; 6,482,827; 6,638,952; 5,677,282; 6,365,630; 6,130,254; 6,455,569;
6,057,369; 6,576,628; 6,110,924; 6,472,396; 6,548,667; 5,618,844; 6,495,578;
6,627,411; 5,514,716; 5,256,657; 5,773,428; 6,037,472; 6,579,890; 5,932,595;
6,013,792; 6,420,415; 5,532,265; 5,639,746; 5,672,598; 5,830,915; 6,630,516;
5,324,634; 6,277,061; 6,140,099; 6,455,570; 5,595,885; 6,093,398; 6,379,667;
5,641,636; 5,698,404; 6,448,058; 6,008,220; 6,265,432; 6,169,103; 6,133,304;
6,541,521; 6,624,196; 6,307,089; 6,239,288; 5,756,545; 6,020,366; 6,117,869;
6,294,674; 6,037,361; 6,399,612; 6,495,568; 6,624,177; 5,948,780; 6,620,835;
6,284,513; 5,977,141; 6,153,612; 6,297,247; 6,559,142; 6,555,535; 6,350,885;
5,627,206; 5,665,764; 5,958,972; 6,420,408; 6,492,422; 6,340,709; 6,022,948;
6,274,703; 6,294,694; 6,531,499; 6,465,508; 6,437,177; 6,376,665; 5,268,384;
5,183,900; 5,189,178; 6,511,993; 6,617,354; 6,331,563; 5,962,466; 5,861,427;
5,830,869; and 6,087,359), cytokine inhibitors (chlorpromazine, mycophenolic acid, rapamycin, 1a-hydroxy vitamin D3), IMPDH (inosine monophosplate dehydrogenase) inhibitors (e.g., mycophenolic acid, ribaviran, aminothiadiazole, thiophenfurin, tiazofurin, viramidine) (Representative examples are included in U.S. Patent, Nos. 5,536,747; 5,807,876; 5,932,600; 6,054,472; 6,128,582;
6,344,465; 6,395,763; 6,399,773; 6,420,403; 6,479,628; 6,498,178; 6,514,979;
6,518,291; 6,541,496; 6,596,747; 6,617,323; and 6,624,184, U.S. Patent Application Nos. 2002/0040022A1, 2002/0052513A1, 2002/0055483A1, 2002/0068346A1, 2002/0111378A1, 2002/0111495A1, 2002/0123520A1, 2002/0143176A1, 2002/0147160A1, 2002/0161038A1, 2002/0173491 A1, 2002/0183315A1, 2002/0193612A1, 2003/0027845A1, 2003/0068302A1, 2003/0105073A1, 2003/0130254A1, 2003/0143197A1, 2003/0144300A1, 2003/0166201 A1, 2003/0181497A1, 2003/0186974A1, 2003/0186989A1, and 2003/0195202A1, and PCT Publication Nos. WO 00/24725A1, WO
00/25780A1, WO 00/26197A1, WO 00/51615A1, WO 00/56331 A1, WO
00/73288A1, W O 01 /00622A1, W O 01 /66706A 1, W O 01 /79246A2, W O
01/81340A2, WO 01/85952A2, WO 02/16382A1, WO 02/18369A2, WO
02/051814A1, WO 021057287A2, WO 02/057425A2, WO 02/060875A1, WO
02/060896A1, WO 02/060898A1, WO 02/068058A2, WO 03/020298A1, WO
03/037349A1, WO 03/039548A1, WO 03/045901A2, WO 03/047512A2, WO
03/053958A1, WO 03/055447A2, WO 03/059269A2, WO 03/063573A2, WO
03/087071A1, WO 99/001545A1, WO 97/40028A1, WO 97/41211A1, WO
98/40381 A1, and WO 99/55663A1 ), p38 MAP kinase inhibitors (MAPK) (e.g., GW-2286, CGP-52411, BIRB-798, SB220025, RO-320-1195, RWJ-67657, RWJ-68354, SCIO-469) (Representative examples are included in U.S. Patent Nos. 6,300,347; 6,316,464; 6,316,466; 6,376,527; 6,444,696; 6,479,507;
6,509,361; 6,579,874, and 6,630,485, and U.S. Patent Application Publication Nos. 2001 /0044538A1, 2002/0013354A1, 2002/0049220A1, 2002/0103245A1, 2002/0151491 A1, 2002/0156114A1, 2003/0018051 A1, 2003/0073832A1, 2003/0130257A1, 2003/0130273A1, 2003/0130319A1, 2003/0139388A1, 2003/0139462A1, 2003/0149031 A1, 2003/0166647A1, and 2003/0181411 A1, and PCT Publication Nos. WO 00/63204A2, WO 01/21591 A1, WO 01/35959A1, WO 01/74811A2, WO 02/18379A2, WO 02/064594A2, WO 02/083622A2, WO
02/094842A2,W0 02/096426A1, WO 02/101015A2, WO 02/103000A2, WO
03/008413A1, WO 03/016248A2, WO 03/020715A1, WO 03/024899A2, WO
03/031431A1, WO 03/040103A1, WO 03/053940A1, WO 03/053941 A2, WO
03/063799A2, WO 03/079986A2, WO 03/080024A2, WO 03/082287A1, WO
97/44467A1, WO 99/01449A1, and WO 99/58523A1 ), and immunomodulatory agents (rapamycin, everolimus, ABT-578, azathioprine azithromycin, analogues of rapamycin, tacrolimus and derivatives thereof (e.g., EP 018416281 and those described in U.S. Patent No. 6,258,823) and everolimus and derivatives thereof (e.g., U.S. Patent No. 5,665,772). Further representative examples of sirolimus analogues and derivatives include ABT-578 and those found in PCT
Publication Nos. WO 97/10502, WO 96/41807, WO 96/35423, WO 96/03430, WO 96/00282, WO 95/16691, WO 95/15328, WO 95/07468, WO 95/04738, WO 95/04060, WO 94/25022, WO 94/21644, WO 94/18207, WO 94/10843,
10, WO 94/04540, WO 94/02485, WO 94/02137, WO 94/02136, WO
93/25533, WO 93/18043, WO 93/13663, WO 93/11130, WO 93/10122, WO

93/04680, WO 92/14737, and WO 92/05179 and in U.S. Patent Nos. 6,342,507;
5,985,890; 5,604,234; 5,597,715; 5,583,139; 5,563,172; 5,561,228; 5,561,137;
5,541,193; 5,541,189; 5,534,632; 5,527,907; 5,484,799; 5,457,194; 5,457,182;
5,362,735; 5,324,644; 5,318,895; 5,310,903; 5,310,901; 5,258,389; 5,252,732;
5,247,076; 5,225,403; 5,221,625; 5,210,030; 5,208,241; 5,200,411; 5,198,421;
5,147,877; 5,140,018; 5,116,756; 5,109,112; 5,093,338; and 5,091,389.
Other examples of drugs that may be included in the compositions and devices of the invention include tyrosine kinase inhibitors, such as imantinib, ZK-222584, CGP-52411, CGP-53716, NVP-AAK980-NX, CP
127374, CP-564959, PD-171026, PD-173956, PD-180970, SU-0879, and SKI-606. Other examples of drugs that may be included in the compositions and devices of the invention include MMP inhibitors such as nimesulide, PKF-241-466, PKF-242-484, CGS-27023A, SAR-943, primomastat, SC-77964, PNU-171829, AG-3433, PNU-142769, SU-5402, and dexlipotam. Other examples of drugs that may be included in the compositions and devices of the invention include p38 MAP kinase inhibitors such as CGH-2466 and PD-98-59. Other examples of of drugs that may be included in the compositions and devices of the invention include immunosuppressants such as argyrin B, macrocyclic lactone, ADZ-62-826, CCI-779, tilomisole, amcinonide, FK-778, AVE-1726, and MDL-28842. Other examples of cytokine inhibitors include TNF-484A, PD-172084, CP-293121, CP-353164, and PD-168787. Other examples of drugs that may be included in the compositions and devices of the invention include include NFKB inhibitors, such as, AVE-0547, AVE-0545, and IPL-576092.
Other examples of drugs that may be included in the compositions and devices of the invention include include HMGCoA reductase inhibitors, such as, pravestatin, atorvastatin, fluvastatin, dalvastatin, glenvastatin, pitavastatin, CP-83101, U-20685, apoptosis antagonist (e.g., troloxamine, TCH-346 (N-methyl-N-propargyl-10-aminomethyl-dibenzo(b,f)oxepin), caspase inhibitors (e.g., PF-5901 (benzenemethanol, alpha-pentyl-3-(2-quinolinylmethoxy)-), and JNK
inhibitor (e.g., AS-602801 ).
Within various embodiments of the invention, a device incorporates or is coated with a composition which promotes fibrosis (and/or restenosis), as well as a composition or compound which acts to stimulate cellular proliferation. Representative examples of agents that stimulate cellular proliferation include, pyruvic acid, naltrexone, leptin, D-glucose, insulin, amlodipine, alginate oligosaccharides, minoxidil, dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME (L-NG-nitroarginine methyl ester (hydrochloride)), all-trans retinoic acid (ATRA), and analogues and derivatives thereof. Other examples of agents that stimulate cellular proliferation include:
sphingosine 1-phosphate receptor agonist (e.g., FTY-720 (1,3-propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-,hydrochloride; immunostimulants, such as Imupedone (methanone, [5-amino-2-(4-methyl-1-piperidinyl)phenyl](4-chlorophenyl)-, DIAPEP227 synthetic peptide (Peptor Ltd., Israel)); and nerve growth factor agonist, e.g., NG-012 (5H,9H,13H,21 H,25H,-dibenzo[k,u][1,5,9,15,19] pentaoxacyclotetracosin-5,9,13,21,25-pentone, 7,8,11,12,15,16,23,24,27,28-decahydro-2,4,18,20-tetrahydroxy-11-(hydroxymethyl)-7,15,23,27-tetramethyl-, NG-121, SS-701 (2,2':6',2"-terpyridine, 4'-(4-methylphenyl)-, trihydrochloride, AMPAIex (piperidine, 1-(6-quinoxalinylcarbonyl)-, RGH-2716 (8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-1-oxa-3,8-diaza-spiro[4.5] decan-2-one, arid TDN-345 (1-oxa-3,8-diazaspiro[4.5]decan-2-one, 8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-).
Within various embodiments of the invention, a device incorporates or is coated on one aspect with a composition which promotes fibrosis (and/or restenosis), as well as with a composition or compound which prevents restenosis on another aspect of the device. Representative examples of agents that inhibit restenosis include paclitaxel, sirolimus, everolimus, vincristine, biolimus, mycophenolic acid, ABT-578, cervistatin, simvastatin, methylprednisolone, dexamethasone, ,actinomycin-D, angiopeptin, L-arginine, estradiol, 17-(3-estradiol, tranilast, methotrexate, batimistat, halofuginone, BCP-671, QP-2, lantrunculin D, cytochalasin A, nitric oxide, and analogues and derivatives thereof.
The medical implant may include a fibrosing agent and an anti-thrombotic agent and/or antiplatelet agent, which reduces the likelihood of thrombotic events upon implantation of a medical implant. Within various embodiments of the invention, a device is coated on one aspect with a composition which promotes fibrosis (and/or restenosis), as well as being coated with a composition or compound which prevents thrombosis on another aspect of the device. Representative examples of anti-thrombotic and/or antiplatelet agents include heparin, heparin fragments, organic salts of heparin, heparin complexes (e.g., benzalkonium heparinate, tridodecylammonium heparinate), dextran, sulfonated carbohydrates such as dextran sulphate, coumadin, coumarin, heparinoid, danaparoid, argatroban chitosan sulfate, chondroitin sulfate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, streptokinase, and factor Xa inhibitors, such as DX9065a, magnesium, and tissue plasminogen activator. In one aspect, the anti-thrombotic agent is a modified heparin compound, such as a hydrophobically modified heparin or modified hirudin compound (e.g., stearylkonium heparin, benzalkonium heparin, cetylkonium heparin, or trdodecylmethyl ammonium heparin). Further examples of anti-thrombotic agents include plasminogen, lys-plasminogen, alpha-2-antiplasmin, urokinase, ticlopidine, clopidogrel, giycoprotein Ilb/Illa inhibitors such as abcixamab, eptifibatide, and tirogiban. Other agents capable of affecting the rate of clotting include glycosaminoglycans, danaparoid, 4-hydroxycourmarin, warfarin sodium, dicumarol, phenprocoumon, indan-1,3-dione, acenocoumarol, anisindione, and rodenticides including bromadiolone, brodifacoum, diphenadione, chlorophacinone, and pidnone. The thrombogenicity of a medical implant may be reduced by coating the implant with a polymeric formulation that has anti-thrombogenic properties. For example, a medical device may be coated with a hydrophilic polymer gel. The polymer gel can comprise a hydrophilic, biodegradable polymer that is physically removed from the surface of the device over time, thus reducing adhesion of platelets to the device surface.
The gel composition can include a polymer or a blend of polymers.
Representative examples include alginates, chitosan and chitosan sulfate, hyaluronic acid, dextran sulfate, PLURONIC polymers (e.g., F-127 or F87) and chain extended PLURONIC polymers (BASF Corporation, Mt. Olive, NJ), various polyester-polyether block copolymers of various configurations (e.g., AB, ABA, or BAB, where A is a polyester such as PLA, PGA, PLGA, PCL or the like), examples of which include MePEG-PLA, PLA-PEG-PLA, and the like). In one embodiment, the anti-thrombotic composition can include a crosslinked gel formed from a combination of molecules (e.g., PEG) having two or more terminal electrophilic groups and two or more nucleophilic groups.
In one aspect, the present invention also provides for the combination of a medical implant (as well as compositions and methods for making medical implants) that includes a fibrosing agent and an anti-infective agent, which reduces the likelihood of infections in medical implants.
Infection is a common complication of the implantation of foreign bodies such as medical devices. Foreign materials provide an ideal site for micro- organisms to attach and colonize. It is also hypothesized that there is an impairment of host defenses to infection in the microenvironment surrounding a foreign material.
These factors make medical implants particularly susceptible to infection and make eradication of such an infection difficult, if not impossible, in most cases.
The present invention provides agents (e.g., chemotherapeutic agents) that can be incorporated onto or into, or released from, an implantable device, and which have potent antimicrobial activity at extremely low doses. A
wide variety of anti-infective agents can be utilized in combination with a fibrosing agent according to the invention. Discussed in more detail below are several representative examples of Chemotehrapeutic/anti-infective agents that can be used: (A) anthracyclines (e.g., doxorubicin and mitoxantrone), (B) fluoropyrimidines (e.g., 5-FU), (C) folic acid antagonists (e.g., methotrexate), (D) podophylotoxins (e.g., etoposide), (E) camptothecins, (F) hydroxyureas, and (G) platinum complexes (e.g., cisplatin).
(A) Anthracyclines Anthracyclines have the following general structure, where the R
groups may be a variety of organic groups:
R
R
According to U.S. Patent 5,594,158, suitable R groups are as follows: R~ is CH3 or CH20H; R2 is daunosamine or H; R3 and R4 are independently one of OH, N02, NH2, F, CI, Br, I, CN, H or groups derived from these; R5 is hydrogen, hydroxyl, or methoxy; and R6_$ are all hydrogen.
Alternatively, R5 and R6 are hydrogen and R~ and R$ are alkyl or halogen, or vice versa.
According to U.S. Patent 5,843,903, R~ may be a conjugated peptide. According to U.S. Patent 4,296,105, R5 may be an ether linked alkyl group. According to U.S. Patent 4,215,062, R5 may be OH or an ether linked alkyl group. R~ may also be linked to the anthracycline ring by a group other than C(O), such as an alkyl or branched alkyl group having the C(O) linking moiety at its end, such as -CH2CH(CH2-X)C(O)-R~, wherein X is H or an alkyl group (see, e.g., U.S. Patent 4,215,062). R2 may alternately be a group linked by the functional group =N-NHC(O)-Y, where Y is a group such as a phenyl or substituted phenyl ring. Alternately R3 may have the following structure:

~NH
R1o in which R9 is OH either in or out of.the plane of the ring, or is a second sugar moiety such as R3. Rio may be H or form a secondary amine with a group such as an aromatic group, saturated or partially saturated 5 or 6 membered heterocyclic having at least one ring nitrogen (see U.S. Patent 5,843,903).
Alternately, Rio may be derived from an amino acid, having the structure -C(O)CH(NHR~~)(R~2), in which R~~ is H, orforms~a C3_4 membered alkylene with R~2. R~2 may be H, alkyl, aminoalkyl, amino, hydroxyl, mercapto, phenyl, benzyl or methylthio (see U.S. Patent 4,296,105).
Exemplary anthracyclines are doxorubicin, daunorubicin, idarubicin, epirubicin, pirarubicin, zorubicin, and carubicin. Suitable compounds have the structures:

O OH

H
Rs Doxorubicin:OCH3 C(O)CH20H OH out of ring plane Epirubicin:

(4' epimer OCH3 C(O)CH20H OH in ring plane of doxorubicin) Daunorubicin:OCH3 C(O)CH3 OH out of ring plane Idarubicin: H C(O)CH3 OH out of ring plane Pirarubicin:OCH3 C(O)CH2OH

Zorubicin: OCH3 C(CH3)(=N)NHC(O)C6H5 OH

Carubicin: OH C(O)CH3 OH out of ring plane Other suitable anthracyclines are anthramycin, mitoxantrone, menogaril, nogalamycin, aclacinomycin A, olivomycin A, chromomycin A3, and plicamycin having the structures:
24 ' .NH2 Menogaril H OCH~ H
OH 4 HN~ OOH Nogalarrycin asugar H COOCf-l3 NH
sugar: H3C CH3 H3C0 ~~ OCH,, OH ~ H~ OOH
NH
NGtoxantrone 0 ocH, cH, ",, off Other representative anthracyclines include, FCE 23762, a doxorubicin derivative (Quaglia etal., J, Liq. Chromatogr. 77(18):3911-3923, 1994), annamycin (Zoo et al., J. Pharm. Sci. 82(11 ):1151-1154, 1993), ruboxyl (Rapoport et al., J. Controlled Release 58(2):153-162, 1999), anthracyciine disaccharide doxorubicin analogue (Pratesi et al., Clin. Cancer Res.
4(11 ):2833-2839, 1998), N-(trifluoroacetyl)doxorubicin and 4'-O-acetyl-N-(trifluoroacetyl)doxorubicin (Berube & Lepage, Synth. Common. 28(6):1109-1116, 1998), 2-pyrrolinodoxorubicin (Nagy et al., Proc. Nat'I Acad. Sci.
U.S.A.
95(4):1794-1799, 1998), disaccharide doxorubicin analogues (Arcamone et al., J. Nat'I Cancer Inst. 89(16):1217-1223, 1997), 4-demethoxy-7-O-[2,6-dideoxy-4-O-(2,3,6-trideoxy-3-amino-a-L-lyxo-hexopyranosyl)-a-L-lyxo-hexopyranosyl]-adriamicinone doxorubicin disaccharide analogue (Monteagudo et aL, Carbohydr. Res. 300(1 ):11-16, 1997), 2-pyrrolinodoxorubicin (Nagy et al., Proc.
Naf'I Acad. Sci. U. S. A. 94(2):652-656, 1997), morpholinyl doxorubicin analogues (Duran et al., Cancer Chemother. PharmacoL 38(3):210-216, 1996), enaminomalonyl-[3-alanine doxorubicin derivatives (Seitz ef al., Tetrahedron Lett. 36(9):1413-16, 1995), cephalosporin doxorubicin derivatives (Vrudhula et al., J. Med. Chem. 38(8):1380-5, 1995), hydroxyrubicin (Solary et al., Int. J.
Cancer 58(1 ):85-94, 1994), methoxymorpholino doxorubicin derivative (Kohl et .7 .2 a s4 Olivorrydn A COCH(CI-h)2 CI-1~ COCH, H
Chromottydn A,, CQCH3 CI-la COCI-la CFi3 Plicarrydn H H H CI-h al., Cancer Chemother. Pharmacol. 33(1 ):10-16, 1993), (6-maleimidocaproyl)hydrazone doxorubicin derivative (Willner et al., Bioconjugate Chem. 4(6):521-7, 1993), N-(5,5-diacetoxypent-1-yl) doxorubicin (Cherif &
Farquhar, J. Med. Chem. 35(17):3208-14, 1992), FCE 23762 methoxymorpholinyl doxorubicin derivative (Ripamonti et al., Br. J. Cancer 65(5):703-7, 1992), N-hydroxysuccinimide ester doxorubicin derivatives (Demant et al., Biochim. Biophys. Acta 1118(1 ):83-90, 1991 }, poiydeoxynucleotide doxorubicin derivatives (Ruggiero et al., Biochim.
Biophys.
Acta 1129(3):294-302, 1991 ), morpholinyl doxorubicin derivatives (EPA
434960), mitoxantrone doxorubicin analogue (Krapcho et al., J. Med. Chem.
34(8):2373-80. 1991 ), AD198 doxorubicin analogue (Traganos et al., Cancer Res. 51(14):3682-9, 1991 ), 4-demethoxy-3'-N-trifluoroacetyldoxorubicin (Norton et al., Drug Des. Delivery 6(2):123-9, 1990), 4'-epidoxorubicin (Drzewoski et al., Pol. J. Pharmacol. Pharm. 40(2):159-65, 1988; Weenen et al., Eur. J. Cancer Clin. Oncol. 20(7):919-26, 1984), alkylating cyanomorpholino doxorubicin derivative (Scudder et al., J. Nat'! Cancer lnst. 80(16):1294-8, 1988), deoxydihydroiodooxorubicin (EPA 275966), adriblastin (Kalishevskaya et al., Vestn. Mosk. Univ., 16(Biol. 1 ):21-7, 1988), 4'-deoxydoxorubicin (Schoelzel et al., Leuk. Res. 10(12):1455-9, 1986), 4-demethyoxy-4'-o-methyldoxorubicin (Giuliani et al., Proc. Int. Congr. Chemother. 16:285-70-285-77, 1983), 3'-deamino-3'-hydroxydoxorubicin (Norton et al., J. Antibiot. 37(8):853-8, 1984), demethyoxy doxorubicin analogues (Barbieri et al., Drugs Exp. Clin. Res.
10(2):85-90, 1984), N-L-leucyl doxorubicin derivatives (Trouet et al., Anthracyclines (Pros. Int. Symp. Tumor Pharmacother. ), 179-81, 1983), 3'-deamino-3'-(4-methoxy-1-piperidinyl) doxorubicin derivatives (U.S. 4,314,054), 3'-deamino-3'-(4-mortholinyl) doxorubicin derivatives (U.S. 4,301,277), 4'-deoxydoxorubicin and 4'-o-methyldoxorubicin (Giuliani et al., Int. J. Cancer 27(1 ):5-13, 1981 ), aglycone doxorubicin derivatives (Chan & Watson, J.
Pharm.
Sci. 67(12):1748-52, 1978), SM 5887 (Pharma Japan 1468:20, 1995), MX-2 (Pharma Japan 1420:19, 1994), 4'-deoxy-13(S)-dihydro-4'-iododoxorubicin (EP
275966), morpholinyl doxorubicin derivatives (EPA 434960), 3'-deamino-3'-(4-methoxy-1-piperidinyl) doxorubicin derivatives (U.S. 4,314,054), doxorubicin-14-valerate, morpholinodoxorubicin (U.S. 5,004,606), 3'-deamino-3'-(3"-cyano-4"-morpholinyl doxorubicin; 3'-deamino-3'-(3"-cyano-4"-morpholinyl)-13-dihydoxorubicin); (3'-deamino-3'-(3"-cyano-4"-morpholinyl) daunorubicin; 3'-deamino-3'-(3"-cyano-4"-morpholinyl)-3-dihydrodaunorubicin; and 3'-deamino-3'-(4"-morpholinyl-5-iminodoxorubicin and derivatives (U.S. 4,585,859), 3'-deamino-3'-(4-methoxy-1-piperidinyl) doxorubicin derivatives (U.S. 4,314,054) and 3-deamino-3-(4-morpholinyl) doxorubicin derivatives (U.S. 4,301,277).
(B) Fluoropyrimidine analogues In another aspect, the therapeutic agent is a fluoropyrimidine analog, such as 5-fluorouracil, or an analogue or derivative thereof, including carmofur, doxifluridine, emitefur, tegafur, and floxuridine. Exemplary compounds have the structures:
A

R2~ F
N
O N
R' R~ R2 5-FluorouracilH H

Carmofur C(O)NH(CH2)5CH3 H

DoxifluridineA~ H

Floxuridine A2 H

Emitefur CH20CH2CH3 B

Tegafur C H

CN
O ~ ~ O O
O N O
C
O
Other suitable fluoropyrimidine analogues include 5-FudR (5-fluoro-deoxyuridine), or an analogue or derivative thereof, including 5-iododeoxyuridine (5-IudR), 5-bromodeoxyuridine (5-BudR), fluorouridine triphosphate (5-FUTP), and fluorodeoxyuridine monophosphate (5-dFUMP).
Exemplary compounds have the structures:
5-Fluoro-2'-deoxyuridine: R = F
5-Bromo-2'-deoxyuridine: R = Br 5-lodo-2'-deoxyuridine: R = I
Other representative examples of fluoropyrimidine analogues include N3-afkyiated analogues of 5-fluorouracil (Kozai et al., J. Chem. Soc., Perkin Trans. 7(19):3145-3146, 1998), 5-fluorouracil derivatives with 1,4-oxaheteroepane moieties (Gomez et al., Tetrahedron 54(43):13295-13312, 1998), 5-fluorouracil and nucleoside analogues (Li, Anticancer Res. 17(1A):21-27, 1997), cis- and trans-5-fluoro-5,6-dihydro-6-alkoxyuracil (Van der Wilt et al., Br. J. Cancer 68(4):702-7, 1993), cyclopentane 5-fluorouracil analogues (Hronowski & Szarek, Can. J. Chem. 70(4):1162-9, 1992), A-OT-fluorouracil (Zhang et al., Zongguo Yiyao Gongye Zazhi 20(11 ):513-15, 1989), N4-trimethoxybenzoyl-5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine (Miwa et al., Chem. Pharm. Bull. 38(4):998-1003, 1990), 1-hexylcarbamoyl-5-fluorouracil (Hoshi et al., J. Pharmacobio-Dun. 3(9):478-81, 1980; Maehara et al., Chemotherapy (Basel) 34(6):484-9, 1988), B-3839 (Prajda et al., In Vivo 2(2):151-4, 1988), uracil-1-(2-tetrahydrofuryl)-5-fluorouracil (Anai et al., Oncology 45(3):144-7, 1988), 1-(2'-deoxy-2'-fluoro-~3-D-arabinofuranosyl)-5-fluorouracil (Suzuko et al., Mol. Pharmacol. 37(3):301-6, 1987), doxifluridine (Matuura et al., Oyo Yakuri 29(5):803-31, 1985), 5'-deoxy-5-fluorouridine (Bollag & Hartmann, Eur. J. Cancer 76(4):427-32, 1980), 1-acetyl-3-O-toluyl-5-fluorouracil (Okada, Hiroshima J. Med. Sci. 28(1 ):49-66, 1979), 5-fluorouracil-m-formylbenzene-sulfonate (JP 55059173), N'-(2-furanidyl)-5-fluorouracil (JP
53149985) and 1-(2-tetrahydrofuryl)-5-fluorouracil (JP 52089680).

These compounds are believed to function as therapeutic agents by serving as antimetabolites of pyrimidine.
(C) Folic acid antagonists In another aspect, the therapeutic agent is a folic acid antagonist, such as methotrexate or derivatives or analogues thereof, including edatrexate, trimetrexate, raltitrexed, piritrexim, denopterin, tomudex, and pteropterin.
Methotrexate analogues have the following general structure:
R~ ~ R \ N"Rg R \~g R6 ~ R R2 ~N
R' R~
Ra The identity of the R group may be selected from organic groups, particularly those groups set forth in U.S. Patent Nos. 5,166,149 and 5,382,582. For example, R~ may be N, R2 may be N or C(CH3), R3 and R3' may H or alkyl, e.g., CH3, R4 may be a single bond or NR, where R is H or alkyl group. R5, R6, and/or R$ may be H, OCH3, or alternately they can be halogens or hydro groups. R~ is a side chain of the general structure:
NH

HO

O

>H

n wherein n = 1 for methotrexate, n = 3 for pteropterin. The carboxyl groups in the side chain may be esterified or form a salt such as a Zn2+ salt. R9 and Rio can be NH2 or may be alkyl substituted.

Exemplary folic acid antagonist compounds have the structures:
Ro R~ R2 R3 Rd R5 Rs R~ Rs MethotrexateNHa N N H N(CH3) H H A (n=1H
) EdatrexateNH2 N N H CH(CH2CHs)H H A (n=1H
) TrimetrexateNH2 CH C(CHs)H NH H OCH3 OCH3 OCH3 PteropterinOH N N H NH H H A (n=3)H

DenopterinOH N N CH3 N(CH3) H H A (n=1H
) PeritreximNHS N C(CH3)H single OCH3 H H OCH3 bond A: p NH
HO
O
o OH
HOOC~ O ~ H3 ~ ~ ~CH3 S N ~ \~IN'H
HOOC~NH
O
Tomudex Other representative examples include 6-S-aminoacyloxymethyl mercaptopurine derivatives (Harada et al., Chem. Pharm. Bull. 43(10):793-6, 1995), 6-mercaptopurine (6-MP) (Kashida et al,, Biol. Pharm. Bull. 18(11 ):1492-7, 1995), 7,8-poiymethyleneimidazo-1,3,2-diazaphosphorines (Nilov et al,, Mendeleev Commun. 2:67, 1995), azathioprine (Chifotides et al., J. Inorg.
Biochem. 56(4):249-64, 1994), methyl-D-glucopyranoside mercaptopurine derivatives (Da Silva et al., Eur, J. Med. Chem. 29(2):149-52, 1994) and s-alkynyl mercaptopurine derivatives (Ratsino et al., Khim.-Farm. Zh. 75(8):65-7, 1981 ); indoline ring and a modified ornithine or glutamic acid-bearing methotrexate derivatives (Matsuoka et al., Chem. Pharm. Bull. 45(7):1146-1150, 1997), alkyl-substituted benzene ring C bearing methotrexate derivatives (Matsuoka et al., Chem. Pharm. Bull. 44(12):2287-2293, 1996), benzoxazine or benzothiazine moiety-bearing methotrexate derivatives (Matsuoka et al., J.
Med. Chem. 40(1 ):105-111, 1997), 10-deazaaminopterin analogues (DeGraw et al., J. Med. Chem. 40(3):370-376, 1997), 5-deazaaminopterin and 5,10-dideazaaminopterin methotrexate analogues (Piper et al., J. Med. Chem.
40(3):377-384, 1997), indoline moiety-bearing methotrexate derivatives (Matsuoka et al., Chem. Pharm. Bull. 44(7):1332-1337, 1996), lipophilic amide methotrexate derivatives (Pignatello et al., VIlorld Meet. Pharm. Biopharm.
Pharm. Technol., 563-4, 1995), L-threo-(2S,4S)-4-fluoroglutamic acid and DL-3,3-difluoroglutamic acid-containing methotrexate analogues (Hart et al., J.
Med. Chem. 39(1 ):56-65, 1996), methotrexate tetrahydroquinazoline analogue (Gangjee, et al., J. Heterocycl. Chem. 32(1 ):243-8, 1995), N-(a-aminoacyl) methotrexate derivatives (Cheung et al., Pteridines 3(1-2):101-2, 1992), biotin methotrexate derivatives (Fan et al., Pteridines 3(1-2):131-2, 1992), D-glutamic acid or D-erythrou, threo-4-fluoroglutamic acid methotrexate analogues (McGuire et al., Biochem. Pharmacol. 42(12):2400-3, 1991 ), a,y-methano methotrexate analogues (Rosowsky et al., Pteridines 2(3):133-9, 1991 ), 10-deazaaminopterin (10-EDAM) analogue (Braakhuis et al., Chem. Biol.
Pteridines, Proc. Int. Symp. Pteridines Folic Acid Deriv., 1027-30, 1989), y-tetrazole methotrexate analogue (Kalman et al., Chem. Biol. Pteridines, Proc.
Int. Symp. Pteridines Folic Acid Deriv., 1154-7, 1989), N-(L-a-aminoacyl) methotrexate derivatives (Cheung et al., Heterocycles 28(2):751-8, 1989), meta and ortho isomers of aminopterin (Rosowsky et al., J. Med. Chem. 32(12):2582, 1989), hydroxymethylmethotrexate (DE 267495), y-fluoromethotrexate (McGuire et al., Cancer Res. 49(16):4517-25, 1989), polyglutamyl methotrexate derivatives (Kumar et al:, Cancer Res. 46(10):5020-3, 1986), gem-diphosphonate methotrexate analogues (WO 88/06158), a- and y-substituted methotrexate analogues (Tsushima et al., Tetrahedron 44(17):5375-87, 1988), 5-methyl-5-deaza methotrexate analogues (4,725,687), N8-acyl-Na-(4-amino-4-deoxypteroyl)-L-ornithine derivatives (Rosowsky et al., J. Med. Chem.
37(7):1332-7, 1988), 8-deaza methotrexate analogues (Kuehl et al., Cancer Res. 48(6):1481-8, 1988), acivicin methotrexate analogue (Rosowsky et al., J.
Med. Chem. 30(8):1463-9, 1987), polymeric platinol methotrexate derivative (Carraher et al., Polym. Sci. Technol. (Plenum), 35(Adv. Biomed. Polym.):311-24, 1987), methotrexate-y-dimyristoylphophatidylethanolamine (Kinsky et al., Biochim. Biophys. Acta 977(2):211-18, 1987), methotrexate polyglutamate analogues (Rosowsky et al., Chem. Biol. Pteridines, Pteridines Folic Acid Deriv., Proc. Int. Symp. Pteridines Folic Acid Deriv.: Chem., Biol. Clin.
Aspects:
985-8, 1986), poly-y-glutamyl methotrexate derivatives (Kisliuk et al., Chem.
Biol. Pteridines, Pteridines Folic Acid Deriv., Proc. Int. Symp. Pteridines Folic Acid Deriv.: Chem., Biol. Clin. Aspects: 989-92, 1986), deoxyuridylate methotrexate derivatives (Webber et al., Chem. Biol. Pteridines, Pteridines Folic Acid Deriv., Proc. Int. Symp. Pteridines Folic Acid Deriv.: Chem., Biol. Clin.
Aspects: 659-62, 1986), iodoacetyl lysine methotrexate analogue (Delcamp et al., Chem. Biol. Pteridines, Pteridines Folic Acid Deriv., Proc. Int. Symp.
Pteridines Folic Acid Deriv.: Chem., Biol. Clin. Aspects: 807-9, 1986), 2,.omega.-diaminoalkanoid acid-containing methotrexate analogues (McGuire et al., Biochem. Pharmacol. 35(15):2607-13, 1986), polyglutamate methotrexate derivatives (Kamen & Winick, Methods Enzymol. 122(Vitam.
Coenzymes, Pt. G):339-46, 1986), 5-methyl-5-deaza analogues (Piper et al., J.
Med. Chem. 29(6):1080-7, 1986), quinazoline methotrexate analogue (Mastropaolo et al., J. Med. Chem. 29(1 ):155-8, 1986), pyrazine methotrexate analogue (Lever & Vestal, J. Heterocycl. Chem. 22(1 ):5-6, 1985), cysteic acid and homocysteic acid methotrexate analogues (4,490,529), y-tert-butyl methotrexate esters (Rosowsky et al., J. Med. Chem. 28(5):660-7, 1985), fluorinated methotrexate analogues (Tsushima et al., Heterocycles 23(1 ):45-9, 1985), folate methotrexate analogue (Trombe, J. Bacteriol. 760(3):849-53, 1984), phosphonoglutamic acid analogues (Sturtz & Guillamot, Eur. J. Med.
Chem.--Chim. Ther. 79(3):267-73, 1984), poly (L-lysine) methotrexate conjugates (Rosowsky et al., J. Med. Chem. 27(7):888-93, 1984), dilysine and trilysine methotrexate derivates (Forsch & Rosowsky, J. Org. Chem.
49(7):1305-9, 1984), 7-hydroxymethotrexate (Fabre et al., Cancer Res.
43(10):4648-52, 1983), poly-y-glutamyl methotrexate analogues (Piper &
Montgomery, Adv. Exp. Med. Biol., 163(Folyl Antifolyl Polyglutamates):95-100, 1983), 3',5'-dichloromethotrexate (Rosowsky & Yu, J. Med. Chem. 26(10):1448-52, 1983), diazoketone and chloromethylketone methotrexate analogues (Gangjee et al., J. Pharm. Sci. 77(6):717-19, 1982), 10-propargylaminopterin and alkyl methotrexate homologs (Piper et al., J. Med. Chem. 25(7):877-80, 1982), lectin derivatives of methotrexate (Lin et al., JNCI 66(3):523-8, 1981 ), polyglutamate methotrexate derivatives (Galivan, Mol. Pharmacol. 17(1 ):105-10, 1980), halogentated methotrexate derivatives (Fox, JNCI 58(4):J955-8, 1977), 8-alkyl-7,8-dihydro analogues (Chaykovsky et al., J. Med. Chem.
20(10):J1323-7, 1977), 7-methyl methotrexate derivatives and dichloromethotrexate (Rosowsky & Chen, J. Med. Chem. 17(12):J1308-11, 1974), lipophilic methotrexate derivatives and 3',5'-dichloromethotrexate (Rosowsky, J. Med. Chem. 16(10):J1190-3, 1973), deaza amethopterin analogues (Montgomery et al., Ann. N. Y. Acad. Sci. 186:J227-34, 1971 ), MX068 (Pharma Japan, 1658:18, 1999) and cysteic acid and homocysteic acid methotrexate analogues (EPA 0142220);
These compounds are believed to act as antimetabolites of folic acid.
(D) Podophyllotoxins In another aspect, the therapeutic agent is a Podophyllotoxin, or a derivative or an analogue thereof. Exemplary compounds of this type are etoposide or teniposide, which have the following structures:
Etoposide CH3 Teniposide s 0"
Other representative examples of podophyllotoxins include Cu(11)-VP-16 (etoposide) complex (Tawa et al., Bioorg. Med. Chem. 6(7):1003-1008, 1998), pyrrolecarboxamidino-bearing etoposide analogues (Ji et al., Bioorg.
Med. Chem. Lett. 7(5):607-612, 1997), 4(i-amino etoposide analogues (Hu, University of North Carolina Dissertation, 1992), y-lactone ring-modified arylamino etoposide analogues (Zhou et al., J. Med. Chem. 37(2):287-92, 1994), N-glucosyl etoposide analogue (Allevi et al., Tetrahedron Lett.
34(45):7313-16, 1993), etoposide A-ring analogues (Kadow et al., Bioorg. Med.
Chem. Lett. 2(1 ):17-22, 1992), 4'-deshydroxy-4'-methyl etoposide (Saulnier et al., Bioorg. Med. Chem. Lett. 2(10):1213-18, 1992), pendulum ring etoposide analogues (Sinha et al., Eur. J. Cancer 26(5):590-3, 1990) and E-ring desoxy etoposide analogues (Saulnier et al., J. Med. Chem. 32(7):1418-20, 1989).

These compounds are believed to act as topoisomerase II
inhibitors and/or DNA cleaving agents.
(E) Camptothecins In another aspect, the therapeutic agent is camptothecin, or an analogue or derivative thereof. Camptothecins have the following general structure.
In this structure, X is typically O, but can be other groups, e.g., NH
in the case of 21-lactam derivatives. R~ is typically H or OH, but may be other groups, e.g., a terminally hydroxylated C~_3 alkane. R2 is typically H or an amino containing group such as (CH3)2NHCH2, but may be other groups e.g., N02, NH2, halogen (as disclosed in, e.g., U.S. Patent 5,552,156) or a short alkane containing these groups. R3 is typically H or a short alkyl such as C2H5.
R4 is typically H but may be other groups, e.g., a methylenedioxy group with R~.
Exemplary camptothecin compounds include topotecan, irinotecan (CPT-11)"9-aminocamptothecin, 21-lactam-20(S)-camptothecin, 10,11-methylenedioxycamptothecin, SN-38, 9-nitrocamptothecin, 10-hydroxycamptothecin. Exemplary compounds have the structures:

R~ RZ R3 Camptothecin: H H H
Topotecan: OH (CH3)ZNHCH~ H
SN-38: OH H C~HS
X: O for most analogs, NH for 21-lactam analogs Camptothecins have the five rings shown here. The ring labeled E must be intact (the lactone rather than carboxylate form) for maximum activity and minimum toxicity.
Camptothecins are believed to function as topoisomerase I
inhibitors and/or DNA cleavage agents.
(F) Hydroxyureas The therapeutic agent of the present invention may be a hydroxyurea. Hydroxyureas have the following general structure:

~N N~
~ ' R2 R~
Suitable hydroxyureas are disclosed in, for example, U.S. Patent No. 6,080,874, wherein R1 is:
and R2 is an alkyl group having 1-4 carbons and R3 is one of H, acyl, methyl, ethyl, and mixtures thereof, such as a methylether.

Other suitable hydroxyureas are disclosed in, e.g., U.S. Patent No. 5,665,768, wherein R~ is a cycloalkenyl group, for example N-[3-[5-(4-fluorophenylthio)-furyl]-2-cyclopenten-1-yl]N-hydroxyurea; R2 is H or an alkyl group having 1 to 4 carbons and R3 is H; X is H or a cation.
Other suitable hydroxyureas are disclosed in, e.g., U.S. Patent No. 4,299,778, wherein R~ is a phenyl group substituted with one or more fluorine atoms; R2 is a cyclopropyl group; and R3 and X is H.
Other suitable hydroxyureas are disclosed in, e.g., U.S. Patent No. 5,066,658, wherein R2 and R3 together with the adjacent nitrogen form:
c~~2)~
Y . /N-/ iCN2)m wherein m is 1 or 2, n is 0-2 and Y is an alkyl group.
In one aspect, the hydroxyurea has the structure:

,0H

Hydroxyurea These compounds are thought to function by inhibiting DNA
synthesis.
(G) Platinum complexes In another aspect, the therapeutic agent is a platinum compound.
In general, suitable platinum complexes may be of Pt(ll) or Pt(IV) and have this basic structure:

z1 X
R1\Pt~
R~ ~Y

wherein X and Y are anionic leaving groups such as sulfate, phosphate, carboxylate, and halogen; R1 and R2 are alkyl, amine, amino alkyl may be further substituted, and are basically inert or bridging groups. For Pt(II) complexes Z1 and Z2 are non-existent. For Pt(IV) Z1 and Z2 may be anionic groups such as halogen, hydroxy, carboxylate, ester, sulfate or phosphate.
See, e.g., U.S. Patent Nos. 4,588,831 and 4,250,189.
Suitable platinum complexes may contain multiple Pt atoms. See, e.g., U.S. Patent Nos. 5,409,915 and 5,380,897. For example bisplatinum and triplatinum complexes of the type:
z1 z1 I R X I
X~ / I ~ , R2 Y/ It~A/ It\Y
z2 Z2 X\ I /RI X\ I ~A\ I /X
Pt Pt \ Pt Y/ I ~A/ ( \Y RZ I \Y
Zz Zz Z2 ZI ZI
X\ I / Rz Rz~ ( / X
Y/ It\A/ It\Y
Zz Zz . Zz\Pt/ R
Y/I\ZI
X
Exemplary platinum compounds are cisplatin, carboplatin, oxaliplatin, and miboplatin having the structures:

NH3 O O~
It CI-It-NH3 I ~NH3 O
CI
O
Cisplatin Carboplatin O O H H
\l O NHS O N
\ /
Pt Pt / ' H
O \NH °~'\ O N
z / _.
O O H
Oxaliplatin Miboplatin Other representative platinum compounds include (CPA)~Pt[DOLYM] and (DACH)Pt[DOLYM] cisplatin (Choi et al., Arch.
Pharmacal Res. 22(2):151-156, 1999), Cis-[PtCl2(4,7-H-5-methyl-7-oxo]1,2,4[triazolo[1,5-a]pyrimidine)2] (Navarro et al., J. Med. Chem.
41(3):332-338, 1998), [Pt(cis-1,4-DACH)(trans-CI2)(CBDCA)] ~'/2MeOH cisplatin (Shamsuddin et al., Inorg. Chem. 36(25):5969-5971, 1997), 4-pyridoxate diammine hydroxy platinum (Tokunaga et al., Pharm. Sci. 3(7):353-356, 1997), Pt(II) ... Pt(II) (Pt2[NHCHN(C(CH2)(CH3))]4) (Navarro et al., Inorg. Ghem.
35(26):7829-7835, 1996), 254-S cisplatin analogue (Koga et al., Neurol. Res.
18(3):244-247, 1996), o-phenylenediamine ligand bearing cisplatin analogues (Koeckerbauer & Bednarski, J. Inorg. Biochem. 62(4):281-298, 1996), traps, cis-[Pt(OAc)212(en)] (Kratochwil et al., J. Med. Chem. 39(13):2499,-2507, 1996}, estrogenic 1,2-diarylethylenediamine ligand (with sulfur-containing amino acids and glutathione) bearing cisplatin analogues (Bednarski, J. Inorg. Biochem.
62(1):75, 1996), cis-1,4-diaminocyclohexane cisplatin analogues (Shamsuddin et al., J. Inorg. Biochem. 61'(4):291-301, 1996), 5' orientational isomer of cis-[Pt(NH3)(4-aminoTEMP-O)~d(GpG))] (Dunham & Lippard, J. Am. Chem. Soc.
117(43):10702-12, 1995), chelating diamine-bearing cisplatin analogues (Koeckerbauer & Bednarski, J. Pharm. Sci. 84(7):819-23, 1995), 1,2-diarylethyleneamine ligand-bearing cisplatin analogues (Otto et al., J. Cancer Res. Clip. Oncol. 121(1 ):31-8, 1995), (ethylenediamine)platinum(II) complexes (Pasini et al., J. Chem. Soc., Dalton Traps. 4:579-85, 1995), CI-973 cisplatin analogue (Yang et al., Int. J. Oncol. 5(3):597-602, 1994), cis-diaminedichloroplatinum(II) and its analogues cis-1,1-cyclobutanedicarbosylato(2R)-2-methyl-1,4-butanediamineplatinum(II) and cis-diammine(glycolato)platinum (Claycamp & Zimbrick, J. Inorg. Biochem.
26(4):257-67, 1986; Fan et al., Cancer Res. 48(11 ):3135-9, 1988; Heiger-Bernays et al., Biochemistry 29(36):8461-6, 1990; Kikkawa et al., J. Exp.
Clin.
Cancer Res. 12(4):233-40, 1993; Murray et al., Biochemistry 31(47):11812-17, 1992; Takahashi et al., Cancer Chemother. Pharmacol. 33(1 ):31-5, 1993), cis-amine-cyclohexylamine-dichloroplatinum(II) (Yoshida et al., Biochem.
Pharmacol. 48(4):793-9, 1994), gem-diphosphonate cisplatin analogues (FR
2683529), (meso-1,2-bis(2,6-dichloro-4-hydroxyplenyl)ethylenediamine) dichloroplatinum(II) (Bednarski et al., J. Med. Chem. 35(23):4479-85, 1992), cisplatin analogues containing a tethered dansyl group (Hartwig et al., J. Am.
Chem. Soc. 114(21 ):8292-3, 1992), platinum(II) polyamines (Siegmann et al., Inorg. Met.-Containing Polym. Mater., (Proc. Am. Chem. Soc. Int. Symp.), 335-61, 1990), cis-(3H)dichloro(ethylenediamine)platinum(II) (Eastman, Anal.
Biochem. 197(2):311-15, 1991 ), trans-diamminedichloroplatinum(II) and cis-(Pt(NH3)~(N3-cytosine)CI) (Bellon & Lippard, Biophys. Chem. 35(2-3):179-88, 1990), 3H-cis-1,2-diaminocyclohexanedichloroplatinum(II) and 3H-cis-1,2-diaminocyclohexanemalonatoplatinum (II) (Oswald et al., Res. Commun. Chem.
Pathol. Pharmacol. 64(1 ):41-58, 1989), diaminocarboxylatoplatinum (EPA
296321 ), trans-(D,1 )-1,2-diaminocyclohexane carrier ligand-bearing platinum analogues (Wyrick & Chaney, J. Labelled Compd. Radiopharm. 25(4):349-57, 1988), aminoalkylaminoanthraquinone-derived cisplatin analogues (Kitov et al., Eur. J. Med. Chem. 23(4):381-3, 1988), spiroplatin, carboplatin, iproplatin and JM40 platinum analogues (Schroyen et al., Eur. J. Cancer Clin. Oncol.
24(8):1309-12, 1988), bidentate tertiary diamine-containing cisplatinum derivatives (Orbell et al., Inorg. Chim. Acta 152(2):125-34, 1988), platinum(II), platinum(IV) (Liu & Wang, Shandong Yike Daxue Xuebao 24(1 ):35-41, 1986), cis-diammine(1,1-cyclobutanedicarboxylato-)platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40) (Begg et al., Radiother. Oncol.
9(2):157-65, 1987), JM8 and JM9 cisplatin analogues (Harstrick et al., Int. J.
Androl. 10(1 ); 139-45, 1987), (NPr4)2((PtCL4).cis-(PtCl2-(NH2Me)2)) (Brammer et al., J. Chem. Soc., Chem. Commun. 6:443-5, 1987), aliphatic tricarboxylic acid platinum complexes (EPA 185225), and cis-dichloro(amino acid)(tert-butylamine)platinum(II) complexes (Pasini & Bersanetti, Inorg.
Chim.
Acta 107(4):259-67, 1985). These compounds are thought to function by binding to DNA, i.e., acting as alkylating agents of DNA.

As medical implants are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area, design and portions of the implant coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the medical implant, the preferred anticancer/anti-infective agents, used alone or in combination, should be administered under the following dosing guidelines:
(a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the implant components, or applied without a carrier polymer, the total dose of doxorubicin applied to the implant should not exceed 25 mg (range of 0.1~ p,g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ~,g to 5 mg. The dose per unit area (i.e., the amount of drug as a function of the surface area of the portion of the implant to which drug is applied and/or incorporated) should fall within the range of 0.01 ~,g - 100 ~,g per mm2 of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the implant surface at a dose of 0.1 ~,g/mmz - 10 p,g/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the implant surface such that a minimum concentration of 10'x- 10~ M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10'4 M;
although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the implant such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week - 6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
Utilizing mitoxantrone as another example ofi an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the implant, or applied without a carrier polymer, the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 pg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 pg to 1 mg. The dose per unit area (i.e., the amount of drug as a function of the surface area of the portion of the implant to which drug is applied andlor incorporated) should fall within the range of 0.01 ~g - 20 ~g per mm2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the implant surface at a dose of 0.05 ~g/mm2 - 3 p,g/mm2.
As different polymer and non-polymer coatings wilt release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the implant surface such that a minimum concentration of 10-5 -10-6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the implant surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10-5 M; although for some embodiments lower drug levels wiN
be sufficient). In a preferred embodiment, mitoxantrone is released from the surface of the implant such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week - 6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
(b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fiuorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the implant, or applied without a carrier polymer, the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 ~.g to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 ~,g to 25 mg. The dose per unit area (i.e., the amount of drug as a function of the surface area of the , portion of the implant to which drug is applied and/or incorporated) should fall within the range of 0.1 ~,g -1 mg per mm2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the implant surface at a dose of 1.0 ~.g/mm2 - 50 ~.g/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the implant surface such that a minimum concentration of 10-4 - 10-' M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10-4 M;
although for some embodiments tower drug levels will be sufficient). in a preferred embodiment, 5-fluorouracil is released from the implant surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week - 6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
(c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the cardiac implant, or applied without a carrier polymer, the total dose of etoposide applied should not exceed 25 mg (range of 0.1 p,g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 p,g to 5 mg. The dose per unit area (i.e., the amount of drug as a function of the surface area of the portion of the implant to which drug is applied and/or incorporated) should fall within the range of 0.01 p,g - 100 ~.g per mm2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the implant surface at a dose of 0.1 ~.g/mm2 - 10 p.g/mma. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the implant surface such that a concentration of 10-5- 10-6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e., are in excess of 10-5 M; although for some embodiments lov~ier drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the implant such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week - 6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention;
the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
(d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and/or podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the implant coating.
Similarly anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and/or podophylotoxins (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. The anti-infective agent may be further combined with antithrombotic and/or antiplatelet agents (for example, heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, streptokinase, and/or tissue plasminogen activator) to enhance efficacy.

C. Methods for Generating Medical Devices Which Contain or Release a Fibrosis-Inducing Agent In the practice of this invention, drug-coated, drug-impregnated, or drug containing implants and medical devices are provided which induce adhesion or fibrosis in the surrounding tissue, or facilitate "anchoring" of the device/implant in situ, thus enhancing the efficacy. Within various embodiments, fibrosis is induced by local or systemic release of specific pharmacological agents that become localized to the tissue adjacent to the device or implant. There are numerous methods available for optimizing delivery of the fibrosis-inducing agent to the site of the intervention and several of these are described below.
1 ) Devices and Implants That Contain or Release Fibrosis-Inducing Agents Medical devices or implants of the present invention contain and/or are adapted to release an agent which induces fibrosis or adhesion to the surrounding tissue. Medical devices or implants may be adapted to have ' incorporated into their structure a fibrosis-inducing agent, adapted to have a surface coating of a fibrosis-inducing agent and/or adapted to release a fibrosis-inducing agent by (a) directly affixing to the implant or device a desired fibrosis-inducing agent or composition containing the fibrosis-inducing agent (e.g., by either spraying the medical implant with a drug and/or carrier (polymeric or non-polymeric)-drug composition to create a film or coating on all, or parts of the internal or external surface of the device; by dipping the implant or device into a drug and/or carrier (polymeric or non-polymeric)-drug solution to coat all or parts of the device or implant; or by other covalent or non-covalent (e.g., mechanically attached via knotting or the use of an adhesive or thermal treatment, electrostatic, ionic, hydrogen bonded or hydrophobic interactions) attachment of the therapeutic agent to the device or implant surface); (b) by coating the medical device or implant with a substance such as a hydrogel which can in turn absorb the desired fibrosis-inducing agent or composition;
(c) by interweaving a "thread" composed of, or coated with, the fibrosis-inducing agent into the medical implant or device (e.g., a polymeric strand composed of materials that induce fibrosis (e.g., silk, collagen, EVA, PLA, polyurethanes, polymerized drug compositions) or polymers which comprise and/or release a fibrosis-inducing agent from the thread); (d) by covering all, or portions of the device or implant with a sleeve, cover or mesh containing a fibrosis-inducing agent (i.e., a covering comprised of a fibrosis-inducing agent - polymers such as silk, collagen, EVA, PLA, polyurethanes or polymerized compositions containing fibrosis-inducing agents); (e) constructing all, or parts of the device or implant itself with the desired agent or composition (e.g., constructing the device from polymers such as silk, collagen, EVA, PLA, polyurethanes or polymerized compositions of fibrosis-inducing agents); (f) otherwise impregnating the device or implant with the desired fibrosis-inducing agent or composition; (g) scoring (i.e., creating ridges or indentations) on all, or parts, of the device or implant surface to produce irritation of the tissue and ultimately fibrosis; (h) composing all, or parts, of the device or implant from metal alloys that induce fibrosis (e.g., copper); (i) constructing all, or parts of the device or implant itself from a degradable or non-degradable polymer that releases one or more fibrosis-inducing agents; (j) utilizing specialized multi-drug releasing medical device systems (described, e.g., in U.S. Patent No. 6,562,065; U.S.
Patent Application Publication Nos. 2003/0199970 and 2003/0167085; and in PCT Publication Nos. WO 03/015664 and WO 02/32347) to deliver fibrosis-inducing agents alone or in combination.
In one aspect, a medical device may be modified by attaching fibers (threads) to the surface of the device. The fibers may be polymeric and/or may be formed of or coated with a fibrosing material, such as silk. For example, the threads may be formed from a silk suture material. The presence of the threads can result in an enhanced cellular and/or extracellular matrix response to the exterior of the device. The threads can be attached to the device by using any one or a combination of the following methods, including use of an adhesive, thermal welding, stitching, wrapping, weaving, knotting, and the like. The threads can be coated with a material that delays the time it takes for the thread material to come into contact with the surrounding tissue and blood, thus allowing placement of the device without concern of thrombotic events due to the presence of the polymeric threads. Examples of materials that can be used to prepare coatings capable of degrading or dissolving upon implantation include gelatin, polyesters (e.g., PLGA, PLA, MePEG-PLGA, PLGA-PEG-PLGA, and blends thereof), lipids, fatty acids, sugar esters, nucleic acid esters, polyanhydrides, polyorthoesters, and PVA. The coating may further contain a fibrosing agent and/or a biologically active agent that may, for example, reduce the probability of an immediate thrombotic event (e.g., heparin, hydrophobic quaternary amine heparin complexes, and the like). In addition to the polymeric threads, all or a portion of the device may be coated with a polymeric carrier that contains a fibrosis-inducing agent.
The fibers (threads) may further comprise a coating or composition that is affected by an applied magnetic field. For example, a device such as a stent graft may be coated with polymeric threads that are coated, contain, or are formed from a fibrosing agent (e.g., silk suture). A
magnetic field can be applied to the coated device to orient and align the polymeric fibers relative to each other and the surface of the device to increase the surface area of the fibers exposed to biological mediators which would stimulate a fibrotic reaction. The magnetically active component can be associated with the polymeric fiber using a variety of methods. The magnetically active component may be incorporated during manufacture of the fiber, for example, by incorporating a magnetically active material such as magnetite into a polymer feed prior to extrusion of the polymeric fiber. The magnetically active component can be coated onto the entire fiber or a portion of the fiber using, for example, an adhesive or a polymeric coating. The polymeric fiber (or a portion thereof) can be heated or plasticized with a solvent and then rolled in the magnetically active component, such that the magnetic material protrudes above the surface of the fiber or is embedded into the surface of the fiber.
The threads (either with or without a magnetic component) may be attached to the' device in various configurations that can result in either partial or complete coverage of the exterior of the device. The polymeric threads may be affixed to the ends of a device or to the central portion of a device, and the attachment may be in a vertical, horizontal, or diagonal manner.
2) Systemic, Regional and Local Delivery of Fibrosis-Inducing Agents A variety of drug-delivery technologies are available for systemic, regional and local delivery of therapeutic agents. Several of these techniques may be suitable to achieve preferentially elevated levels of fibrosis-inducing agents in the vicinity of the medical device or implant, including: (a) using drug-delivery catheters for local, regional or systemic delivery of fibrosing agents to the tissue surrounding the device or implant (typically, drug delivery catheters are advanced through the circulation or inserted directly into tissues under radiological guidance until they reach the desired anatomical location; the fibrosing agent can then be released from the catheter lumen in high local concentrations in order to deliver therapeutic doses of the drug to the tissue surrounding the device or implant); (b) drug localization techniques such as magnetic, ultrasonic or MRI-guided drug delivery; (c) chemical modification of the fibrosis-inducing drug or formulation designed to increase uptake of the agent into damaged tissues (e.g., modification of the drug or formulation to include antibodies directed against damaged or healing tissue components such as macrophages, neutrophils, smooth muscle cells, fibroblasts, extracellular matrix components, neovascular tissue); (d) chemical modification of the fibrosis-inducing drug or formulation designed to localize the drug to areas of bleeding or disrupted vasculature such as encapsulation of the drug into site directed liposomes; and/or (e) direct injection of the fibrosis-inducing agent, for example under endoscopic vision.
3) Infiltration of Fibrosis-Inducing Agents into the Tissue Surrounding a Device or Implant Alternatively, the tissue cavity into which the device or implant is placed can be treated with a fibrosis-inducing agent prior to, during, or after the implantation procedure. This can be accomplished in several ways including:
(a) topical application of the fibrosing agent into the anatomical space where the device can be placed (particularly useful for this embodiment is the use of polymeric carriers which release the fibrosing agent over a period ranging from several hours to several weeks - fluids, suspensions, emulsions, microemulsions, microspheres, pastes, gels, microparticulates, sprays, aerosols, solid implants and other formulations which release a fibrosing agent can be delivered into the region where the device or implant can be inserted via specialized delivery catheters or other applicators); (b) microparticulate silk and/or silk strands (e.g., linear, branched, and/or coiled) are also useful for directed delivery into the implantation site; (c) sprayable collagen-containing formulations such as COSTASIS (Angiotech Pharmaceuticals, Inc., Vancouver, BC) or materials made from 4-armed thiol PEG (10K), a 4-armed NHS
PEG(10K) and methylated collagen (described below), or materials made from 4-armed thiol PEG (10K), a 4-armed NHS PEG(10K) and collagen or gelatin, either alone, or loaded with a fibrosis-inducing agent, applied to the implantation site (or the implant/device surFace); (d) sprayable in situ forming PEG-containing formulations such as COSEAL (Angiotech Pharmaceuticals, Inc., Canada), FOCALSEAL (Genzyme Corporation, Cambridge, MA), SPRAYGEL or DURASEAL (both from Confluent Surgical, Inc., Waltham, MA), either alone, or loaded with a fibrosis-inducing agent, applied to the implantation site (or the implant/device surface); (e) fibrinogen-containing formulations such as FLOSEAL or TISSEAL (both from Baxter Healthcare Corporation; Fremont, CA), either alone, or loaded with a fibrosis-inducing agent, applied to the implantation site (or the implant/device surface); (f) hyaluronic acid-containing formulations (either non-crosslinked, crosslinked or chemically modified) such as PERLANE or RESTYLANE (both from Q-Med AB, Sweden), HYLAFORM (Inamed Corporation; Santa Barbara, CA), SYNVISC
(Biomatrix, Inc.; Ridgefied, NJ), SEPRAFILM or SEPRACOAT (both from Genzyme Corporation; Cambridge, MA) loaded with a fibrosis with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface);
(g) polymeric gels for surgical implantation such as REPEL (Life Medical Sciences, Inc.; Princeton, NJ) or FLOWGEL (Baxter Healthcare Corporation, Deerfield, IL) loaded with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface); (h) orthopedic "cements" used to hold prostheses and tissues in place loaded with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface), such as OSTEOBOND
(Zimmer, Inc., Warsaw, IN), LVC (Wright Medical Technology, Inc:, Arlington, TN), SIMPLEX P (Stryker Corporation, Kalamazoo, MI), PALACOS (Smith &
Nephew PLC Corporation, United Kingdom), and ENDURANCE (Johnson &
Johnson, Inc., New Brunswick, NJ); (i) surgical adhesives containing one or more cyanoacrylate monomers (e.g., methyl cyanoacrylate, ethyl cyanoacrylate, butyl cyanoacrylate, octyl cyanoacrylate, methoxypropyl cyanoacrylate) such as DERMABOND (Johnson & Johnson, Inc.), INDERMIL
(United States Surgical; Norwalk, CT), GLUSTITCH (Blacklock Medical Products, Inc., Canada) or TISSUMEND II (Veterinary Products Laboratories;
Phoenix, AZ), VETBOND (3M Company; St. Paul, MN), TISSUEMEND (TEI
Biosciences, Inc.; Boston, MA), HISTOACRYL or HISTOACRYL BLUE (Davis &
Geck; St. Louis, MO) and ORABASE SOOTHE-N-SEAL LIQUID
PROTECTANT (Colgate-Palmolive Company; New York; NY), either alone, or loaded with a fibrosis-inducing agent, applied to the implantation site (or the implantldevice surface); (j) implants containing hydroxyapatite (or synthetic bone material such as calcium sulfate, VITOSS and CORTOSS (both from Orthovita, Inc., Malvern, PA)) loaded with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface); (k) other biocompatible tissue fillers loaded with a fibrosis-inducing agent, such as those made by BioCure, Inc. (Norcross, GA), 3M Company and Neomend, Inc. (Sunnyvale, CA), loaded with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface); (i) polysaccharide gets such as the ADCON series of gels (Gliatech, Inc.; Cleveland, OH); (m) films, sponges or meshes such as INTERCEED or VICRYL mesh (Ethicon, Inc., a Johnson & Johnson Company, Somerville, NJ), and GELFOAM (Pharmacia & Upjohn Company; Kalamazoo, MI) loaded with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface); (n) a hydrogel that is formed from an amino-functionalized polyethylene glycol (e.g., 4-armed tetra-amino PEG [10k]) and a 4-armed NHS functionalized PEG (e.g., pentaerythritol polyethylene glycol)ether tetra-succinimidyl glutarate [10K]). This hydrogel may further contain collagen, methylated collagen and/or gelatin. This hydrogel can further comprise the fiibrosis-inducing agents described above (e.g., silk powder or silk threads), and (o) compositions that enhance osteointegration and/or osteogenesis, including materials composed of beta -tricalcium phosphate (e.g., VITOSS, PROOSTEON 5008 made by E-Interpose-Cross International), hydroxyapatite or Ca~o(P04)60H (e.g., OSTEOGRAF made by Ceramed Denta, Inc., Lakewood, CO), calcium carbonate or CaC03, calcium sulfate (e.g., OSTEOSET and ALLOMATRIX made by Wright Medical Technology, lnc.), calcium phosphate (e.g., CALCIBON made by Merck & Co., Inc., Whitehouse Station, NJ, NORIAN SRS made by Synthes-Strates, Switzerland), as well as synthetic bone fillers (e.g., CORTOSS and processed bone fillers, e.g., BIOOSS made by Geistlich Biomaterials, lnc., Switzerland). Representative examples of these materials are described in U.S. Patent Nos. 3,929,971, 4,861,733; 6,527,810; 4,772,468; 4,882,149; 5,167,961; 6,576,015; 4,839,215;
5,614,206; 5,807,567; 6,030,636; 6,652,887; 6,206,957; 6,485,754; 4,347,234;
4,291,013; 5,129,905; 5,336,264; 5,569,442; 5,571,493; 5,683,667; 5,709,742;
5,820,632; 5,658,332; 5,681,872; 5,914,356; 5,939,039; 6,325,987; 6,383,519;
6,458,162; 6,736,799; 6,521,246; and 6,709,744.
In one aspect, the fibrosis-inducing agent may be delivered as a solution. The fibrosis-inducing agent can be incorporated directly into the solution to provide a homogeneous solution or dispersion. In certain embodiments, the solution is an aqueous solution. The aqueous solution may further include buffer salts, as well as viscosity modifying agents (e.g., hyaluronic acid, alginates, CMC, and the like). In another aspect of the invention, the solution can include a biocompatible solvent, such as ethanol, DMSO, glycerol, PEG-200, PEG-300 or NMP.
4) Coating and Sustained-Release Preparations of Fibrosis-Inducing Agents For many of the aforementioned embodiments, the fibrosis-inducing agent can be incorporated or coated onto the device. For example, a desired fibrosis-inducing agent may be admixed with, blended with, conjugated to, or, otherwise modified to contain a polymeric composition (which may be either biodegradable or non-biodegradable) or non-polymeric composition. The polymeric or non-polymeric composition (i.e., carrier) can be used to coat the device or as a component of the materials used to manufacture the device. In other embodiments, the localized sustained delivery of the fibrosis inhibiting agent may be required. For example, a desired fibrosis-inducing agent may be admixed with, blended with, conjugated to, or, otherwise modified to contain a polymeric composition (which may be either biodegradable or non-biodegradable) or non-polymeric composition in order to release the fibrosis-inducing agent over a period of time. For the above embodiments, biodegradable and non-biodegradable polymers, polymer conjugates as well as non-polymeric materials can be used to accomplish the incorporation of the fibrosis-inducing agent onto or into the device.
Representative examples of biodegradable polymers suitable for the delivery of fibrosis-inducing agents include albumin, collagen, gelatin, hyaluronic acid, starch, cellulose and cellulose derivatives (e.g., methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose phthalate), casein, dextrans, polysaccharides, fibrinogen, poly(ether ester) multiblock copolymers, based on polyethylene glycol) and poly(butylene terephthalate), tyrosine-derived polycarbonates (e.g., U.S. Patent No. 6,120,491), poly(hydroxyl acids), poly(D,L-lactide), poly(D,L-lactide-co-glycolide), poly(glycolide), poly(hydroxybutyrate), polydioxanone, poly(alkylcarbonate) and poly(orthoesters), polyesters, poly(hydroxyvaleric acid), polydioxanone, polyethylene terephthalate), poly(malic acid), poly(tartronic acid), poly(acrylamides), polyanhydrides, polyester-amides), polyester-imides), polyester-areas), polyester-urethane-areas), poly(anhydride-esters), poly(anhydride-imides), polyphosphazenes, poly(amino acids), poly(alkylene oxide)-polyester) block copolymers (e.g., X-Y, X-Y-X or Y-X-Y, where X is a polyalkylene oxide and Y is a polyester (e.g., PLGA, PLA, PCL, polydioxanone and copolymers thereof), and copolymers as well as blends thereof. (see generally, Illum, L., Davids, S.S. (eds.) "Polymers in Controlled Drug Delivery"
Wright, Bristol, 1987; Arshady, J. Controlled Release 17:1-22, 1991; Pitt, Int. J.
Phar. 59:173-196, 1990; Holland et al., J. Controlled Release 4:155-0180, 1986).
Representative examples of non-degradable polymers suitable for the delivery of fibrosis-inducing agents include polyethylene-co-vinyl acetate) ("EVA") copolymers, silicone rubber, acrylic polymers (e.g., polyacrylic acid, polymethylacrylic acid, polymethylmethacrylate, poly(butyl methacrylate)), poly(alkylcyanoacrylate) (e.g., poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(hexylcyanoacrylate), and poly(octylcyanoacrylate)), polyethylene, polypropylene, polyamides (nylon 6,6), polyurethanes (including hydrophilic polyurethanes), polyester-urethanes), poly(ether-urethanes), polyester-urea), poly(carbonate urethanes, polyethers (poly(ethylene oxide), polypropylene oxide), polyoxyalkylene ether block copolymers based on ethylene oxide and propylene oxide such as PLURONICs and PLURONICs R and poly(tetramethylene glycol)), styrene-based polymers (polystyrene, polystyrene sulfonic acid), poly(styrene)-block-poly(isobutylene)-block-poly(styrene), poly(styrene)-poly(isoprene) block copolymers), and vinyl polymers (polyvinylpyrrolidone, polyvinyl alcohol), polyvinyl acetate phthalate) as well as copolymers and blends thereof. Polymers may also be developed which are either anionic (e.g., alginate, carrageenan, carboxymethyl cellulose, poly(acrylamido-2-methyl propane sulfonic acid) and copolymers thereof, poiy(methacrylic acid) and copolymers thereof, and poly(acrylic acid) and copolymers thereof, as well as blends thereof) or cationic (e.g., chitosan, poly-L-lysine, polyethylenimine, and poly(allyl amine) and blends thereof (see generally, Dunn et al., J. Applied Polymer Sci. 50:353-365, 1993; Cascone et al., J. Materials Sci.: Materials in Medicine 5:770-774, 1994; Shiraishi et al., Biol. Pharm. Bull. 76(11 ):1164-1168, 1993; Thacharodi and Rao, Inf'I J.
Pharm.
120:115-118, 1995; Miyazaki et al., Int'I J. Pharm. 7 78:257-263, 1995).

Particularly preferred polymeric carriers include polyethylene-co-vinyl acetate), cellulose esters (nitrocellulose), poly(hydroxymethacrylate), poly(methylmethacrylate), polyethylene-co-acrylic acid), poly(vinylpyrrolidone) polyurethanes (e.g., CHRONOFLEX AL and CHRONOFLEX AR (both from CardioTech International, Inc., Woburn, MA) and BIONATE (Polymer Technology Group, Inc., Emeryville, CA), poly (D,L-lactic acid) oligomers and polymers, poly (L-lactic acid) oligomers and polymers, poly (glycolic acid), copolymers of lactic acid and glycolic acid, poly (caprolactone), poly (valerolactone), polyanhydrides, poly(anhydride esters), polyester-amides), polyester-ureas), copolymers of poly (caprolactone) or poly (lactic acid) with a polyethylene glycol (e.g., MePEG), silicone rubbers, poly(styrene)block-poly(isobutylene)-block-poly(styrene), poly(acrylate) polymers, and blends, admixtures, or co-polymers of any of the above. Other preferred polymers include collagen, poly(alkylene oxide)-based polymers, polysaccharides such as hyaluronic acid, chitosan and fucans, and copolymers of polysaccharides with degradable polymers, as well as crosslinked compositions of the above.
Other representative polymers capable of sustained localized delivery 'of fibrosis-inducing agents include carboxylic polymers, polyacetates, polyacrylamides, polycarbonates, polyethers, substituted polyethylenes, polyvinylbutyrals, polysilanes, polyureas, polyoxides, polystyrenes, polysulfides, polysulfones, polysulfonides, polyvinylhalides, pyrrolidones, isoprene rubbers, thermal-setting polymers, cross-linkable acrylic and methacrylic polymers, ethylene acrylic acid copolymers, styrene acrylic copolymers, vinyl acetate polymers and copolymers, vinyl acetal polymers and copolymers, epoxies, melamines, other amino resins, phenolic polymers, and copolymers thereof, water-insoluble cellulose ester polymers (including cellulose acetate propionate, cellulose acetate, nitrocellulose, cellulose acetate butyrate, cellulose nitrate, cellulose acetate phthalate, and mixtures thereof), polyvinylpyrrolidone (pvp), polyethylene glycols, polyethylene oxides, polyvinyl alcohol, polyethers, polyhydroxyacrylate, dextran, xanthan, hydroxypropyl cellulose, methyl cellulose, and homopolymers and copolymers of N-vinylpyrrolidone, N-vinyllactam, N-vinyl butyrolactam, N-vinyl caprolactam, other vinyl compounds having polar pendant groups, acrylate and methacrylate having hydrophilic esterifying groups, hydroxyacrylate, and acrylic acid, and combinations thereof;
cellulose esters and ethers, ethyl cellulose, nitro-cellulose, hydroxyethyl cellulose, cellulose nitrate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, polyacrylate, natural and synthetic elastomers, acetal, styrene polybutadiene, acrylic resin, polyvinylidene chloride, polycarbonate, homopolymers and copolymers of vinyl compounds, polyvinylchloride, and polyvinylchloride acetate.
Representative examples of patents relating to drug-delivery polymers and their preparation include PCT Publication Nos. WO 98/19713, WO 01/17575, WO 01/41821, WO 01/41822, and WO 01/15526 (as well as their corresponding U.S. applications), and U.S. Patent Nos. 4,500,676, 4,582,865, 4,629,623, 4,636,524, 4,713,448, 4,795,741, 4,913,743, 5,069,899, 5,099,013, 5,128,326, 5,143,724, 5,153,174, 5,246,698, 5,266,563, 5,399,351, 5,525,348, 5,800,412, 5,837,226, 5,942,555, 5,997,517, 6,007,833, 6,071,447, 6,090,995, 6,106,473, 6,110,483, 6,121,027, 6,156,345, 6,214,901, 6,368,611 6,630,155, 6,528,080, RE37,950, 6,46,1631, 6,143,314, 5,990,194, 5,792,469, 5,780,044, 5,759,563, 5,744,153, 5,739,176, 5,733,950, 5,681,873, 5,599,552, 5,340,849, 5,278,202, 5,278,201, 6,589,549, 6,287,588, 6,201,072, 6,117,949, 6,004,573, 5,702,717, 6,413,539, and 5,714,159, 5,612,052 and U.S. Patent Application Publication Nos. 2003/0068377, 2002/0192286, 2002/0076441, and 2002/0090398.
It should be obvious to one of skill in the art that the polymers as described herein can also be blended or copolymerized in various compositions as required to deliver therapeutic doses of fibrosis-inducing agents to blood vessels in the treatment site.
Polymeric carriers for fibrosis-inducing agents can be fashioned in a variety of forms, with desired release characteristics and/or with specific properties depending upon the device, composition or implant being utilized.
For example, polymeric carriers may be fashioned to release a fibrosis-inducing agent upon exposure to a specific triggering event such as pH (see, e.g., Heller et al., "Chemically Self-Regulated Drug Delivery Systems," in Polymers in Medicine III, Elsevier Science Publishers B.V., Amsterdam, 1988, pp. 175-188;
Kang et al., J. Applied Polymer Sci. 48:343-354, 1993; Dong et al., J.
Controlled Release 79:777-778, 7992; Dong and Hoffman, J. Controlled Release 15:141-152, 1991; Kim et al., J. Controlled Release 28:143-152, 1994; Cornejo-Bravo et al., J. Controlled Release 33:223-229, 1995; Wu and Lee, Pharm. Res.
10(10):1544-1547, 1993; Serres et al., Pharm. Res. 73(2):196-201, 1996;
Peppas, "Fundamentals of pH- and Temperature-Sensitive Delivery Systems,"
in Gurny et al. (eds.), Pulsatile Drug Delivery, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1993, pp. 41-55; Doelker, "Cellulose Derivatives," 1993, in Peppas and Langer (eds.), Biopolymers I, Springer-Verlag, Berlin). Representative examples of pH-sensitive polymers include poly(acrylic acid) and its derivatives (including for example, homopolymers such as poly(aminocarboxylic acid); poly(acrylic acid); poly(methyl acrylic acid), copolymers of such homopolymers, and copolymers of poly(acrylic acid) and acrylmonomers such as those discussed above. Other pH sensitive polymers include polysaccharides such as cellulose acetate phthalate;
hydroxypropylmethylcellulose phthalate; hydroxypropylmethylcellulose acetate succinate; cellulose acetate trimellilate; and chitosan. Yet other pH
sensitive polymers include any mixture of a pH sensitive polymer and a water-soluble polymer.
Likewise, fibrosis-inducing agents can be delivered via polymeric carriers which are temperature sensitive (see, e.g., Chen et al., "Novel Hydrogels of a Temperature-Sensitive Pluronic Grafted to a Bioadhesive Polyacrylic Acid Backbone for Vaginal Drug Delivery," in Proceed. Intern.
Symp.
Control. Rel. Bioact. Mater. 22:167-168, Controlled Release Society, Inc., 1995;
Okano, "Molecular Design of Stimuli-Responsive Hydrogels for Temporal Controlled Drug Delivery," in Proceed. Intern. Symp. Control. Rel. Bioact.
Mater. 22:111-112, Controlled Release Society, Inc., 1995; Johnston et al., Pharm. Res. 9(3):425-433, 1992; Tung, Int'I J. Pharm. 707:85-90, 1994; Harsh and Gehrke, J. Controlled Release 77:175-186, 1991; Bae et al., Pharm. Res.
8(4):531-537, 1991; Dinarvand and D'Emanuele, J. Controlled Release 36:221-227, 1995; Yu and Grainger, "Novel Thermo-sensitive Amphiphilic Gels: Poly N-isopropylacrylamide-co-sodium acrylate-co-n-N-alkylacrylamide Network Synthesis and Physicochemical Characterization," Dept. of Chemical &
Biological Sci., Oregon Graduate Institute of Science & Technology, Beaverton, OR, pp. 820-821; Zhou and Smid, "Physical Hydrogels of Associative Star Polymers," Polymer Research Institute, Dept. of Chemistry, College of Environmental Science and Forestry, State Univ. of New York, Syracuse, NY, pp. 822-823; Hoffman et al., "Characterizing Pore Sizes and Water 'Structure' in Stimuli-Responsive Hydrogels," Center for Bioengineering, Univ. of Washington, Seattle, WA, p. 828; Yu and Grainger, "Thermo-sensitive Swelling Behavior in Crosslinked N-isopropylacrylamide Networks: Cationic, Anionic and Ampholytic Hydrogels," Dept. of Chemical & Biological Sci., Oregon Graduate Institute of Science & Technology, Beaverton, OR, pp. 829-830; Kim et al., Pharm. Res. 9(3):283-290, 1992; Bae et al., Pharm. Res. 8(5):624-628, 1991;
Kono et al., J. Controlled Release 30:69-75, 1994; Yoshida et al., J.
Controlled Release 32:97-102, 1994; Okano et ai., J. Controlled Release 36:125-133, 1995; Chun and Kim, J. Confrolled Release 38:39-47, 1996; D'Emanuele and Dinarvand, Int'I J. Pharm. 118:237-242, 1995; Katono et al., J. Controlled Release 16:215-228, 1991; Hoffman, "Thermally Reversible Hydrogels Containing Biologically Active Species," in Migliaresi et al. (eds.), Polymers in Medicine 11I, Elsevier Science Publishers B.V., Amsterdam, 1988, pp. 161-167;
Hoffman, "Applications of Thermally Reversible Polymers and Hydrogels in Therapeutics and Diagnostics," in Third International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, Feb. 24-27, 1987, pp.
297-305; Gutowska et al., J. Controlled Release 22:95-104, 1992; Pafasis and Gehrke, J. Controlled Release 18:1-12, 1992; Paavola et al., Pharm. Res.
12(12):1997-2002, 1995).
Representative examples of thermogelling polymers, and their gelatin temperature [LCST (°C)] include homopolymers such as poly(N-methyl-N-n-propylacrylamide), 19.8; poly(N-n-propylacrylamide), 21.5;
poly(N-methyl-N-isopropylacrylamide), 22.3; poly(N-n-propylmethacrylamide), 28.0; poly(N-isopropylacrylamide), 30.9; poly(N, n-diethylacrylamide), 32.0;
poly(N-isopropylmethacrylamide), 44.0; poly(N-cyclopropylacrylamide), 45.5;
poly(N-ethylmethyacrylamide), 50.0; poly(N-methyl-N-ethylacrylamide), 56.0;
poly(N-cyclopropylmethacryiamide), 59.0; and poly(N-ethylacrylamide), 72Ø
Moreover, thermogelling polymers may be made by preparing copolymers between (among) monomers of the above, or by combining such homopolymers with other water-soluble polymers such as acrylmonomers (e.g., acrylic acid and derivatives thereof, such as methylacrylic acid, acrylate and derivatives thereof, such as butyl methacrylate, acrylamide, and N-n-butyl acrylamide).
Other representative examples of thermogelling polymers include cellulose ether derivatives such as hydroxypropyl cellulose, 41 °C;
methyl cellulose, 55°C; hydroxypropylmethyl cellulose, 66°C; and ethylhydroxyethyl cellulose, polyalkylene oxide-polyester block copolymers of the structure X-Y, Y-X-Y and X-Y-X where X is a polyalkylene oxide and Y is a biodegradable polyester (e.g., PLG-PEG-PLG) and PLURONICS such as F-127, 10 - 15°C;
L-122, 19°C; L-92, 26°C; L-81, 20°C; and L-61, 24°C.

Representative examples of patents relating to thermally gelling polymers and their preparation include U.S. Patent Nos. 6,451,346; 6,201,072;
6,117,949; 6,004,573; 5,702,717; and 5,484,610 and PCT Publication Nos. WO
99/07343; WO 99/18142; WO 03/17972; WO 01182970; WO 00/18821; WO
97/15287; WO 01/41735; WO 00/00222 and WO 00/38651.
Fibrosis-inducing agents may be linked by~occlusion in the matrices of the polymer, bound by covalent linkages, or encapsulated in microcapsules. Within certain preferred embodiments of the invention, therapeutic compositions are provided in non-capsular formulations such as microspheres (ranging from nanometers to micrometers in size), pastes, and threads of various size, films and sprays.
Within certain aspects of the present invention, therapeutic compositions may be fashioned in any size ranging from 50 nm to 500 ~,m, depending upon the particular use. These compositions can be in the form of microspheres (porous or non-porous), microparticles, and/or nanoparticles.
These compositions can be formed, for example, by spray-drying methods, milling methods, coacervation methods, W/O (water-oil) emulsion methods, W/O/W emulsion methods, and solvent evaporation methods. In some embodiments, these compositions can include microemulsions, emulsions, liposomes and micelles. Alternatively, such compositions may also be readily applied as a "spray", which solidifies into a film or coating for use as a device/implant surFace coating or to line the tissues of the implantation site.
Such sprays may be prepared from microspheres of a wide array of sizes, including for example, from 0.1 ~m to 3 p,m, from.10 pm to 30 pm, and from 30 p,m to 100 p,m.
Therapeutic compositions of the present invention may also be prepared in a variety of paste or gel forms. For example, within one embodiment of the invention, therapeutic compositions are provided which are liquid at one temperature (e.g., temperature greater than 37°C, such as 40°C, 45°C, 50°C, 55°C or 60°C), and solid or semi-solid at another temperature (e.g., ambient body temperature, or any temperature lower than 37°C). Such "thermopastes" may be readily made utilizing a variety of techniques (see, e.g., PCT Publication WO 98/24427). Other pastes may be applied as a liquid, which solidify in vivo due to dissolution of a water-soluble component of the paste and precipitation of encapsulated drug into the aqueous body environment. These pastes and gels containing fibrosis-inducing agents are particularly useful for application to the surface of tissues which can be in contact with the implant or device.
In one aspect, the fibrosing agent or a composition comprising the fibrosing.agent may be combined with a film or mesh or may be in the form or a film or mesh.
Films or meshes may take a variety of forms including, but not limited to, surgical meshes, membranes (e.g., barrier membranes), surgical sheets, surgical patches, surgical wraps, bandages, liquid bandages, surgical dressings, gauze, fabrics, tapes, surgical membranes, polymer matrices, shells, envelopes, tissue coverings, and other types of surgical matrices, and scaffolds.
In one aspect, the device comprises or may be in the form of a film. The film may be formed into one of many geometric shapes. Depending on the application, the film may be formed into the shape of a tube or may be a thin, elastic sheet of polymer. Generally, films are less than 5, 4, 3, 2, or 1 mm thick, more preferably less than 0.75 mm, 0.5 mm, 0.25 mm, or, 0.10 mm thick.
Films can also be generated of thicknesses less than 50 ~ri-i, 25 ~m .or 10 Vim.
Films generally are flexible with a good tensile strength (e.g., greater than 50, preferably greater than 100, and more preferably greater than 150 or 200 N/cm~), good adhesive properties (i.e., adheres to moist or wet surfaces), and have controlled permeability. Polymeric films (which may be porous or non-porous) are particularly useful for application to the surface of a device or implant as well as to the surface of tissue, cavity or an organ.
Films may be made by several processes, including for example, by casting, and by spraying, or may be formed at the treatment site in situ.
For example, a sprayable formulation may be applied onto the treatment site which then forms into a solid film.
In another aspect, the device may comprise or be in the form of a mesh. A mesh, as used herein, is a material composed of a plurality of fibers or filaments (i.e., a fibrous material), where the fibers or filaments are arranged in such a manner (e.g., interwoven, knotted, braided, overlapping, looped, knitted, interlaced, intertwined, webbed, felted, and the like) so as to form a porous structure. Typically, a mesh is a pliable material, such that it has sufficient flexibility to be wrapped around a device. In certain aspects, the mesh may be sufficiently pliable so as to be capable of being wrapped around the external surface of a body passageway or cavity, or a portion thereof. The mesh may be capable of providing support to the structure (e.g., the vessel or cavity wall).
In certain aspects, the mesh may be adapted to release an amount of the therapeutic agent.
Mesh materials may take a variety of forms. For example, the mesh may be in a woven, knit, or non-woven form and may include fibers or filaments that a,re randomly oriented relative to each other or that are arranged in an ordered array or pattern. In one embodiment, for example, a mesh may be in the form of a fabric, such as, for example, a knitted, braided, crocheted, woven, non-woven (e.g., a melt-blown or wet-laid) or webbed fabric. In one embodiment, a mesh may include a natural or synthetic biodegradable polymer that may be formed into a knit mesh, a weave mesh, a sprayed mesh, a web mesh, a braided mesh, a looped mesh, and the like. Preferably, a mesh or wrap has intertwined threads that form a porous structure, which may be, for example, knitted, woven, or webbed.
The structure and properties of the mesh used in a device depend on the application and the desired mechanical (i.e., flexibility, tensile strength, and elasticity), degradation properties, and the desired loading and release characteristics for the selected therapeutic agent(s). The mesh should have mechanical properties, such that the device can remain sufficiently strong until the surrounding tissue has healed. Factors that affect the flexibility and mechanical strength of the mesh include, for example, the porosity, fabric thickness, fiber diameter, polymer composition (e.g., type of monomers and initiators), process conditions, and the additives that are used to prepare the material.
~ Typically, the mesh possesses sufficient porosity to permit the flow of fluids through the pores of the fiber network and to facilitate tissue ingrowth. Generally, the interstices of the mesh should be wide enough apart to allow light visible by eye, or fluids, to pass through the pores. However, materials having a more compact structure also may be used. The flow of fluid through the interstices of the mesh may depend on a variety of factors, including, for example, the stitch count or thread density. The porosity of the mesh may be further tailored by, for example, filling the interstices of the mesh with another material (e.g., particles or polymer) or by processing the mesh (e.g., by heating) in order to reduce the pore size and to create non-fibrous areas. Fluid flow through the mesh of the invention can vary depending on the properties of the fluid, such as viscosity, hydrophilicity/hydrophobicity, ionic concentration, temperature, elasticity, pseudoplasticity, particulate content, and the tike. The interstices of the mesh can be large enough so as to not prevent the release of impregnated or coated therapeutic agents) from the mesh, and the interstices preferably do not prevent the exchange of tissue fluid at the application site.
Mesh materials should be sufficiently flexible so as to be capable of conforming to,the shape of a device surface or an anatomotical surface. In certain cases, the mesh material may be sufficiently flexible so as to be capable of being wrapped around all or a portion of the external surface of a body passageway or cavity. Flexible mesh materials are typically in the form of flexible woven or knitted sheets having a thickness ranging from about 25 microns to about 3000 microns; preferably from about 50 to about 1000 microns. Mesh materials for use in the practice of the invention typically range from about 100 to 400 microns in thickness.
The diameter and length of the fibers or filaments may range in size depending on the form of the material (e.g., knit, woven, or non-woven), and the desired elasticity, porosity, surface area, flexibility, and tensile strength.
The fibers may be of any length, ranging from short filaments to long threads (i.e., several microns to hundreds of meters in length). Depending on the application, the fibers may have a monofilament or a multifilament construction.
The mesh may include fibers that are of same dimension or of different dimensions, and the fibers may be formed from the same or different types of biodegradable polymers. Woven materials, for example, may include a regular or irregular array of warp and weft strands and may include one type of polymer in the weft direction and another type (having the same or a different degradation profile from the first polymer) in the warp direction. The degradation profile of the weft polymer may be different than or the same as the degradation profile of the warp polymer. Similarly, knit materials may include one or more types (e.g., monofilament, multi-filament) and sizes of fibers and may include fibers made from the same or from different types of biodegradable polymers.

The structure of the mesh (e.g., fiber density and porosity) may impact the amount of therapeutic agent that may be loaded into or onto the device. For example, a fabric having a loose weave characterized by a low fiber density and high porosity can have a lower thread count, resulting in a reduced total fiber volume and surface area. As a result, the amount of agent that may be loaded into or onto, with a fixed carrier: therapeutic agent ratio, the fibers can be lower than for a fabric having a high fiber density and lower porosity. It is generally preferable that the mesh also should not invoke . biologically detrimental inflammatory or toxic response, should be capable of being fully metabolized in the body, have an acceptable shelf life (of about at least one year or more), and be easily sterilized.
The device may include multiple mesh materials in any combination or arrangement. For example, a portion of the device may be a knitted material and another portion may be a woven material. In another embodiment, the device may more than one layer (e.g., a layer of woven material fused to a layer of knitted material or to another layer of the same type or a different type of woven material). In some embodiments, multi-layer constructions (e.g., device having two or more layers of material) may be used, for example, to enhance the performance properties of the device (e.g. for enhancing the rigidity or for altering the porosity, elasticity, or tensile strength of the device) or for increasing the amount of drug loading.
The mesh or film may be formed of or include a polymer. The polymer may be a biodegradable or a non-biodegradable polymer, or a combination thereof.
Biodegradable compositions that may be used to prepare the mesh of film include polymers that comprise albumin, collagen, hyaluronic acid and derivatives, sodium alginate and derivatives, chitosan and derivatives gelatin, starch, cellulose polymers (for example methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose phthalate), casein, dextran and derivatives, polysaccharides, poly(caprolactone), fibrinogen, poly(hydroxyl acids), poly(L-lactide) poly(D,L lactide), poly(D,L-lactide-co-glycolide), poly(L-lactide-co-glycolide), copolymers of lactic acid and glycolic acid, copolymers of s-caprolactone and lactide, copolymers of glycolide and s-caprolactone, copolymers of lactide and 1,4-dioxane-2-one, polymers and copolymers that include one or more of the residue units of the monomers D-lactide, L-lactide, D,L-lactide, glycolide, s-caprolactone, trimethylene carbonate, 1,4-dioxane-2-one or 1,5-dioxepan-2-one, poly(glycolide), poly(hydroxybutyrate), poly(alkylcarbonate) and poly(orthoesters), polyesters, poly(hydroxyvaleric acid), polydioxanone, poly(ethylerie terephthalate), poly(malic acid), 0l tartronic acid , pol anh drides, pol hos hazenes, pol amino acids .
p Y( ) Y Y Yp p Y( ) These compositions include copolymers of the above polymers as well as blends and combinations of the above polymers. (see, generally, Illum, L., Davids, S.S. (eds.) "Polymers in Controlled Drug Delivery" Wright, Bristol, 1987;
Arshady, J. Controlled Release 7 7:1-22, 1991; Pitt, Int. J. Phar. 59:173-196, 1990; Holland et al., J. Controlled Release 4:155-0180, 1986).
In one aspect, the mesh or film includes a biodegradable or resorbable polymer that is formed from one or more monomers selected from the group consisting of lactide, glycolide, e-caprolactone, trimethylene carbonate, 1,4-dioxan-2-one, 1,5-dioxepan-2-one, 1,4-dioxepan-2-one, hydroxyvalerate, and hydroxybutyrate. In one aspect, the polymer may include, for example, a copolymer of a lactide and a glycolide. In another aspect, the polymer includes a poly(caprolactone). In yet another aspect, the polymer includes a poly(lactic acid), poly(L-lactide)/poly(D,L-Lactide) blends or copolymers of L-lactide and D,L-lactide. In yet another aspect, the polymer includes a copolymer of lactide and e-caprolactone. In yet another aspect, the polymer includes a polyester (e.g., a poly(lactide-co-glycolide). The poly(lactide-co-glycolide) may have a lactide:glycolide ratio ranges from about 20:80 to about 2:98, a lactide:glycolide ratio of about 10:90, or a lactide:glycolide ratio of about 5:95. In one aspect, the poly(lactide-co-glycolide) is poly(L-lactide-co-glycolide). Other examples of biodegradable materials include polyglactin, polyglycolic acid, autogenous, heterogenous, and xenogeneic tissue (e.g., pericardium or small intestine submucosa), and oxidized, regenerated cellulose. These meshes can be knitted, woven or non-woven meshes. Other examples of non-woven meshes include electrospun materials.
Representative examples of non-biodegradable compositions for use in forming films and meshes include ethylene-co-vinyl acetate copolymers, acrylic-based and methacrylic-based polymers (e.g., poly(acrylic acid), poly(methylacrylic acid), poly(methylmethacrylate), poly(hydroxyethylmethacrylate), poly(alkylcynoacrylate), poly(alkyl acrylates), poly(alkyl methacrylates)), polyolefins such as polyethylene) or poly(propylene), polyamides (e.g., nylon 6;6), poly(urethanes) (e.g.
poly(ester urethanes), poly(ether urethanes), poly(carbonate urethanes), poly(ester-urea)),polyesters (e.g., PET, polybutyleneterephthalate, and polyhexyleneterephthalate), polyethers (poly(ethylene oxide), polypropylene oxide), polyethylene oxide)-polypropylene oxide) copolymers, diblock and triblock copolymers, poly(tetramethylene glycol)), silicone containing polymers and vinyl-based polymers (polyvinylpyrrolidone, polyvinyl alcohol), polyvinyl acetate phthalate), poly(styrene-co-isobutylene-co-styrene), fluorine containing polymers (fluoropolymers) such as fluorinated ethylene propylene (FEP) or polytetrafluoroethylene (e.g., expanded PTFE}.
A variety of film mesh materials have been described which may be combined with a scarring agent. For example, the film or mesh may be a biodegradable polymeric matrix that conforms to the tissue and releases the agent in a controlled release manner. See e.g., U.S. Patent No. 6,461,640.
The film or mesh may be a self-adhering silicone sheet which is impregnated with an antioxidant and/or antimicrobial. See e.g., U.S. Patent No. 6,572,878.
The film or mesh may be a pliable shield with attachment ports and fenestrations that is adapted to cover a bony dissection in the spine. See e.g., U.S. Patent No. 5,868,745 and U.S. Patent Application No. 2003/0078588.
The film or mesh may be a resorbable micro-membrane having a single layer of non-porous polymer base material of poly-lactide. See e.g., U.S. Patent No.
6,531,146 and U.S. Application No. 2004/0137033. The film or mesh may be a wound dressing garment composed of an outer pliable layer and a self-adhesive inner gel lining which serves as a dressing for contacting wounds.
See e.g., U.S. Patent No. 6,548,728. The film or mesh may be a bandage with a scar treatment pad with a layer of silicone elastomer or silicone gel. See e.g., U.S. Patent Nos. 6,284,941 and 5,891,076. The film or mesh may be a crosslinkable system with at least three reactive compounds each having a polymeric molecular core with at least one functional group. See e.g., U.S.
Patent No. 6,458,889. The film or mesh may be composed of a prosthetic fabric having a 3-dimensional structure separating two surfaces in which one is open to post-surgical cell colonization and one is linked to a film of collagenous material. See e.g., U.S. Patent No. 6,451,032. The film or mesh may be composed by crosslinking two synthetic polymers, one having nucleophilic groups and the other having electrophilic groups, such that they form a matrix that may be used to incorporate a biologically active compound. See e.g., U.S.
Patent Nos. 6,323,278; 6,166,130; 6,051,648 and 5,874,500. The film or mesh may be a conformable warp-knit fabric of oxidized regenerated cellulose or other bioresorbable material which acts like a physical barrier to prevent postoperative adhesions. See e.g., U.S. Patent No. 5,007,916. Meshes for use in the practice of the invention also are described in U.S. Patent Nos.
6,575,887, and co-pending application, entitled "Perivascular Wraps," filed September 26, 2003 (U.S. Ser. No. (U.S. Ser. No. 10/673,046), which is hereby incorporated by reference in its entirety.
In one aspect, the fibrosing agent can be incorporated into a biodegradable or dissolvable film or mesh that is then applied to the treatment site prior or post implantation of the prosthesis/implant. Exemplary materials for the manufacture of these films or meshes are hyaluronic acid (crosslinked or non-crosslinked), cellulose derivatives (e.g., hydroxypropyl cellulose), PLGA, collagen and crosslinked polyethylene glycol).
Films and meshes, which may be combined with one or more scarring agents according to the present invention, include commercially available products. Examples of films and meshes into which a fibrosis-inducing agent can be incorporated include INTERCEED (Johnson & Johnson, Inc.), PRECLUDE (W.L. Gore), and POLYACTIVE (poly(ether ester) multiblock copolymers (Osteotech, Inc., Shrewsbury, NJ), based on polyethylene glycol) and poly(butylene terephthalate), and SURGICAL absorbable hemostat gauze-like sheet from Johnson & Johnson. Another mesh is a prosthetic polypropylene mesh with a bioresorbable coating called SEPRAMESH
Biosurgical Composite (Genzyme Corporation, Cambridge, MA). One side of the mesh is coated with a bioresorbable layer of sodium hyaluronate and carboxymethylcellulose, providing a temporary physical barrier that separates the underlying tissue and organ surfaces from the mesh. The other side of the mesh is uncoated, allowing for complete tissue ingrowth similar to bare polypropylene mesh. In one embodiment, the fibrosis-inducing agent may be applied only to the uncoated side of SEPRAMESH and not to the sodium hyaluronate/ carboxymethylcellulose coated side. Other films and meshes include: (a) BARD MARLEX mesh (C.R. Bard, Inc.), which is a very dense knitted fabric structure with low porosity; (b) monofilament polypropylene mesh such as PROLENE available from Ethicon, Inc. Somerville, NJ (see, e.g., U.S.
_ Patent Nos. 5,634,931 and 5,824,082)); (c) SURGISIS GOLD and SURGISIS
IHM soft tissue graft (both from Cook Surgical, Inc.) which are devices specifically configured for use to reinforce soft tissue in repair of inguinal hernias in open and laparoscopic procedures; (d) thin walled polypropylene surgical meshes such as are available from Atrium Medical Corporation (Hudson, NH) under the trade names PROLITE, PROLITE ULTRA, a ~ d LITEMESH; (e) COMPOSIX hernia mesh (C.R. Bard, Murray Hill, NJ), which incorporates a mesh patch (the patch includes two layers of an inert synthetic mesh, generally made of polypropylene, and is described in U.S. Patent No.
6,280,453)~that includes a filament to stiffen and maintain the device in a flat configuration; (f) VISILEX mesh (from C.R. Bard, Inc.), which is a polypropylene mesh that is constructed with monofilament polypropylene; (g) other meshes available from C.R. Bard, Inc. which include PERFIX Plug, KUGEL Hernia Patch, 3D MAX mesh, LHI mesh, DULEX mesh, and the VENTRALEX Hernia Patch; and (h) other types of polypropylene monofilament hernia mesh and plug products include HERTRA mesh 1, 2, and 2A, HERMESH 3, 4 & 5 and HERNIAMESH plugs T1, T2, and T3 from Herniamesh USA, Inc. (Great Neck, NY).
Other examples of commercially available meshes which may be combined with fibrosing agents include the following. Boston Scientific Corporation sells the TRELEX NATURAL Mesh which is composed of a knitted polypropylene material. Ethicon, Inc. makes the absorbable VICRYL

(polyglactin 910) meshes (knitted and woven) and MERSILENE Polyester Fiber Mesh. Dow Corning Corporation (Midland,. MI) sells a mesh material formed from silicone elastomer known as SILASTIC Rx Medical Grade Sheeting (Platinum Cured). United States Surgical / Syneture (Norwalk, CT) sells a mesh made from absorbable polyglycolic acid under the trade name DEXON
Mesh Products. Membrane Accurel Systems (Germany) sells the CELGARD
microporous polypropylene fiber and membrane. Gynecare Worldwide, a division of Ethicon, Inc. sells a mesh material made from oxidized, regenerated cellulose known as INTERCEED TC7.
Numerous types of meshes and films and polymers for use with meshes and films have been described above. Methods for incorporating the fibrosing compositions onto or into the film or mesh include: (a) affixing (directly or indirectly) to the film or mesh a fibrosing composition (e.g., by either a spraying process or dipping process as described above , with or without a carrier), (b) incorporating or impregnating into the film or mesh a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier (c) by coating the film or mesh with a substance such as a hydrogel which can in turn absorb the fibrosing composition, (d) constructing the film or mesh itself or a portion of the film or mesh with a fibrosing composition, or (e) by covalently binding the fibrosing agent directly to the film or mesh surface or to a linker (small molecule or polymer) that is coated or attached to the film or mesh surFace. For; devices that are coated, the coating process can be performed in such a manner as to (a) coat only one surface of the film or mesh or (b) coat all or parts of both sides of the film or mesh.
The therapeutic agents) may be an integral part of the film or mesh (i.e., may reside within the fibers of the mesh). The fibrosis inhibiting agent can be incorporated directly into the film or mesh or it can be incorporated into a secondary carrier (polymeric or non-polymeric), as ' described above, that is then incorporated into the film or mesh.
Alternatively, or in addition, the film or mesh may be coated with a fibrosing agent or a composition that includes the fibrosing agent. The coating may take the form of a surface-adherent coating, mask, film, gel, foam, or mold.
A variety of polymeric compositions have been described that may be used in conjunction with the films and meshes of the invention. Such compositions may be in the form of, for example, gels, sprays, liquids, and pastes, or may be polymerized from monomeric or prepolymeric constituents in situ. For example, the composition may be a polymeric tissue coating which is formed by applying a polymerization initiator to the tissue and then covering it with a water-soluble macromer that is polymerizable using free radical initiators under the influence of UV light. See e.g., U.S. Patent Nos. 6,177,095 and 6,083,524. The composition may be an aqueous composition including a surfactant, pentoxifylline and a polyoxyalkylene polyether. See e.g., U.S.
Patent No. 6,399,624. The composition may be a hydrogel-forming, self-solvating, absorbable polyester copolymers capable of selective, segmental association into compliant hydrogels mass upon contact with an aqueous environment. See e.g., U.S. Patent No. 5,612,052. The composition may be composed of fluent pre-polymeric material that is emitted to the tissue surface and then exposed to activating energy in situ to initiate conversion of the applied material to non-fluent polymeric form. See e.g., U.S. Patent Nos.
6,004,547 and 5,612,050. The composition may be composed of a gas mixture of oxygen present in a volume ratio of 1 to 20%. See e.g., U.S. Patent No.
6,428,500. The composition may be composed of an anionic polymer having an acid sulfate and sulfur content greater than 5% which acts to inhibit monocyte or macrophage invasion. See e.g., U.S. Patent No. 6,417,173. The composition may be composed of a non-gelling polyoxyalkylene composition with or without a therapeutic agent. See e.g., U.S. Patent No. 6,436,425. The composition may be coated onto tissue surfaces and may be composed of an aqueous solution of a hydrophilic, polymeric material (e.g., polypeptides or polysaccharide) having greater than 50,000 molecular weight and a concentration range of 0.01 % to 15% by weight. See e.g., U.S. Patent No.
6,464,970.
Other representative examples of polymeric compositions which may be coated onto the film or mesh include polyethylene glycol)-based systems, hyaluronic acid and crosslinked hyaluronic acid compositions. These compositions can be applied as the final composition or they can be applied as materials that form crosslinked gel in sifu.
Other compositions that can be combined with scarring agents in conjunction with films and meshes, include, but are not limited to: (a) sprayable PEG-containing formulations such as COSEAL, SPRAYGEL, FOCALSEAL or DURASEAL; (b) hyaluronic acid-containing formulations such as RESTYLANE, HYLAFORM, PERLANE, SYNVISC, SEPRAFILM, SEPRACOAT, INTERGEL, (c) polymeric gels such as REPEL or FLOWGEL, (d) dextran sulfate gels such as the ADCON range of products, and (e) lipid based compositions such as ADSURF (Brittania Pharmaceuticals).
Prior to implantation, the film or mesh may be trimmed or cut from a sheet of bulk material to match the configuration of the widened foramen, canal, or dissection region, or at a minimum, to overlay the exposed tissue area. The film or mesh may be bent or shaped to match the particular configuration of the placement region. The film or mesh may also be rolled in a cuff shape or cylindrical shape and placed around the exterior periphery of the desired tissue. The film or mesh may be provided in a relatively large bulk sheet and then cut into shapes to mold the particular structure and surface topography of the tissue or device to be wrapped. Alternatively, the film or mesh may be pre-shaped into one or more patterns for subsequent use. The films and meshes may be typically rectangular in shape and be placed at the desired location within the surgical site by direct surgical placement or by endoscopic techniques. The film or mesh may be secured into' place by wrapping it onto itself (i.e., self-adhesive), or by securing it with sutures, staples, sealant, and the like. Alternatively, the film or mesh may adhere readily to tissue and therefore, additional securing mechanisms may not be required.Within further aspects of the present invention, polymeric carriers are provided which are adapted to contain and release a hydrophobic fibrosis-inducing compound, and/or the carrier containing the hydrophobic compound, in combination with a carbohydrate, protein or polypeptide. Within certain embodiments, the polymeric carrier contains or comprises regions, pockets, or granules of one or more hydrophobic compounds. For example, within one embodiment of the invention, hydrophobic compounds may be incorporated within a matrix which contains the hydrophobic fibrosis-inducing compound, followed by incorporation of the matrix within the polymeric carrier. A
variety of matrices can be utilized in this regard, including for example, carbohydrates and polysaccharides such as starch, cellulose, dextran, methylcellulose, sodium alginate, heparin, chitosan and hyaluronic acid and proteins or polypeptides such as albumin, collagen and gelatin. Within alternative embodiments, hydrophobic compounds may be contained within a hydrophobic core, and this core contained within a hydrophilic shell.
, Within another aspect of the present invention, polymeric carriers can be materials that are formed in situ. In one embodiment, the precursors can be monomers or macromers that contain unsaturated groups which can be polymerized or crosslinked. The monomers or macromers can then, for example, be injected into the treatment area or onto the surface of the treatment area and polymerized or crosslinked in situ using a radiation source (e.g., visible or UV light) or a free radical system (e.g., potassium persulfate and ascorbic acid or iron and hydrogen peroxide). The polymerization or crosslinking step can be performed immediately prior to, simultaneously to, or post injection of the reagents into the treatment site. Representative examples of compositions that undergo free radical polymerization or crosslinking reactions are described in WO 01/44307, WO 01/68720, WO 02/072166, WO
03/043552, WO 93/17669, and WO 00/64977, U.S. Patent Nos. 5,900,245;
6,051,248; 6,083,524; 6,177,095; 6,201,065; 6,217,894; 6,639,014;'6,352,710;
6,410,645; 6,531,147; 5,567,435; 5,986,043; and 6,602,975, and U.S. Patent Application Publication Nos. 2002/012796, 2002/0127266, 2002/0151650, 2003/0104032, 2002/0091229, and 2003/0059906.
In another embodiment, the reagents can undergo an electrophilic-nucleophilic reaction to produce a crosslinked matrix. Polymers terminated with nucleophilic groups such as amine, sulfhydryl, hydroxyl, -PH2 or CO-NH-NH2 can be used as the nucleophilic reagents and polymers terminated with electrophilic groups such as succinimidyl, carboxylic acid, aldehyde, epoxide, isocyanate, vinyl, vinyl sulfone, maleimide, -S-S-(C5H4N) or activated esters, such as are used in peptide synthesis can be used as the electrophilic reagents. For example, a 4-armed thiol derivatized polyethylene glycol) (e.g., pentaerythritol polyethylene glycol)ether tetra-sulfhydryl) can be reacted with a 4 armed NHS-derivatized polyethylene glycol (e.g., pentaerythritol polyethylene glycol)ether tetra-succinimidyl glutarate) under basic conditions (pH > about 8). Representative examples of compositions that undergo such electrophilic-nucleophilic crosslinking reactions are described, for example, in U.S. Patent. Nos. 5,752,974; 5,807,581; 5,874,500; 5,936,035; 6,051,648;
6,165,489; 6,312,725; 6,458,889; 6,495,127; 6,534,591; 6,624,245; 6,566,406;
6,610,033; 6,632,457; U.S. Patent Application Publication No.
2003/0077272A1; and co-pending patent applications entitled "Tissue Reactive Compounds and Compositions and Uses Thereof' (U.S. Serial No. 60/437,384, filed December 30, 2002, and U.S. Serial No. 60/44,924, filed January 17, 2003) and "Drug Delivery from Rapid Gelling Polymer Composition" (U.S. Serial No. 60/437,471, filed December 30, 2002, and U.S. Serial No. 60/440,875, filed January 17, 2003).
In another embodiment, the electrophilic- or nucleophilic-terminated polymers can further comprise a polymer that can enhance the mechanical and/or adhesive properties of the in situ forming compositions.
This polymer can be a degradable or non-degradable polymer. For example, the polymer may be collagen or a collagen derivative, for example methylated collagen. An example of an in situ forming composition uses pentaerythritol polyethylene glycol)ether tetra-sulfhydryl] (4-armed thiol PEG), pentaerythritol polyethylene glycol)ether tetra-succinimidyl glutarate] (4-armed NHS PEG) and methylated collagen as the reactive reagents. This composition, when mixed with the appropriate buffers can produce a crosslinked hydrogel. (See, e.g., U.S. Patent Nos. 5,874,500; 6,051,648; 6,166,130; 5,565,519 and 6,312,725).
In another embodiment, the in situ forming material polymer can be a polyester. Polyesters that can be used in in situ forming compositions include poly(hydroxyesters). In,another embodiment, the polyester can comprise the residues of one or more of the monomers selected from lactide, lactic acid, glycolide, glycolic acid, e-caprolactone, gamma-caprolactone, hydroxyvaleric acid, hydroxybutyric acid, beta-butyrolactone, gamma-butyrolactone; gamma-valerolactone, y-decanoiactone, ~-decanolactone, trimethylene carbonate, 1,4-dioxane-2-one or 1,5-dioxepan-2-one.
Representative examples of these types of compositions are described in U.S.
Patent. Nos. 5,874,500; 5,936,035; 6,312,725; 6,495,127 and PCT Publication Nos. W O 2004/028547.
In another embodiment, the electrophilic-terminated polymer can be partially or completely replaced by a small molecule or oligomer that comprises an electrophilic group (e.g., disuccinimidyl glutarate).
In another embodiment, the nucleophilic-terminated polymer can be partially or completely replaced by a small molecule or oligomer that comprises a nucleophilic group (e.g., dicysteine, dilysine, trilysine, etc.).
Other examples of in situ forming materials that can be used include those based on the crosslinking of proteins {described in, for example, U.S. Patent Nos. RE38158; 4,839,345; 5,514,379, 5,583,114; 6,310,036;
6,458,147; 6,371,975; US Patent Application Publication Nos.
2004/0063613A1, 2002/0161399A1, and 2001/0018598A1, and PCT
Publication Nos. WO 03/090683] WO 01/45761, WO 99/66964, and WO
96/03159) and those based on isocyanate or isothiocyanate capped polymers (see, e.g., PCT Publication No. WO 04/021983).
Other examples of in situ forming materials can include reagents that comprise one or more cyanoacrylate groups. These reagents can be used to prepare a pofy(alkylcyanoacrylate) or poiy(carboxyalkylcyanoacrylate) (e.g., poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(hexylcyanoacrylate), poly(methoxypropylcyanoacrylate), and poly(octylcyanoacrylate)).
Examples of commercially available cyanoacrylates that can be used include DERMABOND, INDERMIL, GLUSTITCH, VETBOND, HISTOACRYL, TISSUEMEND, TISSUMEND II, HISTOACRYL BLUE and ORABASE SOOTHE-N-SEAL LIQUID PROTECTANT.
In another embodiment, the cyanoacrylate compositions can further comprise additives to stabilize the reagents or alter the rate of reaction of the cyanoacrylate. For example, a trimethylene carbonate based polymer or an oxalate polymer of polyethylene glycol) or a s-caprolactone based copolymer can be mixed with a 2-alkoxyalkylcyanoacrylate (e.g., 2-methoxypropylcyanoacrylate). Representative examples of these compositions are described in U.S. Patent Nos. 5,350,798 and 6,299,631.
In another embodiment, the cyanoacrylate composition can be prepared by capping heterochain polymers with a cyanoacrylate group. The cyanoacrylate-capped heterochain polymer preferably has at least two cyanoacrylate ester groups per chain. The heterochain polymer can comprise an absorbable poly(ester), polyester-carbonate), poly(ether-carbonate) and poly(ether-ester). The poly(ether-esters described in U.S. Patent Nos.
5,653,992 and 5,714,159 can also be used as the heterochain polymers. A
triaxial poly(g-caprolactone-co-trimethylene carbonate) is an example of a polyester-carbonate) that can be used. The heterochain polymer may be a polyether. Examples of polyethers that can be used include polyethylene glycol), polypropylene glycol) and block copolymers of polyethylene glycol) and pofy(propylene glycol) (e.g., PLURONICS group of polymers including but not limited to PLURONIC F127 or F68). Representative examples of these compositions are described in U.S. Patent No. 6,699,940.
As described above, the fibrosing agent can be coated onto the entire device or a portion of the device using the polymeric coatings described above. This can be accomplished, for example, by dipping, spraying, electrospinning, painting or by vacuum deposition. In addition to the coating compositions and methods described above, there are various other coating compositions and methods that are known in the art. Representative examples of these coating compositions and methods are described in U.S. Patent. Nos.
6,610,016; 6,358,557; 6,306,176; 6,110,483; 6,106,473; 5,997,517; 5,800,412;
5,525,348; 5,331,027; 5,001,009; 6,562,136; 6,406,754; 6,344,035; 6,254,921;
6,214,901; 6,077,698; 6,603,040; 6,278,018; 6,238,799; 6,096,726; 5,766,158;
5,599,576; 4,119,094; 4,100,309; 6,599,558; 6,369,168; 6,521,283; 6,497,916;
6251964; 6,225,431; 6,087,462; 6,083,257; 5,739,237; 5,739,236; 5,705,583;
5648442; 5645883; 5,556,710; 5,496,581; 4,689,386; 6,214,115; 6,090,901;
6,599,448; 6,054,504; 4,987,182; 4,847,324; and 4,642,267, U.S. Patent Application Publication Nos. 2003/0129130; 2001/0026834; 2003/0190420;
2001 /0000785; 2003/0059631; 2003/0190405; 2002/014658'1; 2003/020399;
2003/0129130, 2001/0026834; 2003/0190420; 2001/0000785; 2003/0059631;
2003/0190405; 200210146581; and 2003/020399, and PCT Publication Nos.
WO 02/055121; WO 01/57048; WO 01/52915; and WO 01/01957.
Within another aspect of the invention, the biologically active agent can be delivered with a non-polymeric agent. Examples of non-polymeric agents include sucrose derivatives (e.g., sucrose acetate isobutyrate, sucrose oleate), sterols such as cholesterol, stigmasterol, beta-sitosterol, and estradiol;
cholesteryl esters such as cholesteryl stearate; C~2 -C24 fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, and lignoceric acid; C~$ -C36 mono-, di- and triacylglycerides such as glyceryl monooleate, glyceryl monolinoleate, glyceryl monolaurate, glyceryl monodocosanoate, glyceryl monomyristate, glyceryl monodicenoate, glyceryl dipalmitate, glyceryl didocosanoate, glyceryl dimyristate, glyceryl didecenoate, glyceryl tridocosanoate, glyceryl trimyristate, glyceryl tridecenoate, glycerol tristearate and mixtures thereof; sucrose fatty acid esters such as sucrose distearate and sucrose palmitate; sorbitan fatty acid esters such as sorbitan monostearate, sorbitan monopalmitate and sorbitan tristearate; C~6 -C~$ fatty alcohols such as cetyl alcohol, myristyl alcohol, stearyl alcohol, and cetostearyl alcohol; esters of fatty alcohols and fatty acids such as cetyl palmitate and cetearyl palmitate; anhydrides of fatty acids such as stearic anhydride;
phospholipids including phosphatidylcholine (lecithin), phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, and lysoderivatives thereof;
sphingosine and derivatives thereof; spingomyelins such as stearyl, palmitoyl, and tricosanyl spingomyelins; ceramides such as stearyl and palmitoyl ceramides; glycosphingolipids; lanolin and lanolin alcohols, calcium phosphate, sintered and unscintered hydoxyapatite, zeolites; and combinations and mixtures thereof.
Representative examples of patents relating to non-polymeric delivery systems and their preparation include U.S. Patent Nos. 5,736,152;
5,888,533; 6,120,789; 5,968,542; and 5,747,058.
Other carriers that may likewise be utilized to contain and deliver fibrosis-inducing agents described herein include: hydroxypropyl cyclodextrin (Cserhati and Hollo, Int. J. Pharm. 108:69-75, 1994), liposomes (see, e.g., Sharma et al., Cancer Res. 53:5877-5881, 1993; Sharma and Straubinger, Pharm. Res. 11(60):889-896, 1994; WO 93/18751; U.S. Patent No. 5,242,073), liposome/gel (WO 94/26254), nanocapsules (Bartoli et al., J.
Microencapsulation 7(2):191-197, 1990), micelles (Alkan-Onyuksel et al., Pharm. Res. 11(2):206-212, 1994), nanoparticles (Violante and Lanzafame PAACR), nanoparticles - modified (U.S. Patent No. 5,145,684), nanoparticles (surface modified) (U.S. Patent No. 5,399,363), micelle (surfactant) (U.S.
Patent No. 5,403,858), synthetic phospholipid compounds (U.S. Patent No.
4,534,899), gas borne dispersion (U.S. Patent No. 5,301,664), liquid emulsions, foam, spray, gel, lotion, cream, ointment, dispersed vesicles, particles or droplets solid- or liquid- aerosols, microemulsions (U.S. Patent No.
5,330,756), polymeric shell (nano- and micro- capsule) (U.S. Patent No. 5,439,686), emulsions (Tarr et al., Pharm Res. 4: 62-165, 1987), nanospheres (Hagan et al., Proc. Intern. Symp. Control Rel. 8ioact. Mater. 22, 1995; Kwon et al., Pharm Res. 12(2):192-195; Kwon et al., Pharm Res. 10(7):970-974; Yokoyama et al., J. Contr. Rel. 32:269-277, 1994; Gref et al., Science 263:1600-1603, 1994; Bazile et al., J. Pharm. Sci. 84:493-498, 1994) and implants (U.S.
Patent No. 4,882,168, Jampel et al., Invest. Ophthalm. Vis. Science 34(11 ):3076-3083, 1993; Walter et al., Cancer Res. 54:22017-2212, 1994).
In another embodiment, the fibrosis inducing agent can be incorporated into a composition that enhances osteointegration and/or osteogenesis. Examples of these compositions include materials composed of beta -tricalcium phosphate (e.g., VITOSS, PROOSTEON 500R), hydroxyapatite or Ca~o(P04)60H (e.g., OSTEOGRAF, calcium carbonate or CaC03, calcium sulfate (e.g., OSTEOSET and ALLOMATRIX), calcium phosphate (e.g., CALCIBON or NORIAN SRS) as well as synthetic bone fillers (e.g., CORTOSS) and processed bone fillers (e.g., BIOOSS ). Representative examples of these materials are described in U.S. Patent Nos. 3,929,971, 4,861,733; 6,527,810;
4,772,468; 4,882,149; 5,167,961; 6,576,015; 4,839,215; 5,614,206; 5,807,567;
6,030,636; 6,652,887; 6,206,957; 6,485,754; 4,347,234; 4,291,013; 5,129,905;
5,336,264; 5,569,442; 5,571,493; 5,683,667; 5,709,742; 5,820,632; 5,658,332;
5,681,872; 5,914,356; 5,939,039; 6,325,987; 6,383,519; 6,458,162; 6,736,799;
6,521,246; and 6,709,744.
Within another aspect of the invention, the fibrosis-inducing agent can further comprise a secondary carrier. The secondary carrier can be in the form of microspheres (e.g., PLGA, PLLA, PDLLA, PCL, gelatin, pofydioxanone, poly(alkylcyanoacrylate)), nanospheres (e.g., PLGA, PLLA, PDLLA, PCL, gelatin, polydioxanone, poly(alkylcyanoacrylate)), liposomes, emulsions, microemulsions, micelles (e.g.,SDS, block copolymers of the form X-Y, X-Y-X
or Y-X-Y, where X is a poly(alkylene oxide) or an alkyl ether thereof and Y is a polyester (e.g., PLGA, PLLA, PDLLA, PCL, polydioxanone)), zeolites or cyclodextrins.
Within another aspect'of the invention, these fibrosis-inducing agent/secondary carrier compositions can be a) incorporated directly into or onto the device, b) incorporated into a solution, c) incorporated into a gel or viscous solution, d) incorporated into the composition used for coating the device, or e) incorporated into or onto the device following coating of the device with a coating composition.
For example, fibrosis-inducing agent loaded PLGA microspheres may be incorporated into a polyurethane coating solution which is then coated onto the device.
In yet another example, the device can be coated with a polyurethane and then allowed to partially dry such that the surface is still tacky.
A particulate form of the fibrosis-inducing agent or fibrosis-inducing agent/secondary carrier can then be applied to all or a portion of the tacky coating after which the device is dried.

In yet another example, the device can be coated with one of the coatings described above. A thermal treatment process can then,be used to soften the coating, after which the fibrosis-inducing agent or the fibrosis-inducing agent/secondary carrier is applied to the entire device or to a portion of the device (e.g., outer surface).
Within another aspect of the invention, a coated device which inhibits or reduces an in vivo fibrotic reaction is further coated with a compound or composition which delays the release of and/or activity of the fibrosis-inducing agent. Representative examples of such agents include biologically inert materials such as gelatin, PLGA/MePEG film, PLA, polyurethanes, silicone rubbers, surfactants, lipids, or polyethylene glycol, as well as biologically active materials such as heparin (e.g., to induce coagulation).
For example, in one embodiment of the invention, the active agent on the device is top-coated with a physical barrier. Such barriers can include non-degradable materials or biodegradable materials such as gelatin, PLGA/MePEG film, PLA, polyethylene glycol, or the like. In one embodiment, the rate of diffusion of the therapeutic agent in the barrier coat is slower that the rate of diffusion of the therapeutic agent,in the coating layer. In the case of PLGA/ MePEG, once the PLGA/ MePEG becomes exposed to the bloodstream, the MePEG can dissolve out of the PLGA, leaving channels through the PLGA to an underlying layer containing the fibrosis-inducing agent (e.g., silk or cyclosporine A), which can then diffuse into the vessel wall and initiate its biological activity.
In another embodiment of the invention, for example, a particulate form of the active agent (e.g., silk or cyclosporine A) may be coated onto the device using a polymer (e.g., PLG, PLA, or polyurethane). A second polymer, that dissolves slowly or degrades (e.g., MePEG-PLGA or PLG) and that does not contain the active agent, may be coated over the first layer. Once the top layer dissolves or degrades, it exposes the under coating, which allows the active agent to be exposed to the treatment site or to be released from the coating.
Within another aspect of the invention, the outer layer of the coated device, which induces an in vivo fibrotic response, is further treated to crosslink the outer layer of the coating. This can be accomplished by subjecting the coated device to a plasma treatment process. The degree of crosslinking and nature of the surface modification can be altered by changing the RF power setting, the location with respect to the plasma, the duration of treatment as well as the gas composition introduced into the plasma chamber.
Protection of a biologically active surface can also be utilized by coating the device or implant surface with an inert molecule that prevents access to the active site through steric hindrance, or by coating the surface with an inactive form of the fibrosis-inducing agent, which is later activated. For example, the device can be coated with an enzyme, which causes either release of the fibrosis-inducing agent or activates the fibrosis-inducing agent.
Another example of a suitable device surface coating includes an anti-coagulant such as heparin, which can be coated on top of the fibrosis-inducing agent such that the presence of the heparin or other anti-coagulant delays coagulation at the treatment site. As the heparin or other anticoagulant dissolves away, the anticoagulant activity may slow or stop, and the newly exposed fibrosis-inducing agent (e.g., silk or cyclosporine A) is capable of inhibiting or reducing fibrosis from occurring in the adjacent tissue.
In another strategy, the device can be coated with an inactive form of the fibrosis-inducing agent, which is then activated once the device is deployed. Such activation may be achieved by injecting another material into the treatment area after the device (as described below) is deployed or after the fibrosis-inducing agent has been administered to the treatment area (via, e.g., injections, spray, wash, drug delivery catheters or balloons). For example, the device may be coated with an inactive form of the fibrosis-inducing agent.
Once the device is deployed, the activating substance is injected or applied into or onto the treatment site where the inactive form of the fibrosis-inducing agent has been applied.
For example, a device may be coated with a biologically active fibrosis-inducing agent, in the usual manner. The coating containing the active fibrosis-inducing agent may then be covered (e.g., coated) with polyethylene glycol. The PEG and the fibrosing agent containing coating may be bonded through the formulation of a bond between reactive groups on the two layers.
For example, an ester bond may be formed using a condensation reaction.
Prior to the deployment of the device, an esterase is injected into the treatment site around the outside of the implanted device. The esterase can cleave the bond between the ester and the fibrosis-inducing agent, thereby allowing the agent to initiate fibrosis.

In another aspect, a medical device may include a plurality of reservoirs within its structure, each reservoir configured to house and protect a therapeutic drug. The reservoirs may be formed from divets in the device surface or micropores or channels in the device body. In one aspect, the reservoirs are formed from voids in the structure of the device. The reservoirs may house a single type of drug or more than one type of drug. The drugs) may be formulated with a carrier (e.g., a polymeric or non-polymeric material) that is loaded into the reservoirs. The filled reservoir can function as a drug delivery depot which can release drug over a period of time dependent on the release kinetics of the drug from the carrier. In certain embodiments, the reservoir may be loaded with a plurality of layers. Each layer may include a different drug having a particular amount (dose) of drug, and each layer may have a different composition to further tailor the amount of drug that is released from the substrate. The multi-layered carrier may further include a barrier layer that prevents release of the drug(s). The barrier layer can be used, for example, to control the direction that the drug elutes from the void.
Within certain embodiments of the invention, the therapeutic compositions may also comprise additional ingredients such as surfactants (e.g., PLURONICS, such as F-127, L-122, L-101, L-92, L-81, and L-61 ), anti-inflammatory agents, anti-thrombotic agents, anti-infective agents, preservatives, anti-oxidants and/ or anti-platelet agents.
Within certain embodiments of the invention, the therapeutic agent or carrier can also comprise radio-opaque, echogenic materials and magnetic resonance imaging (MRI) responsive materials (i.e., MRI contrast agents) to aid in visualization of the device under ultrasound, fluoroscopy and/or MRI. For example, a device may be made with or coated with a composition which is echogenic or radiopaque (e.g., made with echogenic or radiopaque with materials such as powdered tantalum, tungsten, barium carbonate, bismuth oxide, barium sulfate, metrazimide, iopamidol, iohexol, iopromide, iobitridol, iomeprol, iopentol, ioversol, ioxilan, iodixanol, iotrolan, acetrizoic acid derivatives, diatrizoic acid derivatives, iothalamic acid derivatives, ioxithalamic acid derivatives, metrizoic acid derivatives, iodamide, lypophylic agents, iodipamide and ioglycamic Acid or, by the addition of microspheres or bubbles which present an acoustic interFace). Visualization of a device by ultrasonic imaging may be achieved using an echogenic coating.
Echogenic coatings are described in, e.g., U.S. Patent Nos. 6,106,473 and 6,610,016. For visualization under MRI, contrast agents (e.g., gadolinium (III) chelates or iron oxide compounds) may be incorporated into or onto the device, such as, as a component in a coating or within the void volume of the device (e.g., within a lumen, reservoir, or within the structural material used to form the device). In some embodiments, a medical device may include radio-opaque or MRI visible markers (e.g., bands) that may be used to orient and guide the device during the implantation procedure.
Medical implants may, alternatively, or in addition, be visualized under visible light, using fluorescence, or by other spectroscopic means.
Visualization agents that can be included for this purpose include dyes, pigments, and other colored agents. In one aspect, the medical implant may further include a colorant to improve visualization of the implant in vivo and/or ex vivo. Frequently, implants can be difficult to visualize upon insertion, especially at the margins of implant. A coloring agent can be incorporated into a medical implant to reduce or eliminate the incidence or severity of this problem. The coloring agent provides a unique color, increased contrast, or unique fluorescence characteristics to the device. In one aspect, a solid implant is provided that includes a colorant such that it is readily visible (under visible light or using a fluorescence technique) and easily differentiated from its implant site. In another aspect, a colorant can be included in a liquid or semi-solid composition. For example, a single component of a two component mixture maybe colored, such that when combined ex-vivo or in-vivo, the mixture is sufficiently colored.
The coloring agent may be, for example, an endogenous compound (e.g., an amino acid or vitamin) or a nutrient or food material and may be a hydrophobic or a hydrophilic compound. Preferably, the colorant has a very low or no toxicity at the concentration used. Also preferred are colorants that are safe and normally enter the body through absorption such as ~i-carotene. Representative examples of colored nutrients (under visible light) include fat soluble vitamins such as Vitamin A (yellow); water soluble vitamins such as Vitamin B12 (pink-red) and folic acid (yellow-orange); carotenoids such as ~-carotene (yellow-purple) and lycopene (red). Other examples of coloring agents include natural product (berry and fruit) extracts such as anthrocyanin (purple) and saffron extract (dark red). The coloring agent may be a fluorescent or phosphorescent compound such as a-tocopherolquinol (a Vitamin E
derivative) or L-tryptophan. Derivatives, analogues, and isomers of any of the above colored compounds also may be used. The method for incorporating a colorant into an implant or therapeutic composition may be varied depending on the properties of and the desired location for the colorant., For example, a hydrophobic colorant may be selected for hydrophobic matrices. The colorant may be incorporated into a carrier matrix, such as micelles. Further, the pH
of the environment may be controlled to further control the color and intensity.
In one aspect, the composition of the present invention include one or more coloring agents, also referred to as dyestuffs, which will be present in an effective amount to impart observable coloration to the composition, e.g., the gel. Examples of coloring agents include dyes suitable for food such as those known as F. D. & C. dyes and natural coloring agents such as grape skin extract, beet red powder, beta carotene, annato, carmine, turmeric, paprika, and so forth. Derivatives, analogues, and isomers of any of the above colored compound also may be used. The method for incorporating a colorant into an implant or therapeutic composition may be varied depending on the properties of and the desired location for the colorant. For example, a hydrophobic colorant may be selected for hydrophobic matrices. The colorant may be incorporated into a carrier matrix, such as micelles. Further, the pH of the environment may be controlled to further control the color and intensity. , In one aspect, the compositions of the present invention include one or more preservatives or bacteriostatic agents, present in an effective amount to preserve the composition and/or inhibit bacterial growth in the composition, for example, bismuth tribromophenate, methyl hydroxybenzoate, bacitracin, ethyl hydroxybenzoate, propyl hydroxybenzoate, erythromycin, chlorocresol, benzalkonium chlorides, and the like: Additional examples of the preservative include paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, and the like. In one aspect, the compositions of the present invention include one or more bactericidal (also known as bacteriacidal) agents.
In one aspect, the compositions of the present invention include one or more antioxidants, present in an effective amount. Examples of the antioxidant include sulfites, alpha-tocopherol and ascorbic acid.
Within related aspects of the present invention, devices and compositions are provided that may or may not be associated with a device, which release an agent which induces fibrosis in vivo upon deployment of the device or administration of the composition. In certain aspects, the fibrosis-inducing agent or composition that comprises the fibrosis-inducing agent is delivered locally or regionally to the treatment site from the device or composition.
Within certain aspects of the present invention, the therapeutic composition should be biocompatible, and release one or more fibrosing agents over a period of several hours, days, or months.
The devices of the present invention may be configured to release the scarring agent at one or more phases, the one or more phases having similar or different performance (e.g., release) profiles. The therapeutic agent may be made available to the tissue at amounts which may be sustainable, intermittent, or continuous; in one or more phases; and/or rates of delivery;
effective to increase or promote any one or more components of fibrosis (or scarring), including: formation of new blood vessels (angiogenesis), migration and proliferation of connective tissue cells (such as fibroblasts or smooth muscle cells), deposition of extracellular matrix (ECM), and remodeling (maturation and organization of the fibrous tissue); or the agent can act as a vascular wall irritant.
Thus, the release rate may be programmed to impact fibrosis (or scarring) by releasing the scarring agent at a time such that at least one of the components of fibrosis is promoted or increased. Moreover, the predetermined release rate may reduce agent loading and/or concentration as well as potentially providing minimal drug washout and thus, increases efficiency of drug effect. Any one of at least one scarring agents) may perform one or more functions, including promoting the formation of new blood vessels (angiogenesis), promoting the migration and proliferation of connective tissue cells (such as fibroblasts or smooth muscle cells), promoting the deposition of extracellular matrix (ECM), promoting remodeling (maturation and organization of the fibrous tissue) and/or acting as a vascular wall irritant. In one embodiment, the rate of release may provide a sustainable level of the scarring agent to the treatment site. In another embodiment, the rate of release is substantially constant. The rate may decrease and/or increase over time, and it may optionally include a substantially non-release period. The release rate may comprise a plurality of rates. In an embodiment, the plurality of release rates may include rates selected from the group consisting of substantially constant, decreasing, increasing, and substantially non-releasing.

The total amount of scarring agent made available on, in or near the device may be in an amount ranging from about 0.01 pg (micrograms) to about 2500 mg (milligrams). Generally, the scarring agent may be in the amount ranging from 0.01 pg to about 10 pg; or from 10 pg to about 1 mg; or from 1 mg to about 10 mg; or from 10 mg to about 100 mg; or from 100 mg to about 500 mg; or from 500 mg to about 2500 mg.
The surface amount of scarring agent on, in or near the device may be in an amount ranging from less than 0.01 pg to about 250 pg per mm2 of device surface area. Generally, the scarring agent may be in the amount ranging from less than 0.01 pg/mm2; or,from 0.01 pg to about 10 pg/mm2; or from 10 pg to about 25 pg/mm2; or from 25 pg to about 250 pg/mm2.
The scarring agent that is on, in or near the device may be released from the composition and/or device in a time period that may be measured from the time of implantation, which ranges from about less than 1 day to about 180 days. Generally, the release time may also be from about less than 1 day to about 7 days; from 7 days to about 14 days; from 14 days to about 28 days; from 28 days to about 56 days; from 56 days to about 90 days;
from 90 days to about 180 days.
In one aspect, "quick release" or "burst" therapeutic compositions are provided that release greater than 10%, 20%, or 25% (w/v) of a fibrosis-inducing agent over a period of 7 to 10 days. Such "quick release"
compositions should, within certain embodiments, be capable of releasing therapeutic levels (where applicable) of a desired fibrosing agent. Within other embodiments, "slow release" therapeutic compositions are provided that release less than 1 % (w/v) of a fibrosis-inducing agent over a period of 7 to days. Within other embodiments therapeutic compositions are provided that release either less than 1 % (w/v) of a fibrosing-inducing agent over a period longer than 10 days or do not release the therapeutic composition at a(1, but maintain the composition for a very long period of time such as for the entire duration of the device placement in the body.
The amount of scarring agent released from the composition and/or device as a function of time may be determined based on the in vitro release characteristics of the agent from the composition. The in vitro release rate may be determined by placing the scarring agent within the composition or device in an appropriate buffer such as 0.1 M phosphate buffer (pH 7.4)) at 37 °C. Samples of the buffer solution are then periodically removed for analysis by either HPLC or by gravimetric means, and the buffer is replaced to avoid any saturation effects.
Based on the in vitro release rates, the release of scarring agent per day may range from an amount ranging from about 0.0 pg (micrograms) to about 2500 mg (milligrams). Generally, the scarring agent that may be released in a day may be in the amount ranging from 0.0 to 0.01 pg; 0.01 pg to about 10 pg; or from 10 pg to about 1 mg; or from 1 mg to about 10 mg; or from mg to about 100 mg; or from 100 mg to about 500 mg; or from 500 mg to about 2500 mg. In one embodiment, the scarring agent is made available to the 10 susceptible tissue site in a constant but substantially unchanging manner so that the agent remains at the tissue essentially permanently. In another embodiment, the scarring agent is made available to the susceptible tissue in a sustained and/or controlled manner which results in increased efficiency and/or efficacy. Further, the release rates may vary during either or both of the initial and subsequent release phases. There may also be additional phases) for release of the same substances) and/or different substance(s).
Further, therapeutic compositions of the present invention should preferably be have a stable shelf-life for at least several months and capable of being produced and maintained under sterile conditions. The composition may be sterile either by preparing them under aseptic environment and/or they may be terminally sterilized using methods available in the art. Many pharmaceuticals are manufactured to be sterile and this criterion is defined by the USP XXII <1211 >. The term "USP" refers to U.S. Pharmacopeia (see www.usp.org, Rockville, MD). Sterilization may be accomplished by a number of means accepted in the industry and listed in the USP XXII <1211 >, including gas sterilization, ionizing radiation or, when appropriate, filtration.
Sterilization may be maintained by what is termed asceptic processing, defined also in USP
XXII <1211 >. Acceptable gases used for gas sterilization include ethylene oxide. Acceptable radiation types used for ionizing radiation methods include gamma, for instance from a cobalt 60 source and electron beam. A typical dose of gamma radiation is 2.5 MRad. Sterilization may also occur by terminally using gamma radiation or electron beam sterilization methods.
Filtration may be accomplished using a filter with suitable pore size, for example 0.22 ~,m and of a suitable material, for instance polytetrafluoroethylene (e.g., TEFLON). A combination of these methods may also be used to prepare the composition in the sterile form.

In'another aspect, the compositions and devices of the present invention are contained in a container that allows them to be used for their intended purpose. Properties of the container that are important are a volume of empty space to allow for the addition of a constitution medium, such as water or other aqueous medium, e.g., saline, acceptable light transmission characteristics in order to prevent light energy from damaging the composition in the container (refer to USP XXII <661 >), an acceptable limit of extractables within the container material (refer to USP XXII), an acceptable barrier capacity for moisture (refer to USP XXII <671 >) or oxygen. In the case of oxygen penetration, this may be controlled by including in the container, a positive pressure of an inert gas, such as high purity nitrogen, or a noble gas, such as argon.
Typical materials used to make containers for pharmaceuticals include USP Type I through III and Type NP glass (refer to USP XXII <661 >), polyethylene, TEFLON, silicone, and gray-butyl rubber. For parenterals, USP
Types I to III glass and polyethylene are preferred.
It should be readily evident to one of skill in the art that any of the previously described fibrosis inducing agents, or derivatives and analogues thereof, can be utilized to create variations of the above compositions without deviating from the spirit and scope of the invention. It should also be apparent that the agent can be utilized in a composition with or without polymer carrier and that altering the carrier does not deviate from the scope of this invention.
For all the previously described embodiments, examples of suitable fibrosing agents include tissue irritants such tissue as silk, wool, asbestos, silica, bleomycin, neomycin, talcum powder, metallic beryllium, and copper are particularly suitable for the practice of this invention. Other agents which may be incorporated into or onto the implant or device or released from the implant or device include extracellular matrix components such as fibrous structural proteins (e.g., fibrillar collagens, nonfibrillar collagen and elastins), adhesive glycoproteins (e.g., laminin and fibronectin), proteoglycans (e.g., heparin sulphate, chondroitin sulphate, dermatan sulphate), hyaluronan (e.g., hyaluronic acid), secreted protein acidic and rich in cysteine (SPARC), thrombospondins, tenacin, inhibitors of matrix metalloproteinases (e.g., TIMPs and synthetic TIMPs such as marimistat, batimistat, doxycycline, tetracycline, minocycline, TROCADE, Ro-1130830, CGS 27023A, BMS-275291 ) and polylysine. Growth factors and inflammatory cytokines involved in angiogenesis, fibroblast migration, fibroblast proliferation, ECM synthesis and tissue remodeling such as epidermal growth factor (EGF) family, transforming growth factor-a (TGF- a), transforming growth factor-~i (TGF-9-1, TGF-9-2, TGF-9-3), platelet-derived growth factor (PDGF), fibroblast growth factor (acidic - aFGF; and basic - bFGF), bone morphogenic proteins, activins, vascular endothelial growth factor (VEGF, VEGF-B, VEGF-C, placental growth factor -PIGF), angiopoietins, insulin-like growth factors (IGF), hepatocyte hrowth factor (HGF), connective tissue growth factor (CTGF), myeloid colony-stimulating factors (CSFs), granulocyte-macrophage colony-stimulating factors (GM-CSF), granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), erythropoietin, interleukins (particularly IL-1, IL-8, IL-6), tumor necrosis factor-a (TNF9), nerve growth factor (NGF), interFeron-a, interferon-Vii, and growth hormone (GH) are also suitable for incorporation and release from specific intravascular devices. Other agents which may be coated onto or released by the implant or device include adhesives such as cyanoacrylate or materials made from 4-armed thiol PEG (10K), a 4-armed NHS PEG(10K) and methylated collagen.
5) Coating of devices with fibrosis-inducing agents As described above, a range of polymeric and non-polymeric materials can be used to incorporate the fibrosis-inducing agent onto or into a device. Coating of the device with these fibrosis-inducing agent containing compositions or with the fibrosis-inducing agent only is one process that can be used to incorporate the fibrosis-inducing agent into or onto the device.
a) Dip coating.
Dip coating is an example of a coating process that can be used to associate the fibrosis-inducing agent with the device. In one embodiment, the fibrosis-inducing agent is dissolved in a solvent for the fibrosis agent and is then coated onto the device.
Fibrosis-inducing agent with an inert solvent In one embodiment, the solvent is an inert solvent for the device such that the solvent does not dissolve the medical device to any great extent and is not absorbed by the device to any great extent. The device can be immersed, either partially or completely, in the fibrosis-inducing agent/solvent solution for a specific period of time. The rate of immersion into the fibrosis-inducing agent/solvent solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec). The device can then be removed from the solution. The rate at which the device can be withdrawn from the solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec). The coated device can be air-dried. The dipping process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to reduce residual solvent levels. This process can result in the fibrosis-inducing agent being coated on the surface of the device.
Fibrosis-inducina.agent with a swelling solvent In one embodiment, the solvent is one that can not dissolve the device but can be absorbed by the device. These solvents can thus swell the device to some extent. The device can be immersed, either partially or completely, in the fibrosis-inducing agent/solvent solution for a specific period of time (seconds to days). The rate of immersion into the fibrosis-inducing agent/solvent solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec).
The device can then be removed from the solution. The rate at which the device can be withdrawn from the solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec). The coated device can be air-dried. The dipping process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to reduce residual solvent levels. This process can result in the fibrosis-inducing agent being adsorbed into the medical device. The fibrosis-inducing agent may also be present on the surface of the device. The amount of surface associated fibrosis-inducing agent may be reduced by dipping the coated device into a solvent for the fibrosis-inducing agent or by spraying the coated device with a solvent for the fibrosis-inducing agent.
Fibrosis-inducing agent with a solvent In one embodiment, the solvent is one that can be absorbed by the device and that can dissolve the device. The device can be immersed, either partially or completely, in the fibrosis-inducing agent/solvent solution for a specific period of time (seconds to hours). The rate of immersion into the fibrosis-inducing agent/solvent solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec). The device can then be removed from the solution. The rate at which the device can be withdrawn from the solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec). The coated device can be air-dried.
The dipping process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to reduce residual solvent levels. This process can result in the fibrosis-inducing agent being adsorbed into the medical device as well as being surface associated.
Preferably, the exposure time of the device to the solvent may be such as to not incur significant permanent dimensional changes to the device. The fibrosis-inducing agent may also be present on the surface of the device. The amount of surface associated fibrosis-inducing agent may be reduced by dipping the coated device into a solvent for the fibrosis-inducing agent or by spraying the coated device with a solvent for the fibrosis-inducing agent.
In one embodiment, the fibrosis-inducing agent and a polymer are dissolved in a solvent, for both the polymer and the fibrosing agent, and are then coated onto the device.
In the above description, the device can be a device that has not been modified or device that has been further modified by coating with a polymer, surface treated by plasma treatment, flame treatment, corona treatment, surface oxidation or reduction, surface etching, mechanical smoothing or roughening, or grafting prior to the coating process.
In any one of the above dip coating methods, the surface of the device can be treated with a plasma polymerization method prior to coating of the scarring agent or scarring agent containing composition, such that a thin polymeric layer is deposited onto the device surface. Examples of such methods include parylene coating of devices and the use of various monomers such hydrocyclosiloxane monomers. Parylene coating may be especially advantageous if the device, or portions of the device, are composed of materials (e.g., stainless steel, nitinol) that do not allow incorporation of the therapeutic agents) into the surface layer using one of the above methods. A
parylene primer layer may be deposited onto the device using a parylene coater (e.g., PDS 2010 LABCOTER2 from Cookson Electronics) and a suitable reagent (e.g., di-p-xylylene or dichloro-di-p-xylylene) as the coating feed material. Parylene compounds are commercially available, for example, from Specialty Coating Systems, Indianapolis, IN), including PARYLENE N (di-p-xylylene), PARYLENE C (a monchlorinated derivative of PARYLENE N, and PARYLENE D, a dichlorinated derivative of Parylene NJ).

Fibrosis-inducing agent/polymer with an inert solvent In one embodiment, the solvent is an inert solvent for the device such that the solvent does not dissolve the medical device to any great extent and is not absorbed by the device to any great extent. The device can be immersed, either partially or completely, in the fibrosis-inducing agent/polymer/solvent solution for a specific period of time. The rate of immersion into the fibrosis-inducing agent/polymer/solvent solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec). The device can then be removed from the solution. The rate at which the device can be withdrawn from the solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec). The coated device can be air-dried. The dipping process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to°reduce residual solvent levels. This process can result in the fibrosis-inducing agent/polymer being coated on the surface of the device.
Fibrosis-inducing agent/polymer with a swelling solvent In one embodiment, the solvent is one that can not dissolve the device but can be absorbed by the device. These solvents can thus, swell the device to some extent. The device can be immersed, either partially or completely, in the fibrosis-inducing agent/polymer/solvent solution for a specific period of time (seconds to days). The rate of immersion into the fibrosis-inducing agent/polymer/solvent solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec). The device can then be removed from the solution. The rate at which the device can be withdrawn from the solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec). The coated device can be air-dried.
The dipping process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to reduce residual solvent levels. This process can result in the fibrosis-inducing agent/polymer being coated onto the surface of the device as well as the potential for the fibrosis-inducing agent being adsorbed into the medical device. The fibrosis-inducing agent may also be present on the surface of the device. The amount of surface associated fibrosis-inducing agent may be reduced by dipping the coated device into a solvent for the fibrosis-inducing agent or by spraying the coated device with a solvent for the fibrosis-inducing agent.

Fibrosis-inducing agent/polymer with a solvent In one embodiment, the solvent is one that can be absorbed by the device and that can dissolve the device. The device can be immersed, either partially or completely, in the fibrosis-inducing agent/solvent solution for a specific period of time (seconds to hours). The rate of immersion into the fibrosis-inducing agent/solvent solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec). The device can then be removed from the solution. The rate at which the device can be withdrawn from the solution can be altered (e.g., 0.001 cm per sec to 50 cm per sec). The. coated device can be air-dried.
The dipping process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to reduce residual solvent levels. In the preferred embodiment, the exposure time of the device to the solvent may be such that there is not significant permanent dimensional changes to the device (other than those associated with the coating itself).
The fibrosis-inducing agent may also be present on the surface of the device. The amount of surface associated fibrosis-inducing agent may be reduced by dipping the coated device into a solvent for the fibrosis-inducing agent or by spraying the coated device with a solvent for the fibrosis-inducing agent.
In the above description the device can be a device that has not been modified as well as a device that has been further modified by coating with a polymer (e.g., parylene), surface treated by plasma treatment, flame treatment, corona treatment, surface oxidation or reduction, surface etching, mechanical smoothing or roughening, or grafting prior to the coating process.
In another embodiment, a suspension of the fibrosis-inducing agent in a polymer solution can be prepared. The suspension can be prepared by choosing a solvent that can dissolve the polymer but not the fibrosis-inducing agent or a solvent that can dissolve the polymer and in which the fibrosis-inducing agent is above its solubility limit. In similar processes described above, a device can be dipped into the suspension of the fibrosis-inducing agent and polyi~ner solution such that the device is coated with a polymer that has a fibrosing agent suspended within it.
b) Spray coating Spray coating is another type of coating process that can be used.
In the spray coating process, a solution or suspension of the fibrosis-inducing agent, with or without a polymeric or non-polymeric carrier, is nebulized and directed to the device to be coated by a stream of gas. One can use spray devices such as an air-brush (for example models 2020, 360, 175, 100, 200, 150, 350, 250, 400, 3000, 4000, 5000, 6000 from Badger Air-brush Company, Franklin Park, IL), spray painting equipment, TLC reagent sprayers (for example Part # 14545 and 14654, Alltech Associates, Inc. Deerfield, IL, and ultrasonic spray devices (for example those available from Sono-Tek, Milton, NY). One can also use powder sprayers and electrostatic sprayers.
In one embodiment, the fibrosis-inducing agent is dissolved in a solvent for the fibrosis agent and is then sprayed onto the device.
Fibrosis-inducinct agent with an inert solvent In one embodiment, the solvent is an inert solvent for the device such that the solvent does not dissolve the medical device to any great extent and is not absorbed by the device to any great extent. The device can be held in place or the device can be mounted onto a mandrel or rod that has the ability to move in an X, Y or Z plane or a combination of these planes. Using one of the above described spray devices, the device can be spray coated such that the device is either partially or completely coated with the fibrosis-inducing agent/solvent solution. The rate of spraying of the fibrosis-inducing agent/solvent solution can be altered (e.g., 0.001 ml per sec to 10 ml per sec) to ensure that a good coating of the fibrosis-inducing agent is obtained. The coated device can be air-dried. The spray coating process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to reduce residual solvent levels. This process can result in the fibrosis-inducing agent being coated on the surface of the device.
Fibrosis-inducing agent with a swelling solvent In one embodiment, the solvent is one that can not dissolve the device but can be absorbed by the device. These solvents can thus swell the device to some extent. The device can be spray coated, either partially or completely, in the fibrosis-inducing agent/solvent solution. The rate of spraying of the fibrosis-inducing agent/solvent solution can be altered (e.g., 0.001 ml per sec to 10 ml per sec) to ensure that a good coating of the fibrosis-inducing agent is obtained. The coated device can be air-dried. The spray coating process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to reduce residual solvent levels. This process can result in the fibrosis-inducing agent being adsorbed into the medical device. The fibrosis-inducing agent may also be present on the surface of the device. The amount of surface associated fibrosis-inducing agent may be reduced by dipping the coated device into a solvent for the fibrosis-inducing agent or by spraying the coated device with a solvent for the fibrosis-inducing agent.
Fibrosis-inducing agent with a solvent In one embodiment, the solvent is one that can be absorbed by the device and that can dissolve the device. The device can be spray coated, either partially or completely, in the fibrosis-inducing agent/solvent solution.
The rate of spraying of the fibrosis-inducing agent/solvent solution can be altered (e.g., 0.001 ml per sec to 10 ml per sec) to ensure that a good coating of the fibrosis-inducing agent is obtained. The coated device can be air-dried.
The spray coating process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to reduce residual solvent levels. This process can result in the fibrosis-inducing agent being adsorbed into the medical device as well as being surface associated.
Preferably, the exposure time of the device to the solvent may be such as to not incur significant permanent dimensional changes to the device. The fibrosis-inducing agent may also be present on the surface of the device. The amount of surface associated fibrosis-inducing agent may be reduced by dipping the coated device into a solvent for the fibrosis-inducing agent or by spraying the coated device with a solvent for the fibrosis-inducing agent.
In one embodiment, the fibrosis-inducing agent and a polymer are dissolved in a solvent, for both the polymer and the fibrosing agent, and are then spray coated onto the device. In the above description, the device can be a device that has not been modified as well as a device that has been further modified by coating with a polymer (e.g., parylene), surface treated by plasma treatment, flame treatment, corona treatment, surface oxidation or reduction, surface etching, mechanical smoothing or roughening, or grafting prior to the coating process.
Fibrosis-inducing agent/polymer with an inert solvent In one embodiment, the solvent is an inert solvent for the device such that the solvent does not dissolve the medical device to any great extent and is not absorbed by the device to any great extent. The device can be spray coated, either partially or completely, in the fibrosis-inducing agent/polymer/solvent solution for a specific period of time. The rate of spraying of the fibrosis-inducing agent/solvent solution can be altered (e.g., 0.001 ml per sec to 10 ml per sec) to ensure that a good coating of the fibrosis-inducing agent is obtained. The coated device can be air-dried. The spray coating process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to reduce residual solvent levels. This process can result in the fibrosis-inducing agent/polymer being coated on the surface of the device.
_Fibrosis-inducing ac~ent/polymer with a swelling solvent In one embodiment, the solvent is one that can not dissolve the device but can be absorbed by the device. These solvents can thus swell the device to some extent. The device can be spray coated, either partially or completely, in the fibrosis-inducing agent/polymer/solvent solution. The rate of spraying of the fibrosis-inducing agent/solvent solution can be altered (e.g., 0.001 ml per sec to 10 ml per sec) to ensure that a good coating of the fibrosis-inducing agent is obtained. The coated device can be air-dried. The spray coating process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to reduce residual solvent levels. This process can result in the fibrosis-inducing agent/polymer being coated onto the surface of the device as well as the potential for the fibrosis-inducing agent being adsorbed into the medical device. The fibrosis-inducing agent may also be present on the surface of the device. The amount of surFace associated fibrosis-inducing agent may be reduced by dipping the coated device into a solvent for the fibrosis-inducing agent or by spraying the coated device with a solvent for the fibrosis-inducing agent.
_Fibrosis-inducing aaent/polymer with a solvent In one embodiment, the solvent is one that can be absorbed by the device and that can dissolve the device. The device can be spray coated, either partially or completely, in the fibrosis-inducing agent/solvent solution.
The rate of spraying of the fibrosis-inducing agent/solvent solution can be altered (e.g., 0.001 ml per sec to 10 ml per sec) to ensure that a good coating of the fibrosis-inducing agent is obtained. The coated device can be air-dried.

The spray coating process can be repeated one or more times depending on the specific application. The device can be dried under vacuum to reduce residual solvent levels. Preferably, the exposure time of the device to the solvent may be such as to not incur significant permanent dimensional changes to the device (other than those associated with the coating itself). The fibrosis-inducing agent may also be present on the surface of the device. The amount of surface associated fibrosis-inducing agent may be reduced by dipping the coated device into a solvent for the fibrosis-inducing agent or by spraying the coated device with a solvent for the fibrosis-inducing agent.
In the above description, the device can be a device that has not been modified as well as a device that has been further modified by coating with a polymer (e.g., parylene), surface treated by plasma treatment, flame treatment, corona treatment, surface oxidation or reduction, surface etching, mechanical smoothing or roughening, or grafting prior to the coating process.
c) Direct attachment In certain embodiments, the fibrosis inducing agent can be attached directly to the device. This can be accomplished by using an adhesive (e.g., cyanoacrylate, polymer/solvent solution), using a thermal process and or by sewing the fibrosis agent into or onto the device. In one embodiment, the fibrosis inducing agent can be in the form of particles (irregular, regular, porous, spherical), threads, fibers, knits, weaves or electrospun material. For example, silk can be prepared as a knitted, woven or electrospun material. This material can then be placed on the surface of the device. Sutures and/or an adhesive can then be used to secure the silk material to the device.
In another embodiment, the fibrosis inducing agent can be dissolved in a suitable solvent. This solution can then be applied to the device using an electrospraying or electrospinning process. Polymeric,or non-polymeric additives can be added to this solution to assist in the electrospraying or electrospinning process and or to assist in the adhesion of the fibrosis inducing agent to the device. For example, silk can be dissolved in HFIP and this can then be electrosprayed or electrospun onto the device (e.g., stent).
In another embodiment, the fibrosis-inducing agent can be incorporated into the device during or post manufacture of the device. For example silk fibers could be woven into a hernia mesh to provide a product that contains the fibrosis-inducing agent that is incorporated into the device.

D. Methods for Utilizing Medical Implants Medical devices and implants of the present invention may be utilized to induce a fibrotic reaction around the device/implant that results in an enhanced bond between the tissue and the prosthesis. Such medical devices and implants provide a solution to the following common problems associated with a variety of clinical interventions.
Treatments for Degenerative Disc Disease (DDD) Back pain is the number one cause of healthcare expenditures in the United States and accounts for over $50 billion in costs annually ($100 billion worldwide). Over 12 million people in the U.S. have some form of degenerative disc disease (DDD) and 10% of them (1.2 million) can require surgery to correct their problem.
In healthy individuals, the vertebral column is composed of vertebral bone plates separated by intervertebral discs that form strong joints and absorb spinal compression during movement. The intervertebral disc is comprised of an inner gel-like substance called the nucleus pulposus which is surrounded by a tough fibrocartilagenous capsule called the annulus fibrosis.
The nucleus pulposus is composed of a loose framework of collagen fibrils and connective tissue cells (resembling fibroblasts and chondrocytes) embedded in a gelatinous matrix of glycosaminoglycans and water. The annulus fibrosus is composed of numerous concentric rings of fibrocartilage that anchor into the vertebral bodies. The most common cause of DDD occurs when tears in the annulus fibrosis create an area of localized weakness that allow bulging, herniation or sequestration of the nucleus pulposis and annulus fibrosis into the spinal canal and/or spinal foramena. The bulging or herniated disc often compresses nerve tissue such as spinal cord fibers or spinal cord nerve root fibers. Pressure on the spinal cord or nerve roots from the damaged intervertebral disc results in neuronal dysfunction (numbness, weakness, tingling), crippling pain, bowel or bladder disturbances and can frequently cause long-term disability. Although many cases of DDD can spontaneously resolve, a significant number of patients can require surgical intervention in the form of minimally invasive procedures, microdiscectomy, major surgical resection of the disc, spinal fusion (fusion of adjacent vertebral bone plates using various techniques and devices), and/or implantation of an artificial disc. The present invention provides for the application of an adhesion or fibrosis-inducing agent in the surgical management of DDD.
(i) Minimally Invasive Treatments of DDD
The present invention provides injectable compositions that include a bulking or filling agent and a fibrosing agent for direct injection into damaged intervertebral discs. An injectable material containing a fibrosis-inducing agent that can be injected into an intervertebral disc space (alone or in combination with polymeric carrier, which may be in the form, e.g., of a gel, paste, or spray) is used to enhance scarring and support the annular ring of the disc (e.g., by inducing the production of fibrous tissue and fibrocartilage), thus reducing the risk of disc rupture and restoring disc function without surgery (embodiments for application during disc surgery are described below). In another embodiment, the injectable composition containing a fibrosis-inducing agent can further contain an agent that promotes bone growth if permanent fixation (immobilization) of adjacent vertebra is desired.
In this procedure, a needle is inserted into the intervertebral disc, a guidewire is advanced into the tissue and a dual lumen catheter (for many of the hydrogels described below such as COSEAL, COSTAS1S, FLOSEAL, TISSEAL, VITOSS, and materials made from 4-armed thiol PEG (10K), 4-armed NHS PEG(10K) and methylated collagen, such as described above or a single lumen catheter (for materials such as cyanoacrylate, CORTOSS, bone cement, apatitehydroxyapatite, calcium phosphate, calcium sulfate, hyaluronic acid, proteins, carbohydrates, sclerosing agents, and the like) is advanced into the disc. When performing direct injection of the intervertebral disc, techniques can be used to enhance visualization of needle (or catheter) placement within the disc including, but not limited to, the use of a needle coated with an ultrasound imaging coating formulation, such as ECHO-COAT (Angiotech Pharmaceuticals, Inc.) or the addition of contrast agents (e.g., barium, tantalum, technitium, gadolinium, etc.) for localization by x-ray. After correct positioning has been confirmed, the guidewire is removed, and a composition containing a fibrosis-inducing agent, with or without a bone morphogenic protein(s), andlor an osteogenic growth factor (such as transforming growth factor, platelet-derived growth factor, fibroblast growth factor) is injected via the catheter into the disc. Chemonucleolysis agents such as collagenase, chymopapain or other tissue-degrading enzymes may also be used to chemically degrade the remaining disc tissue prior to the injection of the fibrosing composition.
Over time the fibrosis-inducing agent, with or without a bone morphogenic protein, and/or an osteogenic growth factor can encourage fibrous ankylosis, followed by bony ankylosis of the intervertebral space leading to increased stability and reduced pain.
The injectable material may contain a polymer system that can provide sustained release of the fibrosis-inducing agent, bone morphogenic protein, and/or osteogenic growth factor to enhance efficacy and reduce the need for repeat administrations of active agents. The polymeric injection material suitable for delivery of a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor that promotes bone growth can be either a non-degradable or a degradable material. Suitable non-degradable materials include crosslinked compositions that comprise PVA, PVP, polyacrylamide, methyl methacrylate (MMA) and methyl methacrylate-styrene (MMA-styrene) which when mixed together form polymethyl methacrylate (PMMA) or bone cement (e.g., SIMPLEX P made by Stryker Howmedica, ZIMMER REGULAR
and ZIMMER LOW VISCOSITY CEMENT, PALACOS, CMW-1 and CMW-2, ENDURANCE), synthetic cancellous bone void fillers (e.g., CORTOSS), pHEMA, polyvinyl PEG), polystyrene sulfonate), poly(acrylic acid), poly(methacrylic acid), as well as other polymers that are known to form hydrogels. Other compositions include blends and copolymers of the agents listed above. Suitable degradable materials include, but are not limited to, resorbable ceramics composed of ~i-tricalcium phosphate (e.g., VITOSS and PROOSTEON 5008 ), hydroxyapatite or Ca~o(P04)60H (e.g., BIOOSS and OSTEOGRAF)! calcium carbonate or CaC03, calcium sulfate (e.g., OSTEOSET
and ALLOMATRIX made by Wright Medical Technology, Inc.), calcium phosphate (e.g., CALCIBON or NORIAN SRS), crosslinked materials of PEG, gelatin, collagen, bone allografts (e.g., ALLOGRO (Allosource Corporation, Centennial, CO), ORTHOBLAST (GenSci Regeneration Sciences, Inc., Canada), OPTEFORM (Exactech, Inc., Gainesville, FL), GRAFTON
(Osteotech, Inc., Eatontown, NJ), mesenchymal stem cells, hyaluronic acid, hyaluronic acid derivatives, polysaccharides, carbohydrates, proteins (e.g., albumin, casein, whey proteins, plant proteins, and fish proteins), autologous bone, demineralized bone matrix, cellulose derivatives (e.g., HPC), chitosan, chitosan derivatives, polyester-polyalkylene oxide block copolymers (e.g., PLGA - PEG-PLGA and MePEG - PLGA, and the like) and other low molecular weight polymers that can be excreted. An injectable material of particular interest is prepared from a 4-armed thiol PEG (10K), a 4-armed NHS PEG(10K) and methylated collagen such as described above.
In a preferred embodiment, the injectable material also contains a biologically active agent capable of inducing fibrosis and ankylosis in the disc space. In one embodiment, the injectable material is loaded with a fibrosis-inducing agent and injected into the intervertebral disc to help repair the annulus and prevent herniation of the nucleus pulposis. In another embodiment, the injectable material contains biologically active agents capable of inducing bone growth such bone morphogenic proteins and growth factors (transforming growth factor, platelet-derived growth factor, fibroblast growth factor) to promote bony ankylosis and fusion of adjacent vertebra.
In addition to, or in lieu of, fibrosis-inducing agents, bone morphogenic proteins and growth factors, the injectable material can be utilized to deliver a sclerosant to the articular space. Sclerosants include compounds such as ethanol, DMSO, surfactants, sucrose, NaCI, dextrose, glycerin, minocycline, tetracycline, doxycycline, polidocanol, sodium tetradecyl sulfate, sodium morrhuate, sotradecol and others. The injectable material can further comprise agents such as glycerol, glycerin, PEG 200, triethyl citrate, and triacetin as plasticizers.
The injectable materials described above can be further modified to be comprised of, or contain, polymeric threads. Polymeric threads have the ability to induce a fibroproliferative response from the surrounding tissue.
These polymer threads can be degradable or non-degradable. Degradable threads can be composed of degradable polyesters, polyanhydrides, poly(anhydride esters), polyester-amides), polyester-ureas), polyorthoesters, polyphosphoesters, polyphosphazines, cyanoacrylate polymers, collagen, chitosan, hyaluronic acid, chromic cat gut, alginates, starch, cellulose, cellulose esters, blends and copolymers thereof, as well as other known degradable polymers. Non-degradable polymers that can be used include, but are not limited to, polyesters (e.g., PET), polyurethanes, silicones, PE, PP, PS, PAA, PMA, silk, blends, copolymers thereof as well as other known polymers. The threads can be composed of a single composition or composed of a blend of differing compositions. The polymeric threads themselves can be further modified through the addition of a polymeric coating applied to the threads.
The polymer used for coating the thread can be similar to that described above for the threads themselves. The polymer coating may further comprise a biologically active agent that has the ability to induce a fibroproliferative or osteogenic response. The agents that can be used are further described in the section (vi) below.
The injectable materials described above can be utilized to deliver a particulate material that has the ability to induce fibrosis in the intervertebral disc. These particles can be either degradable or non-degradable and are similar to those described above for threads. Additional particulate materials useful for the practice of this embodiment include silk, talc, starch, glass, silicates, silica, calcium phosphate, calcium sulfate, calcium carbonate, hydroxyapatite, synthetic mineral (e.g., VITOSS and CORTOSS, PMMA, silver nitrate, ceramic particles and other inorganic particles known in the art to induce a fibroproliferative response followed by mineralization. The particles used in this embodiment can be all of the same composition or a blend of differing compositions. These particles can also be used as a coating applied to the polymeric strands as described above.
The injectable materials can also be constructed such that it is comprised of both polymeric threads and particles. The threads and particles used are similar to those described above and may be of uniform composition or blended composition. Virtually any combination of threads of differing compositions and particles of differing compositions can be utilized in this embodiment. The hydrogel, the polymeric threads, and the particles can all be utilized to deliver one or more biologically active agents, as described below.
One specific composition comprises rods prepared from a methylated collagen - crosslinked polyethylene glycol) composition such as described above, which has powdered silk particles and/or mineral particles added to the composition prior to curing. Once deployed, the rod can absorb water, fill the disc space and adhere to any fibrocartilage or exposed bone.
This expansion can prevent the rod from moving, while the powdered silk and/or mineral particles can initiate an ankylosing response. As the material starts to degrade, the material can support the bone tissue ingrowth that is initiated and potentiated by the particles. Bone morphogenic proteins and/or growth factors (described previously and below) are also useful for inclusion in this composition. To further increase the rate of initiation of this fibroproliferative response, a sclerosant such as a surfactant (SDS), ethanolamine oleate or DMSO can be added. In addition, one can also add or replace all (or a portion) of the 4-armed thiol PEG with a 4-armed amino PEG.
The amino PEG can provide a gel that can take a longer time to degrade and can provide some positive charge to further attract cellular material.
Another embodiment consists of an injectable implant composed of silk fibers or from a polymerized version of the fibrosing agent itself (i.e., repeating units of the fibrosing agent polymerized together). Bone morphogenic proteins and/or growth factors (described previously and below) also may be added to this composition.
In addition to the hydrogels, bone cements, and materials containing calcium phosphate described above, there are several other injectable compositions suitable for use in minimally invasive intervertebral disc procedures. All involve the deployment of a biomaterial into the nucleus pulposis with or without the addition of a fibrosis-inducing agent, bone morphogenic protein(s), and/or a suitable growth factor(s). The following compositions can be delivered into the intervertebral disc via specialized delivery catheters, an endoscope, a needle or other applicator, a surgically placed drain or access port, or other transdermal access device, including administration of: (a) fluids, suspensions, emulsions, microemulsions, microspheres, pastes, gels, microparticulates, sprays, aerosols, solid implants and other formulations which release a biologically active fibrosis-inducing agent(s); (b) microparticulate silk and/or silk strands (linear, branched, and/or coiled) either alone, or loaded with an additional fibrosis-inducing agent, bone morphogenic protein, and/or growth factor are also useful for directed injection into the intervertebral disc; (c) injectable collagen-containing formulations such as COSTASIS or materials made from 4-armed thiol PEG (10K), 4-armed NHS
PEG(10K) and methylated collagen such as described above, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the intervertebral disc; (d) injectable PEG-containing formulations such as COSEAL, FOCALSEAL, SPRAYGEL or DURASEAL, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic , protein, and/or growth factor, injected into the intervertebral disc; (e) fibrinogen-containing formulations such as FLOSEAL or TISSEAL, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the intervertebral disc; (f) hyaluronic acid-containing formulations such as RESTYLANE, HYLAFORM, PERLANE, SYNVISC, SEPRAFILM, SEPRACOAT either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor injected into the intervertebral disc;
(g) polymeric gels for surgical implantation such as REPEL or FLOWGEL either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor injected into the intervertebral disc; (h) orthopedic "cements" such as OSTEOBOND, low viscosity cement (LVC), SIMPLEX P, PALACOS, CORTOSS and ENDURANCE, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor injected into the intervertebral disc; (i) surgical adhesives containing, cyanoacrylates such as DERMABOND, INDERMIL, GLUSTITCH, VETBOND, HISTOACRYL, TISSUEMEND, TISSUMEND II, HISTOACRYL BLUE and ORABASE SOOTHE-N-SEAL LIQUID PROTECTANT or as described above, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the intervertebral disc; (j) surgical implants containing hydroxyapatite, calcium phosphate (such as VITOSS ), or calcium sulfate, alone or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the intervertebral disc;
(k) other biocompatible tissue fillers, such as those made by BioCure, 3M
Company and Neomend, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the intervertebral disc; (I) polysaccharide gels such as the ADCON series of gels, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the intervertebral disc; (m) films, sponges or meshes such as INTERCEED, VICRYL mesh, and GELFOAM either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the intervertebral disc; and/or (n) a hydrogel that is formed from an amino-functionalized polyethylene glycol (e.g., 4-armed tetra-amino PEG [10k]) and a 4-armed NHS functionalized PEG (e.g., pentaerythritol polyethylene glycol)ether tetra-succinimidyl glutarate [10K]). This hydrogel may further contain collagen, methylated collagen and/or gelatin. This hydrogel can further comprise the fibrosis-inducing agents described above (e.g., silk powder or silk threads). In many of these embodiments, it may also be useful to add a radio-opaque material (e.g., tantalum, barium, other metal, or a contrast material) such that the injected material can be visualized radiographically or by MRI.
It should be apparent to one of skill in the art that potentially any fibrosis-inducing agents described above may be utilized alone, or in combination, in the practice of this embodiment. Exemplary fibrosing agents for use in spinal prostheses (e.g., devices and bulking agents) include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
Optionally, the device may additionally comprise an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-Vii, IL-8, IL-6, or growth hormone) and/or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).
Furthermore, the device may comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof. The administration and dosages of these agents for use in these embodiments are described in section (vi) below.
(ii) Open Surgical Disc Resection and Microdiscectomy Spinal disc removal is mandatory and urgent in cauda equine syndrome when there is a significant neurological deficit; particularly bowel or bladder dysfunction. Ifi is also performed electively to relieve pain and eliminate lesser neurological symptoms.
For open surgical resection of a ruptured lumbar disc (laminectomy) the patient is placed in a modified kneeling position under general anesthesia. An incision is made in the posterior midline and the tissue is dissected away to expose the appropriate interspace; the ligamentum flavum is dissected and in some cases portions of the bony lamina are removed to allow adequate visualization. The nerve root is carefully retracted away to expose the herniated fragment and the defect in the annulus. Typically, the cavity of the disc is entered from the tear in the annulus and the loose fragments of the nucleus pulposus are removed with pituitary forceps. Any additional fragments of disc sequestered inside or outside of the disc space are also carefully removed and the disc space is forcefully irrigated to remove to remove any residual fragments. If tears are present in the dura, the dura is closed with sutures that are often augmented with fibrin glue. The tissue is then closed with absorbable sutures.
Microlumbar disc excision (microdiscectomy) can be performed as an outpatient procedure and has largely replaced laminectomy as the intervention of choice for herniated discs. A one inch incision is made from the spinous process above the disc afFected to the spinous process below. Using an operating microscope, the tissue is dissected down to the ligamentum flavum and bone is removed from the lamina until the nerve root can be clearly identified. The nerve root is carefully retracted and the tears in the annulus are visualized under magnification. Microdisc forceps are used to remove disc fragments through the annular tear and any sequestered disc fragments are also removed. As with laminectomy, the disc space is irrigated to remove any disc fragments, any dural tears are repaired and the tissue is closed with absorbable sutures. It should be noted that anterior (abdominal) approaches can also be used for both open and endoscopic lumbar disc excision. Cervical and thoracic disc excisions are similar to lumbar procedures and can also be performed from a posterior approach (with laminectomy) or as an anterior discectomy with fusion.
The present invention provides injectable compositions to promote scarring of the annulus, scarring of dural defects and stabilization of adjacent vertebra. The fibrosing agent or fibrosing agent containing composition is delivered under direct vision during open or endoscopic disc excision. Here the composition containing the fibrosis-inducing agent is applied to the annulus or the dural defect directly (in open surgical procedures) or through the side port of an endoscope. The fibrosis-inducing agent can assist in the production of strong fibrotic tissue in the annulus fibrosis at the previous site of herniation or rupture. This can reinforce the weak portion of the intervertebral disc and reduce the likelihood of subsequent re-rupture. In dural defects, the fibrosis-inducing agent can assist in the healing of the dura and prevent complications such as CSF leakage.
The material may also be composed of a polymer system to provide sustained release of the fibrosis-inducing agent. The material suitable for delivery of a fibrosis-inducing agent for the purposes of this invention can be composed of a non-degradable or a degradable material. Suitable non-degradable materials can include crosslinked compositions that comprise PVA, PVP, polyacryiamide, methyl methacrylate (MMA) and methyl methacrylate styrene (MMA-styrene) which when mixed together form polymethyl methacrylate (PMMA) or bone cement (e.g., SIMPLEX P ZIMMER REGULAR
orZIMMER LOW VISCOSITY CEMENT, PALACOS, CMW-1, CMW-2 or ENDURANCE ), synthetic cancellous bone void fillers (e.g., CORTOSS), pHEMA, polyvinyl PEG), polystyrene sulfonate), poly(acrylic acid), poly(methacrylic acid), as well as other polymers that are known to form hydrogels. Additional compositions include blends and copolymers of the agents listed above. Suitable degradable materials include, but are not limited to, resorbable ceramics composed of a-tricalcium phosphate (e.g., VITOSS and PROOSTEON 5008 ), hydroxyapatite or Ca~o(P04)60H (e.g., BIOOSS, OSTEOGRAF ), calcium carbonate or CaC03, calcium sulfate (e.g., OSTEOSET and ALLOMATRIX ), calcium phosphate (e.g., CALCIBON or NORIAN SRS), crosslinked materials of PEG, gelatin, collagen, bone allografts (e.g., ALLOGRO, ORTHOBLAST, OPTEFORM, GRAFTON), mesenchymal stem cells, hyaluronic acid, hyaluronic acid derivatives, polysaccharides, carbohydrates, proteins (e.g., albumin, casein, whey proteins, plant proteins, and fish proteins), autologous bone, demineralized bone matrix, cellulose derivatives (HPC etc), chitosan, chitosan derivatives, polyester-polyalkylene oxide block copolymers (e.g., PLGA - PEG-PLGA and MePEG - PLGA, and the like) and other low molecular weight polymers that can be excreted.
One material that is of particular interest for use in annulus and dural repairs during intervertebral disc surgery is an injectable material prepared from a 4-armed thiol PEG (10K), a 4-armed NHS PEG(10K) and methylated collagen such as described above. In a preferred embodiment, the injectable material also contains a biologically active agent capable of inducing fibrosis to reinforce the annulus fibrosis (to reduce the risk of repeat herniation or rupture) or assist in the repair of dural defects (to prevent CSF leaks).
Preferred biologically active agents for use in combination with the injectable material include fibrosis-inducing agents and growth factors (e.g., transforming growth factor, platelet-derived growth factor, fibroblast growth factor), whose dosages and release kinetics are all described in detail in section (vi) below.
The materials described above can further modified to be comprised of, or contain, polymeric threads. Polymeric threads have the ability to induce a fibroproliferative response in the annulus fibrosis or the dura.
These polymer threads can be degradable or non-degradable. Degradable threads can be composed of degradable polyesters, polyanhydrides, poly(anhydride esters), polyester-amides), polyester-ureas), polyorthoesters, polyphosphoesters, polyphosphazines, cyanoacrylate polymers, collagen, chitosan, hyaluronic acid, chromic cat gut, alginates, starch, cellulose, cellulose esters, blends and copolymers thereof, as well as other known degradable polymers. Non-degradable polymers that can be used include, but are not limited to, polyesters (e.g., PET), polyurethanes, silicones, PE, PP, PS, PAA, PMA, silk, blends, copolymers thereof. The threads used can be composed of a single composition or composed of a blend of differing compositions. The polymeric threads themselves can be further modified through the addition of a polymeric coating applied to the threads. The polymer used for coating the thread can be similar to that described above for the threads themselves. The polymer coating may further comprise a biologically active agent that has the ability to induce a fibroproliferative response. The agents that can be used are further described in the section (vi) below.
The materials described above can also be utilized to deliver a particulate material that has the ability to induce fibrosis. These particles can be either degradable or non-degradable and are similar to those described above for threads. In addition to those, particulate materials useful for the practice of this embodiment include silk, talc, starch, glass, silicates, silica, calcium phosphate, calcium sulfate, calcium carbonate, hydroxyapatite, synthetic mineral (e.g., VITOSS and CORTOSS), PMMA, silver nitrate, ceramic particles and other inorganic particles known in the art to induce a fibroproliferative response followed by mineralization. The particles used in this embodiment can be all of the same composition or a blend of differing compositions. These particles can also be used as a coating applied to the polymeric strands as described above.
As is readily apparent, the materials used in the present invention can also be constructed such that they are comprised of both polymeric threads and particles. The threads and particles used are similar to those described above and may be of uniform composition or blended composition. Virtually any combination of threads of differing compositions and particles of differing compositions can be utilized in this embodiment. The hydrogels (e.g., injectable materials prepared from a 4-armed thiol PEG (10K), a 4-armed NHS
PEG(10K) and methylated collagen), the polymeric threads, and the particles can all be utilized to deliver one or more biologically active agents, as described below.
Other compositions are suitable for use in open surgical disc resection and microdiscectomy. All involve the deployment of a biomaterial and a fibrosis-inducing agent to reinforce the annulus fibrosis or assist in dural repair. The following compositions can be delivered during surgical disc resection and microdiscectomy either directly, using specialized delivery catheters, via an endoscope, or through a needle or other applicator: (a) fluids, suspensions, emulsions, microemulsions, microspheres, pastes, gels, microparticulates, sprays, aerosols, solid implants and other formulations which release a fibrosis-inducing agent(s); (b) microparticulate silk and/or silk strands (linear, branched, and/or coiled) either alone, or loaded with an additional fibrosis-inducing agent and/or growth factor; (c) collagen-containing formulations such as COSTASIS or materials made from 4-armed thiol PEG
(10K), 4-armed NHS PEG(10K) and methylated collagen such as described above, either alone, or loaded with a fibrosis-inducing agent and/or growth factor; (d) injectable PEG-containing formulations such as COSEAL, FOCALSEAL, SPRAYGEL or DURASEAL loaded with a fibrosis-inducing agent and/or growth factor; (e) fibrinogen-containing formulations such as FLOSEAL
or TISSEAL loaded with a fibrosis-inducing agent and/or growth factor; (f) hyaluronic acid-containing formulations such as RESTYLANE, HYLAFORM, PERLANE, SYNVISC, SEPRAFILM, SEPRACOAT loaded with a fibrosis-inducing agent and/or growth factor; (g) polymeric gels for surgical implantation such as REPEL or FLOWGEL loaded with a fibrosis-inducing agent and/or growth factor injected into the joint space; (h) orthopedic "cements" such as OSTEOBOND, LVC, SIMPLEX P, PALACOS, CORTOSS, and ENDURANCE
loaded with a fibrosis-inducing agent and/or growth factor; (i) surgical adhesives containing cyanoacrylates such as DERMABOND, INDERMIL, GLUSTITCH, VETBOND, HISTOACRYL, TISSUEMEND, TISSUMEND II, HISTOACRYL
BLUE and ORABASE SOOTHE-N-SEAL LIQUID PROTECTANT or as described above, loaded with a fibrosis-inducing agent and/or growth factor;
(j) surgical implants containing hydroxyapatite, calcium phosphate (such as VITOSS, Orthovita), or calcium sulfate loaded with a fibrosis-inducing agent and/or growth factor; (k) other biocompatible tissue fillers, such as those made by BioCure, 3M Company and Neomend loaded with a fibrosis-inducing agent and/or growth factor; (I) polysaccharide gels such as the ADCON series of gels loaded with a fibrosis-inducing agent and/or growth factor; (m) films, sponges or meshes such as INTERCEED, VICRYL mesh, and GELFOAM either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the intervertebral disc; and/or (n) a hydrogel that is formed from an amino-functionalized polyethylene glycol (e.g., 4-armed tetra-amino PEG [10k]) and a 4-armed NHS functionalized PEG (e.g., pentaerythritol polyethylene glycol)ether tetra-succinimidyl glutarate [1 OK]). This hydrogel may further contain collagen, methylated collagen and/or gelatin. This hydrogel can further comprise the fibrosis-inducing agents described above (e.g., silk powder or silk threads).and/or (m) films, sponges or meshes such as INTERCEED, VICRYL mesh, and GELFOAM either alone, or loaded with a fibrosis-inducing agent and/or growth factor.
It should be apparent to one of skill in the art that potentially any fibrosis-inducing agents described above may be utilized alone, or in combination, in the practice of this embodiment. Exemplary fibrosing agents for use in spinal prostheses (e.g., devices and bulking agents) include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
Optionally, the device may additionally comprise an inflammatory cytokine (e.g., TGF~, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-[3, IL-8, IL-6, and growth hormone) and/or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof. The administration and dosages of these agents for use in these embodiments are described in section (vi) below.
(iii) Treatments of Vertebral Compression Fractures Osteoporosis is a progressive degenerative bone disease characterized by decreased bone mineral density, degradation of bone microarchitecture and reduced bone strength. The weakened bone is often unable to withstand stress, or even normal weight-bearing activities, and is at an increased risk for sustaining fractures. Fractures are the most common clinical manifestation of osteoporosis and the condition is often asymptomatic until the breakage occurs. Osteoporosis is the cause of 1.3 million fractures each year in the U.S. and is estimated to cost the healthcare system over $10 billion annually. Fractures of the hip, wrist and other long bones are common in osteoporosis, but approximately 550,000 patients in the U.S. (700,000 worldwide) suffer vertebral compression fractures as a result of their disease.
Here, the weakened cancellous bone of the vertebral column essentially collapses (compresses) under the weight placed on it during normal activities and the vertebra loses height (i.e., the center of the vertebra collapses and the two endplates of the vertebra move closer together). Compression of the vertebra leads to pain, a loss of height, curvature of the spine (kyphosis), and in some cases, breathing problems due to pressure placed on the chest cavity and lungs.
Traditionally, vertebral compression fractures have been treated conservatively with bed rest. In severe cases, spinal fusion and/or open fracture reduction (repairing the fracture with surgically placed orthopedic plates and screws) have also been used in the management of vertebral compression fractures. Recently, two minimally invasive procedures - vertebroplasty and kyphoplasty - have been developed to treat vertebral compression fractures due to osteoporosis or, less commonly, due to bone tumors. Vertebroplasty utilizes bone cement (polymethylmethacrylate - PMMA) injected under pressure into the fracture under x-ray guidance to stabilize the fracture, provide support and reduce pain. This procedure can often be performed as an outpatient and provides almost immediate symptomatic relief and early mobilization. Kyphoplasty involves the insertion of a balloon (KYPHX
Inflatable Bone Tamp made by Kyphon Inc., Sunnyvale, CA) into the fracture which is then inflated inside the bone to create a void, stabilize the fracture and straighten the bone and spine (i.e., restore the vertebral height lost as a result of the compression fracture). The surgeon then injects bone filler (typically PMMA or a calcium phosphate-based material) via specialized access devices (Inflation Syringe and Bone Access System also made by Kyphon, Inc.
(Sunnyvale, CA) into the space under C-arm image-guided fluoroscopy to support the fractured vertebra). Injecting the bone cement into the balloon-created cavity enables the injection to be performed under low pressure and reduces the incidence of neurological injury associated with cement leakage.
In vertebroplasty, where the cement is injected under pressure, cement leakage occurs in 30-73% of patients versus only 8-9% of those treated with kyphoplasty.
In both vertebroplasty and kyphoplasty the fractured bone is reinforced and replaced by bone cement. Unfortunately, bone cement is significantly stronger than the adjacent bone and can exert an incompressible mass effect on the surrounding vertebra leading to compressions and fractures in the vertebra above and below the treated segment. The present invention provides injectable compositions that include a bulking or filling agent and a fibrosing agent for direct injection into vertebral compression fractures as part of vertebroplasty or kyphoplasty. A material containing a fibrosis-inducing agent (alone or in combination with polymeric carrier, which may be in the form of, e.g., a gel, paste, or spray) is injected into a vertebral compression fracture can be used to promote the growth of endogenous scar tissue to fill the vertebral body defect, thus more closely mimicking normal tissue dynamics and reducing the incidence of adjacent vertebral fractures. In another embodiment, the injectable composition containing a fibrosis-inducing agent can further contain an agent that promotes bone growth (e.g., bone morphogenic proteins, growth factors, etc.). When performing an injection into a vertebral compression fracture, it may also be necessary to add compositions to enhance visualization of needle (or catheter). Suitable agents and methods for use in combination with a fibrosis-inducing agent (with or without an agent that promotes bone growth) include, but are not limited to, the use of a needle coated with ECHO-COAT or the addition of contrast agents (e.g., barium, tantalum, technitium, gadolinium) for localization by x-ray or MRI.
The injectable material may also contain a polymer system that can provide sustained release of the fibrosis-inducing agent (with or without a concominant bone morphogenic protein, and/or osteogenic growth factor) to enhance efficacy and reduce the need for repeat administrations of active agents. Preferred polymeric carriers for delivery of a injectable fibrosis-inducing agent (with or without a bone morphogenic protein, and/or growth factor that promotes bone growth) for the treatment of vertebral compression fractures are degradable materials which, after providing initial tissue support, are gradually replaced by the body's own scar tissue. Suitable degradable materials for use in this embodiment include, but are not limited to, resorbable ceramics composed of ~i-tricalcium phosphate (e.g., VITOSS and PROOSTEON 5008 ), hydroxyapatite or Ca~o(P04)60H (e.g., BIOOSS and OSTEOGRAF ), calcium carbonate or CaC03, calcium sulfate (e.g., OSTEOSET and ALLOMATRIX ), calcium phosphate (e.g., CALCIBON or NORIAN SRS), crosslinked materials of PEG, gelatin, collagen, bone allografts (e.g., ALLOGRO, ORTHOBLAST, OPTEFORM, GRAFTON), mesenchymal stem cells, hyaluronic acid (such as RESTYLANE, HYLAFORM, PERLANE, SYNVISC, SEPRAFILM, SEPRACOAT), hyaluronic acid derivatives, polysaccharides, carbohydrates, fibrinogen-containing formulations (such as FLOSEAL or TISSEAL), proteins (e.g., albumin, casein, whey proteins, plant proteins, and fish proteins, and the like), autologous bone, demineralized bone matrix, cellulose derivatives (e.g., HPC etc), chitosan, chitosan derivatives, polyester-polyalkylene oxide block copolymers (e.g., PLGA - PEG-PLGA and MePEG - PLGA, and the like) and other low molecular weight polymers that can be excreted. Injectable PEG-containing formulations such as COSEAL, FOCALSEAL, SPRAYGEL or DURASEAL loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor can also be used for injection into a vertebral compression fracture. Loading these materials with a fibrosis-inducing agent (with or without a bone morphogenic protein, and/or growth factor that promotes bone growth) can produce an injectable material that can provide initial support and symptomatic relief, but degrade with time as the body's own scar tissue grows in to repair the defect.
One injectable material that is of particular interest for injection into vertebral compression fractures is prepared from a 4-armed thiol PEG
(10K), a 4-armed NHS PEG(10K) and methylated collagen such as described above. In a preferred embodiment, the injectable material also contains a biologically active fibrosis-inducing agent (with or without a bone morphogenic protein, and/or growth factor that promotes bone growth). In one embodiment, the injectable material is loaded with a fibrosis-inducing agent is injected into a vertebral compression fracture to provide stability and symptomatic relief, form a scaffold that supports fibrous and bony ingrowth, deliver active agents that can promote repair, and degrade once tissue repair is complete. In another embodiment, the injectable material contains biologically active agents capable of inducing bone growth such bone morphogenic proteins and growth factors (transforming growth factor, platelet-derived growth factor, fibroblast growth factor) to promote bony ankylosis and fusion of adjacent vertebra. In some circumstances, the injectable material may contain a fibrosis-inducing agent as well as a bone morphogenic protein and/or growth factors that promote bone growth.
In certain embodiments (for example, in the treatment of more unstable fractures) it may be desirable to use a bone cement to deliver the fibrosis-inducing agent to a vertebral compression fracture. Suitable non-degradable materials include crosslinked compositions that comprise PVA, PVP, polyacrylamide, methyl methacrylate (MMA) and methyl methacrylate styrene (MMA-styrene) which when mixed together form polymethyl methacrylate (PMMA) or bone cement (e.g., SIMPLEX P, ZIMMER REGULAR
and ZIMMER LOW VISCOSITY CEMENT, PALACOS, CMW-1, CMW-2 or ENDURANCE). Also of utility in this embodiment are synthetic cancellous bone void fillers (e.g., CORTOSS), pHEMA, polyvinyl PEG), polystyrene sulfonate), poly(acrylic acid), poly(methacrylic acid), as well as other polymers that are known to form hydrogels. Surgical adhesives containing cyanoacrylates such as DERMABOND, INDERMIL, GLUSTITCH, TISSUEMEND, VETBOND, HISTOACRYL BLUE and ORABASE SOOTHE-N-SEAL LIQUID
PROTECTANT loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor are also suitable for injection into vertebral compression fracture. Additional compositions include blends and copolymers of the agents listed above. In each case the material is loaded with a fibrosis-inducing agent (with or without a bone morphogenic protein, and/or growth factor that promotes bone growth) and injected into a vertebral compression fracture (as part of vertebroplasty or kyphoplasty) to stabilize the fracture and encourage the ingrowth of tissue. The addition of fibrous tissue in and around the non-degradable implant can make the material behave more like native tissue and reduce the incidence of adjacent fractures.
All of the injectable materials described above can be further modified to be comprised of, or contain, polymeric threads. Polymeric threads have the ability to induce a fibroproliferative response from the surrounding tissue. These polymer threads can be degradable or non-degradable.
Degradable threads can be composed of degradable polyesters, polyanhydrides, polyorthoesters, polyphosphoesters, polyphosphazines, cyanoacrylate polymers, collagen, chitosan, hyaluronic acid, chromic cat gut, alginates, starch, cellulose, cellulose esters, blends and copolymers thereof, as well as other known degradable polymers. Non-degradable polymers that can be used include, but are not limited to, polyesters (e.g., PET), polyurethanes, silicones, PE, PP, PS, PAA, PMA, silk, blends, copolymers thereof as well as other known polymers. The threads used can be composed of a single composition or composed of a blend of differing compositions. The polymeric threads themselves can be further modified through the addition of a polymeric coating applied to the threads. The polymer used for coating the thread can be similar to that described above for the threads themselves. The polymer coating may further comprise a biologically active agent that has the ability to induce a fibroproliferative or osteogenic response. The fibrosis-inducing agents that can be used are further described in the section (vi) below.
The injectable materials described above can be utilized to deliver a particulate material that has the ability to induce fibrosis in an intervertebral fracture. These particles can be either degradable or non-degradable and are similar to those described above for threads. Microparticulate silk and/or silk strands (linear, branched, and/or coiled) either alone, or loaded with an additional fibrosis-inducing agent, bone morphogenic protein, and/or growth factor are also useful for directed injection into a vertebral compression fracture.
Additional particulate materials useful far the practice of this embodiment include talc, starch, glass, silicates, silica, calcium phosphate, calcium sulfate, calcium carbonate, hydroxyapatite, synthetic mineral (e.g., VITOSS and CORTOSS), PMMA, silver nitrate, ceramic particles and other inorganic particles known in the art to induce a fibroproliferative response followed by mineralization. The particles used in this embodiment can be all of the same composition or a blend of differing compositions. These particles can also be used as a coating applied to the polymeric strands as described above.
The injectable materials can also be constructed such that it is comprised of both polymeric threads and particles. The threads and particles used are similar to those described above and may be of uniform composition or blended composition. Virtually any combination of threads of differing compositions and particles of differing compositions can be utilized in this embodiment. The hydrogels, the polymeric threads, and the particles can all be utilized to deliver one or more biologically active agents, as described below.
One specific composition comprising threads and/or particles is prepared from 4-armed thiol PEG (10K), 4-armed NHS PEG(10K) and methylated collagen such as described above and contains powdered silk particles (or silk threads) and/or mineral particles added to the composition prior to curing. Once deployed, the composition can absorb water, fill the fracture space and adhere to adjacent bone. This expansion can stabilize the fracture and restore vertebral height, while the powdered silk and/or mineral particles can initiate an ankylosing response. As the 4-armed thiol PEG (10K), 4-armed NHS PEG(10K) and methylated collagen composition starts to degrade, the material can support the bone tissue ingrowth that is initiated and potentiated by the particles. Bone morphogenic proteins and/or growth factors (described previously and below) are also useful for inclusion in this composition. In addition, one may also add or replace all (or a portion) of the 4-armed thiol PEG
with a 4-armed amino PEG. The amino PEG can provide a gel that can take a longer time to degrade and can provide some positive charge to further attract cellular material.
A second specific embodiment consists of an injectable implant composed of silk fibers or a polymerized version of the fibrosing agent itself (i.e., repeating units of the fibrosing agent polymerized together). Bone morphogenic proteins andlor growth factors (described previously and below) may also be added to this composition.
It should be apparent to one of skill in the art that potentially any fibrosis-inducing agents described above may be utilized alone, or in combination, in the practice of this embodiment. Exemplary fibrosing agents for use in spinal prostheses (e.g., devices and bulking agents) include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
Optionally, the device may additionally comprise an inflammatory cytokine (e.g., TGF~3, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-Vii, IL-8, IL-6, and growth hormone)and/or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof.
The administration and dosages of these agents for use in the above embodiments are described in section (vi) below.
(iv) Spinal Fusion Devices In some cases, it may be necessary to promote bony fusion of adjacent vertebral segments (in effect biologically "welding" the segments together). Fusion of one or more vertebral segments alleviates pain by restricting vertebral motion across the damaged intervertebral disc(s).
Surgical spinal fusion can be accomplished using a variety of procedures, implants and devices.

Typically, the vertebral canal is exposed through open surgery (either anteriorly and/or posteriorly) and all or parts of the damaged disc are removed sufficient to allow decompression of the affected cord or nerve roots.
Bone grafts (autografts or allografts) or bone substitutes are used to promote vertebral fusion, while the fixation devices serve to immobilize the region until bony fixation takes place. As part of the spinal fusion surgery, it is often necessary to augment the procedure through the insertion of an implant or device that stabilizes the fusing spinal segments while the bone graft or bone substitute fuses the mobile segments. Examples of implants and devices designed to splint the segments during the healing process include: fusion devices (including fusion baskets, fusion cage apparatus, interbody cages, interbody implants, fusion cage anchoring devices, fusion stabilization chamber, fusion cage anchoring plates), bone fixation devices (including anchoring bone plates, bone screws, and other fixation hardware) and tissue fillers/implants (including bone cement, allograft material, autograft material, collagen, and other biocompatible tissue fillers). All of these implants are suitable for coating with, or delivery of, a fibrosis-inducing agents) to promote healing and accelerate fusion of the vertebral bodies.
Spinal fusion cages are interbody devices that fit within the intervertebral space and/or the anterior region of the vertebral column.
Fusion cages have various shapes including rectangular or cylindrical and a plurality of openings and helical threading. Fusion cages are often composed of an outer body and a hollow cavity that may or may not be used to insert bone growth-promoting material for stimulating bone fusion. For example, the prosthesis may be an interbody fusion cage that has an externally threaded stem projecting from a domed outer end which is fixed using an assembly of a plate, a fastener and bone screws. See e.g., U.S. 6,156,037. The prosthesis may be a fusion cage with a threaded outer surface adapted for promoting fusion with bone structures when a bone-growth-inducing substance is packed into the cage body. See e.g., U.S. 4,961,740; 5,015,247; 4,878,915; and 4,501,269.
The prosthesis may be a generally tubular shell with a helical thread projecting with a plurality of pillars with holes to facilitate bone ingrowth and mechanical anchoring (see e.g., U.S. 6,071,310 and 5,489,308) or it may be biologically active and serve to promote fusion with the adjacent vertebral bone plates (see e.g., U.S. 5,489,308 and 6,520,993). Other U.S. patents that describe threaded spinal implants include U.S. Patent Nos. 5,263,953; 5,458,638; and 5,026,373.

In another aspect, the prosthesis may be a bone fixation device designed to promote vertebral fusion in order to limit movement between adjacent vertebrae. For example, bone dowels, rods, hooks, wires, wedges, plates, screws and other components may be used to fix the vertebral segments into place. The fixation device may fit within the intervertebral space or it may encompass both the intervertebral space and the anterior region of the vertebral column or it may only encompass the anterior region of the vertebral column. A bone fixation device may be used with a fusion cage to assist in stabilizing the device within the intervertebral area. For example, the prosthesis may be in the form of a solid annular body having a plurality of discrete bone-engaging teeth protruding on the superior and inferior surfaces and having a central opening that may be filled with a bone growth-promoting material. See e.g., U.S. 6,520,993. The prosthesis may have a disk-like body with weld-like raised parts disposed on opposite surfaces to enhance lateral stability in situ.
See e.g., U.S. 4,917,704. The prosthesis may be composed of opposite end pieces that maintain the height of the intervertebral space with an integral central element that is smaller in diameter wherein osteogenic material is disposed within the annular pocket between the end pieces. See e.g., U.S.
6,146,420. The prosthesis may be composed of first and second side surfaces extending parallel to each other with upper and lower surfaces that engage the adjacent vertebrae. See e.g., U.S. 5,716,415. The prosthesis may be a fusion stabilization chamber composed of a hollow intervertebral spacer and an end portion with at least one hole for affixing into the surrounding bone. See e.g., U.S. 6,066,175. The prosthesis may be composed of a metallic body tapering conically from the ventral to the dorsal end and having a plurality of fishplates extending from opposite sides with openings for bone screws. See e.g., U.S.
4,955,908. The prosthesis may be composed of a pair of plates which may have protrusions for engaging the adjacent vertebrae and an alignment device disposed between the engaging plates for separating the plates to maintain them in lordotic alignment. See e.g., U.S. 6,576,016. The prosthesis may be a plurality of implants that are inserted side by side into the disc space to promote bone fusion across an intervertebral space. See e.g., U.S. 5,522,899. The prosthesis may be an anchoring device composed of an anchoring plate with a central portion configured for attachment to a vertebral implant (e.g., fusion cage) and the end portions adapted to fasten in a fixed manner to a bony segment of the vertebra. See e.g., U.S. 6,306,170. The prosthesis may be a bone fixation apparatus composed of a bone plate and a fastener apparatus (e.g., bone screws). See e.g., U.S. 6,342,055; 6,454,769; 6,602,257; and 6,620,163.
Spinal prostheses, which may be combined with one or more fibrosis-inducing agents according to the present invention, include commercially available products. Examples include: the INTERFIX Threaded Fusion Device (by Medtronic Sofamor Danek, Memphis, TN), the BAK/C
Cervical Interbody Fusion System and the CERVI-LOK Cervical Fixation System (by Centerpulse SPINE-TECH, Minneapolis, MN), the SC-ACUFIX
Anterior Cervical Plate System (by Spinal Concepts, Austin, TX), the ACROFLE
TDR prostheses and the CHARITE Artificial Disc (by DePuy Spine, Inc., Raynham, MA), the PRODISC system and PRODISC Cervical-C IDE disc replacement (by Synthes-Stratec, Switzerland) and the PROSTHETIC DISC
NUCLEUS (by Raymedica, Inc., Minneapolis, MN).
In all of the aforementioned spinal fusion devices, the addition of a fibrosis-inducing agent may assist in the spinal fusion process by promoting the production of fibrous tissue. In one aspect, the present invention provides spinal fusion devices (including fusion baskets, fusion cage apparatus, interbody cages, interbody implants, fusion cage anchoring devices, fusion stabilization chamber, fusion cage anchoring plates; bone fixation devices including anchoring bone plates, bone screws, and other fixation hardware; and tissue fillers/implants including bone cement, allograft material, autograft material, collagen, and other biocompatible tissue fillers) that include a fibrosis-inducing agent or a composition that includes a fibrosis-inducing agent to promote scarring and fixation of the device into the surrounding bone. In one aspect, a spinal fusion device is coated with a fibrosing agent or a composition that includes the fibrosing agent to enhance healing. In another aspect, the fibrosing agent may be incorporated into the glue/cement that holds the spinal fusion device in place. In another aspect, the spinal fusion device is covered (all or in part) with a silk mesh or lattice to encourage scarring and anchoring into the surrounding bone. For example, a silk mesh or lattice can be coated onto all or a portion of the surface of fusion cage or other bone fixation hardware to encourage scarring and anchoring into the surrounding bone.
Numerous polymeric and non-polymeric carrier systems described previously can be used to provide sustained release of the fibrosis inducing agent from the spinal fusion device. Methods for incorporating fibrosing compositions onto or into the spinal fusion devices include: (a) directly affixing to the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (b) directly incorporating into the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (c) by coating the device with a substance such as a hydrogel which can in turn absorb the fibrosing composition; (d) by interweaving a fibrosing composition (for example a silk strand or another polymeric thread which releases a fibrosis-inducing agent) into the device structure; (e) by inserting the device into a sleeve or mesh which is comprised of, or coated with, a fibrosing composition;
(f) constructing the device itself, or a portion of the device, with a fibrosing composition; or (g) by covalently binding the fibrosing agent directly to the device surface, or to a linker (small molecule or polymer) that is coated or attached to the device surface. For these devices, the coating process can be performed in such a manner as to (a) coat the surfaces of the device that is in contact with the bone, (b) coat the surfaces of the device that are not in contact with the bone or (c) coat all or parts of both the bone-contacting and non-bone contacting surfaces of the device.
In addition to coating the spinal fusion device with the fibrosing composition, the fibrosis-inducing agent can be mixed with the materials that are used in the construction of the device such that the fibrosing agent is incorporated into the final device.
It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agents described above may be utilized alone, or in combination, in the practice of this embodiment. Exemplary fibrosing agents for use in spinal fusion devices (including fusion baskets, fusion cage apparatus, interbody cages, interbody implants, fusion cage anchoring devices, fusion stabilization chamber, fusion cage anchoring plates; bone fixation devices including anchoring bone plates, bone screws, and other fixation hardware; and tissue fillers/implants including bone cement, allograft material, autograft material, collagen, and other biocompatible tissue fillers) include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
Optionally, the device may additionally comprise an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-~, IL-8, IL-6, and growth hormone) and/or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof.
The administration and dosages of these agents for use in these embodiments are described in section (vi) below.
(v) Intervertebral Disc Prostheses In certain cases of DDD, the damaged vertebral segment may be treated using a intervertebral disc prosthesis that maintains vertebral anatomy and movement within the vertebral joint. This is often conducted when damage to more than one vertebral segment occurs. As used herein, the term "intervertebral disc prostheses" (or "artificial disc") refers to implants and/or devices that are located in, on, or near the spine and which enhance the ability of the spine to perform its function in the patient. Examples of intervertebral disc prostheses include, without limitation, artificial spinal discs and related devices including vertebral implants, vertebral disc prostheses, lumbar disc implants, cervical disc implants, implantable intervertebral prostheses, spinal prostheses, artificial discs, prosthetic implants, prosthetic spinal discs, spinal disc endoprostheses, spinal implants, artificial spinal discs, intervertebral implants, implantable spinal grafts, artificial lumbar discs, spinal nucleus implants, and intervertebral disc spacers.
An artificial disc suitable for combining with a fibrosis-inducing agent according to the present invention may be composed of a single material or several materials including, without limitation, allograft bone material (see e.g., U.S. 6,143,033), metals (see e.g., U.S. 4,955,908), and/or synthetic materials (see e.g., U.S. 6,264,695; 6,419,706; 5,824,093; and 4,911,718). The prosthesis must be biocompatible and may consist of biodegradable or non-biodegradable components depending on the intended function of the device.
See e.g., U.S. 4,772,287. The intervertebral disc prosthesis may be biologically inert and serve as a mechanical means of stabilizing the vertebral column (see e.g., U.S. 4,955,908 and 5,716,415) or as a means of preserving spinal function. In another aspect, the prosthesis may be an alternative to spinal fusion. The prosthesis may be a disc designed to provide normal movement between vertebral bone plates. The artificial disc may be intended to mimic the natural shock absorbent function of the natural disc. The artificial disc may be composed of a center core and end elements that support the disc against the adjacent vertebra or it may be intended to replace only a portion of the natural intervertebral disc (e.g., nucleus pulposus). For example, the artificial disc may be in the form of an elastomeric section sandwiched between two rigid plates.
See e.g., U.S. 6,162,252; 5,534,030; 5,017,437; and 5,031,437. The intervertebral disc prosthesis may be an elongated prosthetic disc nucleus composed of a hydrogel core and a constraining flexible jacket that allows the core to deform and reform. See e.g., U.S. 5,824,093. The artificial disc may be composed of a rigid superior and inferior concaval-convex elements and a nuclear body which is located between the concave surfaces to permit movement. See e.g., U.S. 6,156,067. The artificial disc may be a partial spinal prosthesis composed of a core made of an elastic material such as silicone polymer or an elastomer which is covered by a casing made of a rigid material which is in contact with the adjacent vertebrae. See e.g., U.S. 6,419,706. The intervertebral disc prosthesis may replace only the nucleus pulposus tissue by using a spinal nucleus implant comprised of a swellable, biomimetic plastic with a hydrophobic and hydrophilic phase which can be expanded in situ to conform to the natural size and shape. See e.g., U.S. 6,264,695. The artificial disc may be composed of a central core formed from a biocompatible elastomer wrapped by multi-layered laminae made from elastomer and fibers. See e.g., U.S.
4,911,718. The intervertebral disc prosthesis may be composed of a fluid-filled inner bladder with an outer layer of strong, inert fibers intermingled with a bioresorbable material which promotes tissue ingrowth. See e.g., U.S. 4,772, 287.
In one aspect, the present invention provides intervertebral disc prostheses that include a fibrosis-inducing agent or a composition that includes a fibrosis-inducing agent to promote scarring and fixation of the device into the surrounding bone and yet retain the flexibility of the natural disc. In one aspect, an artificial disc is coated with a fibrosis-inducing agent (or a composition that includes a fibrosis-inducing agent) to enhance healing and the formation of fibrous tissue similar to the annulus fibrosis. In another aspect, the fibrosing agent may be incorporated into the glue/cement that holds the artificial disc in place. In another aspect, the intervertebral disc prosthesis is covered (all or in part) with a silk mesh or lattice to encourage scarring and anchoring of the implant into the surrounding bone.
Numerous polymeric and non-polymeric carrier systems described previously can be used to provide sustained release of the fibrosis-inducing agent from the artificial disc. Methods for incorporating fibrosing compositions onto or into intervertebral disc prostheses include: (a) directly affixing to the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (b) directly incorporating into the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (c) by coating the device with a substance such as a hydrogel which can in turn absorb the fibrosing composition; (d) by interweaving a fibrosing composition (for example a silk strand or another polymeric thread which releases a fibrosis-inducing agent) into the device structure; (e) by inserting the device into a sleeve or mesh which is comprised of, or coated with, a fibrosing composition;
(f) constructing the device itself, or a portion of the device, with a fibrosing composition; or (g) by covalently binding the fibrosing agent directly to the device surface, or to a linker (small molecule or polymer) that is coated or attached to the device surface. For these devices, the coating process can be performed in such a manner as to (a) coat the surfaces of the device that is in contact with the vertebral bone, (b) coat the surfaces of the device that are not in contact with the bone or (c) coat all or parts of both the bone-contacting and non-bone contacting surfaces of the device.
In addition to coating the artificial disc with the fibrosing composition, the fibrosing agent can be mixed with the materials that are used to make the device such that the fibrosing agent is incorporated into the final prosthetic intervertebral disc.
In one embodiment, the therapeutic agent can be incorporated directly into the formulation (for example, direct incorporation of the fibrosis-inducing agent into the swellable, biomimetic polymers used to create an artificial nucleus pulposus tissue that expands in situ to conform to the natural size and shape of the intervertebral disc core.). In another embodiment, the fibrosis-inducing agent can be incorporated into a secondary carrier (e.g., micelles, liposomes, emulsions, microspheres, nanospheres etc, as described above) that are then used in the construction of, or as constituents of, an artificial disc.

It should be apparent to one of skill in the art that potentially any fibrosis-inducing agents described above may be utilized alone, or in combination, in the practice of this embodiment. Exemplary fibrosing agents for use in spinal prostheses (e.g., devices and bulking agents) include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
Optionally, the device may additionally comprise an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-Vii, IL-8, IL-6, and growth hormone) and/or a bone hormone) and/or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-[3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof.
The administration and dosages of these agents for use in these embodiments are described in section (vi) below.
(vi) Fibrosis-Inducing Agents for Use in Spinal Conditions As spinal prostheses and injectables are made in a variety of configurations and sizes, the exact dose administered can vary with the amount injected or with the device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured, and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the spinal prostheses, the exemplary fibrosing agents, used alone or in combination, should be administered under the following dosing guidelines:
Utilizing talc as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of talc delivered from a spinal prosthesis, or coated onto the surface of a spinal prosthesis, should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of talc released from the prosthesis should be in the range of 10 p,g to 50 mg. The dose per unit area of the device (i.e., the dosage of talc as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 p,g - 10 p,g per mm2 of surface area coated. In another embodiment, talc should be applied to a spinal prosthesis surface at a dose of 0.05 ~,g/mm2 -10 ~g/mm2 of surface area coated. In one embodiment, talc is released from the surface of a spinal prosthesis or from composition (e.g., a bulking agent) such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. Drug concentrations in a bulking agent or other such material should be within the range described above except values are in mm3. ,For example, talc may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of talc (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as talc is administered at half the above parameters, a compound half as potent as talc is administered at twice the above parameters, etc.).
Utilizing silk as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of silk delivered from a spinal prosthesis, or coated onto the surface of a spinal prosthesis, should not exceed 100 mg (range of 1 pg to 100 mg). In one embodiment, the total amount of silk released from the prosthesis should be in the range of 10 pg to 50 mg. The dose per unit area of the device (i.e., the dosage of silk as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 p.g - 10 p.g per mm2 of surface area coated. In another embodiment, silk should be applied to a spinal prosthesis surface at a dose of 0.05 p.g/mm2 -10 p,g/mmz of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release silk at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the spinal prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of silk is delivered to the tissue. In one embodiment, silk is released from the surface of a spinal prosthesis or from an injectable composition (e.g., a bulking agent) such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, silk may be released in effective concentrations for a period ranging from 1 hour-30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of silk (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as silk is administered at half the above parameters, a compound half as potent as silk is administered at twice the above parameters, etc. ).
Utilizing chitosan as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of chitosan delivered from a spinal prosthesis, or coated onto the surface of a spinal prosthesis, should not exceed 100 mg (range of 1 ~.g to mg). In one embodiment, the total amount of chitosan released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of chitosan as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~,g - 10 p,g per mm2 of surface area coated. In another embodiment, chitosan should be applied to a spinal prosthesis surface at a dose of 0.05 ~,g/mmz -10 pg/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release chitosan at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the spinal prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of chitosan is delivered to the tissue. In one embodiment, chitosan is released from the surface of a spinal prosthesis or from an injectable composition (e.g., a bulking agent) such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, chitosan may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of chitosan (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as chitosan is administered at half the above parameters, a compound half as potent as chitosan is administered at twice the above parameters, etc.).
Utilizing polylysine as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of polylysine delivered from a spinal prosthesis, or coated onto the surface of a spinal prosthesis, should not exceed 100 mg (range of 1 ~,g to mg). In one embodiment, the total amount of polylysine released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of polylysine as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 p,g - 10 ~g per mm2 of surface area coated. In another embodiment, polylysine should be applied to a spinal prosthesis surface at a dose of 0.05 p,g/mm2 -10 ~,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release polylysine at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the spinal prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of polylysine is delivered to the tissue. In one embodiment, polylysine is released from the surface of a spinal prosthesis or from a composition (e.g., a bulking agent) such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, polylysine may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of polylysine (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as polylysine is administered at half the above parameters, a compound half as potent as polylysine is. administered at twice the above parameters, etc.).
Utilizing fibronectin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of fibronectin delivered from a spinal prosthesis, or coated onto the surface of a spinal prosthesis, should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of fibronectin released from the prosthesis should be in the range of 10 ~g to 50 mg. The dose per unit area of the device (i.e., the dosage of fibronectin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~g - 10 ~,g per mm2 of surface area coated. In another embodiment, talc should be applied to a spinal prosthesis surface at a dose of 0.05 ~,g/mm2 -10 ~,g/mm2 of surface area coated. As specific (polymeric and, non-polymeric) drug delivery vehicles and specific medical devices can release fibronectin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the spinal prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of fibronectin is delivered to the tissue. In one embodiment, fibronectin is released from the surface of a spinal prosthesis or from a composition (e.g., a bulking agent) such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, fibronectin may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of fibronectin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as fibronectin is administered at half the above parameters, a compound half as potent as fibronectin is administered at twice the above parameters, etc.).
Utilizing bleomycin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of bleomycin delivered from a spinal prosthesis, or coated onto the surface of a spinal prosthesis, should not exceed 100 mg (range of 0.01 ~g to 100 mg). In one embodiment, the total amount of bleomycin released from the prosthesis should be in the range of 0.10 p.g to 50 mg. The dose per unit area of the device (i.e., the dosage of bleomycin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 ~,g - 10 ~,g per mm2 of surface area coated. In another embodiment, bleomycin should be applied to a spinal prosthesis surface at a dose of 0.005 p.g/mm2 -10 ~,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release bleomycin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the spinal prosthesis such that a minimum concentration of 0.001 nM to 1000 pM of bleomycin is delivered to the tissue. In one embodiment, bleomycin is released from the surface of a spinal prosthesis or from a composition (e.g., a bulking agent) such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, bleomycin may be released in effective concentrations for a period ranging from 1 hour- 30 days.
It should be readily evident given the discussions provided herein that analogues and derivatives of bleomycin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as bleomycin is administered at half the above parameters, a compound half as potent as bleomycin is administered at twice the above parameters, etc.).
Utilizing CTGF as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of CTGF delivered from a spinal prosthesis, or coated onto the surface of a spinal prosthesis, should not exceed 100 mg (range of 0.01 ~g to 100 mg). In one embodiment, the total amount of CTGF released from the prosthesis should be in the range of 0.10 ~g to 50. mg. The dose per unit area of the device (i.e., the dosage of CTGF as a function of the surface area of the portion of the device to which drug is applied andlor incorporated) should fall within the range of 0.005 ~.g - 10 p,g per mm2 of surface area coated. In another embodiment, CTGF
should be applied to a spinal prosthesis surface at a dose of 0.005 ~.g/mm2 -~,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release CTGF at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the spinal prosthesis such that a minimum concentration of 0.001 nM to 1000 pM of CTGF is delivered to the tissue. In one embodiment, CTGF is released from the surface of a spinal prosthesis or from a composition (e.g., a bulking agent) such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, CTGF may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of CTGF (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as CTGF is administered at half the above parameters, a compound half as potent as CTGF is administered at twice the above parameters, etc.).
As described above, the device may additionally comprise an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-Vii, IL-8, IL-6, and growth hormone) and/or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).
Bone morphogenic proteins) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof) are to be used in formulations at concentrations that range from 0.001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the bone morphogenic protein is released in effective concentrations for a period ranging from 1 - 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.001 ~.g to ~
500 mg); preferred 1 ~.g to 250 mg. When used as a device coating, the dose is per unit area of 0.001 p,g - 1000 ~.g per mm2; with a preferred dose of 0.01 ~g/mm2 - 200 ~g/mm2. Minimum concentration of 10-9- 10-4 M of bone morphogenic protein is to be maintained on the device surFace.
Inflammatory cytokines are to be used in formulations at concentrations that range from 0.0001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the inflammatory cytokine is released in effective concentrations for a period ranging from 1 - 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 pg to 100 mg); preferred 0.001 ~,g to 50 mg. When used as a device coating, the dose is per unit area of 0.0001 p,g - 500 ~,g per mm2; with a preferred dose of 0.001 p,g/mma - 200 ~,g/mm2. Minimum concentration of 10-'°- 10-4 g/ml of inflammatory cytokine is to be maintained on the device surface.
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof. Doses used are those concentrations which are demonstrated to stimulate cell proliferation (see Example 16). The proliferative agents are to be used in formulations at concentrations that range from 0.1 ng/ml to 25 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device a interface and formulation volume and or surface area coverage required.
Preferably, the proliferative agent is released in effective concentrations for a period ranging from 1 - 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 ~.g to 200 mg); preferred 0.001 ~g to 100 mg. When used as a device coating, the dose is per unit area of 0.00001 ~g - 500 ~,g per mm2; with a preferred dose of 0.0001 ~,g/mm2 - 200 ~,g/mm2. Minimum concentration of 10-" - 10-6 M of proliferative agent is to be maintained on the device surface.
It should be readily evident to one of skill in the art that any of the previously described fibrosis inducing agents, or derivatives and analogues thereof, can be utilized to create variations of the above compositions without deviating from the spirit and scope of the invention. It should also be apparent that the agent can be utilized in a composition with or without polymer carrier and that altering the carrier does not deviate from the scope of this invention.
Briefly then, some aspects of the present invention are: a method comprising introducing into an intervertebral disc space of a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at the intervertebral disc space of the patient, thereby providing the patient with a beneficial result. Optionally, any one or more of the following criteria may be used to describe this aspect of the invention: the beneficial result is the repair of a spinal disc; the beneficial result is fibrous ankylosis; the beneficial result is bony ankylosis; the agent promotes regeneration; the agent promotes angiogenesis; the agent promotes fibroblast migration; the agent promotes fibroblast proliferation; the agent promotes deposition of extracellular matrix (ECM); the agent promotes remodeling, i.e., the maturation and organization of fibrous tissue; the agent is an arterial vessel wall irritant;
the fibrosing agent is or comprises silk; the fibrosing agent is or comprises silkworm silk; the fibrosing agent is or comprises spider silk; the fibrosing agent is or comprises recombinant silk; the fibrosing agent is or comprises raw silk; the fibrosing agent is or comprises hydrolyzed silk; the fibrosing agent is or comprises acid-treated silk; the fibrosing agent is or comprises acylated silk; the fibrosing agent is in the form of strands; the fibrosing agent is in the form of tufts; the fibrosing agent is in the form of microparticulates; the fibrosing agent is or comprises mineral particles; the fibrosing agent is or comprises talc;
the fibrosing agent is or comprises chitosan; the fibrosing agent is or comprises polylysine; the fibrosing agent is or comprises fibronectin; the fibrosing agent is or comprises bleomycin; the fibrosing agent is or comprises CTGF; the fibrosing agent is in the form of a thread, or is in contact with a thread where, optionally, the thread is biodegradable (e.g., it comprises a material selected from the group consisting of polyester, polyanhydride, poly(anhydride ester), poly(ester-amide), polyester-urea), polyorthoester, polyphosphoester, polyphosphazine, polycyanoacrylate, collagen, chitosan, hyaluronic acid, chromic cat gut, alginate, starch, cellulose and cellulose ester) or the thread is non-biodegradable (e.g., it comprises a material selected from the group consisting of polyester, polyurethane, silicone, polyethylene, polypropylene, polystyrene, polyacrylate, polymethacrylate, and silk), the thread is coated with a polymer, the thread is coated with a pharmaceutical agent that induces a fibrotic response in the patient, the thread is coated with a pharmaceutical agent that induces an osteogenic response in the patient; the composition further comprises an agent that promotes bone growth; the agent that promotes bone growth is a bone morphogenic protein or the agent that promotes bone growth is an osteogenic growth factor (e.g., transforming growth factor, platelet-derived growth factor, and fibroblast growth factor); the composition further comprises a pharmaceutical agent that induces sclerosis (a sclerosant, e.g., a sclerosant is selected from the group consisting of ethanol, dimethyl sulfoxide, sucrose, sodium chloride, dextrose, glycerin, minocycline, tetracycline, doxycycline, polidocanol, sodium tetradecyl sulfate, sodium morrhuate, and sotradecol, or the sclerosant may be a surfactant); the composition further comprises an inflammatory cytokine (e.g., an inflammatory cytokine selected from the group consisting of TGF~, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-Vii, IL-8, IL-6, and growth hormone); the composition further comprises an agent that stimulates cell proliferation (e.g., a cell proliferation agent selected from the group consisting of dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof); the composition further comprises a bulking agent; the composition further comprises a sealant; the composition further comprises a polymeric carrier; the composition further comprises a resorbable ceramic; the composition further comprises a contrast agent; the composition further comprises a thread; the composition is in the form of a gel; the composition is in the form of a paste; the composition is in the form of a spray; the composition is in the form of an aerosol; the composition is in the form of a suspension; the composition is in the form of an emulsion or microemulsion; the composition is in the form of a microsphere; the composition is in the form of a microparticulate; the composition is in the form of a solid implant.
2. Joint Implants The present invention provides for the combination of a fibrosis-inducing agent and a prosthetic joint implant. As used therein, the term "joint implants" refer to implants that are designed to replace joints that have been physically impaired or damaged. Examples of joint implants include, without limitation, orthopedic implants, orthopedic prostheses, modular implants, prosthetic joints, modular prostheses, joint prostheses, partial prostheses, hip implants, knee implants, shoulder implants and digit implants. Other types of orthopedic implants that may be used in conjunction with joint implants include, e.g., hardware, such as internal and external fixation devices, pins, plates and screws.
In one aspect, the orthopedic implant is an internal fixation implant. Internal fixation implants are medical devices that can be implanted (usually permanently) into a patient in minimally invasive orthopedic reconstructions and are often indicated for immobilization and stabilization of extremity fractures and unstable fractures.
Representative examples of internal fixation implants include intramedullary fixation devices such as intermedullary nails and plate and screw combinations; intramedullary rods, vertical transarticular pins for stabilization of severe ankle fractures, plates (e.g., plates made from titanium, stainless steel, and the like), plates with prongs to support subchondral bone, dorsal plates for volar applications, elastic plates,. screws, clips, pins, staples, pegs, wires, sublaminar wires, and metal prostheses for holding vertebrae in place.
Internal fixation implants may be used in a variety of open reduction internal fixation (ORIF) procedures. Open reduction internal fixation is a method of surgically repairing a fractured bone that typically involves either the use of plates and screws or an intramedullary (IM) rod to align and stabilize fractures. For example, IM rods can be inserted into the bone marrow canal in the center of the long bones of the extremities (e.g., femur or tibia).
In another aspect, the orthopedic implant is a component (e.g., a pin, wire, stopper, or dowel) of an external fixation device or an implanted portion (i.e., a portion that is situated within the body of the patient) of an external fixation device (also referred to herein as an "external fixation implant"). External fixation devices are medical devices that can be used to immobilize bones to allow a fracture to heal. External fixation devices are used in a variety of minimally invasive orthopedic surgeries as an alternative to other types of fixation devices, such as casts and internal fixation devices.
Briefly, external fixation may be accomplished by placing pins or screws into the bone on both sides of the fracture. The pins are then secured together outside the skin with clamps and rods which can form an external frame.
An external fixation device typically includes a scaffold or frame that has attached to it wires, pins, and the like which is placed outside of an extremity, such as a limb. The device remains in place until healing has occurred, at which point it is then removed, leaving no foreign material in the extremity.
External fixation devices may take a variety of forms and may have monolateral, multiplanar or hybrid constructions. A monolateral fixation device includes a bar or rail with attached pins that transfix a bone (e.g., a femur). A multiplanar external fixation device can include rings or sections of rings, with attached pins and/or wires, which are used to secure fixation of a bone. A hybrid system can include a frame consisting of both rings (multiplanar) and bars (monolateral).
External fixation devices also may be classified by their function, for example, the device may be stationary or moving. Stationary devices may be used for alignment of the bony fragments (e.g., for acute stabilization of fractures) and remain in place from the time of application to removal. Moving fixation devices, in contrast, may be used in gradual reduction of acute extremity fractures. The configuration of a moving fixation device can change over time for gradual correction.
External fixation devices may be used to treat a variety of conditions. For example, an external fixation device may be used for the fixation of injuries such as joint fractures. External fixation can provide for acute or gradual fracture reduction. In particular, external fixation devices may be used in the treatment of juxta-articular fractures, open fractures, and fractures with bone loss, including, for example, fractures near joints such as distal radius, proximal tibia) plateau, and distal tibia) piton fractures. Other applications of external fixation devices include reconstructive orthopedic procedures such as treatment of deformities, bone loss, contractures, treatment of non-unions (hypertrophic or atrophic), and limb length discrepancy.
A modular prosthesis is a prosthesis that has multiple (two or more) components which can be assembled to form a unitary biomechanical structure. Various features of the components can be adjusted by the surgeon prior to implantation of the prosthesis so as to accommodate the needs of each patient. For example, a modular prosthesis can have component that can be independently adjusted (rotationally and axially) by the surgeon, or the length of a component may be changed. Modular prostheses can be used in a variety of surgical procedures. The modular prosthesis may be an adjustable long bone prosthesis that can be adjusted within the patient to account for discrepancies in the measurement of a long bone to be replaced. Prosthetic joints having modular components exist for replacement of the hip, knee, and ankle joints.
Other representative examples of modular orthopedic prostheses include a modular femoral stem, modular shoulder prosthesis, and modular elbow prostheses.
The long-term cause of failure for many artificial joints is loosening occurring over time between the implant and the surrounding bone that anchors the implant in place. Inadequate bone and tissue growth may lead to unsuccessful acute incorporation of the implant or late loosening may occur with time. In the case of the hip, for example, up to 5% of patients can suffer from joint loosening by 10 years post implant. Symptoms include pain that can become debilitating and ultimately lead to repeat surgery and possible revision of the implant.
(i) Hip Implants In artificial hip joints, the hip implant replaces the head of femur (i.e., ball) and/or the acetabulum (i.e., socket) of the joint. Typically the hip joint is replaced due to irreparable damage caused by non-inflammatory degenerative joint disease (e.g., osteoarthritis, post traumatic arthritis), inflammatory degenerative joint disease (e.g., rheumatoid arthritis, infectious arthritis), trauma (e.g., fracture of the pelvis or hip), congenital hip dysplasia, or joint dislocation and other fracture-induced damage to the femur andlor acetabulum. Hip implants typically include two or three component systems, which include the femoral stem or shank, the femoral neck, and the spherical ball which adapts to the acetabulum or prosthetic acetabular cup. The femoral stem, neck and ball, as well as the acetabular cup may be composed of metal (e.g., titanium, titanium alloy, cobalt-chromium or chromium-molybdenum) or polymer composite. To fix the hip implant to the existing femur of the host, the hip implant may be cemented into the bone usirig bone cement (e.g., methylmethacrylate) or the hip implant may be fixed using a cementless surface treatment (e.g., porous coating, such as hydroxyapatite porous coating, or, spongy coating) whereby the hip implant allows bony growth from the femur to anchor it into place.
in one aspect, hip implants may be used to provide a full hip replacement. For example, the hip implant may be a three-modular designed total prosthesis with primary fixation which may include a partially threaded elongated pin for insertion into the femoral body which provides rotational adjustment between the body and the pin for various alignments and size combinations. See e.g., U.S. 4,938,773. The hip implant may be composed of a ball, neck and fixation element with a bearing element that is adapted to restrain dislocations of the ball and provide a means for selecting the orientation of the fixation element. See e.g., U.S. 6,042,611. The hip implant may be designed of two mutually articulating components composed of a cobalt chromium alloy with one having a low carbon content and the other component having a high carbon content. See e.g., U.S. 5,904,720.

In another aspect, hip implants may be adapted for cementing into place to ensure the implant is stabilized in the accurate position. For example, hip implants may be composed of cement spacers along the shaft which, upon implantation within the medullary canal of the femur, allows for optimal thickness of the cement mantle. See e.g., U.S. 5,314,489.
In another aspect, hip implants may be modular in which components may be adjusted to adapt to the host's shape or dimensions. For example, the hip implant may be a modular hip prosthesis composed of a plurality of .removable, different size tubular sleeves that may be used to extend the femoral stem component or neck size which allows the implant to be custom fitted to a particular host. See e.g., U.S. 5,507,830.
In another aspect, hip implants may be designed to provide shock absorbency within the joint. For example, the hip implant may be composed of an elongate element that extends coaxially from the ball section that slidably extends into a chamber that contains a spring for shock absorbency. See e.g., U.S. 5,389,107. The hip implant may be a modular shock absorbent prosthesis designed to have adjustable femoral stem, neck and ball, as well as adjustable tension due to its unique coupling modular spring mechanism. See e.g., U.S.
6,336,941.
In another aspect, hip implants may be composed of a composite material to provide greater stiffness or retention within the femur. For example, the hip implant may be composed of a plurality of layers of fibers (e.g., composed of carbon, ceramic, metal or fiberglass) in a matrix (e.g., a polymeric matrix) where the fibers may be substantially unidirectional in each respective layer. See e.g., U.S. 5,522,904, 5,163,962, 5,064,439 and 4,892,552. The hip implant may have a stem composed of an inner metal core and an outer composite shell having fibers bonded with a thermoplastic resin and which the distal end is adapted to be inserted into a cavity formed in a bone. See e.g., U.S. 5,314,492. The hip implant may be composed of an expandable material that absorbs body fluid and expands within an opening of the bone of the host's body such that a portion of the implant is retained within the bone and a portion of the implant is outside the bone. See e.g., U.S. 6,361,565.
In another aspect, hip implants may be only partial hip replacements. For example, the hip implant may be a prosthetic acetabular cup assembly being composed of a bearing component for receiving a ball attached to a femur and a shell component for attachment to an acetabulum. See e.g., U.S. 5,049,158. Still other hip implants may be revision hip prostheses which have design features to augment the fixation of the implant into an area with bone-deficiency. For example, the hip implant may be a long stem hip joint prosthetic device having a long distal section of the femoral component which extends beyond the isthmus of the femur when implanted in the medullary canal and is designed with a specially curved distal section. See e.g., U.S.
4,871,369. Additional descriptions of hip implants are provided in U.S.
5,755,810; 5,336,265; 5,286,260; 5,019,108; 4,986,834; 4,808,186; and 4,670,015.
Hip implants, which may be combined with one or more drugs according to the present invention, include numerous commercially available products, for example, the S-ROM Total Hip System and the AML Total Hip System from DePuy Orthopaedics, Inc. (Warsaw, IN) In one aspect, the present invention provides hip prostheses that include a fibrosis-inducing agent or a composition that includes a fibrosis-inducing agent to promote scarring to provide fixation of the device into the surrounding bone. In one aspect, the hip prosthesis is coated with a fibrosing agent or a composition that includes the fibrosing agent. In another aspect, the fibrosing agent may be incorporated into a glue or cement that holds the prosthesis in place. In another aspect, the hip prosthesis is covered (all or in part) with a silk mesh or lattice to encourage scarring and anchoring into the surrounding bone. For example, a silk mesh or lattice can be coated onto all or a portion of the surface of the implant stem to encourage scarring and anchoring into the surrounding bone.
Numerous polymeric and non-polymeric carrier systems described previously can be used in the practice of this embodiment. These compositions can further include one or more fibrosis-inducing agents to promote the formation of granulation tissue. Methods for incorporating fibrosing compositions onto or into the orthopedic implants include: (a) directly affixing to the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (b) directly incorporating into the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (c) by coating the device with a substance such as a hydrogel which can in turn absorb the fibrosing composition; (d) by interweaving fibrosing composition coated thread (or the polymer itself formed into a thread) into the device structure; (e) by inserting the device into a sleeve or mesh which is comprised of or coated with a fibrosing composition; (f) constructing the device itself or a portion of the device with a fibrosing composition; and/or (g) by covalently binding the fibrosing agent directly to the device surface or to a linker (small molecule or polymer) that is coated or attached to the device surface. For these devices, the coating process can be performed in such a manner as to a) coat the surfaces of the device that is in contact with the bone, b) coat the surfaces of the device that are not in contact with the bone or c) coat all or parts of both the bone-contacting and non-bone contacting surface of the device.
In addition to coating the device with the fibrosing composition, the fibrosing agent can be mixed with the materials that are used to make the device such that the fibrosing agent is incorporated into the final device.
It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agents described previously may be utilized alone, or in combination, in the practice of this embodiment. Exemplary fibrosing agents for use in hip prostheses implants include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
As hip prostheses are made in a variety of configurations and sizes, the exact dose administered can vary with device size, surface area and design. However, certain principles can be applied in the application of this art.
Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined.
Regardless of the method of application of the drug to the hip prostheses, the exemplary fibrosing agents, used alone or in combination, should be administered under the following dosing guidelines:
Utilizing talc as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of talc delivered from a hip prosthesis, or coated onto the surface of a hip prosthesis, should not exceed 100 mg (range of 1 ~,g to 100 mg). In one embodiment, the total amount of talc released from the prosthesis should be in the range of 10 ~g to 50 mg. The dose per unit area of the device (i.e., the dosage of talc as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~.g - 10 p,g per mm2 of surface area coated. In another embodiment, talc should be applied to a hip prosthesis surface at a dose of 0.05 ~g/mm2 -10 p,g/mm2 of surface area coated. In one embodiment, talc is released from the surface of a hip prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, talc may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of talc (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as talc is administered at half the above parameters, a compound half as potent as talc is administered at twice the above parameters, etc.).
Utilizing silk as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of silk delivered from a hip prosthesis, or coated onto the surface of a hip prosthesis, should not exceed 100 mg (range of 1 p,g to 100 mg). In one embodiment, the total amount of silk released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of silk as a function of the surFace area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 pg - 10 ~.g per mm2 of surface area coated. In another embodiment, silk should be applied to a hip prosthesis surface at a dose of 0.05 p,g/mm2 -10 p,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release silk at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the hip prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of silk is delivered to the tissue. In one embodiment, silk is released from the surface of a hip prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, silk may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of silk (as described previously) with similar functional activity can be utilized for the purposes of this invention;
the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as silk is administered at half the above parameters, a compound half as potent as silk is administered at twice the above parameters, etc.).
Utilizing chitosan as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of chitosan ,delivered from a hip prosthesis, or coated onto the surface of a hip prosthesis, should not exceed 100 mg (range of 1 pg to 100 mg). In one embodiment, the total amount of chitosan released, from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of chitosan as a function of the surFace area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 p,g - 10 ~,g per mm2 of surface area coated. In another embodiment, chitosan should be applied to a hip prosthesis surface at a dose of 0.05 p.g/mm2 -10 p,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release chitosan at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the hip prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of chitosan is delivered to the tissue. In one embodiment, chitosan is released from the surface of a hip prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, chitosan may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of chitosan (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as chitosan is administered at half the above parameters, a compound half as potent as chitosan is administered at twice the above parameters, etc.).
Utilizing polylysine as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of polylysine delivered from a hip prosthesis, or coated onto the surface of a hip prosthesis, should not exceed 100 mg (range of 1 ~,g to 100 mg). In one embodiment, the total amount of polylysine released from the prosthesis should be in the range of 10 pg to 50 mg. The dose per unit area of the device (i.e., the dosage of polylysine as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~g - 10 ~,g per mm2 of surface area coated. In another embodiment, polylysine should be applied to a hip prosthesis surface at a dose of 0.05 pg/mm2 -10 p,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release polylysine at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the hip prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of polylysine is delivered to the tissue. In one embodiment, polylysine is released from the surface of a hip prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, polylysine may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of polylysine (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as polylysine is administered at half the above parameters, a compound half as potent as polylysine is administered at twice the above parameters, etc.).
Utilizing fibronectin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of fibronectin delivered from a hip prosthesis, or coated onto the surface of a hip prosthesis, should not exceed 100 mg (range of 1 ~,g to 100 mg). In one embodiment, the total amount of fibronectin released from the prosthesis should be in the range of 10 p.g to 50 mg. The dose per unit area of the device (i.e., the dosage of fibronectin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~.g - 10 pg per mm2 of surface area coated. In another embodiment, fibronectin should be applied to a hip prosthesis surface at a dose of 0.05 p,g/mm2 -10 ~.g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release fibronectin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the hip prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of fibronectin is delivered to the tissue. In one embodiment, fibronectin is released from the surface of a hip prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, fibronectin may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of fibronectin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as fibronectin is administered at half the above parameters, a compound half as potent as fibronectin is administered at twice the above parameters, etc.).
Utilizing bleomycin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of bleomycin delivered from a hip prosthesis, or coated onto the surface of a hip prosthesis, should not exceed 100 mg (range of 0.01 ~,g to mg). In one embodiment, the total amount of bleomycin released from the prosthesis should be in the range of 0.10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of bleomycin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 ~,g - 10 ~,g per mm2 of surface area coated. In another embodiment, bleomycin should be applied to a hip prosthesis surface at a dose of 0.005 ~,g/mm2 -10 ~g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release bleomycin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the hip prosthesis such that a minimum concentration of 0.001 nM to 1000 pM of bleomycin is delivered to the tissue. In one embodiment, bleomycin is released from the surface of a hip prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, bleomycin may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of bleomycin (as described previously) with similar functional activity can be utilized for the purposes of this invention;
the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as bleomycin is administered at half the above parameters, a compound half as potent as bleomycin is administered at twice the above parameters, etc.).
Utilizing CTGF as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of CTGF delivered from a hip prosthesis, or coated onto the surface of a hip prosthesis, should not exceed 100 mg (range of 0.01 p,g to 100 mg). In one embodiment, the total amount of CTGF released from the prosthesis should be in the range of 0.10 p,g to 50 mg. The dose per unit area of the device (i.e., the dosage of CTGF as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 ~g - 10 pg per mm2 of surface area coated. In another embodiment, CTGF
should be applied to a hip prosthesis surface at a dose of 0.005 p.g/mm2 -10 p,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release CTGF at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the hip prosthesis such that a minimum concentration of 0.001 nM to 1000 pM of CTGF is delivered to the tissue. In one embodiment, CTGF is released from the surFace of a hip prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, CTGF may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of CTGF (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as CTGF
is administered at half the above parameters, a compound half as potent as CTGF is administered at twice the above parameters, etc.).
Optionally, the device may additionally comprise an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-~3, IL-8, IL-6, and growth hormone) and/or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).
Bone morphogenic proteins) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof) are to be used in formulations at concentrations that range from 0.001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the bone morphogenic protein is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.001 ~,g to 500 mg); preferred 1 pg to 250 mg. When used as a device coating, the dose is per unit area of 0.001 ~,g - 1000 p.g per mm2; with a preferred dose of 0.01 p,g/mm2 - 200 ~,g/mm2. Minimum concentration of 10-9 - 10~ M of bone morphogenic protein is to be maintained on the device surface.
Inflammatory cytokines are to be used in formulations at concentrations that range from 0.0001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the inflammatory cytokine is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 p,g to 100 mg); preferred 0.001 p.g to 50 mg. When used as a device coating, the dose is per unit area of 0.0001 p,g - 500 p,g per mm2; with a preferred dose of 0.001 ~g/mm2 - 200 pg/mm2. Minimum concentration of 10-'°- 10-4 g/ml of inflammatory cytokine is to be maintained on the device surface.
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof. Doses used are those concentrations which are demonstrated to stimulate cell proliferation (see Example 16). The proliferative agents are to be used in formulations at concentrations that range from 0.1 ng/ml to 25 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required.
Preferably, the proliferative agent is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 p,g to 200 mg); preferred 0.001 ~,g to 100 mg. When used as a device coating, the dose is per unit area of 0.00001 p,g - 500 ~.g per mm2; with a preferred dose of 0.0001 ~,g/mm2 - 200 ~g/mma. Minimum concentration of 10-1' - 10-6 M of proliferative agent is to be maintained on the device surface.
It should be readily evident to one of skill in the art that any of the previously described fibrosis inducing agents, or derivatives and analogues thereof, can be utilized to create variations of the above compositions without deviating from the spirit and scope of the invention. It should also be apparent that the agent can be utilized in a composition with or without polymer carrier and that altering the carrier does not deviate from the scope of this invention.
(ii) Knee Implants In one aspect, the present invention provides knee implants that induce fibrosis or adhesion of the implant into the surrounding tissue. Knee replacement surgery is generally indicated for patients with severe knee pain and disability caused by damage to their articular cartilage as a result of rheumatoid arthritis, osteoarthritis or trauma. It is highly successful procedure in relieving pain and restoring joint function. Knee arthroplasty procedures are broadly categorized as primary or revision and are either unicompartmental (partial) or total. Knee prostheses (referred to herein as knee implants) can be used to replace all or a portion of the knee joint. In a total knee arthroplasty (TKA), the diseased cartilage surfaces of the thighbone (femur), the shinbone (tibia) and the kneecap (patella) are replaced by prostheses made of metal alloys (e.g., titanium- or cobalt/chromium-based alloys) and high-grade plastics and polymeric materials (e.g., ultrahigh-density polyethylene). Most of the other structures of the knee, such as the connecting ligaments, remain intact. Up to three bone surfaces may be replaced during a TKA: the distal ends (condyles) of the femur, the proximal surface of the tibia and the posterior surface of the patella. Components are designed so that metal always articulates against plastic, which provides smooth movement and results in minimal wear.

Knee joint implants typically have three components (i.e., a femoral, a tibia), and a patellar component). The metal femoral component curves around the end of the thighbone and has an interior groove so the patella can move up and down smoothly against the bone as the knee bends and straightens. Usually, one large piece is used to resurface the end of the bone. If only one condyle of the femur is damaged, a smaller piece may be used (unicompartmental knee replacement) to resurface just that part of the bone. Some designs (e.g., posterior stabilized designs) have an internal post with a circular-shaped device (cam) that works with a corresponding tibia) component to help prevent the femur from sliding forward too far on the tibia when the knee is bent. The tibia) component is a flat metal platform with a polyethylene cushion. The cushion may be part of the platform (fixed) or separate (mobile) with either a flat surface (PCL-retaining) or a raised, sloping surface (PCL-substituting). The patellar component is a dome-shaped piece of polyethylene that duplicates the shape of the kneecap anchored to a flat metal plate. Once the knee prosthesis is implanted and aligned, the knee replacement is fixed in place by cement, using a cementless procedure, or via a hybrid fixation procedure.
A variety of knee prostheses have been described. For example, knee prostheses have been described in U.S. Patent Nos. 6,443,991;
6,402,786; 6,068,658; 6,558,427; 6,554,866; 6,447,549; 6,419,707; 6,143,034;
6,120,546; and 6,074,424. Knee implants suitable for combining with one or more fibrosis-inducing agents according to the present invention, include numerous commercially available products. These include, for example, the NEXGEN LEGACY Knee Posterior Stabilized (LPS) and NEXGEN LEGACY
LPS Femoral Component from Zimmer. Other examples of knee implants suitable for the delivery of fibrosis-inducing agents include Stryker Howmedica Osteonics DURACON Total Knee System, SCORPIO Knee System, and SCORPIO Cruciate Retaining Single Axis Knee; implants available from DePuy Orthopaedics such as the LCS Total Knee System, P.F.C. Sigma RP Platform Knee System, Keane Uni-Compartmental Knee System, P.F.C. Sigma Uni-Compartmental Knee System, AMK Total Knee System, P.F.C. Sigma Knee System (Cruciate-Retaining), the P.F.C. Sigma Knee System (Cruciate-Substituting), the Coordinate Revision Knee System, the P.F.C. Sigma Knee System TC3 Revision implant, and the S-ROM Noiles Rotating Hinge; knee implants from Smith & Nephew Orthopaedics such as the GENESID I and GENESIS If Total Knee Systems. Other manufacturers of primary and revision knee joint implants suitable for use in this invention include Biomet, Inc.
(Warsaw, IN), Sulzer Orthopedics, Inc. (Austin, TX), Wright Medical Technologies, Exactech, Inc., Encore Orthopedics Corporation (Henderson, NV), Implex now known as Zimmer, Inc., SteIKast Company (McMurray, PA), Hayes Medical, Inc. (El Dorado Hills, CA), and Link Orthopedics (PineBrook, NJ).
In one aspect, the present invention provides knee prostheses that include a fibrosis-inducing agent or a composition that includes a fibrosis-inducing agent to promote scarring and fixation of the device into the surrounding bone. In one aspect, the knee prosthesis is coated with a fibrosing agent or a composition that includes the fibrosing agent. In another aspect, the fibrosing agent, may be incorporated into the glue or cement that holds the prosthesis in place. In another aspect, the knee prosthesis is covered (all or in part) with a silk mesh or lattice to encourage scarring and anchoring into the surrounding bone. For example, a silk mesh or lattice can be coated onto all or a portion of the surface of the implant stem to encourage scarring and anchoring into the surrounding bone.
Numerous polymeric and non-polymeric carrier systems described above can be used in the practice of this embodiment. These compositions can further include one or more fibrosis-inducing agents to promote the formation of granulation tissue. Methods for incorporating fibrosing compositions onto or into the orthopedic implants include: (a) directly affixing to the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (b) directly incorporating into the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (c) by coating the device with a substance such as a hydrogel which can in turn absorb the fibrosing composition; (d) by interweaving fibrosing composition coated thread (or the polymer itself formed into a thread) into the device structure; (e) by inserting the device into a sleeve or mesh which is comprised of or coated with a fibrosing composition; (f) constructing the device itself or a portion of the device with a fibrosing composition, or (g) by covalently binding the fibrosing agent directly to the device surface or to a tinker (small molecule or polymer) that is coated or attached to the device surface. For these devices, the coating process can be performed in such a manner as to a) coat the surfaces of the device that is in contact with the bone, b) coat the surfaces of the device that are not in contact with the bone or c) coat all or parts of both the bone-contacting and non-bone contacting surface of the device.
In addition to coating the device with the fibrosing composition, the fibrosing agent can be mixed with the materials that are used to make the device such that the fibrosing agent is incorporated into the final device.
It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agents described above may be utilized alone, or in combination, in the practice of this embodiment. Exemplary fibrosing agents for use in knee prostheses include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
As knee prostheses are made in a variety of configurations and sizes, the exact dose administered can vary with device size, surface area and design. However, certain principles can be applied in the application of this art.
Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined.
Regardless of the method of application of the drug to the knee prostheses, the exemplary fibrosing agents, used alone or in combination, should be administered under the following dosing guidelines:
Utilizing talc as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of talc delivered from a knee prosthesis, or coated onto the surface of a knee prosthesis, should not exceed 100 mg (range of 1 ~,g to 100 mg). In one embodiment, the total amount of talc released from the prosthesis should be in the range of 10 p.g to 50 mg. The dose per unit area of the device (i.e., the dosage of talc as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 _ ~.g - 10 p,g per mm2 of surface area coated. In another embodiment, talc should be applied to a knee prosthesis surface at a dose of 0.05 ~.g/mm2 -10 ~,g/mma of surface area coated. In one embodiment, talc is released from the surface of a knee prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, talc may be released in effective concentrations for a period ranging from 1 hour- 30 days.

It should be readily evident given the discussions provided herein that analogues and derivatives of talc (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as talc is administered at half the above parameters, a compound half as potent as talc is administered at twice the above parameters, etc. ).
Utilizing silk as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of silk delivered from a knee prosthesis, or coated onto the surface of a knee prosthesis, should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of silk released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of silk as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~.g - 10 ~g per mm2 of surface area coated. In another embodiment, silk should be applied to a knee prosthesis surface at a'dose of 0.05 ~,g/mm2 -10 ~g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release silk at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the knee prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of silk is delivered to the tissue. In one embodiment, silk is released from the surface of a knee prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, silk may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of silk (as described previously) with similar functional activity can be utilized for the purposes of this invention;
the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as silk is administered at half the above parameters, a compound half as potent as silk is administered at twice the above parameters, etc.).

Utilizing chitosan as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of chitosan delivered from a knee prosthesis, or coated onto the ~5 surface of a knee prosthesis, should not exceed 100 mg (range of 1 p,g to mg). In one embodiment, the total amount of chitosan released from the prosthesis should be in the range of 10 pg to 50 mg. The dose per unit area of the device (i.e., the dosage of chitosan as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~,g - 10 ~g per mm2 of surface area coated. In another embodiment, chitosan should be applied to a knee prosthesis surface at a dose of 0.05 pg/mm2 -10 p,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release chitosan at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the knee prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of chitosan is delivered to the tissue. In one embodiment, chitosan is released from the surface of a knee prosthesis (e.g., a bulking agent) such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, chitosan may be released in effective concentrations for a period ranging from 1 hour-days. It should be readily evident given the discussions provided herein that analogues and derivatives of chitosan (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the 25 analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as chitosan is administered at half the above parameters, a compound half as potent as chitosan is administered at twice the above parameters, etc.).
Utilizing polylysine as a exemplary fibrosis-inducing agent, 30 whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of polylysine delivered from a knee prosthesis, or coated onto the surface of a knee prosthesis, should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of polylysine released from the prosthesis should be in the range of 10 p,g to 50 mg. The dose per unit area of the device (i.e., the dosage of polylysine as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~.g - 10 ~,g per mm2 of surface area coated. In another embodiment, polylysine should be applied to a knee prosthesis surface at a dose of 0.05 ~.g/mm2 -10 ~,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release polylysine at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the knee prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of polylysine is delivered to the tissue. In one embodiment, polylysine is released from the surface of a knee prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, polylysine may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of polylysine (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as polylysine is administered at half the above parameters, a compound half as potent as polylysine is administered at twice the above parameters, etc.).
Utilizing fibronectin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of fibronectin delivered from a knee prosthesis, or coated onto the surface of a knee prosthesis, should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of fibronectin released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of fibronectin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~g - 10 ~,g per mm2 of surface area coated. In another embodiment, fibronectin should be applied to a knee prosthesis surface at a dose of 0.05 ~,g/mm2 -10 ~g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release fibronectin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the knee prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of fibronectin is delivered to the tissue. In one embodiment, fibronectin is released from the surface of a knee prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, fibronectin may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of fibronectin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as fibronectin is administered at half the above parameters, a compound half as potent as fibronectin is administered at twice the above parameters, etc.).
Utilizing bleomycin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of bleomycin delivered from a knee prosthesis, or coated onto the surface of a knee prosthesis, should not exceed 100 mg (range of 0.01 ~g to 100 mg). In one embodiment, the total amount of bleomycin released from the prosthesis should be in the range of 0.10 ~.g to 50 mg. The dose per unit area of the device (i.e., the dosage of bleomycin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 p,g - 10 ~,g per mm2 of surface area coated. In another embodiment, bleomycin should be applied to a knee prosthesis surface at a dose of 0.005 ~,g/mm2 -10 ~g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release bleomycin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the knee prosthesis such that a minimum concentration of 0.001 nM to 1000 pM of bleomycin is delivered to the tissue. In one embodiment, bleomycin is released from the surface of a knee prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, bleomycin may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of bleomycin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as bleomycin is administered at half the above parameters, a compound half as potent as bleomycin is administered at twice the above parameters, etc.).
Utilizing CTGF as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of CTGF delivered from a knee prosthesis, or coated onto the surface of a knee prosthesis, should not exceed 100 mg (range of 0.01 ~,g to 100 mg). In one embodiment, the total amount of CTGF released from the prosthesis should be in the range of 0.10 ~g to 50 mg. The dose per unit area of the device (i.e., the dosage of CTGF as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 ~,g - 10 pg per mm2 of surface area coated. In another embodiment, CTGF
should be applied to a knee prosthesis surface at a dose of 0.005 ~,g/mm2 -10 ~.g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release CTGF at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the knee prosthesis such that a minimum concentration of 0.001 nM to 1000 pM of CTGF is delivered to the tissue. In one embodiment, CTGF is released from the surface of a knee prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, CTGF may be released in effective concentrations for a period ranging from 1 hour- 30 days. It.should be readily evident given the discussions provided herein that analogues and derivatives of CTGF (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as CTGF
is administered at half the above parameters, a compound half as potent as CTGF is administered at twice the above parameters, etc.).
Optionally, the device may additionally comprise an inflammatory cytokine (e.g., TGF(3, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-~, IL-8, IL-6, and growth hormone) and/or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).

Bone morphogenic proteins) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof) are to be used in formulations at concentrations that range from 0.001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the bone morphogenic protein is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.001 ~.g to 500 mg); preferred 1 p,g to 250 mg. When used as a device coating, the dose is per unit area of 0.001 ~,g - 1000 ~,g per mm2; with a preferred dose of 0.01 ~,g/mm2 - 200 ~,g/mm2. Minimum concentration of 10-9 - 10-4 M of bone morphogenic protein is to be maintained on the device surface.
Inflammatory cytokines are to be used in formulations at concentrations that range from 0.0001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area .
coverage required. Preferably, the inflammatory cytokine is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 ~.g to 100 mg); preferred 0.001 pg to 50 mg. When used as a device coating, the dose is per unit area of 0.0001 ~,g - 500 ~g per mm2; with a preferred dose of 0.001 ~,g/mmz - 200 ~,g/mm2. Minimum concentration of 10-'°- 10-4 g/ml of inflammatory cytokine is to be maintained on the device surface.
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof. Doses used are those concentrations which are demonstrated to stimulate cell proliferation (see, e.g., Example 16). The proliferative agents are to be used in formulations at concentrations that range from 0.1 ng/ml to 25 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required.

Preferably, the proliferative agent is released in effective concentrations for a period ranging from 1 = 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 p.g to 200 mg); preferred 0.001 ~,g to 100 mg. When used as a device coating, the dose is per unit area of 0.00001 ~.g - 500 p,g per mm2; with a preferred dose of 0.0001 p,g/mm2 - 200 ~,g/mm2. Minimum concentration of 10-" - 10-6 M of proliferative agent is to be maintained on the device surface.
It should be readily evident to one of skill in the art that any of the previously described fibrosis inducing agents, or derivatives and analogues thereof, can be utilized to create variations of the above compositions without deviating from the spirit and scope of the invention. It should also be apparent that the agent can be utilized in a composition with or without polymer carrier and that altering the carrier does not deviate from the scope of this invention.
(iii) Shoulder Implants Shoulder joint reconstruction is typically indicated to alleviate pain and restore lost function arising from medical conditions such as fractures, osteoarthritis, rheumatoid arthritis, avascular necrosis, and tumor growth (benign or malignant). Hemiarthroplasties (partial shoulder implants), which involve implanting only the humeral components, typically are performed on patients suffering from shoulder fractures and avascular necrosis. Total shoulder replacement (implanting of both the humeral and glenoid components) is more common in patients suffering from osteoarthritis and rheumatoid arthritis. Joint replacement in conjunction with excision of a tumor is fairly rare, occurring in less than one percent of patients who receive shoulder replacement surgeries. In a cancer patient, removal of bone may necessitate partial or total replacement of the joint.
Numerous shoulder prostheses have been described (see, e.g., U.S. Patent Nos. 6,494,913; 6,193,758; 6,168,628; 6,102,953; 6,045,582;
5,961,555; 5,593,448; 5,549,682; and 5,108,440). Shoulder implants suitable for combining with one or more fibrosis-inducing agents according to the present invention, include numerous commercially available products. These include shoulder implants manufactured by DePuy Orthopaedics (e.g., GLOBAL TX Total Shoulder System, GLOBAL Shoulder Eccentric Head, GLOBAL Total Shoulder System), Biomet (e.g., Bio-Modular, Bi-Angular/Bi-Polar, Proximal Humeral Replacement, and Integrated Shoulder System), Stryker Howmedica Osteonics (e.g., SOLAR Shoulder Bipolar Heads, Humeral Heads, Humeral Components, and Glenoid Components), Sulzer (e.g., Anatomical Shoulder and Select Shoulder), Zimmer (Bigliani/Flatow Shoulder), and Smith & Nephew Orthopaedics (e.g., COFIELD 2 Total Shoulder System, NEER II Total Shoulder System, and Modular Shoulder System).
In one aspect, the present invention provides shoulder prostheses that include a fibrosis-inducing agent or a composition that includes a fibrosis-inducing agent to promote scarring and fixation of the device into the surrounding bone. In one aspect, the shoulder prosthesis is coated with a fibrosing agent or a composition that includes the fibrosing agent. In another aspect, the fibrosing agent may be incorporated into the glue or cement that holds the prosthesis in place. In another aspect, the shoulder prosthesis is covered (all or in part) with a silk mesh or lattice to encourage scarring and anchoring into the surrounding bone. For example, a silk mesh or lattice can be coated onto all or a portion of the surface of the implant stem to encourage scarring and anchoring into the surrounding bone.
Numerous polymeric and non-polymeric carrier systems described above can be used in the practice of this embodiment. These compositions can further include one or more fibrosis-inducing agents to promote the formation of granulation tissue. Methods for incorporating fibrosing compositions onto or into the orthopedic implants include: (a) directly affixing to the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (b) directly incorporating into the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (c) by coating the device with a substance such as a hydrogel which can in turn absorb the fibrosing composition; (d) by interweaving fibrosing composition coated thread (or the polymer itself formed into a thread) into the device structure; (e) by inserting the device into a sleeve or mesh which is comprised of or coated with a fibrosing composition; (f) constructing the device itself or a portion of the device with a fibrosing composition; or (g) by covalently binding the fibrosing agent directly to the device surface or to a linker (small molecule or polymer) that is coated or attached to the device surface. For these devices, the coating process can be performed in such a manner as to a) coat the surfaces of the device that is in contact with the bone, b) coat the surfaces of the device that are not in contact with the bone or c) coat all or parts of both the bone-contacting and non-bone contacting surface of the device.
In addition to coating the device with the fibrosing composition, the fibrosing agent can be mixed with the materials that are used to make the device such that the fibrosing agent is incorporated into the final device.
It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agents described above may be utilized alone, or in combination, in the practice of this embodiment. Exemplary fibrosing agents for use in shoulder prostheses include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
As shoulder prostheses are made in a variety of configurations and sizes, the exact dose administered can vary with device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the shoulder prostheses, the exemplary fibrosing agents, used alone or in combination, should be administered under the following dosing guidelines:
Utilizing talc as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of talc delivered from a shoulder prosthesis, or coated onto the surface of a shoulder prosthesis, should not exceed 100 mg (range of 1 pg to 100 mg). In one embodiment, the total amount of talc released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of talc as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~,g - 10 p,g per mm2 of surface area coated. In another embodiment, talc should be applied to a shoulder prosthesis surface at a dose of 0.05 ~.g/mm2 -10 pg/mm2 of surface area coated. In one embodiment, talc is released from the surface of a shoulder prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, talc may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of talc (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as talc is administered at half the above parameters, a compound half as potent as talc is administered at twice the above parameters, etc. ).
Utilizing silk as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of silk delivered from a shoulder prosthesis, or coated onto the surface of a shoulder prosthesis, should not exceed 100 mg (range of 1 p,g to 100 mg). In one embodiment, the total amount of silk released from the prosthesis should be in the range of 10 p,g to 50 mg. The dose per unit area of the device (i.e., the dosage of silk as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 p,g - 10 ~,g per mm2 of surface area coated. ~In another embodiment, silk should be applied to a shoulder prosthesis surface at a dose of 0.05 pg/mm2 -10 p,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release silk at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the shoulder prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of silk is delivered to the tissue. In one embodiment, silk is released from the surface of a shoulder prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, silk may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of silk (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as silk is administered at half the above parameters, a compound half as potent as silk is administered at twice the above parameters, etc.).
Utilizing chitosan as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of chitosan delivered from a shoulder prosthesis, or coated onto the surface of a shoulder prosthesis, should not exceed 100 mg (range of 1 p,g to 100 mg). In one embodiment, the total amount of chitosan released from the prosthesis should be in the range of 10 ~g to 50 mg. The dose per unit area of the device (i.e., the dosage of chitosan as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 p,g - 10 p,g per mm2 of surface area coated. In another embodiment, chitosan should be applied to a shoulder prosthesis surface at a dose of 0.05 ~g/mm2 -10 ~,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release chitosan at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the shoulder prosthesis such that a minimum concentration of 0.01 nM to 1000 pM
of chitosan is delivered to the tissue. In one embodiment, chitosan is released from the surface of a shoulder prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, chitosan may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of chitosan (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as chitosan is administered at half the above parameters, a compound half as potent as chitosan is administered at twice the above parameters, etc.).
Utilizing polylysine as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of polylysine delivered from a shoulder prosthesis, or coated onto the surface of a shoulder prosthesis, should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of polylysine released from the prosthesis should be in the range of 10 p,g to 50 mg. The dose per unit area of the device (i.e., the dosage of polylysine as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 pg - 10 p,g per mm2 of surface area coated. In another embodiment, polylysine should be applied to a shoulder prosthesis surface at a dose of 0.05 p.g/mm2 -10 p,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release polylysine at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the shoulder prosthesis such that a minimum concentration of 0.01 nM to 1000 pM
of polylysine is delivered to the tissue. In one embodiment, polylysine is released from the surface of a shoulder prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months.
~10 For example, polylysine may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of polylysine (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as polylysine is administered at half the above parameters, a compound half as potent as polylysine is administered at twice the above parameters, etc.).
Utilizing fibronectin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of fibronectin delivered from a shoulder prosthesis, or coated onto the surface of a shoulder prosthesis, should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of fibronectin released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of fibronectin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~g - 10 pg per mm2 of surface area coated.
In another embodiment, fibronectin should be applied to a shoulder prosthesis surface at a dose of 0.05 pg/mm2 -10 p.g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release fibronectin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the shoulder prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of fibronectin is delivered to the tissue. In one embodiment, fibronectin is released from the surface of a shoulder prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months, For example, fibronectin may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of fibronectin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as fibronectin is administered at half the above parameters, a compound half as potent as fibronectin is administered at twice the above parameters, etc.).
Utilizing bleomycin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of bleomycin delivered from a shoulder prosthesis, or coated onto the surface of a shoulder prosthesis, should not exceed 100 mg (range of 0.01 ~.g to 100 mg). In one embodiment, the total amount of bleomycin released from the prosthesis should be in the range of 0.10 ~g to 50 mg. The dose per unit area of the device (i.e., the dosage of bleomycin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 ~.g - 10 ~g per mm2 of surface area coated.
In another embodiment, bleomycin should be applied to a shoulder prosthesis surface at a dose of 0.005 ~,g/mm2 -10 pg/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release bleomycin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the shoulder prosthesis such that a minimum concentration of 0.001 nM to 1000 pM of bleomycin is delivered to the tissue. In one embodiment, bleomycin is released from the surface of a shoulder prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months.
For example, bleomycin may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of bleomycin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as bleomycin is administered at half the above parameters, a compound half as potent as bleomycin is administered at twice the above parameters, etc.).
Utilizing CTGF as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of CTGF delivered from a shoulder prosthesis, or coated onto the surface of a shoulder prosthesis, should not exceed 100 mg (range of 0.01 p,g to 100 mg).
In one embodiment, the total amount of CTGF released from the prosthesis should be in the range of 0.10 ~,g to 50 mg. The dose per unit area of thel device (i.e., the dosage of CTGF as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 p,g - 10 p,g per mm2 of surface area coated. In another embodiment, CTGF should be applied to a shoulder prosthesis surface at a dose of 0.005 ~g/mm2 -10 pg/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release CTGF at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the shoulder prosthesis such that a minimum concentration of 0.001 nM to 1000 pM
of CTGF is delivered to the tissue. In one embodiment, CTGF is released from the surface of a shoulder prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, CTGF
may be released in effective concentrations for a period ranging from 1 hour-days. It should be readily evident given the discussions provided herein that analogues and derivatives of CTGF (as described previously) with similar 25 functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as CTGF is administered at half the above parameters, a compound half as potent as CTGF is administered at twice the above 30 parameters, etc.).
Optionally, the device may additionally comprise an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-~3, IL-8, IL-6, and growth hormone) and/or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).

Bone morphogenic proteins) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof) are to be used in formulations at concentrations that range from 0.001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the bone morphogenic protein is released in effective concentrations for a period ranging from 1 - 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.001 pg to 500 mg); preferred 1 pg to 250 mg. When used as a device coating, the dose is per unit area of 0.001 ~,g - 1000 p,g per mm2; with a preferred dose of 0.01 ~g/mm2 - 200 p.glmm2. Minimum concentration of 10-9 - 10-4 M of bone morphogenic protein is to be maintained on the device surface.
Inflammatory cytokines are to be used in formulations at concentrations that range from 0.0001 ~rg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the inflammatory cytokine is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 ~g to 100 mg); preferred 0.001 pg to 50 mg. When used as a device coating, the dose is per unit area of 0.0001 pg - 500 ~,g per mm2; with a preferred dose of 0.001 ~,g/mm2 - 200 p.g/mm2. Minimum concentration of 10-1°- 104 g/ml of inflammatory cytokine is to be maintained on the device surface.
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof. Doses used are those concentrations which are demonstrated to stimulate cell proliferation (see, e.g., Example 16). The proliferative agents are to be used in formulations at concentrations that range from 0.1 ng/ml to 25 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required.

Preferably, the proliferative agent is released in effective concentrations for a period ranging from 1 - 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 ~,g to 200 mg); preferred 0.001 ~,g to 100 mg. When used as a device coating, the dose is per unit area of 0.00001 ~,g - 500 ~,g per mm2; with a preferred dose of 0.0001 ~g/mmZ - 200 ~,g/mm2. Minimum concentration of 10-" - 10-6 M of proliferative agent is to be maintained on the device surface.
It should be readily evident to one of skill in the art that any of the previously described fibrosis inducing agents, or derivatives and analogues thereof, can be utilized to create variations of the above compositions without deviating from the spirit and scope of the invention. It should also be apparent that the agent can be utilized in a composition with or without polymer carrier and that altering the carrier does not deviate from the scope of this invention.
(iv) Infiltration of Fibrosing-Inducing Agents into the Tissue Surrounding an Artificial Joint Alternatively, the tissue cavity into which the artificial joint is placed (usually the bony cavity where the stem of the artificial joint is inserted) can be treated with a fibrosis-inducing agent prior to, during, or after the implantation of the prosthetic joint. This can be accomplished in several ways including: (a) topical application of the fibrosing agent into the anatomical space where the artificial joint can be placed (particularly useful for this embodiment is the use of polymeric carriers which release the fibrosing agent over a period ranging from several hours to several weeks - fluids, suspensions, emulsions, microemulsions, microspheres, pastes, gels, microparticulates, sprays, aerosols, solid implants and other formulations which release a fibrosing agent can be delivered into the region where the prosthetic joint can be inserted); (b) microparticulate silk and/or silk strands (linear, branched, and/or coiled) for directed delivery into the implantation site; (c) sprayable collagen-containing formulations such as COSTASIS or materials made from 4-armed thiol PEG (10K), a 4-armed NHS PEG(10K) and methylated collagen such as described above, either alone, or loaded with a fibrosis-inducing agent, applied to the implantation site (or the implant/device surface); (d) sprayable PEG-containing formulations such as COSEAL, FOCALSEAL, SPRAYGEL or DURASEAL, either alone, or loaded with a fibrosis-inducing agent, applied to the implantation site (or the implant/device surface); (e) fibrinogen-containing formulations such as FLOSEAL or TISSEAL, either alone, or loaded with a fibrosis-inducing agent, applied to the implantation site (or the implant/device surface); (f) hyaluronic acid-containing formulations such as RESTYLANE, HYLAFORM, PERLANE, SYNVISC, SEPRAFILM, SEPRACOAT loaded with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface); (g) polymeric gels for surgical implantation such as REPEL or FLOWGEL loaded with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface); (h) orthopedic cements used to hold prostheses and tissues in place loaded with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface), such as OSTEOBOND, LVC, SIMPLEX P, PALACOS, and ENDURANCE; (i) surgical adhesives containing cyanoacrylates such as DERMABOND, INDERMIL, GLUSTITCH, VETBOND, HISTOACRYL, TISSUEMEND, TISSUMEND II, HISTOACRYL BLUE and ORABASE
SOOTHE-N-SEAL LIQUID PROTECTANT or as described above, either alone, or loaded with a fibrosis-inducing agent, applied to the implantation site (or the implant/device surface); (j) implants containing hydroxyapatite (or synthetic bone material such as calcium sulfate, VITOSS and CORTOSS) loaded with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface); (k) other biocompatible tissue fillers loaded with a fibrosis-inducing agent, such as those made by BioCure, 3M Company and Neomend, loaded with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface); (I) polysaccharide gels such as the ADCON series of gels; (m) films, sponges or meshes such as INTERCEED, VICRYL mesh, and GELFOAM either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into or around the joint;
and/or (n) a hydrogel that is formed from an amino-functionalized polyethylene glycol (e.g., 4-armed tetra-amino PEG [10k]) and a 4-armed NHS functionalized PEG (e.g., pentaerythritol polyethylene glycol)ether tetra-succinimidyl glutarate [10K]). This hydrogel may further contain collagen, methylated collagen and/or gelatin. This hydrogel can further comprise the fibrosis-inducing agents described above (e.g., silk powder or silk threads).(m) films, sponges or meshes such as INTERCEED, VICRYL mesh, and GELFOAM loaded with a fibrosis-inducing agent applied to the implantation site (or the implant/device surface).

It should be apparent to one of skill in the art that potentially any fibrosis-inducing agents described above may be utilized alone, or in combination, in the practice of this embodiment. Exemplary fibrosing agents for infiltration into the tissues surrounding a joint prosthesis include talc, silk, woof, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
As joint prostheses are made in a variety of configurations and sizes, the exact dose administered into the tissue surrounding the implant can vary with device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the implanted portion of the device), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug, the exemplary fibrosing agents, used alone or in combination, should be administered under the following dosing guidelines:
Utilizing talc as an exemplary fibrosis-inducing agent, whether it is applied using a polymeric carrier or applied without a polymeric carrier, the total dose of talc delivered should not exceed 100 mg (range of 1 pg to 100 mg). In one embodiment, the total amount of talc released from around the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of talc as a function of the surface area of the implanted portion of the device) should fall within the range of 0.05 ~g - 10 p.g per mm2. In one embodiment, talc is released such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, talc may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of talc (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as talc is administered at half the above parameters, a compound half as potent as talc is administered at twice the above parameters, etc. ).
Utilizing silk as an exemplary fibrosis-inducing agent, whether it is applied using a polymeric carrier or applied without a polymeric carrier, the total dose of silk delivered into the tissue surrounding a prosthesis should not exceed 100 mg (range of 1 ~.g to 100 mg). In one embodiment, the total amount of silk released around the prosthesis should be in the range of 10 ~.g to 50 mg. The dose per unit area of the device (i.e., the dosage of silk as a function of the surface area of the portion of the device which is implanted) should fall within the range of 0.05 ~g - 10 ~,g per mm2. As specific (polymeric and non-polymeric) drug delivery vehicles can release silk at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug such that a minimum concentration of 0.01 nM to 1000 pM of silk is delivered to the tissue. In one embodiment, silk is released into the tissue surrounding a prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, silk may be released in effective concentrations for a period ranging from 1 hour- 30 days.
It should be readily evident given the discussions provided herein that analogues and derivatives of silk (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as silk is administered at half the above parameters, a compound half as potent as silk is administered at twice the above parameters, etc.).
Utilizing chitosan as an exemplary fibrosis-inducing agent, whether it is applied using a polymeric carrier or applied without a polymeric carrier, the total dose of chitosan delivered into the tissue surrounding a prosthesis should not exceed 100 mg (range of 1 ~,g to 100 mg). In one embodiment, the total amount of chitosan released around the prosthesis should be in the range of 10 ~g to 50 mg. The dose per unit area of the device (i.e., the dosage of chitosan as a function of the surface area of the portion of the device which is implanted) should fall within the range of 0.05 ~,g - 10 ~g per mm2. As specific (polymeric and non-polymeric) drug delivery vehicles can release chitosan at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug such that a minimum concentration of 0.01 nM to 1000 pM of chitosan is delivered to the tissue. In one embodiment, chitosan is released into the tissue surrounding a prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, chitosan may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of chitosan (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as chitosan is administered at half the above parameters, a compound half as potent as chitosan is administered at twice the above parameters, etc.).
Utilizing polylysine as an exemplary fibrosis-inducing agent, whether it is applied using a polymeric carrier or applied without a polymeric carrier, the total dose of polylysine delivered into the tissue surrounding a prosthesis should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of polylysine released should be in the range of 10 ~g to 50 mg. The dose per unit area of the device (i.e., the dosage of polylysine as a function of the surface area of the implanted portion of the device) should fall within the range of 0.05 ~,g - 10 ~.g per mm2. As specific (polymeric and non-polymeric) drug delivery vehicles can' release polylysine at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug such that a minimum concentration of 0.01 nM
to 1000 pM of polylysine is delivered to the tissue. In one embodiment, polylysine is released into the region surrounding a prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, polylysine may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of polylysine (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as polylysine is administered at half the above parameters, a compound half as potent as polylysine is administered at twice the above parameters, etc.).
Utilizing fibronectin as an exemplary fibrosis-inducing agent, whether it is applied using a polymeric carrier or applied without~a polymeric carrier, the total dose of fibronectin delivered into the tissue surrounding a prosthesis should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of fibronectin released should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of fibronectin as a function of the surface area of the portion of the device which is implanted) should fall within the range of 0.05 ~,g - 10 ~,g per mm2. As specific (polymeric and non-polymeric) drug delivery vehicles can release fibronectin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug such that a minimum concentration of 0.01 nM
to 1000 pM of fibronectin is delivered to the tissue surrounding the prosthesis.
In one embodiment, fibronectin is released adjacent to the artificial joint such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, fibronectin may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of fibronectin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as fibronectin is administered at half the above parameters, a compound half as potent as fibronectin is administered at twice the above parameters, etc.).
Utilizing bleomycin as an exemplary fibrosis-inducing agent, whether it is applied using a polymeric carrier or applied without a polymeric carrier, the total dose of bleomycin delivered into the tissue surrounding a prosthesis should not exceed 100 mg (range of 0.01 ~,g to 100 mg). In one embodiment, the total amount of bleomycin released should be in the range of 0.10 ~g to 50 mg. The dose per unit area of the device (i.e., the dosage of bleomycin as a function of the surface area of the portion of the device which is implanted) should fall within the range of 0.005 ~,g - 10 ~.g per mm2. As specific (polymeric and non-polymeric) drug delivery vehicles can release bleomycin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug such that a minimum concentration of 0.001 nM to 1000 pM of bleomycin is delivered to the tissue surrounding the joint prosthesis. In one embodiment, bleomycin is released around the prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, bleomycin may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of bleomycin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as bleomycin is administered at half the above parameters, a compound half as potent as bleomycin is administered at twice the above parameters, etc.).
Utilizing CTGF as an exemplary fibrosis-inducing agent, whether it is applied using a polymeric carrier or applied without a polymeric carrier, the total dose of CTGF delivered into the tissue surrounding a prosthesis should not exceed 100 mg (range of 0.01 pg to 100 mg). In one embodiment, the total amount of CTGF released should be in the range of 0.10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of CTGF as a function of the surface area of the portion of the device which is implanted) should fall within the range of 0.005 ~,g - 10 pg per mm2. As specific (polymeric and non-polymeric) drug delivery vehicles can release CTGF at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug such that a minimum concentration of 0.001 nM to 1000 pM of CTGF is delivered to the tissue surrounding the artificial joint. In one embodiment, CTGF is released such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, CTGF may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of CTGF (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as CTGF is administered at half the above parameters, a compound half as potent as CTGF is administered at twice the above parameters, etc.).
Optionally, the device may additionally comprise an inflammatory cytolcine (e.g., TGF~, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-Vii, IL-8, IL-6, and growth hormone) and/or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).
Bone morphogenic proteins) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof) are to be used in formulations at concentrations that range from 0.001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the bone morphogenic protein is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.001 p,g to 500 mg); preferred 1 ~,g to 250 mg. When used as a device coating, the dose is per unit area of 0.001 ~.g - 1000 ~,g per mm2; with a preferred dose of 0.01 g,glmm2 - 200 p,g/mmz. Minimum concentration of 10-9- 10-4 M of bone morphogenic protein is to be maintained on the device surface.
Inflammatory cytokines are to be used in formulations at concentrations that range from 0.0001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the inflammatory cytokine is released in effective concentrations for a period ranging from 1 - 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 ~g to 100 mg); preferred 0.001 ~.g to 50 mg. When used as a device coating, the dose is per unit area of 0.0001 ~g - 500 ~.g per mm2; with a preferred dose of 0.001 ~g/mm2 - 200 ~.g/mm2. Minimum concentration of 10-1°- 10-4 g/ml of inflammatory cytokine is to be maintained on the device surface.
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof. Doses used are those concentrations which are demonstrated to stimulate cell proliferation (see, e.g., Example 16). The proliferative agents are to be used in formulations at concentrations that range from 0.1 ng/ml to 25 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required.
Preferably, the proliferative agent is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 ~,g to 200 mg); preferred 0.001 p.g to 100 mg. When used as a device coating, the dose is per unit area of 0.00001 ~,g - 500 ~,g per mm2; with a preferred dose of 0.0001 ~g/mm~ - 200 ~,g/mm2. 'Minimum concentration of 10-" - 10-6 M of proliferative agent is to be maintained on the device surFace.
It should be readily evident to one of skill in the art that any of the previously described fibrosis inducing agents, or derivatives and analogues thereof, can be utilized to create variations of the above compositions without deviating from the spirit and scope of the invention. It should also be apparent that the agent can be utilized in a composition with or without polymer carrier and that altering the carrier does not deviate from the scope of this invention.
3. Dental Devices In one aspect, the present invention provides dental devices and implants that include a fibrosis or adhesion-inducing agent to assist in the incorporation of the implant into the surrounding tissue. A variety of devices is used in dental applications. Representative examples include dental implants and guided bone regeneration devices.
In one aspect, a dental implant of specific importance is a small titanium fixture that serves as a replacement for the root portion of a missing natural tooth. The dental implant is placed in the bone of the upper or lower jaw and functions as an anchor for the replacement tooth. They may be used to support the replacement of a single missing tooth or a complete functional set for individuals who have lost many or all of their teeth. Dental implants can be implanted in the bone (endosteal) or on the bone (subperiosteal). Endosteal implants are the most commonly used type of implant. There are various types of endosteal implants, which may include screws, cylinders or blades surgically placed into the jawbone. Each implant holds one or more prosthetic teeth. This type of implant is generally used as an alternative for patients with bridges or removable dentures. Subperiosteal implants are placed on top of the jaw with the metal framework's posts protruding through the gum to hold the prosthesis.
These types of implants are used for patients who are unable to wear conventional dentures and who have minimal bone height.
A variety of dental implants suitable for combination with a fibrosis-inducing agent have been described (see, e.g., U.S. Patent Nos.
6,627,321; 6,582,228; 6,572,373; 6,527,553; and 6,506,051).
In one aspect, the fibrosing agent may be incorporated into the glue or cement that holds the device in place. In another aspect, the dental device is covered (all or in part) with a silk mesh or lattice to encourage scarring and anchoring into the surrounding bone. For example, a silk mesh or lattice can be coated onto all or a portion of the surface of the implant stem to encourage scarring and anchoring into the surrounding bone.
In another aspect, the device used to deliver a fibrosis-inducing agent may be a guided tissue regeneration (GTR) device, such as a GTR
membrane. A GTR membrane is a resorbable or non-resorbable membrane made of biologically or non-biologically derived material. GTR membranes may be used in conjunction with a dental implant or to treat bone loss. GTR
membranes may be made from a variety of materials, including, e.g., collagen (e.g., porcine collagen, types l and II), PTFE, polylactic acid, lactide and glycolide polymers, and ePTFE). GTR membranes are commercially available from W.L. Gore & Associates (Newark, DE) (e.g., GORE-TEX and GORE-RESOLUT regenerative material), Guidor, Atrix Laboratories, Inc. (Fort Collins, CO), Geistlich Biomaterials, Inc. (e.g., BIO-GIDE)~ LifeCore Biomedical, Inc.
(Chaska, MN), Ethicon Inc. (e.g., VICRYL), THM Biomedical now known as Kensey Nash Corporation (Exton, PA), and Suzler Calcitek, Inc. (Carlsbad, CA).
In another aspect, the dental device suitable for combining with a fibrosis-inducing agent is used for guided bone regeneration (GBR) to augment insufficient bone tissue and guide regrowth. GBR devices include, e.g., resorbable bone substitutes for filling bony defects. Such devices may consist of biomaterials (e.g., demineralized bone and bovine-derived materials) and synthetic materials, such as crystalline hydroxyapatite and calcium sulfate. A
variety of dental bone substitutes are commercially available, including the following products: OSTEOGRAF/N, OSTEOGRAF/LD, OSTEOGRAF/D, AND
PERMARIDGE (all from Ceramad), bioactive glass, such as PERIOGLAS (U.S.
Biomaterials), OSTEOGEN (Impladent, Inc.), VITOSS and CORTOSS.
In another aspect, the present invention provides dental implants containing a fibrosis-inducing agent for use in the treatment of common periodontal conditions. Briefly, periodontal disease is an inflammatory disease of the supporting structures of the teeth, including the ligaments, cementum, periosteum, alveolar bone and adjacent gingiva which anchor the teeth in place.
The condition begins with bleeding of the gums, but can progress to loosening of the teeth, receding gums, abscesses in pockets between the gums and the teeth, and necrotizing ulcerative gingivitis. In advanced stages, procedures such as gingivectomy, gingivoplasty, and correction of the bony architecture of the teeth may be required for treatment of the condition. Traditional treatment involves open-flap debridement of the periodontal pocket with removal of diseased cementum, periodontal ligament and alveolar bone that have been destroyed by periodontal infection. Unfortunately, epithelial tissue can occasionally migrate into the surgically created defect impairing proper healing of the cementum, ligament and bone.
Dental implants have been developed in an attempt to control the healing process and optimize tissue regeneration. Commonly used implants include permanent implants, such as e-PTFE membranes (e.g., GORE-TEX
from W.L. Gore). Commonly used implants include, e.g., BIOMEND, available from Sulzer Medica, fnc. (Houston, TX), which is a collagen membrane composed of compressed Type I collagen matrix derived from bovine Achilles tendon. The collagen membrane (supplied as sheets, e.g., 15mm x 20mm;
20mm x 30mm; and 30mm x 40mm) is cut to the appropriate size and shape, hydrated and placed as a barrier between the overlying gingival tissue and the debrided periodontal defect; the barrier can be sutured in place, but this is not always required. The membrane is placed snugly against the tooth root and draped over the surrounding alveolar bone (extending at least 3 mm beyond the defect margins) to effectively maintain the regenerative space. Primary closure with mucoperiosteal flaps over the collagen membrane is important as exposure of the membrane to the oral cavity can result in premature degradation. The barrier prevents faster growing epithelial tissue from entering the region and allows the slower growing periodontal ligament and bone cells to repopulate the area and effect appropriate healing. The collagen membrane is bioresorbable, is retained for 6 to 7 weeks, and is fully absorbed by host enzymes (e.g., collagenase) within 8 weeks.
However, limited durability of the collagen implant can become a clinical problem if it completely absorbs prior to the completion of healing -this is particularly relevant with large tissue defects. In an attempt to address this problem, manufacturers have attempted to produce a collagen implant with improved durability through increased collagen crosslinking (often through exposure of the collagen to aldehydes). Utilizing this process, products such as BIOMEND EXTEND (Sulzer Medica, Inc.) can function as a barrier for longer periods of time, such that the collagen is not absorbed into the surrounding tissue for approximately 18 weeks. Another collagen dental implant product, OSSIX (Colbar R&D Ltd., Israel), uses a metabolite to crosslink collagen and prolong the structural integrity of the matrix for periods of up to 6 months.
In addition to the commercially available collagen-based products for the management of periodontal disease described above, other types of collagen-based implants may be used in the practice of the invention.
Representative examples of such implants include those that are used in variety of dental procedures including: COLLATAPE (Sulzer Medics, Inc.), which is a collagen-based implant used in the repair of minor oral wounds, closure of grafted sites and repair of Schneiderian Membranes; COLLACOTE
(Sulzer Medics, Inc.), a collagen-based wound dressing used for palatal donor sites and in mucosal flaps; and COLLAPLUG (Sulzer Medics, Inc.), a solid collagen-based implant used in the repair of larger tissue defects such extraction sites or biopsy sites.
In one aspect, the present invention provides dental devices that include a fibrosis-inducing agent or a composition that includes a fibrosis-inducing agent to promote fibrosis in the periodontal pocket. In one aspect, the dental device or material used to fill or maintain the periodontal pocket is coated with, composed of, or contains a fibrosing agent or a composition that includes a fibrosing agent.
Numerous polymeric and non-polymeric carrier systems described above can be used in the practice of this embodiment. These compositions can further include one or more fibrosis-inducing agents to promote the formation of fibrous tissue around the dental implant. Methods for incorporating fibrosing compositions onto or into the dental implant (such as endosteal or perioosteal titanium implants) include: (a) directly affixing to the dental hardware a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (b) directly incorporating into the dental hardware a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (c) by coating the dental hardware with a substance such as a hydrogel which can in turn absorb the fibrosing composition; (d) by interweaving a thread coated with a fibrosis-inducing composition (or the a fibrosis-inducing polymer itself formed into a thread) into the device structure; (e) by inserting the device ,.
into a sleeve or mesh which is comprised of, or coated with, a fibrosing composition; (f) constructing the device itself, or a portion of the device, with a composition containing a fibrosing agent; or (g) by covalently binding the fibrosing agent directly to the device surface or to a linker (small molecule or polymer) that is coated or attached to the device surface. For dental hardware devices, the coating process can be performed in such a manner as to (a) coat the surfaces of the device that is in contact with the bone, (b) coat the surfaces of the device that are not in contact with the bone or (c) coat all or parts of both the bone-contacting and non-bone contacting surface of the device. In addition to coating the device with the fibrosing composition, the fibrosing agent can be mixed with the materials that are used to make the device such that the fibrosing agent is incorporated into the final device.
. For the management of periodontal disease, polymeric gels, pastes, injectables, solutions, microparticles and solid implants placed into the periodontal pocket are a preferred form of locally delivering a fibrosis-inducing agent. All involve the deployment of a biomaterial containing a fibrosis-inducing agent into the surgically-created periodontal pocket (a's described above).
The practice of this embodiment can be performed in several ways including: (a) topical application of the fibrosing agent onto the periodontal pocket (particularly useful for this embodiment is the use of polymeric carriers which release the fibrosing agent over a period ranging from several hours to several weeks - fluids, suspensions, emulsions, microemulsions, microspheres, pastes, gels, microparticulates, sprays, aerosols, solid implants and other formulations which release a fibrosing agent and can be delivered into the region via specialized delivery catheters or other applicators); (b) placement of microparticulate silk and/or silk strands (linear, branched, and/or coiled) into the periodontal pocket; (c) sprayable collagen-containing formulations~such as COSTASIS or materials made from 4-armed thiol PEG (10K), a 4-armed NHS
PEG(10K) and methylated collagen such as described above, either alone, or loaded with a fibrosis-inducing agent, applied into periodontal pocket; (d) sprayable PEG-containing formulations such as COSEAL, FOCALSEAL, SPRAYGEL or DURASEAL, either alone, or loaded with a fibrosis-inducing agent, applied to the periodontal pocket; (e) fibrinogen-containing formulations such as FLOSEAL or TISSEAL, either alone, or loaded with a fibrosis-inducing agent, applied to the periodontal pocket; (f) hyaluronic acid-containing formulations such as RESTYLANE, HYLAFORM, PERLANE, SYNVISC, SEPRAFILM, SEPRACOAT loaded with a fibrosis-inducing agent applied to the periodontal pocket; (g) polymeric gels for surgical implantation such as REPEL
or FLOWGEL loaded with a fibrosis-inducing agent applied to the periodontal pocket; (h) orthopedic "cements" such as OSTEOBOND, LVC, SIMPLEX P, PALACOS, ENDURANCE, and CORTOSS loaded with a fibrosis-inducing agent applied to the periodontal pocket; (i) surgical adhesives containing cyanoacrylates such as DERMABOND, INDERMIL, GLUSTITCH, VETBOND, HISTOACRYL, TISSUEMEND, TISSUMEND II, HISTOACRYL BLUE and ORABASE SOOTHE-N-SEAL LIQUID PROTECTANT or as described above loaded with a fibrosis-inducing agent, applied to the periodontal pocket; (j) surgical implants containing hydroxyapatite, calcium sulfate, or VITOSS loaded with a fibrosis-inducing agent applied to the periodontal pocket; (k) other biocompatible tissue fillers, such as those made by BioCure, 3M Company and Neomend, loaded with a fibrosis-inducing agent, applied to the periodontal pocket; (I) polysaccharide gels such as the ADCON series of gels loaded with a fibrosis-inducing agent applied to the periodontal pocket; (m) films, sponges or meshes such as INTERCEED, VICRYL mesh, and GELFOAM loaded with a fibrosis-inducing agent applied to the periodontal pocket; and/or (n) a hydrogel that is formed from an amino-functionalized polyethylene glycol (e.g., 4-armed tetra-amino PEG [10k]) and a 4-armed NHS functionalized PEG (e.g., pentaerythritol polyethylene glycol)ether tetra-succinimidyl glutarate [10K]).
This hydrogel may further contain collagen, methylated collagen and/or gelatin.
This hydrogel can further comprise the fibrosis-inducing agents described above (e.g., silk powder or silk threads).
In many of the embodiments described above it may also be useful to add a radio-opaque material (such as tantalum, barium, other metal, or contrast material) such that the injected material can be visualized radiographically or by MRI. The contrast agent may be a water soluble or water insoluble radio-opaque material.
It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agents described above may be utilized alone, or in combination, in the practice of this embodiment. Exemplary fibrosing agents for use in dental prostheses include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
Optionally, the device may additionally comprise an inflammatory cytokine (e.g., TGF(3, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-~3, IL-8, IL-6, and growth hormone) or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).
As dental prostheses are made in a variety of configurations and sizes, the exact dose administered can vary with device size, surface area and design. However, certain principles can be applied in the application of this art.
Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined.
Regardless of the method of application of the drug to the dental prostheses or periodontal implant, the exemplary fibrosing agents, used alone or in combination, should be administered under the following dosing guidelines:
Utilizing talc as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of talc delivered from a dental prosthesis, or coated onto the surface of a dental prosthesis, should not exceed 100 mg (range of 1 ~,g to 100 mg). In one embodiment, the total amount of talc released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of talc as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~,g - 10 pg per mm2 of surface area coated. In another embodiment, talc should be applied to a dental prosthesis surface at a dose of 0.05 ~g/mm2 -10 ~g/mm2 of surface area coated. In one embodiment, talc is released from the surface of a dental prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, talc may be released in effective concentrations for a period ranging from 1 hour- 30 days.
It should be readily evident given the discussions provided herein that analogues and derivatives of talc (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as talc is administered at half the above parameters, a compound half as potent as talc is administered at twice the above parameters, etc. ).
Utilizing silk as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of silk delivered from a dental prosthesis, or coated onto the surface of a dental prosthesis, should not exceed 100 mg (range of 1 pg to 100 mg). In one embodiment, the total amount of silk released from the prosthesis should be in the range of 10 p,g to 50 mg. The dose per unit area of the device (i.e., the dosage of silk as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 p.g - 10 p,g per mm2 of surface area coated. In another embodiment, silk should be applied to a dental prosthesis surface at a dose of 0.05 pg/mm2 -10 p,g/mm2 of surface area coated. As specific (polymeric and non-polymeric)~drug delivery vehicles and specific medical devices can release silk at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the dental prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of silk is delivered to the tissue. In one embodiment, silk is released from the surface of a dental prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, silk may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of silk (as described previously) with similar functional activity can be utilized for the purposes of this invention;
the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as silk is administered at half the above parameters, a compound half as potent as silk is administered at twice the above parameters, etc.).
Utilizing chitosan as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier,, the total dose of chitosan delivered from a dental prosthesis, or coated onto the surface of a dental prosthesis, should not exceed 100 mg (range of 1 p.g to mg). In one embodiment, the total amount of chitosan released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of chitosan as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~,g - 10 pg per mm2 of surface area coated. In another embodiment, chitosan should be applied to a dental prosthesis surface at a dose of 0.05 p,g/mm2 -10 ~g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release chitosan at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the dental prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of chitosan is delivered to the tissue. In one embodiment, chitosan is released from the surface of a dental prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, chitosan may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of chitosan (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as chitosan is administered at half the above parameters, a compound half as potent as chitosan is administered at twice the above parameters, etc.).
Utilizing polylysine as a exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of polylysine delivered from a dental prosthesis, or coated onto the surface of a dental prosthesis, should not exceed 100 mg (range of 1 ~,g to mg). In one embodiment, the total amount of polylysine released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of polylysine as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~g - 10 ~g per mm2 of surface area coated. In another embodiment, polylysine should be applied to a dental prosthesis surface at a dose of 0.05 ~,g/mm2 -10 ~,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release polylysine at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the dental prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of polylysine is delivered to the tissue. In one embodiment, polylysine is released from the surface of a dental prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, polylysine may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of polylysine (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as polylysine is administered at half the above parameters, a compound half as potent as polylysine is administered at twice the above parameters, etc.).
Utilizing fibronectin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of fibronectin delivered from a dental prosthesis, or coated onto the surface of a dental prosthesis, should not exceed 100 mg (range of 1 pg to 100 mg). In one embodiment, the total amount of fibronectin released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of fibronectin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~,g - 10 ~,g per mm2 of surface area coated. In another embodiment, talc should be applied to a dental prosthesis surface at a dose of 0.05 ~g/mm2 -10 pg/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release fibronectin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the dental prosthesis such that a minimum concentration of 0.01 nM to 1000 pM of fibronectin is delivered to the tissue. In one embodiment, fibronectin is released from the surface of a dental prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, fibronectin may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should tje readily evident given the discussions provided herein that analogues and derivatives of fibronectin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as fibronectin is administered at half the above parameters, a compound half as potent as fibronectin is administered at twice the above parameters, etc.).
Utilizing bleomycin as a exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of bleomycin delivered from a dental prosthesis, or coated onto the surface of a dental prosthesis, should not exceed 100 mg (range of 0.01 p,g to 100 mg). In one embodiment, the total amount of bleomycin released from the prosthesis should be in the range of 0.10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of bleomycin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 pg - 10 ~g per mm2 of surface area coated. In another embodiment, bleomycin should be applied to a dental prosthesis surface at a dose of 0.005 p.g/mm2 -10 ~g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release bleomycin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the dental prosthesis such that a minimum concentration of 0.001 nM to 1000 pM of bleomycin is delivered to the tissue. In one embodiment, bleomycin is released from the surface of a dental prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months.
For example, bleomycin may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of bleomycin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as bleomycin is administered at half the above parameters, a compound half as potent as bleomycin is administered at twice the above parameters, etc.).
Utilizing CTGF as a exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of CTGF delivered from a dental prosthesis, or coated onto the surface of a dental prosthesis, should not exceed 100 mg (range of 0.01 ~g to 100 mg). In one embodiment, the total amount of CTGF released from the prosthesis should be in the range ofi 0.10 pg to 50 mg. The dose per unit area of the device (i.e., the dosage of CTGF as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 p,g - 10 p,g per mm2 of surface area coated. In another embodiment, CTGF
should be applied to a dental prosthesis surface at a dose of 0.005 p.g/mm2 -p.g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release CTGF at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the dental prosthesis such that a minimum concentration of 0.001 nM to 1000 pM of CTGF is delivered to the tissue. In one embodiment, CTGF is released from the surface of a dental prosthesis such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, CTGF may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of CTGF (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as CTGF
is administered at halfi the above parameters, a compound half as potent as CTGF is administered at twice the above parameters, etc.).
Bone morphogenic proteins) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof), if present, are to be used in formulations at concentrations that range from 0.001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the bone morphogenic protein is released in effective concentrations fior a period ranging from 1 - 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.001 p.g to 500 mg); preferred 1 p,g to 250 mg.
When used as a device coating, the dose is per unit area of 0.001 ~,g - 1000 p,g per mm2; with a preferred dose of 0.01 pg/mm2 - 200 p.g/mm2. Minimum concentration of 10-9- 10-4 M of bone morphogenic protein is to be maintained on the device surface.

inflammatory cytokines, if present, are to be used in formulations at concentrations that range from 0.0001 pg/ml to approximately 20 mglml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the inflammatory cytokine is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typicaNy not to exceed 500 mg (range of 0.0001 p.g to 100 mg); preferred 0.001 p,g to 50 mg. When used as a device coating, the dose is per unit area of 0.0001 p,g - 500 ~,g per mm2; with a preferred dose of 0.001 ~,g/mm2 - 200 pg/mm2. Minimum concentration of 10-'° - 10~ g/ml of inflammatory cytokine is to be maintained on the device surface.
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-~3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-traps retinoic acid (ATRA), and analogues and derivatives thereof. Doses used are those concentrations which are demonstrated to stimulate cell proliferation (see, e.g., Example 16). The proliferative agents are to be used in formulations at concentrations that range from 0Ø1 ng/ml to 25 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required.
Preferably, the proliferative agent is released in effective concentrations for a period ranging from 1 - 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 ~g to~200 mg); preferred 0.001 ~,g to 100 mg. When used as a device coating, the dose is per unit area of 0.00001 ~g - 500 ~g per mm2; with a preferred dose of 0.0001 p,g/mm2 - 200 ~,g/mm2. Minimum concentration of 10y" - 10-6 M of proliferative agent is to be maintained on the device surface.
It should be readily evident to one of skill in the art that any of the previously described fibrosis inducing agents, or derivatives and analogues thereof, can be utilized to create variations of the above compositions without deviating from the spirit and scope of the invention. It should also be apparent that the agent can be utilized in a composition with or without polymer carrier and that altering the carrier does not deviate from the scope of this invention.

4. Orthopedic Implants In one aspect, the present invention provides orthopedic implants that include a fibrosis-inducing agent or a composition that includes a fibrosis-inducing agent to promote scarring and fixation of the device into the surrounding bone or tissue.
(i) Orthopedic Hardware Coated with a Fibrosis-Inducing Aaent In one aspect, the orthopedic implant is an orthopedic "hardware"
device that has been coated with a fibrosing agent or a fibrosing agent containing composition. Representative examples of orthopedic hardware devices include internal and external fixation devices, fixation screws (degradable or non-degradable), interfierential screws (degradable and non-degradable), trochanteric screws, plates, wires (e.g., K-wires), pins, and nails used in fracture repairs, reconstructive procedures, and joint fusion procedures (e.g., ankle fusions, cervical and lumbar spinal fusions). Compositions also are provided for coating devices used in fusion procedures and superior repair of fractures. Orthopedic implants such as, for example, fixation screws, pins, plates, nails, wires and plates coated with a fibrosing agent, coated with a composition containing a fibrosing agent, or composed of a polymer that releases a fibrosing agent (particularly for polymeric, biodegradable orthopedic hardware) are used to encourage better anchorage of the implant into the surrounding bone. Alternatively, or in addition, the fibrosing agent may be incorporated into the glue or cement that holds the implant in place. In another aspect, the orthopedic hardware is covered (all or in part) with a silk mesh or lattice to encourage scarring and anchoring into the surrounding bone. For example, a silk mesh or lattice can be coated onto all or a portion of the surFace of the implant stem to encourage scarring and anchoring into the surrounding bone.
In another aspect, the orthopedic implant is a collagen implant for use as a substitute for autogenous or allogenous bone grafts. A variety of collagen implants have been developed for use in orthopedic surgery as a substitute for autogenous or allogenous bone grafts. Collagen is the principle organic component of bone and can be combined with mineral formulations, autogenous bone marrow, bone graft, and/or growth factors (such as MPs) for use as a bone substitute or a skeletal repair product. Typical applications include, but are not restricted to, total joint replacement surgery (e.g., artificial hips, knees, etc.), spinal fusion surgery, long bone fractures, repair of traumatic bone defects, voids, or gaps, to augment an autograft, and as a bone filler at bone graft harvesting sites. Examples of commercially available collagen-based bone grafts include COLLAGRAFT Paste and COLLAGRAFT Strips made by Angiotech Pharmaceuticals, Inc. COLLAGRAFT is a combination of highly purified Type I bovine dermal fibrillar collagen and a mixture of 65%
hydroxyapatite and 35% tricalcium phosphate. This material closely resembles human bone and is resorbed and replaced with bone during the healing process. Representative examples of bone grafts are described in U.S. Patents No. 6,083,522 and 6,280,474 and in PCT Publication No. WO 98/52498.
Numerous polymeric and non-polymeric carrier systems described above can be used in the practice of this embodiment. These compositions can further include one or more fibrosis-inducing agents to promote the formation of granulation tissue (described further in section (iii) below). Methods for incorporating fibrosing compositions onto or into the orthopedic implants include: (a) directly affixing to the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (b) directly incorporating info the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (c) by coating the device with a substance such as a hydrogel which can in turn absorb the fibrosing composition; (d) by interweaving into the device a thread coated with a fibrosing composition (or a polymeric version of the fibrosing agent is itself formed into a thread); (e) by inserting the device into a sleeve or mesh which is comprised of, or coated with, a fibrosing composition; (f) constructing the device itself or a portion of the device with a fibrosing composition (particularly effective for biodegradable orthopedic hardware and collagen implants); or (g) by covalently binding the fibrosing agent directly to the device surface or to a linker (small molecule or polymer) that is coated or attached to the device surface. For these devices, the coating process can be performed in such a manner as to (a) coat the surfaces of the device that is in contact with the bone; (b) coat the surfaces of the device that are not in contact with bone, or (c) coat all or parts of both the bone-contacting and non-bone contacting surface of the device.
It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agent may be utilized alone, or in combination, in the practice of this embodiment as described above. Exemplary fibrosing agents for use in the coating of orthopedic hardware include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and/or CTGF as well as analogues and derivatives of the aforementioned. The correct administration and dosage is the same as that described previously in section 2(i), 2(ii) and 2(iii) for artificial hips, knees and shoulder prostheses.
(ii) Minimally-Invasive Joint Fusion In another aspect, the present invention provides injectable compositions to promote scarring and fixation (immobilization) of a joint without the need for open surgery. In some clinical situations it is desirable to immobilize a joint that has been severely damaged or is the cause of chronic pain. For example, a composition including an adhesion or fibrosis-inducing agent may be injected into an arthritic or damaged joint to promote scarring and fixation (i.e., immobilization) of the joint (particularly interphalageal joints, tarsal-metatarsal joints, metacarpal joints, ankle joints, knee joints, proximal tibia-fibular joint, hip joint, sacro-iliac joint, acromio-clavicular joint, sterno-clavicular joint and facet joints in the cervical, thoracic, and lumbar spine). In this procedure, a needle is inserted into the joint cavity, a guidewire is advanced into the joint space, a dual lumen catheter (for many of the hydrogels described below such as a material made from 4-armed thiol PEG (10K), a 4-armed NHS
PEG(10K) and methylated collagen such as described above, COSEAL, COSTASIS, FLOSEAL, TISSEAL, VITOSS) or a single lumen catheter (for materials such as cyanoacrylate, CORTOSS, bone cement, hydroxyapatite, calcium phosphate, calcium sulfate, hyaluronic acid, proteins, carbohydrates, sclerosing agents, and the like ) is advanced over the guidewire into the articular space, the guidewire is removed, and a composition containing a fibrosis-inducing agent, bone morphogenic protein(s), and/or osteogenic growth factor (such as transforming growth factor, platelet-derived growth factor, fibroblast growth factor) is injected via the catheter into joint until the joint space is filled. Agents such as collagenase, chymopapain, or other tissue-degrading enzymes may also be used to chemically degrade the remaining cartilage prior to, or during, the injection of the joint-fusing composition. Over time, the fibrosis-inducing agent, bone morphogenic protein, and/or osteogenic growth factor can encourage fibrous ankylosis, followed by bony ankylosis of the treated joint, leading to decreased (or complete loss of) range of motion, stability, and/or reduced pain.

When performing direct injection of the joint, techniques can be used to enhance visualization of needle (or catheter) placement within the joint space including, but not limited to, the use of a needle coated with ECHO-COAT, the injection of air to enable localization by ultrasound, or the addition of contrast agents (barium, tantalum, technetium, gadolinium, and the like) for localization by x-ray or MRI.
One method of administration, the fibrosing agent and/or osteogenic agent is delivered under direct vision during arthroscopic evaluation of the joint. Here the composition containing the fibrosis-inducing agent, bone morphogenic protein, and/or osteogenic growth factor is injected into the articular space through the side port of an arthroscope, preferably after the remaining articular cartilage has been mechanically or chemically debrided. In some cases, the fibrosis-inducing agent may also be delivered directly to the tissue during open joint fusion surgery to enhance the efficacy of this procedure.
The injectable material may be also composed of an injectable polymer system for use in minimally invasive joint fusion. Additionally, the polymer system can provide sustained release of the fibrosis-inducing agent, bone morphogenic protein, andlor osteogenic growth factor to enhance efficacy and reduce the need for repeated intra-articular administrations of active agents. The injection material suitable for delivery of a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor that promotes bone growth for the purposes of this invention can be composed of a non-degradable or a degradable material. Suitable non-degradable materials can include crosslinked compositions that comprise PVA, PVP, polyacrylamide, methyl methacrylate (MMA) and methyl methacrylate styrene (MMA-styrene) which when mixed together form polymethyl methacrylate (PMMA) or bone cement (e.g., SIMPLEX P, ZIMMER REGULAR and ZIMMER LOW VISCOSITY
CEMENT, PALACOS, CMW-1 and CMW-2, ENDURANCE, synthetic cancellous bone void fillers (e.g., CORTOSS), pHEMA, polyvinyl PEG), polystyrene sulfonate), poly(acrylic acid), poly(methacrylic acid), as well as other polymers that are known to form hydrogels. Additional compositions include blends and copolymers of the agents listed above. Suitable degradable materials include, but are not limited to, resorbable ceramics composed of ~i tricalcium phosphate (e.g., VITOSS, PROOSTEON 500R), hydroxyapatite or Ca~o(P04)60H (e.g., BIOOSS, OSTEOGRAF), calcium carbonate or CaC03, calcium sulfate (e.g., OSTEOSET and ALLOMATRIX ), calcium phosphate (e.g., CALCIBON or NORIAN SRS), crosslinked materials of PEG, gelatin, collagen, bone allografts (e.g., ALLOGRO, ORTHOBLAST, OPTEFORM, GRAFTON), mesenchymal stem cells, hyaluronic acid, hyaluronic acid derivatives, polysaccharides, carbohydrates, proteins (e.g., albumin, casein, whey proteins, plant proteins, or fish proteins, and the like), autologous bone, demineralized bone matrix, cellulose derivatives (e.g., HPC), chitosan, chitosan derivatives, polyester-polyalkylene oxide block copolymers (e.g., PLGA - PEG-PLGA or MePEG - PLGA) and other low molecular weight polymers that can be excreted. One material that is of particular interest is prepared from a 4-armed thiol PEG (10K), a 4-armed NHS PEG(10K) and methylated collagen such as described above. In one embodiment, the injectable material also contains a biologically active agent capable of inducing fibrosis and ankylosis in the treated joint. Preferred biologically active agents include fibrosis-inducing agents, bone morphogenic proteins, and growth factors (transforming growth factor, platelet-derived growth factor, fibroblast growth factor), whose dosages and release kinetics are all described in detail in section (iii) below.
In addition to, or in lieu of, fibrosis-inducing agents, bone morphogenic proteins and growth factors, the injectable material can be utilized to deliver a sclerosant to the articular space. Sclerosants include compounds such as ethanol, DMSO, surfactants, sucrose, NaCI, dextrose, glycerin, minocycline, tetracycline, doxycycline, polidocanol, sodium tetradecyl sulfate, sodium morrhuate, sotradecol and others. The hydrogel can further comprise agents such as glycerol, glycerin, PEG 200, triethyl citrate, and triacetin as plasticizers.
The injectable materials described above can further modified to be comprised of, or contain, polymeric threads. Polymeric threads have the ability to induce a fibroproliferative response from the surrounding tissue.
These polymer threads can be degradable or non-degradable. Degradable threads can be composed of degradable polyesters, polyanhydrides, poly(anhydride esters), polyester-amides), polyester-ureas), polyorthoesters, polyphosphoesters, polyphosphazines, cyanoacrylate polymers, collagen, chitosan, hyaluronic acid, chromic cat gut, alginates, starch, cellulose, cellulose esters, blends and copolymers thereof, as well as other known degradable polymers. Non-degradable polymers that can be used include, but are not limited to, polyesters (e.g., PET), polyurethanes, silicones, PE, PP, PS, PAA, PMA, silk, blends, copolymers thereof as well as others known polymers. The threads used can be composed of a single composition or composed of a blend of differing compositions. The polymeric threads themselves can be further modified through the addition of a polymeric coating applied to the threads.
The polymer used for coating the thread can be similar to that described above for the threads themselves. The polymer coating may further comprise a biologically active agent that has the ability to induce a fibroproliferative or osteogenic response. The agents that can be used are further described in the section (iii) below.
The injectable materials described above can be utilized to deliver a particulate material that has the ability to induce ankylosis in the joint.
These particles can be either degradable or non-degradable and are similar to those described above for threads. In addition, particulate materials useful for the practice of this embodiment include talc, starch, glass, silicates, silica, calcium phosphate, calcium sulfate, calcium carbonate, hydroxyapatite, synthetic mineral (VITOSS and CORTOSS), PMMA, silver nitrate, ceramic particles and other inorganic particles known in the art to induce a fibroproliferative response followed by mineralization. The particles used in this embodiment can be all of the same composition or a blend of differing compositions. These particles can also be used as a coating applied to the polymeric strands as described above.
The injectable material can also be constructed such that it is comprised of both polymeric threads and particles. The threads and particles used are similar to those described above and may be of uniform composition or blended composition. ,Virtually any combination of threads of differing compositions and particles of differing compositions can be utilized in this embodiment. The hydrogel, the polymeric threads, and the particles can all be utilized to deliver one or more biologically active agents, as described below.
One specific composition comprises rods prepared from a methylated collagen - crosslinked polyethylene glycol) composition such as described above which has powdered silk particles and/or mineral particles added to the composition prior to curing. Once deployed, the rod can absorb water, fill the joint space and adhere to any articular cartilage or exposed bone.
This expansion can prevent the rod from moving, while the powdered and/or mineral silk can initiate an ankylosing response. As the material starts to degrade, the material can support the bone tissue ingrowth that is initiated and potentiated by the particles. Bone morphogenic proteins and/or growth factors (described previously and below) are also useful for the addition to this composition. To further increase the rate of initiation of this fibroproliferative response, a sclerosant such as a surfactant (SDS), ethanolamine oleate or DMSO can be added. In addition, one may also add or replace all (or a portion) of the 4-armed thiol PEG with a 4-armed amino PEG. The amino PEG can provide a gel that can take a longer time to degrade and can provide some positive charge to further attract cellular material.
A second specific embodiment consists of an injectable implant composed of silk fibers or a polymerized version of the fibrosing agent itself (i.e., repeating units of the fibrosing agent polymerized together). The addition of bone morphogenic proteins and/or growth factors (described previously and below) is also useful for the addition to this composition.
In addition to the hydrogels, bone cements, and materials containing calcium phosphate described above, there are several other injectable compositions suitable for use in minimally invasive joint fusion procedures. All involve the deployment of a biomaterial into the joint space;
with or without, the addition of a fibrosis-inducing agent, bone morphogenic protein(s), and/or a suitable growth factor(s). The following compositions can be delivered into the joint via specialized delivery catheters, an endoscope (arthroscope; typically via a sideport), a needle or other applicator, a surgically placed drain or access port, or~other transdermal access device, including administration of: (a) fluids, suspensions, emulsions, microemulsions, microspheres, pastes, gels, microparticulates, sprays, aerosols, solid implants and other formulations which release a biologically active agent(s); (b) microparticulate silk and/or silk strands (linear, branched, and/or coiled) either alone, or loaded with an additional fibrosis-inducing agent, bone morphogenic protein, andlor growth factor are also useful for directed injection into the joint;
(c) injectable collagen-containing formulations such as COSTASIS or materials prepared from a 4-armed thiol PEG (10K), a 4-armed NHS PEG(10K) and methylated collagen such as described above, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the joint space; (d) injectable PEG-containing formulations such as COSEAL, FOCALSEAL, SPRAYGEL or DURASEAL, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the joint space; (e) fibrinogen-containing formulations such as FLOSEAL or TISSEAL, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the joint space;
(f) hyaluronic acid-containing formulations such as RESTYLANE, HYLAFORM, PERLANE, SYNVISC, SEPRAFILM, SEPRACOAT, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor injected into the joint space; (g) polymeric gels for surgical implantation such as REPEL or FLOWGEL either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor injected into the joint space;
(h) orthopedic "cements" such as OSTEOBOND, LVC, SIMPLEX P, PALACOS, CORTOSS, and ENDURANCE, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor injected into the joint space; (i) surgical adhesives containing cyanoacrylates such as DERMABOND, INDERMIL, GLUSTITCH, VETBOND, HISTOACRYL, TISSUEMEND, TISSUMEND II, HISTOACRYL BLUE and ORABASE SOOTHE-N-SEAL
LIQUID PROTECTANT or as described above, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the joint space; (j) surgical implants containing hydroxyapatite, calcium phosphate (such as VITOSS), or calcium sulfate, alone or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the joint space; (k) other biocompatible tissue fillers, such as those made by BioCure, 3M Company and Neomend, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the joint space; (I) polysaccharide gels such as the ADCON
series of gels, either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the joint space; (m) films, sponges or meshes such as INTERCEED, VICRYL mesh, and GELFOAM either alone, or loaded with a fibrosis-inducing agent, bone morphogenic protein, and/or growth factor, injected into the joint space;
and/or (n) a hydrogel that is formed from an amino-functionalized polyethylene glycol (e.g., 4-armed tetra-amino PEG [10k]) and a 4-armed NHS functionalized PEG
(e.g., pentaerythritol polyethylene glycol)ether tetra-succinimidyl glutarate [10K]). This hydrogel may further contain collagen, methylated collagen and/or gelatin. This hydrogel can further comprise the fibrosis-inducing agents described above (e.g., silk powder or silk threads). In many of these embodiments, it may also be useful to add a radio-opaque material (such as tantalum, barium, other metal, or contrast material) such that the injected material can be visualized radiographically or MRI.

It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agent may be utilized alone, or in combination, in the practice of this embodiment as described above. Exemplary fibrosing agents for use in minimally invasive joint fusion procedures include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, CTGF, bone morphogenic proteins, and/or osteogenic growth factors (such as transforming growth factor, platelet-derived growth factor, fibroblast growth factor) as well as analogues and derivatives of the aforementioned.
' Optionally, the device may alone or additionally comprise an inflammatory cytokine (e.g., TGF(i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-(i, IL-8, IL-6, and growth hormone) or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof.
The correct administration and dosage can be described further in section (c) below.
(iii) Fibrosing Agents for Minimally Invasive Joint Fusion Exemplary fibrosing and osteogenic agents for use in minimally invasive joint fusion include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, CTGF, bone morphogenic proteins, and/or osteogenic growth factors (such as transforming growth factor, platelet-derived growth factor, fibroblast growth factor) as well as analogues and derivatives of the aforementioned. In some clinical situations, repeated injections of the active agents described below may be required.
The exact dose administered can vary depending upon the particular joint being treated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit volume (of the amount being injected), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the affected joint, the exemplary fibrosing agents, bone morphogenic proteins, and/or osteogenic growth factors (such as transforming growth factor, platelet-derived growth factor, fibroblast growth factor), used alone or in combination, should be administered under the following dosing guidelines:
Utilizing talc as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the injectable, or administered without a polymeric carrier, the tots( dose of talc administered into a joint in any single injection should not exceed 100 mg (range of 1 ~.g to 100 mg). In one embodiment, the total amount of talc administered should be in the range of 10 ~g to 50 mg. The dose per unit volume injected should fall within the range of 0.05 p.g - 10 pg per mm3. In one embodiment, talc is released from the injectable such that ankylosis in the joint is promoted for a period ranging from several hours to several months. For example, talc may be released in effective concentrations for a period ranging from 2- 12 weeks. It should be readily evident given the discussions provided herein that analogues and derivatives of talc (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as talc is administered at half the above parameters, a compound half as potent as talc is administered at twice the above parameters, etc.).
Utilizing silk as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the injectable, or administered without a polymeric carrier, the total dose of silk delivered to the joint in any single injection should not exceed 100 mg (range of 1 p,g to 100 mg). In one embodiment, the total amount of silk administered to the joint should be in the range of 10 ~g to 50 mg. The dose per unit volume injected should fall within the range of 0.05 pg - 10 ~g per mm3. As specific (polymeric and non-polymeric) drug delivery vehicles can release silk at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the carrier such that a minimum concentration of 0.01 nM to 1000 pM of silk is continuously delivered to the tissue over the desired therapeutic time period. In one embodiment, silk is released into the joint such that ankylosis is promoted for a period ranging from several hours to several months. For example, silk may be released in effective concentrations for a period ranging from 2-12 weeks. It should be readily evident given the discussions provided herein that analogues and derivatives of silk (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as silk is administered at half the above parameters, a compound half as potent as silk is administered at twice the above parameters, etc.).
Utilizing chitosan as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the injectable, or administered without a polymeric carrier, the total dose of chitosan delivered into the joint should not exceed 100 mg (range of 1 ~.g to 100 mg). In one embodiment, the total amount of chitosan administered into the joint in any single injection should be in the range of 10 p,g to 50 mg. The dose per unit volume injected should fall within the range of 0.05 pg - 10 ~,g per mm3. As specific (polymeric and non-polymeric) drug delivery vehicles can release chitosan at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the carrier such that a minimum concentration of 0.01 nM to 1000 pM of chitosan is continuously delivered to the joint tissue. In one embodiment, chitosan is released into the joint such that ankylosis is promoted for a period ranging from several hours to several months. For example, chitosan may be released in effective concentrations for a period ranging from 2-12 weeks. It should be readily evident given the discussions provided herein that analogues and derivatives of chitosan (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are. then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as chitosan is administered at half the above parameters, a compound half as potent as chitosan is administered at twice the above parameters, etc.).
Utilizing polylysine as a exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the injectable, or administered without a polymeric carrier, the total dose of polylysine delivered into the joint in a single injection should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of polylysine delivered to the joint should be in the range of 10 ~,g to 50 mg. The dose per unit volume injected should fall within the range of 0.05 ~,g -~,g per mm3. In another embodiment, polylysine should be injected into the joint at a dose of 0.05 -10 pg/mm3. As specific (polymeric and non-polymeric) drug delivery vehicles can release polylysine at differing rates, the above dosing parameters should be utilized in combination with the release rate of the 5 drug from the carrier such that a minimum concentration of 0.01 nM to 1000 ~rM
of polylysine is continuously delivered to the joint tissue. In one embodiment, polylysine is administered to the joint such that ankylosis is promoted for a period ranging from several hours to several months. For example, polylysine may be released in effective concentrations for a period ranging from 2-12 10 weeks. It should be readily evident given the discussions provided herein that analogues and derivatives of polylysine (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as polylysine is administered at half the above parameters, a compound half as potent as polylysine is administered at twice the above parameters, etc.).
Utilizing fibronectin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the injectable, or administered without a polymeric carrier, the total dose of fibronectin delivered into the joint in a single injection should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of fibronectin injected into the joint should be in the range of 10 pg to 50 mg. The dose per unit volume of the injection should fall within the range of 0.05 ~g - 10 ~g per mm3. In another embodiment, talc should be administered at a dose of 0.05 -10 ~,g/mm3 of injected material. As specific (polymeric and non-polymeric) drug delivery vehicles can release fibronectin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the carrier such that a minimum concentration of 0.01 nM
to 1000 pM of fibronectin is continuously delivered to the tissue. In one embodiment, fibronectin is released into the joint such that ankylosis is promoted for a period ranging from several hours to several months. For example, fibronectin may be released in effective concentrations for a period ranging from 2-12 weeks. It should be readily evident given the discussions provided herein that analogues and derivatives of fibronectin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as fibronectin is administered at half the above parameters, a compound half as potent as fibronectin is administered at twice the above parameters, etc.).
Utilizing bleomycin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the injectable, or administered without a polymeric carrier, the total dose of bleomycin administered to a joint in a single injection should not exceed 100 mg (range of 0.01 ~,g to 100 mg). In one embodiment, the total amount of bleomycin injected into the joint should be in the range of 0.10 ~,g to 50 mg. The dose per unit volume injected should fall within the range of 0.005 ~,g - 10 ~,g per mm3. As specific (polymeric and non-polymeric) drug delivery vehicles can release bleomycin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the carrier such that a minimum concentration of 0.001 nM to 1000 pM of bleomycin is continuously delivered to the joint. In one embodiment, bleomycin is released from the injection such that ankylosis in the joint is promoted for a period ranging from several hours to several months. For example, bleomycin may be released in effective concentrations for a period ranging from 2-12 weeks. It should be readily evident given the discussions provided herein that analogues and derivatives of bleomycin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as bleomycin is administered at half the above parameters, a compound half as potent as bleomycin is administered at twice the above parameters, etc.).
Utilizing CTGF as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the injectable, or administered without a polymeric carrier, the total dose of CTGF administered to the joint in a single injection should not exceed 100 mg (range of 0.01 ~,g to 100 mg). In one embodiment, the total amount of CTGF
injected into the joint should be in the range of 0.10 ~g to 50 mg. The dose per unit volume of the injection should fall within the range of 0.005 ~,g - 10 ~,g per mm3. In another embodiment, CTGF should be injected at a dose of 0.005-10 p,g/mm3. As specific (polymeric and non-polymeric) drug delivery vehicles can release CTGF at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the carrier such that a minimum concentration of 0.001 nM to 1000 pM of CTGF is continuously delivered to the joint. In one embodiment, CTGF is released from the injectable such that ankylosis in the joint is promoted for a period ranging from several hours to several months. For example, CTGF may be released in effective concentrations for a period ranging from 2-12 weeks. It should be readily evident given the discussions provided herein that analogues and derivatives of CTGF (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as CTGF
is administered at half the above parameters, a compound half as potent as CTGF is administered at twice the above parameters, etc.).
Optionally, the device may alone or additionally comprise an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-Vii, IL-8, IL-6, and growth hormone) or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof).
Inflammatory cytokines are to be used in formulations at concentrations that range from 0.0001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the inflammatory cytokine is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 p,g to 100 mg); preferred 0.001 p,g to 50 mg. When used as a device coating, the dose is per unit area of 0.0001 pg - 500 ~g per mm2; with a preferred dose of 0.001 p,g/mm2 - 200 p,g/mm2. Minimum concentration of 10-'° - 10-4 g/ml of inflammatory cytokine is to be maintained on the device surface.
Bone morphogenic proteins) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7 or an analogue or derivative thereof) are to be used in formulations at concentrations that range from 0.001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, 193 a liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the bone morphogenic protein is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.001 ~g to 500 mg); preferred 1 ~g to 250 mg. When used as a device coating, the dose is per unit area of 0.001 p.g - 1000 ~g per mm2; with a preferred dose of 0.01 ~,g/mm2 - 200 ~.g/mm2. Minimum concentration of 10-9 - 10-4 M of bone morphogenic protein is to be maintained on the device surface.
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradioi, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof. Doses used are those concentrations which are demonstrated to stimulate cell proliferation (Example 16). The proliferative agents are to be used in formulations at concentrations that range from 0.01 ng/mL to 25 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required.
Preferably, the proliferative agent is released in effective concentrations for a period ranging from 1 - 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 ~,g to 200 mg); preferred 0.001 ~,g to 100 mg. When used as a device coating, the dose is per unit area of 0.00001 ~g - 500 ~,g per mm2; with a preferred dose of 0.0001 pg/mm2 - 200 ~glmm2. Minimum concentration of 10-" - 10-6 M of proliferative agent is to be maintained on the device surface.
It should be readily evident to one of skill in the art that any of the previously described fibrosis-inducing agents, bone morphogenic proteins, or osteogenic growth factors, or derivatives and analogues thereof, can be utilized to create variations of the above compositions without deviating from the spirit and scope of the invention. It should also be apparent that the agent can be utilized in a composition with or without polymer carrier and that altering the carrier does not deviate from the scope of this invention.

5. Female and Male Sterilization Devices Permanent, highly reliable, minimally invasive methods of preventing conception are required in both men's and women's health.
Although tubal ligation and vasectomy have a low failure rate (approximately 1 °I°), recently there have been advancements in making the procedures less invasive. This is particularly true for tubal ligation where a surgical procedure, either open or endoscopic, is required to "clip" the fallopian tubes. Newer implants have been designed to obstruct the fallopian tubes (or vas deferens in the male) through the non-surgical placement of implants that block the interior lumen of the reproductive tract. Unfortunately, since the reproductive tract is not physically severed (and the two ends clipped shut as in the surgical procedure), there remains the possibility that the fallopian tube (or vas deferens) can re-cannulate over time and restore fertility. The present invention provides compositions, implants and devices that include a fibrosis-inducing agent to promote scarring of the walls of the reproductive tract in the vicinity of the implant or device. The result is the formation of permanent scar tissue between the walls of the fallopian tube (or vas deferens) that completely obstructs the lumen, prevents the movement of the gametes through the tract, and lowers the failure rate of the procedure (measured as the prevention of unwanted pregnancies).
(i) Permanent Female Contraceptive Devices (a) Fallopian Tube Implants Numerous techniques and devices are known and available to ligate or obstruct the fallopian tube such that the ovum cannot reach the uterus and conception and implantation cannot occur. As described above, surgical ligation andlor clipping of the fallopian tubes has been considered the "gold standard" for permanent contraception in women for many years. Various clamps and clips for this purpose have been described, including for example:
a duct clamp described in U.S. Patent No. 4,489,725; valued sterilization devices described in U.S. Patent Nos. 3,704,704 and 3,777,737; and temporary sterilization devices described in U.S. Patent No. 3,918,431. These devices are suitable for coating with a fibrosis-inducing agent to further enhance their effectiveness and reduce their failure rate. Unfortunately, these procedures have the obvious disadvantage of requiring placement during open or endoscopic surgery.
However, a preferred embodiment of the present invention involves delivering a fibrosis-inducing agent in combination with a variety of devices and implants designed for placement in the fallopian tubes without the need for surgery. Although variable in design, all are intended to be placed transvaginally (i.e., the device or implant is inserted into the vagina, through the uterus, and placed into the interior lumen of the fallopian tube), thus eliminating the need for surgical access to the external (intra-abdominal/pelvic) surface of the fallopian tube via the abdomen. As a result, these implants obstruct the fallopian tube from the inside (luminal surface) and can be performed in a conscious patient in much the same manner as a gynecological exam.
Examples of fallopian tube implants suitable for delivering a fibrosis-inducing agent that enhances tuba( occlusion include: implantable, intrafallopian, female sterilization devices (such as those described in U.S. Patent Nos. 6,245,090;
6,068,626; and 3,675,639); occlusive wire or coil fallopian tube implants (such as those described in U.S. Patent No. 5,601,600); transcatheter occluding implants (such as those described in U.S. Patent No. 6,245,090); and fallopian tube stents (for example those described in U.S. Patent No. 5,474,089). In addition, contraceptive uterine implants, such as intrauterine devices (IUDs), can also be suitable for use in this embodiment.
Specific female sterilization devices (fallopian tube implants) suitable for the delivery of one or more fibrosis-inducing agents according to the present invention include several commercially available products. For example, the ESSURE device is a catheter-delivered stent filled with fiber (a soft micro-insert) designed to occlude the fallopian tubes (Conceptus, Inc., San Carlos, CA) and is described in U.S. Patent Nos: 6,176,240; 6,526,979;
5,601,600; and 5,746,769. The ECLIPSE from Ovion (Redwood City, CA) is a self-expanding nitinol stent filled with polyester fibers that is delivered transvaginally via a catheter into the fallopian tubes. Other contraceptive fallopian tube implants include porous plastic fibers (Adiana, Redwood, CA) and single rod implants such as IMPLANON from Organon Corporation (West Orange, NJ).
Regardless of the specific design, the aforementioned contraceptive implants can be adapted to release an agent which induces fibrosis or adhesion within the fallopian tube. The result can be enhanced scarring around the implant, more complete (and permanent) filling and/or occlusion of the lumen of the fallopian tube, and a reduction in the likelihood that female or male reproductive cells can traverse the blockade and come in contact with each other - thereby reducing the incidence of unwanted intrauterine pregnancy or tubal pregnancy. Fallopian tube implants may be adapted to have a fibrosis-inducing agent incorporated into their structure, adapted to have a surface coating of a fibrosis-inducing agent and/or adapted to release a fibrosis-inducing agent. This can be accomplished in several manners including: (a) directly affixing to the fallopian tube implant/device a desired fibrosis-inducing agent, or affixing a composition containing the fibrosis-inducing agent (for example, by spraying the implant with a drug and/or drug-carrier (polymeric or non-polymeric) composition to create a film/coating on all (or parts) of the internal and/or external surface of the device; by dipping the implant or device into a drug and/or drug-carrier (polymeric or non-polymeric) solution to coat all (or parts) of the device/impiant; or by covalent or non-covalent attachment (such as mechanical attachment via knotting, using an adhesive, thermal treatment, electrostatic attachment, ionic attachment, hydrophobic interactions, or hydrogen bonding) of the therapeutic agent to the device/implant surface); (b) by coating the fallopian tube device/implant with a substance such as a hydrogel which can in turn absorb the desired fibrosis-inducing agent or composition; (c) by interweaving a "thread" composed of, or coated with, the fibrosis-inducing agent into the fallopian tube implant/device (e.g., a polymeric strand composed of a fibrosis-inducing agent (e.g., silk, collagen, EVA, PLA, polyurethanes, polymerized drug compositions) or a thread coated with a polymer which is comprised of, or releases a fibrosis-inducing agent); (d) by covering all, or portions of the fallopian tube device/implant with a sleeve, cover or mesh containing a fibrosis-inducing agent (i.e., a covering comprised of a fibrosis-inducing agent - polymers such as silk, collagen, EVA, PLA, polyure'thanes - or polymerized compositions that release fibrosis-inducing agents); (e) constructing all, or parts of the fallopian tube implant/device from a fibrosis-inducing agent (e.g., constructing it from ,polymers such as silk, collagen, EVA, PLA, polyurethanes or polymerized compositions of fibrosis-inducing agents) - which may be particularly effective for the IMPLANON rod or the Adiana porous fibers; (f) for fallopian tube stent devices (such as the ESSURE or ECLIPSE), the central "filling" material can be composed of, or coated with, the fibrosis-inducing agent (e.g., polymeric fibers composed of a fibrosis-inducing agent (e.g., silk, collagen, EVA, PLA, polyurethanes, polymerized drug compositions) or coating the fibers with a polymer which is comprised of, or releases a fibrosis-inducing agent); (g) otherwise impregnating the fallopian tube implant/device with the desired fibrosis-inducing agent or composition; (h) scoring (i.e., creating ridges or indentations) on all, or parts, of the device or implant surface to produce irritation and ultimately fibrosis; (i) composing all, or parts, of the device or implant from metal alloys that induce fibrosis (e.g., copper); (j) constructing all, or parts of the device or implant itself from a degradable or non-degradable polymer that releases one or more fibrosis-inducing agents - which may be particularly effective for the IMPLANON rod, the Adiana porous fibers or the central filling material in the ESSURE or ECLIPSE devices; and/or (k) utilizing specialized multi-drug releasing medical device systems (described, e.g., in U.S. Patent No. 6,562,065; U.S. Patent Application Publication Nos.
2003/0199970 and 2003/0167085 and in WO 03/015664 and WO 02/32347) to deliver fibrosis-inducing agents alone, or in combination.
It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agent may be utilized alone, or in combination, in the practice of this embodiment as described above. Exemplary fibrosing agents for use in fallopian tube implants and devices include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
Optionally, the device may alone or additionally comprise an inflammatory cytokine (e,g., TGF~, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-(3, IL-8, IL-6, and growth hormone) or a bone morphogenic protein (BMP) (e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, OR
BMP-7 or an analogue or derivative thereof).
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-~i-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof.
The correct administration and dosage can be described further in section (c) below.

(b) Iniectable Fallopian Tube Implants Another preferred embodiment of the present invention involves delivering a fibrosis-inducing agent in combination with a biomaterial designed for injection into the fallopian tubes to "plug" or obstruct the tube. Many different biomaterials are suitable for injection into the fallopian tube via a transvaginal route of administration (i.e., the delivery device is inserted into the vagina, through the uterus, placed into the interior lumen of the fallopian tube, and the biomaterial containing a fibrosis-inducing agent is injected into the lumen of the fallopian tube), thus eliminating the need for surgical access to the external, (intra-abdominaUpelvic) surface of the fallopian tube via the abdomen.
As a result, these implants obstruct the fallopian tube from the inside (luminal surface) and can be performed in a conscious patient in much the same manner as a gynecological exam. The biomaterial can obstruct the lumen of the tube, while the fibrosis-inducing agent encourages the formation of scar tissue between the walls of the fallopian tube to permanently obstruct the lumen, prevent the movement of the gametes through the tract, and lower the failure rate of the procedure (measured as the prevention of unwanted pregnancies).
The injectable material may be composed of a hydrogel for use in the sterilization of a mammalian female. The hydrogel can be composed of a non-degradable or a degradable material. Non-degradable materials can include crosslinked compositions that comprise PVA, PVP, polyacrylamide, pHEMA, polyvinyl PEG), polystyrene sulfonate), poly(acrylic acid), poly(methacrylic acid), as well as other polymers that are known to form hydrogels. Additional compositions include blends and copolymers of the agents listed above. Degradable materials include, but are not limited to, crosslinked materials of PEG, gelatin, collagen, hyaluronic acid, hyaluronic acid derivatives, polysaccharides, carbohydrates, proteins (e.g., albumin, casein, whey proteins, plant proteins, and fish proteins ), cellulose derivatives (e.g., HPC ), chitosan, chitosan derivatives, polyester-polyalkylene oxide block copolymers (e.g., PLGA - PEG-PLGA and MePEG - PLGA,) and other low molecular weight polymers that can be excreted. One material that is of particular interest is prepared from a 4-armed thiol PEG (10K), a 4-armed NHS
PEG(10K) and methylated collagen such as described above. In a preferred embodiment, the hydrogel also contains a biologically active, agent capable of inducing fibrosis in the fallopian tube. Preferred, biologically active, fibrosis-inducing, agents, their dosages and their release kinetics, are all described in detail in section (c) below.
In addition to, or in lieu of, fibrosis-inducing agents, the hydrogel can be utilized to deliver a sclerosant to the fallopian tube. Sclerosants include compounds such as ethanol, DMSO, surfactants, sucrose, NaCI, dextrose, glycerin, minocycline, tetracycline, doxycyciine, polidocanol, sodium tetradecyl sulfate, sodium morrhuate, sotradecol and others. The hydrogel can further comprise agents such as glycerol, glycerin, PEG 200, triethyl citrate, and triacetin as plasticizers.
The hydrogels described above can further modified to be comprised of, or contain, polymeric threads. Polymeric threads have the ability to induce a fibroproliferative response from the surrounding tissue in the fallopian tube. These polymer threads can be degradable or non-degradable.
Degradable threads can be composed of degradable polyesters, polyanhydrides, poly(anhydride esters), polyester-amides), polyester-ureas), polyorthoesters, polyphosphoesters, polyphosphazines, cyanoacrylate polymers, collagen, chitosan, hyaluronic acid, chromic cat gut, alginates, starch, cellulose, cellulose esters, blends and copolymers thereof, as well as other known degradable polymers. Non-degradable polymers that can be used include, but are not limited to, polyesters (e.g., PET), polyurethanes, silicones, PE, PP, PS, PAA, PMA, silk, blends, copolymers thereof as well as other known polymers. The threads used can be composed of a single composition or composed of a blend of differing compositions. The polymeric threads themselves can be further modified through the addition of a polymeric coating applied to the threads. The polymer used for coating the thread can be similar to that described above for the threads themselves. The polymer coating may further comprise a biologically active agent that has the ability to induce a fibroproliferative response. The agents that can be used are further described in the section (c) below.
The hydrogels described above can be utilized to deliver a particulate material that has the ability to induce a fibroproliferative response in the fallopian tube. These particles can be either degradable or non-degradable and are similar to those described above for threads. In addition to those, particulate materials useful for the practice of this embodiment include talc, starch, glass, silicates, silica, silver nitrate, ceramic particles and other inorganic particles known in the art to induce a fibroproliferative response.
The particles used in this embodiment can be all of the same composition or a blend of differing compositions. These particles can also be used as a coating applied to the polymeric strands as described above.
As is readily apparent, the hydrogel can also be constructed such that it is comprised of both polymeric threads and particles. The threads and particles used are similar to those described above and may be of uniform composition or blended composition. Virtually any combination of threads of differing compositions and particles of differing compositions can be utilized in this embodiment. The hydrogel, the polymeric threads, and the particles can all be utilized to deliver one or more biologically active agents, as described below.
In a further embodiment, the hydrogel can be formed into a variety of shapes and sizes for implantation into the fallopian tubes. For example, the hydrogel can be shaped into a rod of the desired length or subsequently cut to the appropriate length. The hydrogel can be made into another shape and then further processed to form a rod of the appropriate dimensions. The rods can be cylindrical in shape or they can have a tapered shape or an hour glass shape.
The hydrogel can also be formed into a rectangular shape by adding the appropriate reagents to a mould and then curing the composition. A cork-borer type device of the appropriate dimensions can be used to produce rods. The thickness of the initial hydrogel can determine if these rods have to be further a cut into the appropriate lengths. These rods can be then dehydrated by freeze ,drying or by air drying. The freeze dried rods may have more of a foam structure while the air dried rods may be of a more solid nature. The particles and/or biologically active agents can be incorporated into the hydrogel prior to the curing stage. The particles can be applied to the surface by rolling the rods in the particles or by applying the particles to the surface by dipping, spraying or painting. The particles can be applied in combination with a coating polymer that may dissolve or degrade. This coating polymer may be gelatin, hydroxypropyl cellulose, MePEG-PLA, MePEG-polyester, polyester-PEG-polyester, or the like.
The polymer threads can be added prior to the curing stage or they can be added after the hydrogel has cured. The polymer threads can be added before or after the drying stage of the rods. The threads may be wrapped around the external surface of the rod. The needle may be used to pass the threads through the rod in a vertical, horizontal, diagonal manner or a combination thereof. The threads may be placed such that they form loops protruding from the surface of the rod.
One specific composition comprises rods prepared from a methylated collagen - crosslinked polyethylene glycol) composition such as described above which has powdered silk particles added to the composition prior to curing. Once deployed, the rod can absorb water and thereby occlude the fallopian tube. This expansion can prevent the rod from moving, while the powdered silk can initiate a fibroproliferative response. As the methylated collagen - crosslinked polyethylene glycol) composition starts to degrade, the material can support the fibrous tissue ingrowth that is initiated and potentiated by the silk particles. To further increase the rate of initiation of this fibroproliferative response, a sclerosant such as a surfactant (SDS), ethanolamine oleate or DMSO can be added. In addition, one may also add or replace all (or a portion) of the 4-armed thiol PEG with a 4-armed amino PEG.
The amino PEG can provide a gel that can take a longer time to degrade and can provide some positive charge to further attract cellular material.
A second specific embodiment consists of an implant composed of silk fibers or from a polymerized version of the fibrosing agent itself (i.e., repeating units of the fibrosing agent polymerized together).
In addition to the hydrogels and related implants described above, there are several other ways to practice this embodiment. All involve the deployment of a biomaterial into the lumen of the fallopian tube with or without the addition of a fibrosis-inducing agent. The practice of this embodiment can be performed in several ways including: (a) topical application of the fibrosing agent onto the luminal surface of the fallopian tube (particularly useful for this embodiment is the use of polymeric carriers which release the fibrosing agent over a period ranging from several hours to several weeks - fluids, , suspensions, emulsions, microemulsions, microspheres, pastes, gels, microparticulates, sprays, aerosols, solid implants and other formulations which release a fibrosing agent can be delivered into the fallopian tube via specialized delivery catheters or other applicators); (b) microparticulate silk and/or silk strands (linear, branched, and/or coiled), either alone, or loaded with an additional fibrosis-inducing agent are also useful for directed injection into the fallopian tube; (c) sprayable collagen-containing formulations such as COSTASIS or materials made from 4-armed thiol PEG (10K), a 4-armed NHS
PEG(10K) and methylated collagen such as described above, either alone, or loaded with a fibrosis-inducing agent, applied to the lumen of the fallopian tube;
(d) sprayable PEG-containing formulations such as COSEAL, FOCALSEAL, SPRAYGEL or DURASEAL, either alone, or loaded with a fibrosis-inducing agent, applied to the lumen of the fallopian tube; (e) fibrinogen-containing formulations such as FLOSEAL or TISSEAL, either alone, or loaded with a fibrosis-inducing agent, applied to the lumen of the fallopian tube; (f) hyaluronic acid-containing formulations such as RESTYLANE, HYLAFORM, PERLANE, SYNVISC, SEPRAFILM, SEPRACOAT loaded with a fibrosis-inducing agent applied to the lumen of the fallopian tube; (g) polymeric gels for surgical implantation such as REPEL or FLOWGEL, either alone, or loaded with a fibrosis-inducing agent applied to the lumen of the fallopian tube; (h) orthopedic "cements" such as OSTEOBOND, LVC, SIMPLEX P, PALACOS, CORTOSS, and ENDURANCE, either alone, or loaded with a fibrosis-inducing agent applied to the luminal surface of the fallopian tube; (i) surgical adhesives containing cyanoacrylates such as DERMABOND, INDERMIL, GLUSTITCH, VETBOND, HISTOACRYL, TISSUEMEND, TISSUMEND II, HISTOACRYL
BLUE and ORABASE SOOTHE-N-SEAL LIQUID PROTECTANT or as described above, either alone, or loaded with a fibrosis-inducing agent, applied to the lumen of the fallopian tube; (j) surgical implants containing hydroxyapatite, calcium phosphate (e.g., VITOSS), or calcium sulfate, either alone, or loaded with a fibrosis-inducing agent applied to the lumen of the fallopian tube; (k) other biocompatible tissue fillers, such as those made by BioCure, 3M Company and Neomend, either alone, or loaded with a fibrosis-inducing agent, applied to the lumen of the fallopian tube; (I) polysaccharide gels such as the ADCON series of gels loaded with a fibrosis-inducing agent applied to the lumen of the fallopian tube; (m) films, sponges or meshes such as INTERCEED, VICRYL mesh, and GELFOAM, either alone, or loaded with a fibrosis-inducing agent applied to the lumen of the fallopian tube and/or (n) a hydrogel that is formed from an amino-functionalized polyethylene glycol (e.g., 4-armed tetra-amino PEG [10k]) and a 4-armed NHS functionalized PEG (e.g., pentaerythritol polyethylene glycol)ether tetra-succinimidyl glutarate [10K]).
This hydrogel may further contain collagen, methylated collagen and/or gelatin.
This hydrogel can further comprise the fibrosis-inducing agents described above (e.g., silk powder or silk threads)..
In many of the embodiments described above it may also be useful to add a radio-opapue material (such as tantalum, technetium, gadolinium, barium, other metal, or contrast material) such that the injected material can be visualized radiographically or MRI. The contrast agent may be a water soluble or water insoluble radio-opaque material. Alternatively the gel or the coated implant can contain air bubbles (e.g., ECHO-COAT) or air can be injected into the tube such that visualization by ultrasound is enhanced.
It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agent may be utilized alone, or in combination, in the practice of this embodiment as described above. Exemplary fibrosing agents for use in fallopian tube implants and devices include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
Optionally, the device may alone or additionally comprise an inflammatory cytokine (e.g., TGF(3, PDGF; VEGF, bFGF, TNFa, NGF, GM-CSF, iGF-a, IL-1, IL-1-(3, IL-8, IL-6, and growth hormone).
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-~i-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATR~), and analogues and derivatives thereof.
The correct administration and dosage can be described further in section (c) below.
(c) Fibrosine~ Agents for Fallopian Tube Implants As fallopian tube implants are made in a variety of configurations and sizes, the exact dose administered can vary with device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the sterilization device, the exemplary fibrosing agents, used alone or in combination, should be administered under the following dosing guidelines:
Utilizing talc as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of talc delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 1 p,g to 100 mg). In one embodiment, the total amount of talc released from the prosthesis should be in the range of 10 ~g to 50 mg. The dose per unit area of the device (i.e., the dosage of talc as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 pg - 10 ~,g per mm2 of surface area coated. In another embodiment, talc should be applied to a sterilization device surface at a dose of 0.05 ~,g/mm2 -10 pg/mm2 of surface area coated.
In one embodiment, talc is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, talc may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of talc (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as talc is administered at half the above parameters, a compound half as potent as talc is administered at twice the above parameters, etc.).
Utilizing silk as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of silk delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of silk released from the prosthesis should be in the range of 10 p.g to 50 mg. The dose per unit area of the device (i.e., the dosage of silk as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 p.g - 10 p,g per mm2 of surface area coated. In another embodiment, silk should be applied to a sterilization device surface at a dose of 0.05 p,g/mm2 -10 ~g/mmZ of surface area coated.
As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release silk at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the sterilization device such that a minimum concentration of 0.01 nM to 1000 pM
of silk is delivered to the tissue. In one embodiment, silk is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, silk may be released in effective concentrations for a period ranging from 1 hour- 30 days.
It should be readily evident given the discussions provided herein that analogues and derivatives of silk (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as silk is administered at half the above parameters, a compound half as potent as silk is administered at twice the above parameters, etc. ).
Utilizing chitosan as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of chitosan delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 1 ~.g to 100 mg). In one embodiment, the total amount of chitosan released from the prosthesis should be in the range of 10 p,g to 50 mg. The dose per unit area of the device (i.e., the dosage of chitosan as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~g - 10 p,g per mm2 of surface area coated. In another embodiment, chitosan should be applied to a sterilization device surface at a dose of 0.05 p,g/mm2 -10 p.g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release chitosan at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the sterilization device such that a minimum concentration of 0.01 nM to 1000 pM of chitosan is delivered to the tissue. In one embodiment, chitosan is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, chitosan may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of chitosan (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as chitosan is administered at half the above parameters, a compound half as potent as chitosan is administered at twice the above parameters, etc.).
Utilizing polylysine as a exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of polylysine delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 1 pg to 100 mg). fn one embodiment, the total amount of polylysine released from the prosthesis should be in the range of 10 ~.g to 50 mg. The dose per unit area of the device (i.e., the dosage of polylysine as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~g -~.g per mm2 of surface area coated. In another embodiment, polylysine should be applied to a sterilization device surface at a dose of 0.05 ~glmm2 -10 p.g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release polylysine at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the sterilization device such that a minimum concentration of 0.01 nM to 1000 pM of polylysine is delivered to the tissue. In one embodiment, polylysine is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, polylysine may be released in effective concentrations for a period ranging from 1 hour- 30 days.
It should be readily evident given the discussions provided herein that analogues and derivatives of polylysine (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as polylysine is administered at half the above parameters, a compound half as potent as polylysine is administered at twice the above parameters, etc.).
Utilizing fibronectin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of fibronectin delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 1 ~,g to 100 mg). In one embodiment, the total amount of fibronectin released from the prosthesis should be in the range of pg to 50 mg. The dose per unit area of the device (i.e., the dosage of fibronectin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~,g -~,g per mm2 of surface area coated. In another embodiment, fibronectin should be applied to a sterilization device surface at a dose of 0.05 ~g/mm2 -10 ~g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release fibronectin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the sterilization device such that a minimum concentration of 0.01 nM to 1000 pM of fibronectin is delivered to the tissue. In one embodiment, fibronectin is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, fibronectin .may be released in effective concentrations for a period ranging from 1 hour- 30 days.
It should be readily evident given the discussions provided herein that analogues and derivatives of fibronectin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as fibronectin is administered at half the above parameters, a compound half as potent as fibronectin is administered at twice the above parameters, etc.).
Utilizing bleomycin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without. a polymeric carrier, the total dose of bleomycin delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 0.01 p,g to 100 mg). In one embodiment, the total amount of bleomycin released from the prosthesis should be in the range of 0.10 p,g to 50 mg. The dose per unit area of the device (i,e., the dosage of bleomycin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 p,g p,g per mm2 of surface area coated. In another embodiment, bleomycin should be applied to a sterilization device surface at a dose of 0.005 p,g/mm2 -10 p,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release bleomycin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the sterilization device such that a minimum concentration of 0.001 nM to 1000 pM of bleomycin is delivered to the tissue. In one embodiment, bleomycin is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, bleomycin may be released in effective concentrations for a period ranging from 1 hour- 30 days.
It should be readily evident given the discussions provided herein that analogues and derivatives of bleomycin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as bleomycin is administered at half the above parameters, a compound half as potent as bleomycin is administered at twice the above parameters, etc.).
Utilizing CTGF as an exemplary fibrosis-inducing agent,'whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of CTGF delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 0.01 p.g to 100 mg). In one embodiment, the total amount of CTGF
released from the prosthesis should be in the range of 0.10 pg to 50 mg. The dose per unit area of the device (i.e., the dosage of CTGF as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 p,g - 10 p,g per mm2 of surface area coated. In another embodiment, CTGF should be applied to a sterilization device surface at a dose of 0.005 pg/mm2 -10 p,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release CTGF at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the a sterilization device such that a minimum concentration of 0.001 nM to 1000 pM of CTGF is delivered to the tissue. In one embodiment, CTGF
is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months.
For example, CTGF may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of CTGF (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as CTGF is administered at half the above parameters, a compound half as potent as CTGF is administered at twice the above parameters, etc.).
Optionally, the device may alone or additionally comprise an inflammatory cytokine (e.g., TGF~, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-(i, IL-8, IL-6, and growth hormone). Inflammatory cytokines are to be used in formulations at concentrations that range from 0.0001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the inflammatory cytokine is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 p,g to 100 mg); preferred 0.001 ~g to 50 mg. When used as a device coating, the dose is per unit area of 0.0001 ~,g -500 p.g per mm2; with a preferred dose of 0.001 p,g/mm2 - 200 pg/mm2.
Minimum concentration of 10-'°- 10~ g/ml of inflammatory cytokine is to be maintained on the device surface.
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof. Doses used are those concentrations which are demonstrated to stimulate cell proliferation (Example 16). The proliferative agents are to be used in formulations at concentrations that range from 0.01 ng/ml to 25 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required.

Preferably, the proliferative agent is released in effective concentrations for a period ranging from 1 -180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 p,g to 200 mg); preferred 0.001 ~,g to 100 mg. When used as a device coating, the dose is per unit area of 0.00001 p.g - 500 ~.g per mm2; with a preferred dose of 0.0001 ~.g/mm2 - 200 ~,g/mm2. Minimum concentration of 10-" - 10-6 M of proliferative agent is to be maintained on the device surface.
It should be readily evident to one of skill in the art that any of the previously described fibrosis inducing agents, or derivatives and analogues thereof, can be utilized to create variations of the above compositions without deviating from the spirit and scope of the invention. It should also be apparent that the agent can be utilized in a composition with or without polymer carrier and that altering the carrier does not deviate from the scope of this invention.
(ii) Male Permanent Contraceptive Devices For permanent contraception in men, vasectomy is a commonly used, highly effective method for the control of fertility. A common vasectomy procedure involves injecting local anesthetic alongside the vas deferens, opening the scrotum with pointed dissecting forceps, pulling the vas through the puncture, and occluding or cutting the vas deferens (e.g., using a ligation technique in which the vas is ligatured at one or both ends with a suture, application of an implantabie clip, or by cutting andlor cauterizing the vas).
(a) Deferens Implants Several devices for mate contraception have been disclosed including valued sterilization devices for surgical insertion within the vas deferens described in U.S. Patent No. 3,704,704 and 3,777,737, a reversible male sterilization device described in U.S. Patent No. 4,682,592, and vasectomy and Intra-Vas devices described in U.S. Patent No. 3,589,355 and 4,200,088, 3,648,683, and 3,589,355. Commercially available vasectomy clips include those produced by Advanced Meditech International, Inc. (Flushing, NY) and the VASCLIP from VMBC, LLC (Roseville, MN)In the present invention, the incorporation of a fibrosis-inducing agent onto or into vasectomy sutures, clips, or implantable devices (such as those described above) can promote fibrosis of the vas deferens, produce a more complete occlusion, and increase the success rate of the procedure.

For clips, sutures, and other implanted devices, there are several methods available for incorporating fibrosing compositions onto or into the vas deferens implant, including: (a) directly affixing to the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (b) directly incorporating into the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (c) by coating the device with a substance such as a hydrogel which can in turn absorb the fibrosing composition; (d) by interweaving into the device structure a thread coated with a fibrosis-inducing agent (or the fibrosis agent-polymer composition itself is formed into a thread); (e) by inserting the device into a sleeve or mesh which is comprised of, or coated with, a fibrosing composition; (f) constructing the device itself (or a portion of the device) with a fibrosing composition; or (g) by covalently binding the fibrosing agent directly to the device surFace or to a linker (small molecule or polymer) that is coated or attached to the device surface.
In addition to coating the device with the fibrosing composition, the fibrosing agent can be mixed with the materials that are used to make the device such that the fibrosing agent is incorporated into the final structure of device itself.
In another embodiment, a film or mesh that further comprises a fibrosis-inducing agent can be wrapped around the vas deferens or a cut portion of the vas deferens. This can promote fibrosis of the cut vas deferens and can increase the success rate of the procedure. In another embodiment, the fibrosis-inducing agent can be incorporated into an in situ forming gel composition. Following the application of a clip, ligation with a suture, or cutting of the vas deferens, the in situ forming composition can be applied to the treatment site (e.g., the cut end of the vas deferens) so as to promote fibrosis and increase the success rate of the procedure.
It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agent may be utilized alone, or in combination, in the practice of this embodiment as described above. Exemplary fibrosing agents for use in vas deferens implants and devices include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.

Optionally, the device may alone or additionally comprise an inflammatory cytokine (e.g., TGF~3, PDGF, VEGF, bFGF, TNFa,, NGF, GM-CSF, IGF-a, IL-1, IL-1-Vii, IL-8, IL-6, and growth hormone).
Furthermore, the device may additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-~3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof.
The correct administration and dosage can be described further in section (c) below.
(b) Iniectable Vas Deferens Implants A particularly preferred embodiment of the present invention involves percutaneous delivery of a fibrosis-inducing agent in combination with a biomaterial designed for injection into the vas deferens to "plug" or obstruct the male reproductive tract. The vas deferens is located by palpation (on both sides), a needle is inserted into the lumen, a guidewire is advanced into the lumen of the vas deferens, a dual lumen catheter (for many of the hydrogels described below such as materials prepared from a 4-armed thiol PEG (10K), a 4-armed NHS PEG(10K) and methylated collagen such as described above, COSEAL, COSTASIS, FLOSEAL, TISSEAL) or a single lumen catheter (for materials such as cyanoacrylate, hyaluronic acid, proteins, carbohydrates, sclerosing agents etc.) is advanced over the guidewire into the lumen of the vas deferens, the guidewire is removed, and a composition containing a fibrosis-inducing agent is injected via the catheter into the vas deferens until the lumen is completely occluded. Techniques can be used to enhance visualization of needle (or catheter) placement within the vas deferens including, but not limited to, the use of a needle coated with ECHO-COAT or the injection of air to enable localization by ultrasound, or the addition of contrast agents (e.g., barium, tantalum, technitium, gadolinium) for localization by x-ray or MRI. The injectable implant can obstruct the vas deferens from the inside (luminal surface) and can be implanted in a conscious patient through a single (left and right) needle puncture - reducing the time required to perform the procedure, the invasiveness (a surgical incision is not required), and the risk of infection.
The biomaterial physically obstructs the lumen of the tube, while the fibrosis-inducing agent encourages the formation of scar tissue between adjacent walls of the vas deferens, leading to permanent obstruction of the lumen. This prevents the movement of sperm cells through the male reproductive tract, and can lower the failure rate of the procedure (measured as the prevention of unwanted pregnancies). .
The injectable material may be composed of a hydrogel for use in the sterilization of a mammalian male. The hydrogel can be composed of a non-degradable or a degradable material. Non-degradable materials can include crosslinked compositions that comprise PVA, PVP, polyacrylamide, pHEMA, pofy(vinyl PEG), polystyrene sulfonate), poly(acrylic acid), poly(methacrylic acid), as well as other polymers that are known to form hydrogels. Additional compositions include blends and copolymers of the agents listed above. Degradable materials include, but are not limited to, crosslinked materials of PEG, gelatin, collagen, hyaluronic acid, hyaluronic acid derivatives, polysaccharides, carbohydrates, proteins (e.g., albumin, casein, whey proteins, plant proteins, and fish proteins), cellulose derivatives (e.g., HPC), chitosan, chitosan derivatives, polyester-polyalkylene oxide block copolymers (e.g., PLGA - PEG-PLGA and MePEG - PLGA, etc) and other low molecular weight polymers that can be excreted. One material that is of particular interest is prepared from a 4-armed thiol PEG (10K), a 4-armed NHS
PEG(10K) and methylated collagen such as described above. The hydrogel may also contain a biologically active agent capable of inducing fibrosis in the vas deferens. Preferred, biologically active, fibrosis-inducing, agents, their dosages and their release kinetics, are all described in detail in section (c) below.
In addition to, or in lieu of, fibrosis-inducing agents, the hydrogel can be utilized to deliver a sclerosant to the vas deferens. Sclerosants include compounds such as ethanol, DMSO, surfactants, sucrose, NaCI, dextrose, glycerin, minocycliiie, tetracycline, doxycycline, poiidocanol, sodium tetradecyl sulfate, sodium morrhuate, sotradecol and others. The hydrogel can further comprise agents such as glycerol, glycerin, PEG 200, triethyl citrate, and triacetin as plasticizers.
The hydrogels described above can further modified to be comprised of, or contain, polymeric threads. Polymeric threads have the ability to induce a fibroproliferative response from the surrounding tissue in the vas deferens. These polymer threads can be degradable or non-degradable.
Degradable threads can be composed of degradable polyesters, polyanhydrides, poly(anhydride esters), polyester-amides), polyester-ureas), polyorthoesters, polyphosphoesters, polyphosphazines, cyanoacrylate polymers, collagen, chitosan, hyaluronic acid, chromic cat gut, alginates, starch, cellulose, cellulose esters, blends and copolymers thereof, as well as other known degradable polymers. Non-degradable polymers that can be used include, but are not limited to, polyesters (e.g., PET), polyurethanes, silicones, PE, PP, PS, PAA, PMA, silk, blends, copolymers thereof as well as other known polymers. The threads used can be composed of a single composition or composed of a blend of differing compositions. The polymeric threads themselves can be further modified through the addition of a polymeric coating applied to the threads. The polymer used for coating the thread can be similar to that described above for the threads themselves. The polymer coating may further comprise a biologically active agent that has the ability to induce a fibroproliferative response. The agents that can be used are further described in the section (c) below.
The hydrogels described above can be utilized to deliver a particulate material that has the ability to induce a fibroproliferative response in the vas deferens. These particles can be either degradable or non-degradable and are similar to those described above for threads. In addition to those, particulate materials useful for the practice of this embodiment include talc, starch, glass, silicates, silica, silver nitrate, ceramic particles and other inorganic particles known in the art to induce a fibroproliferative response.
The particles used in this embodiment can be all of the same composition or a blend of difFering compositions. These particles can also be used as a coating applied to the polymeric strands as described above.
The hydrogel can also be constructed such that it is comprised of both polymeric threads and particles. The threads and particles used are similar to those described above and may be of uniform composition or blended composition. Virtually any combination of threads of differing compositions and particles of differing compositions can be utilized in this embodiment. The hydrogel, the polymeric threads, and the particles can all be utilized to deliver one or more biologically active agents, as described below.
One specific composition comprises rods prepared from a methylated collagen - crosslinked polyethylene glycol) composition such as described above which has powdered silk particles added to the composition prior to curing. Once deployed, the rod can absorb water and thereby occlude the vas deferens. This expansion can prevent the rod from moving, while the powdered silk can initiate a fibroproliferative response. As the methylated collagen-crosslinked polyethylene glycol) material starts to degrade, the material can support the fibrous tissue ingrowth that is initiated and potentiated by the silk particles. To further increase the rate of initiation of this fibroproliferative response, a sclerosant such as a surfactant (SDS), ethanolamine oleate or DMSO can be added. In addition, one. may also add or replace all (or a portion) of the 4-armed thiol PEG with a 4-armed amino PEG.
The amino PEG can provide a gel that can take a longer time to degrade and can provide some positive charge to further attract cellular material.
Another embodiment consists of an injectable implant composed of silk fibers or from a polymerized version of the fibrosing agent itself (i.e., repeating units of the fibrosing agent polymerized together).
In addition to the hydrogels and related implants described above, there are several other ways to practice this embodiment. All involve the deployment of a biomaterial into the lumen of the vas deferens, with or without, the addition of a fibrosis-inducing agent. The practice of this embodiment can be performed in several ways including: (a) injection of the fibrosing agent onto the luminal surface of the vas deferens (particularly useful for this embodiment is the use of polymeric carriers which release the fibrosing agent over a period ranging from several hours to several weeks - fluids, suspensions, emulsions, microemulsions, microspheres, pastes, gels, microparticulates, sprays, aerosols, solid implants and other formulations which release a fibrosing agent can be delivered into the vas deferens via specialized delivery catheters or other applicators); (b) microparticulate silk and/or silk strands (linear, branched, and/or coiled) either alone, or loaded with an additional fibrosis-inducing agent are also useful for directed injection into the vas deferens; (c) injectable collagen-containing formulations such as COSTASIS or materials prepared from a 4-armed thiol PEG (10K), a 4-armed NHS PEG(10K) and methylated collagen such as described above, either alone, or loaded with a fibrosis-inducing agent, injected into the lumen of the vas deferens; (d) injectable PEG-containing formulations such as COSEAL, FOCALSEAL, SPRAYGEL or DURASEAL, either alone, or loaded with a fibrosis-inducing agent, injected into the lumen of the vas deferens; (e) fibrinogen-containing formulations such as FLOSEAL or TISSEAL, either alone, or loaded with a fibrosis-inducing agent, injected into the lumen of the vas deferens; (f) hyaluronic acid-containing formulations such as RESTYLANE, HYLAFORM, PERLANE, SYNVISC, SEPRAFILM, SEPRACOAT, either alone, or loaded with a fibrosis-inducing agent injected into the lumen of the vas deferens; (g) polymeric gels for surgical implantation such as REPEL or FLOWGEL either alone, or loaded with a fibrosis-inducing agent injected into the lumen of the vas deferens; (h) orthopedic "cements" such as OSTEOBOND, LVC, SIMPLEX P, PALACOS, CORTOSS, and ENDURANCE, either alone, or loaded with a fibrosis-inducing agent injected into the luminal surface of the vas deferens; (i) surgical adhesives containing cyanoacrylates such as DERMABOND, INDERMIL, GLUSTITCH, VETBOND, HISTOACRYL, TISSUEMEND, TISSUMEND II, HISTOACRYL BLUE and ORABASE SOOTHE-N-SEAL LIQUID
PROTECTANT or as described above, either alone, or loaded with a fibrosis-inducing agent, injected into the lumen of the vas deferens; (j) surgical implants containing hydroxyapatite such as VITOSS (Orthovita) or calcium sulfate, alone or loaded with a fibrosis-inducing agent injected into the lumen of the vas deferens; (k) other biocompatible tissue fillers, such as those made by BioCure, 3M Company and Neomend, either alone, or loaded with a fibrosis-inducing agent, injected into the lumen of the vas deferens; (I) polysaccharide gels such as the ADCON series of gels, either alone, or loaded with a fibrosis-inducing agent injected into the lumen of the vas deferens; (m) films, sponges or meshes such as INTERCEED, VICRYL mesh, and GELFOAM either alone, or loaded with a fibrosis-inducing agent injected into the lumen of the vas deferens;
and/or (n) a hydrogel that is formed from an amino-functionalized polyethylene glycol (e.g., 4-armed tetra-amino PEG [10k]) and a 4-armed NHS functionalized PEG (e.g., pentaerythritol polyethylene glycol)ether tetra-succinimidyi glutarate [10K]). This hydrogel may further contain collagen, methylated collagen and/or gelatin. This hydrogel can further comprise the fibrosis-inducing agents described above (e.g., silk powder or silk threads)..
In many of the embodiments described above it may also be useful to add a radio-opaque material (such as tantalum, barium, other metal, or contrast material) such that the injected material can be visualized radiographically or by MRI. The contrast agent may be a water soluble or water insoluble radio-opaque material.
It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agent may be utilized alone, or in combination, in the practice of this embodiment as described above. Exemplary fibrosing agents for use in vas deferens implants and devices include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
Optionally, the device may alone or additionally comprise an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-Vii, IL-8, IL-6, and growth hormone).
Furthermore, the device may additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof.
The correct administration and dosage can be described further in section (c) below.
(c) Fibrosing Agents for Vas Deferens Implants As vas deferens implantables and injectables are made in a variety of configurations and sizes, the exact dose administered can vary with device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the sterilization device, the exemplary fibrosing agents, used alone or in combination, should be administered under the following dosing guidelines:
Utilizing talc as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated. into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of talc delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 1 ~.g to 100 mg). In one embodiment, the total amount of talc released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of talc as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~,g - 10 ~g per mm2 of surface area coated. In another embodiment, talc should be applied to a sterilization device surface at a dose of 0.05 ~,g/mm2 -10 ~g/mm2 of surface area coated.

In one embodiment, talc is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, talc may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of talc (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as talc is administered at half the above parameters, a compound half as potent as talc is administered at twice the above parameters, etc.).
Utilizing silk as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of silk delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 1 p,g to 100 mg). In one embodiment, the total amount of silk released from the prosthesis should be in the range of 10 ~.g to 50 mg. The dose per unit area of the device (i.e., the dosage of silk as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~g - 10 ~g per mm2 of surface area coated. In another embodiment, silk should be applied to a sterilization device surface at a dose of 0.05 ~.g/mm2 -10 ~,g/mm2 of surface area~coated.
As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release silk at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the sterilization device such that a minimum concentration of 0.01 nM to 1000 pM
of silk is delivered to the .tissue. In one embodiment, silk is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, silk may be released in effective concentrations for a period ranging from 1 hour- 30 days.
It should be readily evident given the discussions provided herein that analogues and derivatives of silk (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as silk is administered at half the above parameters, a compound half as potent as silk is administered at twice the above parameters, etc.).
Utilizing chitosan as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of chitosan delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 1 ~,g to 100 mg). In one embodiment, the total amount of chitosan released from the prosthesis should be in the range of 10 ~g to 50 mg. The dose per unit area of the device (i.e.the dosage of chitosan as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~.g - 10 ~,g per mm2 of surface area coated. In another embodiment, chitosan should be applied to a sterilization device surface at a dose of 0.05 pg/mm2 -10 ~,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release chitosan at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the sterilization device such that~a minimum concentration of 0.01 nM to 1000 pM of chitosan is delivered to the tissue. In one embodiment, chitosan is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, chitosan may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of chitosan (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as chitosan is administered at half the above parameters, a compound half as potent as chitosan is administered at twice the above parameters, etc.).
Utilizing polylysine as a exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of polylysine delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 1 pg to 100 mg). In one embodiment, the total amount of polylysine released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of polylysine as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~g -~.g per mm2 of surface area coated. In another embodiment, polylysine should be applied to a sterilization device surface at a dose of 0.05 ~g/mm2 -10 pg/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release polylysine at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the sterilization device such that a minimum concentration of 0.01 nM to 1000 pM of polylysine is delivered to the tissue. In one embodiment, polylysine is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, polylysine may be released in effective concentrations for, a period ranging from 1 hour- 30 days.
It should be readily evident given the discussions provided herein that analogues and derivatives of polylysine (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as polylysine is administered at half the above parameters, a compound half as potent as polylysine is administered at twice the above parameters, etc.).
Utilizing fibronectin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of fibronectin delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 1 p,g to 100 mg). In one embodiment, the total amount of fibronectin released from the prosthesis should be in the range of p,g to 50 mg. The dose per unit area of the device (i.e., the dosage of fibronectin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.05 ~g -pg per mm2 of surface area coated. In another embodiment, fibronectin should be applied to a sterilization device surface at a dose of 0.05 ~,g/mmZ -10 p,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release fibronectin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the sterilization device such that a minimum concentration of 0.01 nM to 1000 pM of fibronectin is delivered to the tissue. In one embodiment, fibronectin is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, fibronectin may be released in effective concentrations for a period ranging from 1 hour- 30 days.
It should be readily evident given the discussions provided herein that analogues and derivatives of fibronectin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as fibronectin is administered at half the above parameters, a compound half as potent as fibronectin is administered at twice the above parameters, etc.).
Utilizing bleomycin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of bleomycin delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 0.01 ~g to 100 mg). In one embodiment, the total amount of bleomycin released from the prosthesis should be in the range of 0.10 ~,g to 50 mg. The dose per unit area of the device (i.e., the dosage of bleomycin as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 ~,g ~,g per mm2 of surface area coated. In another embodiment, bleomycin should be applied to a sterilization device surface at a dose of 0.005 p,g/mm2 -10 ~,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release bleomycin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the sterilization device such that a minimum concentration of 0.001 nM to 1000 pM of bleomycin is delivered to the tissue. In one embodiment, bleomycin is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, bleomycin may be released in effective concentrations for a period ranging from 1 hour- 30 days.
It should be readily evident given the discussions provided herein that analogues and derivatives of bleomycin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as bleomycin is administered at half the above parameters, a compound half as potent as bleomycin is administered at twice the above parameters, etc.):
Utilizing CTGF as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, incorporated into an injectable, or applied without a polymeric carrier, the total dose of CTGF delivered from a sterilization device, or coated onto the surface of a sterilization device, should not exceed 100 mg (range of 0.01 ~g to 100 mg). In one embodiment, the total amount of CTGF
released from the prosthesis should be in the range of 0.10 ~g to 50 mg. The dose per unit area of the device (i.e., the dosage of CTGF as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.005 p.g - 10 ~,g per mm2 of surface area coated. In another embodiment, CTGF should be applied to a sterilization device surface at a dose of 0.005 ~,g/mm2 -10 ~g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release CTGF at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the a sterilization device such that a minimum concentration of 0.001 nM to 1000 pM of CTGF is delivered to the tissue. In one embodiment, CTGF
is released from the surface of a sterilization device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months.
For example, CTGF may be released in effective concentrations for a period ranging from 1 hour- 30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of CTGF (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as CTGF is administered at half the above parameters, a compound half as potent as CTGF is administered at twice the above parameters, etc.).
Optionally, the device may alone or additionally comprise an inflammatory cytokine (e.g., TGF~3, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-a, IL-8, IL-6, and growth hormone). Inflammatory cytokines are to be used in formulations at concentrations that range from 0.0001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required. Preferably, the inflammatory cytokine is released in effective concentrations for a period ranging from 1 - 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 ~,g to 100 mg); preferred 0.001 ~,g to mg. When used as a device coating, the dose is per unit area of 0.0001 ~,g -500 ~g per mm2; with a preferred dose of 0.001 ~.g/mm2 - 200 ~.g/mm2.
Minimum concentration of 10-'°- 10'~ g/ml of inflammatory cytokine is to be maintained on the device surface.
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol., estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof. Doses used are those concentrations which are demonstrated to stimulate cell proliferation (Example 16). The proliferative agents are to be used in formulations at concentrations that range from 0.01 ng/ml to 25 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area coverage required.
Preferably, the proliferative agent is released in effective concentrations for a period ranging from 1 - 180 days. The total dose for a single application is typically not to exceed 500 mg (range of 0.0001 ~,g to 200 mg); preferred 0.001 ~g to 100 mg. When used as a device coating, the dose is per unit area of 0.00001 p,g - 500 pg per mm2; with a preferred dose of 0.0001 p.g/mm2 - 200 ~,g/mm2. Minimum concentration of 10-11- 10-6 M of proliferative agent is to be maintained on the device surface.

It should be readily evident to one of skill in the art that any of the previously described fibrosis inducing agents, or derivatives and analogues thereof, can be utilized to create variations of the above compositions without deviating from the spirit and scope of the invention. It should also be apparent that the agent can be utilized in a composition with or without polymer carrier and that altering the carrier does not deviate from the scope of this invention.
6. Urinary Incontinence The present invention provides compositions and devices for use in the management of urinary incontinence. Urinary incontinence, or the involuntary loss of urine, is a common medical condition which affects 20% of women and 1-2% of men at some point in their lifetime. The most common form of incontinence is stress incontinence, or the inadvertent leakage of urine in response to activities that cause an increase in intraabdominal pressure (such as sneezing, coughing, or straining). This occurs when intravesical pressure (pressure in the bladder) exceeds the pressure in the urethra, forcing urine from the bladder and into the urethra in the absence of detrusor (bladder muscle) contraction. Several conditions are thought to result in stress incontinence, including: (1 ) descent of the bladder neck and internal urethral sphincter out of the abdomen; and (2) intrinsic urethral sphincter failure due to trauma, surgery, childbirth or malignancy. Corrective measures are aimed principally at supporting the proximal urethral and' bladder neck within the abdominal cavit b sur ical or non-sur ical means. A second a y y g g pproach involves the use of urethral bulking agents designed to increase urethral pressure and reduce stress incontinence.
Regardless of their composition, urethral bulking agents are designed to provide physical support for the urethra and prevent the leakage of urine. Unfortunately, the symptomatic relief is often only temporary for most patients and the procedure must be repeated. Biodegradable injectable materials (such as collagen, hyaluronic acid and others described below) are absorbed by the body over time and lose their structural integrity -necessitating replacement of the material via repeat injection. Non degradable materials (such as acrylics, hydroxyapatite, polymeric beads, and others described below) do not regenerate the normal structural anatomy or biomechanics of the tissues surrounding the urethra. The addition of a fibrosis-inducing agent to a urethral bulking agent solves several of these problems.

The fibrosis-inducing agent encourages the formation of the body's own fibrous tissue (including collagen) around the urethra. This results in the formation of continuously sustainable connective tissue which supports the urethra in a manner more closely approximating normal pelvic anatomy and biomechanics.
The result is a treatment that lasts longer, provides better symptomatic relief and requires fewer re-interventions.
(i) Iniectable Urinary Bulking Agents Containing a Fibrosing Agent Bulking agents for use in treating urinary incontinence which may be combined with one or more fibrosis-inducing agents according to the present invention, include commercially available products for the management of stress incontinence. CONTIGEN (purified bovine dermal glutaraldehyde crosslinked collagen dispersed in phosphate buffered physiologic saline at 35 mg/ml available through C.R. Bard, Billerica, MA) is a widely used urethral bulking agent. Other collagen based injectable products, including those derived from non-bovine, human, or recombinant sources can also be utilized in this embodiment. Other representative examples of commercially available bulking agents that can be used to treat urinary incontinence include hydroxyapatite loaded gel (COAPATITE from BioForm Medical, Inc., San Mateo, CA), micronized alloderm acellular matrix (CYMETRA from LifeCell Corporation, Branchburg, NJ), non-animal stabilized hyaluronic acid (NASHA
and DEFLUX from Q-Med), pyrolytic carbon-coated micro-beads in hydrogel containing beta-glucan (DURASPHERE from Carbon Medical Technologies, Inc. St. Paul, MN and Boston Scientific Corporation, Natick, MA), engineered collagen fibrils (Organogenesis, Inc., Canton, MA), hylan polymer (HYLAGEL
URO from Genzyme), MACROPLASTIQUE (polydimethylsiloxane in hydrogel carrier) from Uroplasty, Inc. (Minneapolis, MN), microspheres (e.g., acrylic beads, such as those available from Biosphere Medical, Inc. Marlborough, MA), urethral bulking agents containing silk and elastin proteins (Protein Polymer Technologies, San Diego, CA), 'cross-linked silicon microballoon filled with biocompatible polymer (UROVIVE from American Medical Systems, Minnetonka, MN), and URYX bulking agent and Embolyx from Microtherapeutics, Inc., San Clemente, CA and Genyx Medical, Inc., Aliso Viejo, CA. Other manufacturers of carriers suitable for use in bulking compositions include C.R. Bard, Inc. (Murray Hill, NJ), Collagenesis, Inc.
(Acton, MA), American Medical Systems, Mentor, Uromed Corporation (Norwood, MA), Boston Scientific Corporation, Johnson & Johnson (Ethicon, Inc.), Cook Group, Inc. (Bloomington, IN), W.L. Gore & Associates, and SURx, Inc. (Pleasonton, CA).
Administration of a fibrosis-agent loaded bulking agent may typically be performed by transurethral injection. If the carrier of the fibrosis-inducing agent contains collagen, the patient should have completed two skin tests (conducted 2 weeks apart) to test for an allergic response prior to administration. If these tests are negative, the collagen injection containing a fibrosis-inducing agent can be administered to the patient. A refrigerated, single use, pre-loaded syringe agent with a fine gauge needle (23 gauge transurethral injection needle with a stabilizing cannula) containing 2.5 ml of the implant material (the fibrosis-inducing agent and the urethral bulking agent) is used. The patient is placed in the lithotomy position and 10 ml of 2%
lidocaine is inserted into the urethra for anesthesia. In women, the bladder neck is visualized cystoscopically. Via the injection port of the cystoscope, the needle is inserted at the 4 o'clock position, at a sharp angle, 1-1.5 cm distal to the bladder neck into the plane just beneath the bladder mucosa. The needle is then advanced with the cystoscope parallel to the long axis of the urethra until it lies just below the mucosa of the bladder neck. The fibrosis-inducing agent and the urethral bulking agent is injected slowly into this site. The procedure is then repeated at the 3 o'clock position. Methylene blue, or other nontoxic coloring agents, can be added to the implant to assist with visualization of the injection.
Alternatively, periurethral injection of a fibrosis-inducing agent loaded into a urethral bulking agent can also be used for the treatment of incontinence. A refrigerated, single use, pre-loaded syringe with a fine gauge needle (periurethral injection needle) containing 2.5 ml of the implant material (the fibrosis-inducing agent and the urethral bulking agent) is used. The patient is placed in the lithotomy position, 10 ml of 2% lidocaine is inserted into the urethra for anesthesia and the bladder neck is visualized cystoscopically (in men the urethra can also be visualized via suprapubic cystoscopic approach).
The needle is inserted transvaginally or suprapubically into the area immediately adjacent and lateral to the urethra. When it reaches the appropriate position near the bladder neck (as seen cystoscopically and described above), the fibrosis-inducing agent loaded into a urethral bulking agent is injected slowly into this site. Methylene blue, or other nontoxic coloring agents, can be added to the implant to assist with visualization of the injection.

It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agent may be utilized (alone or in combination) with any injectable urethral bulking agent in the practice of this invention.
Exemplary fibrosing agents for use in combination with injectable urethral bulking agents include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
Optionally, the device may alone or additionally comprise an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-(3, IL-8, IL-6, and growth hormone) or an analogue or derivative thereof.
Furthermore, the device may alone or additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-(3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof.
The correct administration and dosage can be described further in section (iii) below.
(ii) Urinary Slings Containing a Fibrosis-Inducing Agent In another aspect, stress incontinence and weakening of the urethra muscle may be treated with a pubovaginal sling procedure. This operation can create enough compression on the urethra to help the patient regain bladder control. Slings for treating urinary incontinence are described in, e.g., U.S. Patent Nos. 6,641,524; 6,592,610; 6,387,040; 6,328,686; 6,306,079;
6,221,005; 6,110,101; 6,056,687;,6,042,536; and 6,042,534 and U.S: Patent Application Publication Nos. 2003/0199732A1; 2003/0149440A1;
2002/0183588A1; 2002/0058959A1; and 2002/0022841 A1.
Slings for use in treating urinary incontinence which may be combined with one or more fibrosis-inducing agents according to the present invention, include numerous commercially available products. For example, the SUSPEND TUTOPLAST (Processed Fascia Lata sling from Mentor) and REPLIFORM Tissue Regeneration Matrix (human allograft dermal collagen fibers from Boston Scientific Corporation (Natick, MA)) can be used. Products such as FORTAGEN Surgical Mesh and GRAFTPATCH (both from Organogenesis Inc., Canton, MA), and SURGISIS (Cook Biotech, Inc., West Lafayette, IN) consist of a multilaminate sheet composed primarily of Type I
collagen (usually porcine or bovine) that is used to reinforce soft tissues during operative repair. Indications include defects of the abdominal and thoracic wall, muscle flap reinforcement, rectal and vaginal prolapse, repair of tissue flap donor sites, ostomy reinforcement, reconstruction of the pelvic floor, hernia repair, suture line reinforcement and reconstructive purposes. Surgical slings, such as the FORTAFLEX Surgical Sling (Organogenesis, Inc.) and the SURGISIS Sling are also composed predominantly of Type I Collagen (usually porcine or bovine) and are utilized in open urological surgery procedures.
Indications include pubourethral support, prolapse repair (urethral, vaginal, rectal and colonic), rectoceles, cystoceles, enteroceles, mastoplexy, reconstruction of the pelvic floor, bladder support, sacrocolposuspension and other reconstructive procedures. Other representative examples of slings for use in the present invention include Tension-Free Vaginal Tape (TVT) from Ethicon, Inc. (Somerville, NJ), the SPARC Female Sling System (a "vaginal tape" product from American Medical Systems), the AMS Silicone-Coated Mesh Sling (American Medical Systems), BIOSLING (InjecTx/ProSurg), VERITAS
Collagen Matrix Urological Sling (Synovis Life Technologies, Inc., St. Paul, MN), slings made from PTFE, such as Gore-Tex MYCROMESH from Gore, the STRATESIS Urethral Sling made from acellular porcine small intestine mucosa (Cook, Inc.), slings made from allograph fascia, such as the ALLOSLING
(Alliant Medical), and slings made from human allograft fascia, such as FASLATA Allograft Tissue (C.R. Bard). Slings can also be prepared from, e.g., polypropylene mesh (C.R. Bard), and MERSILENE polyester fiber mesh (Ethicon, Inc.).
Numerous polymeric and non-polymeric drug delivery systems described above can be used to deliver fibrosis-inducing agents from urological slings and implants. The methods for incorporating fibrosing compositions onto or into the urinary incontinence devices include: (a) directly affixing to the urinary incontinence implant a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (b) directly incorporating into the device a fibrosing composition (e.g., by either a spraying process or dipping process as described above, with or without a carrier); (c) by coating the device with a substance such as a hydrogef which can in turn absorb the fibrosing composition; (d) by interweaving fibrosing composition coated thread (or the polymer itself formed into a thread) into the device structure; (e) by inserting the device into a sleeve or mesh which is comprised of or coated with a fibrosing composition; (f) constructing the device itself or a portion of the device with a fibrosing composition, or (g) by covalently binding the fibrosing agent directly to the device surface or to a linker (small molecule or polymer) that is coated or attached to the device surface. For these devices, the coating process can be performed in such a manner as to a) coat the exterior surfaces of the device, b) coat the interior surfaces of the device or c) coat all or parts of both external and internal surface of the device.
In addition to coating the device with the fibrosing composition, the fibrosing agent can be mixed with the materials that are used to make the device such that the fibrosing agent is incorporated into the final device.
In one embodiment, fibrosis-inducing agents can be incorporated directly into the formulation to produce a suspension or a solution (e.g., silk powder, bleomycin) or it can be incorporated into a secondary carrier (e.g., micelles, liposomes, microspheres, microparticles, nanospheres, microparticulates, emulsions and/or micromulsions) that is then incorporated into the bulking composition. In another embodiment, the fibrosis-inducing agent can be electrostatically or covalently bound to one or more of the polymeric components of the in situ forming composition.
In another embodiment, the fibrosis-inducing agent can be incorporated into the bulking agent during the manufacture of the agent. For example, silk powder can be added as a reagent during the manufacture of microspheres that are used as bulking agents.
It should be apparent to one of skill in the art that potentially any adhesion or fibrosis-inducing agents described above may be utilized alone, or in combination, in the practice of this embodiment. ' Exemplary fibrosing agents for use in urinary incontinence devices and compositions include talc, silk, wool, chitosan, polylysine, fibronectin, bleomycin, and CTGF, as well as analogues and derivatives of the aforementioned.
Optionally, the device may alone or additionally comprise an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa, NGF, GM-CSF, IGF-a, IL-1, IL-1-a, IL-8, IL-6, and growth hormone) or an analogue or derivative thereof.
Furthermore, the device may additionally comprise an agent that stimulates cellular proliferation. Examples include: dexamethasone, isotretinoin (13-cis retinoic acid), 17-[3-estradiol, estradiol, 1-a-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof.
(iii) Fibrosina Agents for Use in Urinary Incontinence Implants As urinary incontinence devices are made in a variety of configurations and sizes (including injectable bulking agents and slings), the exact dose administered can vary with implant or device size, surface area and design. However, certain principles can be applied in the application of this art.
Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined.
Regardless of the method of application of the drug to the urinary incontinence implant or device, the exemplary fibrosing agents, used alone or in combination, should be administered under the following dosing guidelines:
Utilizing talc as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of talc delivered from a urinary incontinence device, or coated onto the surface of a urinary incontinence device, should not exceed 100 mg (range of 1 p.g to 100 mg). In one embodiment, the total amount of talc released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit volume of the injectable urinary bulking agent (i.e., the dosage of talc as a function of the volume of urinary bulking agent injected) should fall within the range of 0.05 pg - 10 pg per mm3. In another embodiment, talc should be applied to a urinary sling incontinence device surface at a dose of 0.05 p,g/mm2 -10 ~,g/mm2 of surface area coated. In one embodiment, talc is released from a urinary incontinence bulking agent, implant or device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, talc may be released in effective concentrations for a period ranging from 1-9 months. It should be readily evident given the discussions provided herein that analogues and derivatives of talc (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as talc is administered at half the above parameters, a compound half as potent as talc is administered at twice the above parameters, etc.).
Utilizing silk as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of silk delivered from a urinary incontinence device, or coated onto the surface of a urinary incontinence device, should not exceed 100 mg (range of 1 ~g to 100 mg). In one embodiment, the total amount of silk released from the prosthesis should be in the range of 10 ~,g to 50 mg. The dose per unit volume of the 1-0 injectable urinary bulking agent (i.e., the dosage of silk as a function of the volume of urinary bulking agent injected) should fall within the range of 0.05 ~g - 10 ~.g per mm3. In another embodiment, silk should be applied to a urinary sling incontinence device surface at a dose of 0.05 pg/mmz -10 pg/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release silk at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary incontinence bulking agent, implant or device such that a minimum concentration of 0.01 nM to 1000 pM of silk is delivered to the tissue. In one embodiment, silk is released from a urinary incontinence bulking agent, implant or device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, silk may be released in effective concentrations for a period ranging from 1-9 months. It should be readily evident given the discussions provided herein that analogues and derivatives of silk (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as silk is administered at half the above parameters, a compound half as potent as silk is administered at twice the above parameters, etc.).
Utilizing chitosan as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of chitosan delivered from a urinary incontinence device, or coated onto the surface of a urinary incontinence device, should not exceed 100 mg (range of 1 ~,g to 100 mg). In one embodiment, the total amount of chitosan released from the prosthesis should be in the range of 10 p,g to 50 mg. The dose per unit volume of the injectable urinary bulking agent (i.e., the dosage of chitosan as a function of the volume of urinary bulking agent injected) should fall within the range of 0.05 ~.g - 10 ~.g per mm3. In another embodiment, chitosan should be applied to a urinary sling incontinence device surface at a dose of 0.05 pg/mm2 -10 ~,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release chitosan at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary incontinence bulking agent, implant or device such that a minimum concentration of 0.01 nM to 1000 pM of chitosan is delivered to the tissue. In one embodiment, chitosan is released from a urinary incontinence bulking agent, implant or device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, chitosan may be released in effective concentrations for a period ranging from 1-9 months. It should be readily evident given the discussions provided herein that analogues and derivatives of chitosan (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as chitosan is administered at half the above parameters, a compound half as potent as chitosan is administered at twice the above parameters, etc.).
Utilizing polylysine as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of polylysine delivered from a urinary incontinence device, or coated onto the surface of a urinary incontinence device, should not exceed 100 mg (range of 1 ~.g to 100 mg). In one embodiment, the total amount of polylysine released from the prosthesis should be in the range of 10 ~.g to 50 mg. The dose per unit volume of the injectable urinary bulking agent (i.e., the dosage of polylysine as a function of the volume of urinary bulking agent injected) should fall within the range of 0.05 ~,g - 10 ~g per mm3. In another embodiment, polylysine should be applied to a urinary sling incontinence device surface at a dose of 0.05 ~,g/mm2 -10 ~,g/mm~ of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release polylysine at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary incontinence bulking agent, implant or device such that a minimum concentration of 0.01 nM to 1000 pM of polylysine is delivered to the tissue.
In one embodiment, polylysine is released from a urinary incontinence bulking agent, implant or device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, polylysine may be released in effective concentrations for a period ranging from 1-9 months. It should be readily evident given the discussions provided herein that analogues and derivatives of polylysine (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as polylysine is administered at half the above parameters, a compound half as potent as polylysine is administered at twice the above parameters, etc. ).
Utilizing fibronectin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of fibronectin delivered from a urinary incontinence device, or coated onto the surface of a urinary incontinence device, should not exceed 100 mg (range of 1 p,g to 100 mg). In one embodiment, the total amount of fibronectin released from the prosthesis should be in the range of 10 ~g to 50 mg. The dose per unit volume of the injectable urinary bulking agent (i.e., the dosage of fibronectin as a function of the volume of urinary bulking agent injected) should fall within the range of 0.05 p,g - 10 p,g per mm3. In another embodiment, talc should be applied to a urinary sling incontinence device surface at a dose of 0.05 ~.g/mm2 -10 ~,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release fibronectin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary incontinence bulking agent, implant or device such that a minimum concentration of 0.01 nM
to 1000 pM of fibronectin is delivered to the tissue. In one embodiment, fibronectin is released from a urinary incontinence bulking agent, implant or device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, fibronectin may be released in effective concentrations for a period ranging from 1-9 months. It should be readily evident given the discussions provided herein that analogues and derivatives of fibronectin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as fibronectin is administered at half the above parameters, a compound half as potent as fibronectin is administered at twice the above parameters, etc.).
Utilizing bleomycin as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of bleomycin delivered from a urinary incontinence device, or coated onto the surface of a urinary incontinence device, should not exceed 100 mg (range of 0.01 p,g to 100 mg). In one embodiment, the total amount of bleomycin released from the prosthesis should be in the range of 0.10 ~.g to mg. The dose per unit volume of the injectable urinary bulking agent (i.e., the dosage of bleomycin as a function of the volume of urinary bulking agent injected) should fall within the range of 0.005 ~,g - 10 ~,g per mm3. In another embodiment, bleomycin should be applied to a urinary sling incontinence device surface at a dose of 0.005 ~,g/mm2 -10 ~.g/mm2 of surface area coated.
As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release bleomycin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary incontinence bulking agent, implant or device such that a minimum concentration of 0.001 nM to 1000 pM of bleomycin is delivered to the tissue. In one embodiment, bleomycin is released from a urinary incontinence bulking agent, implant or device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, bleomycin may be released in effective concentration's for a period ranging from 1-9 months. It should be readily evident given the discussions provided herein that analogues and derivatives of bleomycin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as bleomycin is administered at half the above parameters, a compound-half as potent as bleomycin is administered at twice the above parameters, etc.).

Utilizing CTGF as an exemplary fibrosis-inducing agent, whether it is applied using a polymer coating, incorporated into the polymers which make up the device or implant, or applied without a polymeric carrier, the total dose of CTGF delivered from a urinary incontinence device, or coated onto the surface of a urinary incontinence device, should not exceed 100 mg (range of 0.01 p,g to 100 mg). In one embodiment, the total amount of CTGF released from the prosthesis should be in the range of 0.10 ~.g to 50 mg. The dose per unit volume of the injectable urinary bulking agent (i.e., the dosage of CTGF as a function of the volume of urinary bulking agent injected) should fall within the range of 0.005 ~,g - 10 ~.g per mm3. In another embodiment, CTGF should be applied to a urinary sling incontinence device surface at a dose of 0.005 pg/mm2 -10 ~,g/mm2 of surface area coated. As specific (polymeric and non-polymeric) drug delivery vehicles and specific medical devices can release CTGF at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary incontinence bulking agent, implant or device such that a minimum concentration of 0.001 nM to 1000 pM of CTGF is delivered to the tissue. In one embodiment, CTGF
is released from a urinary incontinence bulking agent, implant or device such that fibrosis in the tissue is promoted for a period ranging from several hours to several months. For example, CTGF may be released in effective concentrations for a period ranging from 1-9 months. It should be readily evident given the discussions provided herein that analogues and derivatives of CTGF (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as CTGF
is administered at half the above parameters, a compound half as potent as CTGF is administered at twice the above parameters, etc.).
Optionally, the device may alone or additionally comprise an inflammatory cytokine (e.g., TGF~i, PDGF, VEGF, bFGF, TNFa., NGF, GM-CSF, IGF-a, IL-1, IL-1-~3, IL-8, IL-6, and growth hormone or an analogue or derivative thereof). Inflammatory cytokines are to be used in formulations at concentrations that range from 0.0001 pg/ml to approximately 20 mg/ml depending on the specific clinical application, formulation type (e.g., gel, liquid, solid, semi-solid), formulation chemistry, duration of required application, type of medical device interface and formulation volume and or surface area DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter 1e Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:

Claims (4228)

1. A method comprising introducing into an intervertebral disc space of a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at the intervertebral disc space of the patient, thereby providing the patient with a beneficial result.
2. The method of claim 1 wherein beneficial result is the repair of a spinal disc.
3. The method of claim 1 wherein the beneficial result is fibrous ankylosis.
4. The method of claim 1 wherein the beneficial result is bony ankylosis.
5. The method of claim 1 wherein the fibrosing agent promotes regeneration.
6. The method of claim 1 wherein the fibrosing agent promotes angiogenesis.
7. The method of claim 1 wherein the fibrosing agent promotes fibroblast migration.
8. The method of claim 1 wherein the fibrosing agent promotes fibroblast proliferation.
9. The method of claim 1 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
10. The method of claim 1 wherein the fibrosing agent promotes tissue remodeling.
11. The method of claim 1 wherein the fibrosing agent is an arterial vessel wall irritant.
12. The method of claim 1 wherein the fibrosing agent is or comprises silk.
13. The method of claim 1 wherein the fibrosing agent is or comprises silkworm silk.
14. The method of claim 1 wherein the fibrosing agent is or comprises spider silk.
15. The method of claim 1 wherein the fibrosing agent is or comprises recombinant silk.
16. The method of claim 1 wherein the fibrosing agent is or comprises raw silk.
17. The method of claim 1 wherein the fibrosing agent is or comprises hydrolyzed silk.
18. The method of claim 1 wherein the fibrosing agent is or comprises acid-treated silk.
19. The method of claim 1 wherein the fibrosing agent is or comprises acylated silk.
20. The method of claim 1 wherein the fibrosing agent is in the form of strands.
21. The method of claim 1 wherein the fibrosing agent is in the form of tufts.
22. The method of claim 1 wherein the fibrosing agent is in the form of microparticulates.
23. The method of claim 1 wherein the fibrosing agent is or comprises mineral particles.
24. The method of claim 1 wherein the fibrosing agent is or comprises talc.
25. The method of claim 1 wherein the fibrosing agent is or comprises chitosan.
26. The method of claim 1 wherein the fibrosing agent is or comprises polylysine.
27. The method of claim 1 wherein the fibrosing agent is or comprises fibronectin.
28. The method of claim 1 wherein the fibrosing agent is or comprises bleomycin.
29. The method of claim 1 wherein the fibrosing agent is or comprises CTGF.
30. The method of claim 1 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
31. The method of claim 30 wherein the thread is biodegradable.
32. The method of claim 31 wherein the biodegradable thread comprises a material selected from the group consisting of polyester, polyanhydride, poly(anhydride ester), poly(ester-amide), poly(ester-urea), polyorthoester, polyphosphoester, polyphosphazine, polycyanoacrylate, collagen, chitosan, hyaluronic acid, chromic cat gut, alginate, starch, cellulose and cellulose ester.
33. The method of claim 30 wherein the thread is non-biodegradable.
34. The method of claim 33 wherein the non-biodegradable thread comprises a material selected from the group consisting of polyester, polyurethane, silicone, polyethylene, polypropylene, polystyrene, polyacrylate, polymethacrylate, and silk.
35. The method of claim 30 wherein the thread is coated with a polymer.
36. The method of claim 30 wherein the thread is coated with a pharmaceutical agent that induces a fibrotic response in the patient.
37. The method of claim 30 wherein the thread is coated with a pharmaceutical agent that induces an osteogenic response in the patient.
38. The method of claim 30 wherein the fibrosing agent is in the form of a particulate.
39. The method of claim 38'wherein the particulate is a biodegradable particulate.
40. The method of claim 39 wherein the biodegradable particulate comprises a material selected from the group consisting of polyester, polyanhydride, poly(anhydride ester), poly(ester-amide), poly(ester-urea), polyorthoester, polyphosphoester, polyphosphazine, polycyanoacrylate, collagen, chitosan, hyaluronic acid, chromic cat gut, alginate, starch, cellulose and cellulose ester.
41. The method of claim 38 wherein the particulate is non-biodegradable.
42. The method of claim 41 wherein the non-biodegradable particulate comprises a material selected from the group consisting of polyester, polyurethane, silicone, polyethylene, polypropylene, polystyrene, polyacrylate, polymethacrylate, and silk.
43. The method of claim 38 wherein the particulate is a particulate form of a member selected from the group consisting of silk, talc, starch, glass, silicate, silica, calcium phosphate, calcium sulfate, calcium carbonate, hydroxyapatite, synthetic mineral, polymethylmethacrylate, silver nitrate, ceramic and other inorganic particles.
44. The method of claim 38 wherein the particulate is coated with a polymer.
45. The method of claim 38 wherein the particulate is coated with a pharmaceutical agent that induces a fibrotic response in the patient.
46. The method of claim 38 wherein the particulate is coated with a member selected from the group consisting of silk, talc, starch, glass, silicate, silica, calcium phosphate, calcium sulfate, calcium carbonate, hydroxyapatite, synthetic mineral, polymethylmethacrylate, silver nitrate, ceramic and other inorganic particles.
47. The method of claim 38 wherein the particulate is coated with a pharmaceutical agent that induces an osteogenic response in the patient.
48. The method of claim 1 wherein the composition further comprises an agent that promotes bone growth.
49. The method of claim 48 wherein the fibrosing agent that promotes bone growth is a bone morphogenic protein.
50. The method of claim 48 wherein the fibrosing agent that promotes bone growth is an osteogenic growth factor.
51. The method of claim 50 wherein the osteogenic growth factor is selected from transforming growth factor, platelet-derived growth factor, and fibroblast growth factor.
52. The method of claim 1 wherein the composition further comprises a pharmaceutical agent that induces sclerosis (a sclerosant).
53. The method of claim 52 wherein the sclerosant is selected from the group consisting of ethanol, dimethyl sulfoxide, sucrose, sodium chloride, dextrose, glycerin, minocycline, tetracycline, doxycycline, polidocanol, sodium tetradecyl sulfate, sodium morrhuate, and sotradecol.
54. The method of claim 52 wherein the sclerosant is a surfactant.
55. The method of claim 1 wherein the composition further comprises an inflammatory cytokine.
56. The method of claim 55 wherein the inflammatory cytokine is selected from the group consisting of TGF.beta., PDGF, VEGF, bFGF, TNF.alpha., NGF, GM-CSF, IGF-a, IL-1, IL-1-.beta., IL-8, IL-6, and growth hormone.
57. The method of claim 1 wherein the composition further comprises an agent that stimulates cell proliferation.
58. The method of claim 57 wherein the fibrosing agent that stimulates cell proliferation is selected from the group consisting of dexamethasone, isotretinoin (13-cis retinoic acid), 17-.beta.-estradiol, estradiol, 1-x-25 dihydroxyvitamin D3, diethylstibesterol, cyclosporine A, L-NAME, all-trans retinoic acid (ATRA), and analogues and derivatives thereof.
59. The method of claim 1 wherein the composition further comprises a bulking agent.
60. The method of claim 1 wherein the composition further comprises a sealant.
61. The method of claim 1 wherein the composition further comprises a polymeric carrier.
62. The method of claim 61 wherein the polymeric carrier provides sustained release for an active component of the composition.
63. The method of claim 61 wherein the polymeric carrier is a non-biodegradable material.
64. The method of claim 63 wherein the non-biodegradable material is crosslinked.
65. The method of claim 64 wherein the crosslinked non-biodegradable material comprises a crosslinked form of polyvinylalcohol, polyvinylpyrrolidone, polyacrylamide, methyl methacrylate or methyl methacrylate-styrene copolymer.
66. The method of claim 63 wherein the non-biodegradable material is a hydogel.
67. The method of claim 61 wherein the polymeric carrier is a biodegradable material.
68. The method of claim 67 wherein the biodegradable material is a crosslinked material prepared from, or incorporating. units of, polyethyleneglycol, gelatin, collagen, bone allografts, mesenchymal stem cells, hyaluronic acid, hyaluronic acid derivatives, polysaccharides, carbohydrates, proteins, autologous bone, demineralized bone matrix, cellulose derivatives, chitosan, chitosan derivatives, and polyester-polyalkylene oxide block copolymers.
69. The method of claim 61 wherein the polymeric carrier is prepared from a 4-armed thiol PEG, a 4-armed NHS PEG, and methylated collagen.
70. The method of claim 1 wherein the composition further comprises a resorbable ceramic.
71. The method of claim 70 wherein the resorbable ceramic comprises, or is prepared from, a material selected from the group consisting of ~-tricalcium phosphate, hydroxyapatite, Ca10(PO4)6OH, calcium carbonate, calcium sulfate and calcium phosphate.
72. The method of claim 1 wherein the composition further comprises a contrast agent.
73. The method of claim 72 wherein the contrast agent responds to x-ray.
74. The method of claim 73 wherein the contrast agent is barium, tantalum, technetium, or gadolinium.
75. The method of claim 1 wherein the composition further comprises a thread.
76. The method of claim 75 wherein the thread is biodegradable.
77. The method of claim 76 wherein the biodegradable thread comprises a material selected from the group consisting of polyester, polyanhydride, poly(anhydride ester), poly(ester-amide), poly(ester-urea), polyorthoester, polyphosphoester, polyphosphazine, polycyanoacrylate, collagen, chitosan, hyaluronic acid, chromic cat gut, alginate, starch, cellulose and cellulose ester.
73. The method of claim 75 wherein the thread is non-biodegradable.
79. The method of claim 78 wherein the non-biodegradable thread comprises a material selected from the group consisting of polyester, polyurethane, silicone, polyethylene, polypropylene, polystyrene, polyacrylate, polymethacrylate, and silk.
80. The method of claim 75 wherein the thread is coated with a polymer.
31. The method of claim 75 wherein the thread is coated with a pharmaceutical agent that induces a fibrotic response in the patient.
82. The method of claim 75 wereinwherein the thread is coated with a pharmaceutical agent that induces a osteogenic response in the patient.
83. The method of claim 1 wherein the composition is in the form of a gel.
84. The method of claim 1 wherein the composition is in the form of a paste.
85. The method of claim 1 wherein the composition is in the form of a spray.
86. The method of claim 1 wherein the composition is in the form of an aerosol.
87. The method of claim 1 wherein the composition is in the form of a suspension.
88. The method of claim 1 wherein the composition is in the form of an emulsion or microemulsion.
89. The method of claim 1 wherein the composition is in the form of a microsphere.
90. The method of claim 1 wherein the composition is in the form of a microparticulate.
91. The method of claim 1 wherein the composition is in the form of a solid implant.
92. An injectable composition comprising a fibrosing agent and a bulking agent.
93. The composition of claim 92 wherein the fibrosing agent promotes fibrosis and promotes regeneration.
94. The composition of claim 92 wherein the fibrosing agent promotes angiogenesis.
95. The composition of claim 92 wherein the fibrosing agent promotes fibroblast migration.
96. The composition of claim 92 wherein the fibrosing agent promotes fibroblast proliferation.
97. The composition of claim 92 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
98. The composition of claim 92 wherein the fibrosing agent promotes tissue remodeling.
99. The composition of claim 92 wherein the fibrosing agent is an arterial vessel wall irritant.
100. The composition of claim 92 wherein the fibrosing agent is or comprises silk.
101. The composition of claim 92 wherein the fibrosing agent is or comprises silkworm silk.
102. The composition of claim 92 wherein the fibrosing agent is or comprises spider silk.
103. The composition of claim 92 wherein the fibrosing agent is or comprises recombinant silk.
104. The composition of claim 92 wherein the fibrosing agent is or comprises raw silk.
105. The composition of claim 92 wherein the fibrosing agent is or comprises hydrolyzed silk.
106. The composition of claim 92 wherein the fibrosing agent is or comprises acid-treated silk.
107. The composition of claim 92 wherein the fibrosing agent is or comprises acylated silk.
108. The composition of claim 92 wherein the fibrosing agent is in the form of strands.
109. The composition of claim 92 wherein the fibrosing agent is in the form of tufts.
110. The composition of claim 92 wherein the fibrosing agent is in the form of microparticulates.
111. The composition of claim 92 wherein the fibrosing agent is or comprises mineral particles.
112. The composition of claim 92 wherein the fibrosing agent is or comprises talc.
113. The composition of claim 92 wherein the fibrosing agent is or comprises chitosan.
114. The composition of claim 92 wherein the fibrosing agent is or comprises polylysine.
115. The composition of claim 92 wherein the fibrosing agent is or comprises fibronectin.
116. The composition of claim 92 wherein the fibrosing agent is or comprises bleomycin.
117. The composition of claim 92 wherein the fibrosing agent is or comprises CTGF.
118. The composition of claim 92 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
119. The composition of claim 118 wherein the thread is biodegradable.
120. The composition of claim 119 wherein the biodegradable thread comprises a material selected from the group consisting of polyester, polyanhydride, poly(anhydride ester), polyester-amide), polyester-urea), polyorthoester, polyphosphoester, polyphasphazine, polycyanoacrylate, collagen, chitosan, hyaluronic acid, chromic cat gut, alginate, starch, cellulose and cellulose ester.
121. The composition of claim 118 wherein the thread is non-biodegradable.
122. The composition of claim 121 wherein the non-bioderadable thread comprises a material selected from the group consisting of polyester, polyurethane, silicone, polyethylene, polypropylene, polystyrene, polyacrylate, polymethacrylate, and silk.
123. The composition of claim 118 wherein the thread is coated with a polymer.
124. The composition of claim 118 wherein the thread is coated with a pharmaceutical agent that induces a fibrotic response in the patient.
125. The composition of claim 118 wherein the thread is coated with a pharmaceutical agent that induces an osteogenic response in the patient.
126. The composition of claim 92 wherein the fibrosing agent is in the form of a particulate.
127. The composition of claim 126 wherein the particulate is a biodegradable particulate.
128. The composition of claim 127 wherein the biodegradable particulate comprises a material selected from the group consisting of polyester, polyanhydride, poly(anhydride ester), polyester-amide), poly(ester-urea), polyorthoester, polyphosphoester, polyphosphazine, polycyanoacrylate, collagen, chitosan, hyaluronic acid, chromic cat gut, alginate, starch, cellulose and cellulose ester.
129. The composition of claim 126 wherein the particulate is non-biodegradable.
130. The composition of claim 129 wherein the non-biodegradable particulate comprises a material selected from the group consisting of polyester, polyurethane, silicone, polyethylene, polypropylene, polystyrene, polyacrylate, polymethacrylate, and silk.
131. The composition of claim 126 wherein the particulate is a particulate form of a member selected from the group consisting of silk, talc, starch, glass, silicate, silica, calcium phosphate, calcium sulfate, calcium carbonate, hydroxyapatite, synthetic mineral, polymethylmethacrylate, silver nitrate, ceramic and other inorganic particles.
132. The composition of claim 126 wherein the particulate is coated with a polymer.
133. The composition of claim 126 wherein the particulate is coated with a pharmaceutical agent that induces a fibrotic response in the patient.
134. The composition of claim 126 wherein the particulate is coated with a member selected from the group consisting of silk, talc, starch, glass, silicate, silica, calcium phosphate, calcium sulfate, calcium carbonate, hydroxyapatite, synthetic mineral, polymethylmethacrylate, silver nitrate, ceramic and other inorganic particles.
135. The composition of claim 126 wherein the particulate is coated with a pharmaceutical agent that induces an osteogenic response in the patient.
136. The composition of claim 92 wherein the composition further comprises an agent that promotes bone growth.
137. The composition of claim 136 wherein the fibrosing agent that promotes bone growth is a bone morphogenic protein.
138. The composition of claim 136 wherein the fibrosing agent that promotes bone growth is an osteogenic growth factor.
139. The composition of claim 138 wherein the osteogenic growth factor is selected from transforming growth factor, platelet-derived growth factor, and fibroblast growth factor.
140. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with treatment of a shoulder capsule injury.
141. The method of claim 140 wherein the agent promotes regeneration.
142. The method of claim 140 wherein the agent promotes angiogenesis.
143. The method of claim 140 wherein the agent promotes fibroblast migration.
144. The method of claim 140 wherein the agent promotes fibroblast proliferation.
145. The method of claim 140 wherein the agent promotes deposition of extracellular matrix (ECM).
146. The method of claim 140 wherein the agent promotes tissue remodeling.
147. The method of claim 140 wherein the agent is an arterial vessel wall irritant.
148. The method of claim 140 wherein the fibrosing agent is or comprises silk.
149. The method of claim 140 wherein the fibrosing agent is in the form of tufts.
150. The method of claim 140 wherein the fibrosing agent is or comprises mineral particles.
151. The method of claim 140 wherein the fibrosing agent is or comprises chitosan.
152. The method of claim 140 wherein the fibrosing agent is or comprises polylysine.
153. The method of claim 140 wherein the fibrosing agent is or comprises fibronectin.
154. The method of claim 140 wherein the fibrosing agent is or comprises bleomycin.
155. The method of claim 140 wherein the fibrosing agent is or comprises CTGF.
156. The method of claim 140 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
157. The method of claim 140 wherein the fibrosing agent is in the form of a particulate.
158. The method of claim 140, wherein the composition comprises a polymer.
159. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
160. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
161. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
162. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
163. The method of claim 140, wherein the composition.
comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
164. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
165. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
166. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
167. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
168. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
169. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
170. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
171. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
172. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
173. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
174. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
175. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
176. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
177. The method of claim 140, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
178. The method of claim 140, wherein the composition further comprises a second pharmaceutically active agent.
179. The method of claim 140, wherein the composition further comprises an anti-inflammatory agent.
180. The method of claim 140, wherein the composition further comprises an agent that inhibits infection.
181. The method of claim 140, wherein the composition further comprises an anthracycline.
182. The method of claim 140, wherein the composition further comprises doxorubicin.
183. The method of claim 140 wherein the composition further comprises mitoxantrone.
184. The method of claim 140 wherein the composition further comprises a fluoropyrimidine.
185. The method of claim 140, wherein the composition further comprises 5-fluorouracil (5-FU).
186. The method of claim 140, wherein the composition further comprises a folic acid antagonist.
187. The method of claim 140, wherein the composition further comprises methotrexate.
188. The method of claim 140, wherein the composition further comprises a podophylotoxin.
189. The method of claim 140, wherein the composition further comprises etoposide.
190. The method of claim 140, wherein the composition further comprises camptothecin.
191. The method of claim 140, wherein the composition further comprises a hydroxyurea.
192. The method of claim 140, wherein the composition further comprises a platinum complex.
193. The method of claim 140, wherein the composition further comprises cisplatin.
194. The method of claim 140 wherein the composition further comprises an anti-thrombotic agent.
195. The method of claim 140, wherein the composition further comprises a visualization agent.
196. The method of claim 140, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
197. The method of claim 140, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
198. The method of claim 140, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
199. The method of claim 140, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
200. The method of claim 140, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
201. The method of claim 140, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
202. The method of claim 140, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
203. The method of claim 140 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
204. The method of claim 140 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
205. The method of claim 140 wherein the composition further comprises an inflammatory cytokine.
206. The method of claim 140 wherein the composition further comprises an agent that stimulates cell proliferation.
207. The method of claim 140 wherein the composition further comprises a polymeric carrier.
208. The method of claim 140 wherein the composition is in the form of a gel, paste, or spray.
209. The method of claim 140 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
210. The method of claim 140 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
211. The method of claim 140 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
212. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
213. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
214. The method of claim 140 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
215. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
216. The method of claim 140 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
217. The method of claim 140 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
218. The method of claim 140 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
219. The method of claim 140 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
220. The method of claim 140 wherein the agent is delivered from a device, wherein the device is sterile.
221. The method of claim 140 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
222. The method of claim 140 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
223. The method of claim 140 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
224. The method of claim 140 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
225. The method of claim 140 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
226. The method of claim 140 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
227. The method of claim 140 wherein the agent is delivered from a device; wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
228. The method of claim 140 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
229. The method of claim 140 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
230. The method of claim 140 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
231. The method of claim 140 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
232. The method of claim 140 wherein the agent is delivered from a device, wherein the device comprises about 0.01 p,g to about 10 µg of the fibrosing agent.
233. The method of claim 140 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
234. The method of claim 140 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
235. The method of claim 140 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
236. The method of claim 140 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
237. The method of claim 140 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
238. The method of claim 140 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
239. The method of claim 140 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
240. The method of claim 140 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
241. The method of claim 140 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
242. The method of claim 140 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
243. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
244. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
245. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
246. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
247. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
248. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
249. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
250. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
251. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
252. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
253. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
254. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
255. The method of claim 140, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
256. The method of claim 140, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
257. The method of claim 140, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
258. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with ligament repair.
259. The method of claim 258 wherein the agent promotes regeneration.
260. The method of claim 258 wherein the agent promotes angiogenesis.
261. The method of claim 258 wherein the agent promotes fibroblast migration.
262. The method of claim 258 wherein the agent promotes fibroblast proliferation.
263. The method of claim 258 wherein the agent promotes deposition of extracellular matrix (ECM).
264. The method of claim 258 wherein the agent promotes tissue remodeling.
265. The method of claim 258 wherein the agent is an arterial vessel wall irritant.
266. The method of claim 258 wherein the fibrosing agent is or comprises silk.
267. The method of claim 258 wherein the fibrosing agent is in the form of tufts.
268. The method of claim 258 wherein the fibrosing agent is or comprises mineral particles.
269. The method of claim 258 wherein the fibrosing agent is or comprises chitosan.
270. The method of claim 258 wherein the fibrosing agent is or comprises polylysine.
271. The method of claim 258 wherein the fibrosing agent is or comprises fibronectin.
272. The method of claim 258 wherein the fibrosing agent is or comprises bleomycin.
273. The method of claim 258 wherein the fibrosing agent is or comprises CTGF.
274. The method of claim 258 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
275. The method of claim 258 wherein the fibrosing agent is in the form of a particulate.
276. The method of claim 258, wherein the composition comprises a polymer.
277. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
278. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
279. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
280. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
281. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
282. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
283. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
284. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
285. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
286. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
287. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
288. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
289. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
290. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
291. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
292. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
293. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
294. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
295. The method of claim 258, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
296. The method of claim 258, wherein the composition further comprises a second pharmaceutically active agent.
297. The method of claim 258, wherein the composition further comprises an anti-inflammatory agent.
298. The method of claim 258, wherein the composition further comprises an agent that inhibits infection.
299. The method of claim 258, wherein the composition further comprises an anthracycline.
300. The method of claim 258, wherein the composition further comprises doxorubicin.
301. The method of claim 258 wherein the composition further comprises mitoxantrone.
302. The method of claim 258 wherein the composition further comprises a fluoropyrimidine.
303. The method of claim 258, wherein the composition further comprises 5-fluorouracil (5-FU).
304. The method of claim 258, wherein the composition further comprises a folic acid antagonist.
305. The method of claim 258, wherein the composition further comprises methotrexate.
306. The method of claim 258, wherein the composition further comprises a podophylotoxin.
307. The method of claim 258, wherein the composition further comprises etoposide.
308. The method of claim 258, wherein the composition further comprises camptothecin.
309. The method of claim 258, wherein the composition further comprises a hydroxyurea.
310. The method of claim 258, wherein the composition further comprises a platinum complex.
311. The method of claim 258, wherein the composition further comprises cisplatin.
312. The method of claim 258 wherein the composition further comprises an anti-thrombotic agent.
313. The method of claim 258, wherein the composition further comprises a visualization agent.
314. The method of claim 258, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
315. The method of claim 258, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
316. The method of claim 258, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
317. The method of claim 258, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
318. The method of claim 258, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
319. The method of claim 258, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
320. The method of claim 258, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
321. The method of claim 258 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
322. The method of claim 258 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
323. The method of claim 258 wherein the composition further comprises an inflammatory cytokine.
324. The method of claim 258 wherein the composition further comprises an agent that stimulates cell proliferation.
325. The method of claim 258 wherein the composition further comprises a polymeric carrier.
326. The method of claim 258 wherein the composition is in the form of a gel, paste, or spray.
327. The method of claim 258 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
328. The method of claim 258 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
329. The method of claim 258 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
330. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
331. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
332. The method of claim 258 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
333. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
334. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
335. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
336. The method of claim 258 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
337. The method of claim 258 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
338. The method of claim 258 wherein the agent is delivered from a device, wherein the device is sterile.
339. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
340. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
341. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
342. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
343. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
344. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
345. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
346. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
347. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
348. The method of claim 258 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
349. The method of claim 258 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
350. The method of claim 258 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
351. The method of claim 258 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
352. The method of claim 258 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
353. The method of claim 258 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
354. The method of claim 258 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
355. The method of claim 258 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
356. The method of claim 258 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
357. The method of claim 258 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
358. The method of claim 258 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
359. The method of claim 258 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
360. The method of claim 258 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
361. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
362. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
363. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
364. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
365. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
366. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
367. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
368. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
369. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001 % to about 1% by weight.
370. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
371. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
372. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
373. The method of claim 258, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
374. The method of claim 258, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
375. The method of claim 258, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
376. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with tendon repair.
377. The method of claim 376 wherein the agent promotes regeneration.
378. The method of claim 376 wherein the agent promotes angiogenesis.
379. The method of claim 376 wherein the agent promotes fibroblast migration.
380. The method of claim 376 wherein the agent promotes fibroblast proliferation.
381. The method of claim 376 wherein the agent promotes deposition of extracellular matrix (ECM).
382. The method of claim 376 wherein the agent promotes tissue remodeling.
383. The method of claim 376 wherein the agent is an arterial vessel wall irritant.
384. The method of claim 376 wherein the fibrosing agent is or comprises silk.
385. The method of claim 376 wherein the fibrosing agent is in the form of tufts.
386. The method of claim 376 wherein the fibrosing agent is or comprises mineral particles.
387. The method of claim 376 wherein the fibrosing agent is or comprises chitosan.
388. The method of claim 376 wherein the fibrosing agent is or comprises polylysine.
389. The method of claim 376 wherein the fibrosing agent is or comprises fibronectin.
390. The method of claim 376 wherein the fibrosing agent is or comprises bleomycin.
391. The method of claim 376 wherein the fibrosing agent is or comprises CTGF.
392. The method of claim 376 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
393. The method of claim 376 wherein the fibrosing agent is in the form of a particulate.
394. The method of claim 376, wherein the composition comprises a polymer.
395. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
396. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
397. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
398. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
399. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
400. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
401. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
402. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
403. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
404. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
405. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
406. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
407. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
408. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
409. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
410. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
411. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
412. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
413. The method of claim 376, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
414. The method of claim 376, wherein the composition further comprises a second pharmaceutically active agent.
415. The method of claim 376, wherein the composition further comprises an anti-inflammatory agent.
416. The method of claim 376, wherein the composition further comprises an agent that inhibits infection.
417. The method of claim 376, wherein the composition further comprises an anthracycline.
418. The method of claim 376, wherein the composition further comprises doxorubicin.
419. The method of claim 376 wherein the composition further comprises mitoxantrone.
420. The method of claim 376 wherein the composition further comprises a fluoropyrimidine.
421. The method of claim 376, wherein the composition further comprises 5-fluorouracil (5-FU).
422. The method of claim 376, wherein the composition further comprises a folic acid antagonist.
423. The method of claim 376, wherein the composition further comprises methotrexate.
424. The method of claim 376, wherein the composition further comprises a podophylotoxin.
425. The method of claim 376, wherein the composition further comprises etoposide.
426. The method of claim 376, wherein the composition further comprises camptothecin.
427. The method of claim 376, wherein the composition further comprises a hydroxyurea.
428. The method of claim 376, wherein the composition further comprises a platinum complex.
429. The method of claim 376, wherein the composition further comprises cisplatin.
430. The method of claim 376 wherein the composition further comprises an anti-thrombotic agent.
431. The method of claim 376, wherein the composition further comprises a visualization agent.
432. The method of claim 376, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
433. The method of claim 376, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
434. The method of claim 376, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
435. The method of claim 376, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
436. The method of claim 376, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
437. The method of claim 376, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
438. The method of claim 376, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
439. The method of claim 376 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
440. The method of claim 376 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
441. The method of claim 376 wherein the composition further comprises an inflammatory cytokine.
442. The method of claim 376 wherein the composition further comprises an agent that stimulates cell proliferation.
443. The method of claim 376 wherein the composition further comprises a polymeric carrier,
444. The method of claim 376 wherein the composition is in the form of a gel, paste, or spray.
445. The method of claim 376 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
446. The method of claim 376 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
447. The method of claim 376 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
448. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
449. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
450. The method of claim 376 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
451. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
452. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
453. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
454. The method of claim 376 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
455. The method of claim 376 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
456. The method of claim 376 wherein the agent is delivered from a device, wherein the device is sterile.
457. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
458. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
459. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
460. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
461. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
462. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
463. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
464. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
465. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
466. The method of claim 376 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
467. The method of claim 376 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
468. The method of claim 376 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
469. The method of claim 376 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
470. The method of claim 376 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
471. The method of claim 376 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
472. The method of claim 376 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
473. The method of claim 376 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
474. The method of claim 376 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
475. The method of claim 376 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
476. The method of claim 376 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 p,g to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
477. The method of claim 376 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
478. The method of claim 376 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
479. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
480. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
481. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
482. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
483. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
484. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
485. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
486. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
487. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
488. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
489. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
490. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
491. The method of claim 376, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
492. The method of claim 376, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
493. The method of claim 376, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
494. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with hernia repair.
495. The method of claim 494 wherein the agent promotes regeneration.
496. The method of claim 494 wherein the agent promotes angiogenesis.
497. The method of claim 494 wherein the agent promotes fibroblast migration.
498. The method of claim 494 wherein the agent promotes fibroblast proliferation.
499. The method of claim 494 wherein the agent promotes deposition of extracellular matrix (ECM).
500. The method of claim 494 wherein the agent promotes tissue remodeling.
501. The method of claim 494 wherein the agent is an arterial vessel wall irritant.
502. The method of claim 494 wherein the fibrosing agent is or comprises silk.
503. The method of claim 494 wherein the fibrosing agent is in the form of tufts.
504. The method of claim 494 wherein the fibrosing agent is or comprises mineral particles.
505. The method of claim 494 wherein the fibrosing agent is or comprises chitosan.
506. The method of claim 494 wherein the fibrosing agent is or comprises polylysine.
507. The method of claim 494 wherein the fibrosing agent is or comprises fibronectin.
508. The method of claim 494 wherein the fibrosing agent is or comprises bleomycin.
509. The method of claim 494 wherein the fibrosing agent is or comprises CTGF.
510. The method of claim 494 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
511. The method of claim 494 wherein the fibrosing agent is in the form of a particulate.
512. The method of claim 494, wherein the composition comprises a polymer.
513. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
514. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
515. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
516. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
517. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
518. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
519. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
520. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
521. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
522. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
523. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
524. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
525. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
526. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
527. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
528. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
529. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
530. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
531. The method of claim 494, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
532. The method of claim 494, wherein the composition further comprises a second pharmaceutically active agent.
533. The method of claim 494, wherein the composition further comprises an anti-inflammatory agent.
534. The method of claim 494, wherein the composition further comprises an agent that inhibits infection.
535. The method of claim 494, wherein the composition further comprises an anthracycline.
536. The method of claim 494, wherein the composition further comprises doxorubicin.
537. The method of claim 494 wherein the composition further comprises mitoxantrone.
538. The method of claim 494 wherein the composition further comprises a fluoropyrimidine.
539. The method of claim 494, wherein the composition further comprises 5-fluorouracil (5-FU).
540. The method of claim 494, wherein the composition further comprises a folic acid antagonist.
541. The method of claim 494, wherein the composition further comprises methotrexate.
542. The method of claim 494, wherein the composition further comprises a podophylotoxin.
543. The method of claim 494, wherein the composition further comprises etoposide.
544. The method of claim 494, wherein the composition further comprises camptothecin.
545. The method of claim 494, wherein the composition further comprises a hydroxyurea.
546. The method of claim 494, wherein the composition further comprises a platinum complex.
547. The method of claim 494, wherein the composition further comprises cisplatin.
543. The method of claim 494 wherein the composition further comprises an anti-thrombotic agent.
549. The method of claim 494, wherein the composition further comprises a visualization agent.
550. The method of claim 494, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
551. The method of claim 494, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
552. The method of claim 494, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
553. The method of claim 494, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
554. The method of claim 494, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
555. The method of claim 494, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
556. The method of claim 494, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
557. The method of claim 494 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
558. The method of claim 494 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
559. The method of claim 494 wherein the composition further comprises an inflammatory cytokine.
560. The method of claim 494 wherein the composition further comprises an agent that stimulates cell proliferation.
561. The method of claim 494 wherein the composition further comprises a polymeric carrier.
562. The method of claim 494 wherein the composition is in the form of a gel, paste, or spray.
563. The method of claim 494 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
564. The method of claim 494 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
565. The method of claim 494 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
566. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
567. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
568. The method of claim 494 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
569. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
570. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
571. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
572. The method of claim 494 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
573. The method of claim 494 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
574. The method of claim 494 wherein the agent is delivered from a device, wherein the device is sterile.
575. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
576. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
577. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
578. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
579. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
580. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
581. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
582. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
583. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
584. The method of claim 494 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
585. The method of claim 494 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
586. The method of claim 494 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
587. The method of claim 494 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
588. The method of claim 494 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
589. The method of claim 494 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
590. The method of claim 494 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
591. The method of claim 494 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
592. The method of claim 494 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
593. The method of claim 494 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
594. The method of claim 494 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
595. The method of claim 494 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
596. The method of claim 494 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
597. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
598. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
599. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
600. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
601. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
602. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
603. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
604. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
605. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001 % to about 1% by weight.
606. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
607. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
608. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
609. The method of claim 494, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
610. The method of claim 494, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
611. The method of claim 494, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
612. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with pulmonary sealing.
613. The method of claim 612 wherein the agent promotes regeneration.
614. The method of claim 612 wherein the agent promotes angiogenesis.
615. The method of claim 612 wherein the agent promotes fibroblast migration.
616. The method of claim 612 wherein the agent promotes fibroblast proliferation.
617. The method of claim 612 wherein the agent promotes deposition of extracellular matrix (ECM).
618. The method of claim 612 wherein the agent promotes tissue remodeling.
619. The method of claim 612 wherein the agent is an arterial vessel wall irritant.
620. The method of claim 612 wherein the fibrosing agent is or comprises silk.
621. The method of claim 612 wherein the fibrosing agent is in the form of tufts.
622. The method of claim 612 wherein the fibrosing agent is or comprises mineral particles.
623. The method of claim 612 wherein the fibrosing agent is or comprises chitosan.
624. The method of claim 612 wherein the fibrosing agent is or comprises polylysine.
625. The method of claim 612 wherein the fibrosing agent is or comprises fibromectin.
626. The method of claim 612 wherein the fibrosing agent is or comprises bleomycin.
627. The method of claim 612 wherein the fibrosing agent is or comprises CTGF.
628. The method of claim 612 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
629. The method of claim 612 wherein the fibrosing agent is in the form of a particulate.
630. The method of claim 612, wherein the composition comprises a polymer.
631. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
632. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
633. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
634. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
635. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
636. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
637. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
638. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
639. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
640. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
641. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
642. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
643. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
644. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
645. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
646. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
647. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
648. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
649. The method of claim 612, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
650. The method of claim 612, wherein the composition further comprises a second pharmaceutically active agent.
651. The method of claim 612, wherein the composition further comprises an anti-inflammatory agent.
652. The method of claim 612, wherein the composition further comprises an agent that inhibits infection.
653. The method of claim 612, wherein the composition further comprises an anthracycline.
654. The method of claim 612, wherein the composition further comprises doxorubicin.
655. The method of claim 612 wherein the composition further comprises mitoxantrone.
656. The method of claim 612 wherein the composition further comprises a fluoropyrimidine.
657. The method of claim 612, wherein the composition further comprises 5-fluorouracil (5-FU).
658. The method of claim 612, wherein the composition further comprises a folic acid antagonist.
659. The method of claim 612, wherein the composition further comprises methotrexate.
660. The method of claim 612, wherein the composition further comprises a podophylotoxin.
661. The method of claim 612, wherein the composition further comprises etoposide.
662. The method of claim 612, wherein the composition further comprises camptothecin.
663. The method of claim 612, wherein the composition further comprises a hydroxyurea.
664. The method of claim 612, wherein the composition further comprises a platinum complex.
665. The method of claim 612, wherein the composition further comprises cisplatin.
666. The method of claim 612 wherein the composition further comprises an anti-thrombotic agent.
667. The method of claim 612, wherein the composition further comprises a visualization agent.
668. The method of claim 612, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
669. The method of claim 612, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
670. The method of claim 612, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
671. The method of claim 612, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
672. The method of claim 612, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
673. The method of claim 612, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
674. The method of claim 612, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
675. The method of claim 612 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
676. The method of claim 612 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
677. The method of claim 612 wherein the composition further comprises an inflammatory cytokine.
678. The method of claim 612 wherein the composition further comprises an agent that stimulates cell proliferation.
679. The method of claim 612 wherein the composition further comprises a polymeric carrier.
680. The method of claim 612 wherein the composition is in the form of a gel, paste, or spray.
681. The method of claim 612 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
682. The method of claim 612 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
683. The method of claim 612 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
684. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
685. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
686. The method of claim 612 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
687. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
688. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
689. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
690. The method of claim 612 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
691. The method of claim 612 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
692. The method of claim 612 wherein the agent is delivered from a device, wherein the device is sterile.
693. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
694. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
695. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
696. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
697. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
698. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
699. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
700. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
701. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
702. The method of claim 612 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
703. The method of claim 612 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
704. The method of claim 612 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
705. The method of claim 612 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
706. The method of claim 612 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
707. The method of claim 612 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
708. The method of claim 612 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
709. The method of claim 612 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
710. The method of claim 612 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
711. The method of claim 612 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
712. The method of claim 612 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
713. The method of claim 612 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
714. The method of claim 612 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
715. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
716. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
717. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
718. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
719. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
720. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
721. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
722. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
723. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001 % to about 1 % by weight.
724. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1 % to about 10% by weight.
725. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
726. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
727. The method of claim 612, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
728. The method of claim 612, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
729. The method of claim 612, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
730. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with treatment or prevention of an aneurysm.
731. The method of claim 730 wherein the agent promotes regeneration.
732. The method of claim 730 wherein the agent promotes angiogenesis.
733. The method of claim 730 wherein the agent promotes fibroblast migration.
734. The method of claim 730 wherein the agent promotes fibroblast proliferation.
735. The method of claim 730 wherein the agent promotes deposition of extracellular matrix (ECM).
736. The method of claim 730 wherein the agent promotes tissue remodeling.
737. The method of claim 730 wherein the agent is an arterial vessel wall irritant.
738. The method of claim 730 wherein the fibrosing agent is or comprises silk.
739. The method of claim 730 wherein the fibrosing agent is in the form of tufts.
740. The method of claim 730 wherein the fibrosing agent is or comprises mineral particles.
741. The method of claim 730 wherein the fibrosing agent is or comprises chitosan.
742. The method of claim 730 wherein the fibrosing agent is or comprises polylysine.
743. The method of claim 730 wherein the fibrosing agent is or comprises fibronectin.
744. The method of claim 730 wherein the fibrosing agent is or comprises bleomycin.
745. The method of claim 730 wherein the fibrosing agent is or comprises CTGF.
746. The method of claim 730 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
747. The method of claim 730 wherein the fibrosing agent is in the form of a particulate.
748. The method of claim 730, wherein the composition comprises a polymer.
749. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
750. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
751. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
752. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
753. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
754. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
755. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
756. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
757. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
758. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
759. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
760. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
761. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
762. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
763. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
764. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
765. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
766. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
767. The method of claim 730, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
768. The method of claim 730, wherein the composition further comprises a second pharmaceutically active agent.
769. The method of claim 730, wherein the composition further comprises an anti-inflammatory agent.
770. The method of claim 730, wherein the composition further comprises an agent that inhibits infection.
771. The method of claim 730, wherein the composition further comprises an anthracycline.
772. The method of claim 730, wherein the composition further comprises doxorubicin.
773. The method of claim 730 wherein the composition further comprises mitoxantrone.
774. The method of claim 730 wherein the composition further comprises a fluoropyrimidine.
775. The method of claim 730, wherein the composition further comprises 5-fluorouracil (5-FU).
776. The method of claim,730, wherein the composition further comprises a folic acid antagonist.
777. The method of claim 730, wherein the composition further comprises methotrexate.
778. The method of claim 730, wherein the composition further comprises a podophylotoxin.
779. The method of claim 730, wherein the composition further comprises etoposide.
780. The method of claim 730, wherein the composition further comprises camptothecin.
781. The method of claim 730, wherein the composition further comprises a hydroxyurea.
782. The method of claim 730, wherein the composition further comprises a platinum complex.
783. The method of claim 730, wherein the composition further comprises cisplatin.
784. The method of claim 730 wherein the composition further comprises an anti-thrombotic agent.
785. The method of claim 730, wherein the composition further comprises a visualization agent.
786. The method of claim 730, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
787. The method of claim 730, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
788. The method of claim 730, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
789. The method of claim 730, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
790. The method of claim 730, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
791. The method of claim 730, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
792. The method of claim 730, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
793. The method of claim 730 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
794. The method of claim 730 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
795. The method of claim 730 wherein the composition further comprises an inflammatory cytokine.
796. The method of claim 730 wherein the composition further comprises an agent that stimulates cell proliferation.
797. The method of claim 730 wherein the composition further comprises a polymeric carrier.
798. The method of claim 730 wherein the composition is in the form of a gel, paste, or spray.
799. The method of claim 730 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
800. The method of claim 730 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
801. The method of claim 730 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
802. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
803. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
804. The method of claim 730 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
805. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
806. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
807. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
808. The method of claim 730 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
809. The method of claim 730 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
810. The method of claim 730 wherein the agent is delivered from a device, wherein the device is sterile.
811. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
812. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
813. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
814. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
815. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
816. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
817. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
818. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
819. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
820. The method of claim 730 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
821. The method of claim 730 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
822. The method of claim 730 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
823. The method of claim 730 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
824. The method of claim 730 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
825. The method of claim 730 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
826. The method of claim 730 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
827. The method of claim 730 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
828. The method of claim 730 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
829. The method of claim 730 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
830. The method of claim 730 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
831. The method of claim 730 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
832. The method of claim 730 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
833. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
834. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
835. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
836. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
837. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
838. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
839. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
840. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
841. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001 % to about 1% by weight.
842. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1 % to about 10% by weight.
843. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
844. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
845. The method of claim 730, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
846. The method of claim 730, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
847. The method of claim 730, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
848. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with embolization.
849. The method of claim 848 wherein the agent promotes regeneration.
850. The method of claim 848 wherein the agent promotes angiogenesis.
851. The method of claim 848 wherein the agent promotes fibroblast migration.
852. The method of claim 848 wherein the agent promotes fibroblast proliferation.
853. The method of claim 848 wherein the agent promotes deposition of extracellular matrix (ECM).
854. The method of claim 848 wherein the agent promotes tissue remodeling.
855. The method of claim 848 wherein the agent is an arterial vessel wall irritant.
856. The method of claim 848 wherein the fibrosing agent is or comprises silk.
857. The method of claim 848 wherein the fibrosing agent is in the form of tufts.
858. The method of claim 848 wherein the fibrosing agent is or comprises mineral particles.
859. The method of claim 848 wherein the fibrosing agent is or comprises chitosan.
860. The method of claim 848 wherein the fibrosing agent is or comprises polylysine.
861. The method of claim 848 wherein the fibrosing agent is or comprises fibronectin.
862. The method of claim 848 wherein the fibrosing agent is or comprises bleomycin.
863. The method of claim 848 wherein the fibrosing agent is or comprises CTGF.
864. The method of claim 848 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
865. The method of claim 848 wherein the fibrosing agent is in the form of a particulate.
866. The method of claim 848, wherein the composition comprises a polymer.
867. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
868. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
869. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
870. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
871. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
872. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
873. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
874. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
875. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
876. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
877. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
878. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
879. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
880. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
881. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
882. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
883. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
884. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, a polyethylene glycol) polymer.
885. The method of claim 848, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
886. The method of claim 848, wherein the composition further comprises a second pharmaceutically active agent.
887. The method of claim 848, wherein the composition further comprises an anti-inflammatory agent.
888. The method of claim 848, wherein the composition further comprises an agent that inhibits infection.
889. The method of claim 848, wherein the composition further comprises an anthracycline.
890. The method of claim 848, wherein the composition further comprises doxorubicin.
891. The method of claim 848 wherein the composition further comprises mitoxantrone.
892. The method of claim 848 wherein the composition further comprises a fluoropyrimidine.
893. The method of claim 848, wherein the composition further comprises 5-fluorouracil (5-FU).
894. The method of claim 848, wherein the composition further comprises a folic acid antagonist.
895. The method of claim 848, wherein the composition further comprises methotrexate.
896. The method of claim 848, wherein the composition further comprises a podophylotoxin.
897. The method of claim 848, wherein the composition further comprises etoposide.
898. The method of claim 848, wherein the composition further comprises camptothecin.
899. The method of claim 848, wherein the composition further comprises a hydroxyurea.
900. The method of claim 848, wherein the composition further comprises a platinum complex.
901. The method of claim 848, wherein the composition further comprises cisplatin.
902. The method of claim 848 wherein the composition further comprises an anti-thrombotic agent.
903. The method of claim 848, wherein the composition further comprises a visualization agent.
904. The method of claim 848, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
905. The method of claim 848, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
906. The method of claim 848, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
907. The method of claim 848, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
908. The method of claim 848, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
909. The method of claim 848, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
910. The method of claim 848, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
911. The method of claim 848 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
912. The method of claim 848 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
913. The method of claim 848 wherein the composition further comprises an inflammatory cytokine.
914. The method of claim 848 wherein the composition further comprises an agent that stimulates cell proliferation.
915. The method of claim 848 wherein the composition further comprises a polymeric carrier.
916. The method of claim 848 wherein the composition is in the form of a gel, paste, or spray.
917. The method of claim 848 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
918. The method of claim 848 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
919. The method of claim 848 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
920. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
921. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
922. The method of claim 848 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
923. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
924. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
925. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
926. The method of claim 848 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
927. The method of claim 848 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
928. The method of claim 848 wherein the agent is delivered from a device, wherein the device is sterile.
929. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
930. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
931. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
932. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
933. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
934. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
935. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
936. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
937. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
938. The method of claim 848 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
939. The method of claim 848 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
940. The method of claim 848 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
941. The method of claim 848 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 µg of the fibrosing agent.
942. The method of claim 848 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 250 mg of the fibrosing agent.
943. The method of claim 848 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
944. The method of claim 848 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
945. The method of claim 848 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
946. The method of claim 848 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
947. The method of claim 848 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
948. The method of claim 848 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
949. The method of claim 848 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
950. The method of claim 848 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
951. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
952. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
953. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
954. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
955. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
956. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
957. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
958. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
959. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
960. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
961. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
962. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
963. The method of claim 848, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
964. The method of claim 848, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
965. The method of claim 848, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
966. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with a fibrotic response between the patient and a soft palate implant.
967. The method of claim 966 wherein the agent promotes regeneration.
968. The method of claim 966 wherein the agent promotes angiogenesis.
969. The method of claim 966 wherein the agent promotes fibroblast migration.
970. The method of claim 966 wherein the agent promotes fibroblast proliferation.
971. The method of claim 966 wherein the agent promotes deposition of extracellular matrix (ECM).
972. The method of claim 966 wherein the agent promotes tissue remodeling.
973. The method of claim 966 wherein the agent is an arterial vessel wall irritant.
974. The method of claim 966 wherein the fibrosing agent is or comprises silk.
975. The method of claim 966 wherein the fibrosing agent is in the form of tufts.
976. The method of claim 966 wherein the fibrosing agent is or comprises mineral particles.
977. The method of claim 966 wherein the fibrosing agent is or comprises chitosan.
978. The method of claim 966 wherein the fibrosing agent is or comprises polylysine.
979. The method of claim 966 wherein the fibrosing agent is or comprises fibronectin.
980. The method of claim 966 wherein the fibrosing agent is or comprises bleomycin.
981. The method of claim 966 wherein the fibrosing agent is or comprises CTGF.
982. The method of claim 966 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
983. The method of claim 966 wherein the fibrosing agent is in the form of a particulate.
984. The method of claim 966, wherein the composition comprises a polymer.
985. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
986. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
987. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
988. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
989. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
990. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
991. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
992. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
993. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
994. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
995. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
996. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
997. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
998. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
999. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
1000. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
1001. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
1002. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
1003. The method of claim 966, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
1004. The method of claim 966, wherein the composition further comprises a second pharmaceutically active agent.
1005. The method of claim 966, wherein the composition further comprises an anti-inflammatory agent.
1006. The method of claim 966, wherein the composition further comprises an agent that inhibits infection.
1007. The method of claim 966, wherein the composition further comprises an anthracycline.
1008. The method of claim 966, wherein the composition further comprises doxorubicin.
1009. The method of claim 966 wherein the composition further comprises mitoxantrone.
1010. The method of claim 966 wherein the composition further comprises a fluoropyrimidine.
1011. The method of claim 966, wherein the composition further comprises 5-fluorouracil (5-FU).
1012. The method of claim 966, wherein the composition further comprises a folic acid antagonist.
1013. The method of claim 966, wherein the composition further comprises methotrexate.
1014. The method of claim 966, wherein the composition further comprises a podophylotoxin.
1015. The method of claim 966, wherein the composition further comprises etoposide.
1016. The method of claim 966, wherein the composition further comprises camptothecin.
1017. The method of claim 966, wherein the composition further comprises a hydroxyurea.
1018. The method of claim 966, wherein the composition further comprises a platinum complex.
1019. The method of claim 966, wherein the composition further comprises cisplatin.
1020. The method of claim 966 wherein the composition further comprises an anti-thrombotic agent.
1021. The method of claim 966, wherein the composition further comprises a visualization agent.
1022. The method of claim 966, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
1023. The method of claim 966, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
1024. The method of claim 966, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
1025. The method of claim 966, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
1026. The method of claim 966, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
1027. The method of claim 966, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
1028. The method of claim 966, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
1029. The method of claim 966 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
1030. The method of claim 966 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
1031. The method of claim 966 wherein the composition further comprises an inflammatory cytokine.
1032. The method of claim 966 wherein the composition further comprises an agent that stimulates cell proliferation.
1033. The method of claim 966 wherein the composition further comprises a polymeric carrier.
1034. The method of claim 966 wherein the composition is in the form of a gel, paste, or spray.
1035. The method of claim 966 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
1036. The method of claim 966 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
1037. The method of claim 966 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
1038. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
1039. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
1040. The method of claim 966 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
1041. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
1042. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
1043. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
1044. The method of claim 966 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
1045. The method of claim 966 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
1046. The method of claim 966 wherein the agent is delivered from a device, wherein the device is sterile.
1047. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
1048. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
1049. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
1050. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
1051. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
1052. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
1053. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
1054. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
1055. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
1056. The method of claim 966 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
1057. The method of claim 966 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
1058. The method of claim 966 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
1059. The method of claim 966 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
1060. The method of claim 966 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
1061. The method of claim 966 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
1062. The method of claim 966 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
1063. The method of claim 966 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1064. The method of claim 966 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1065. The method of claim 966 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1066. The method of claim 966 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1067. The method of claim 966 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1068. The method of claim 966 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1069. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
1070. The method of claim 966, wherein the agent is delivered from a' device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
1071. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
1072. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
1073. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
1074. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
1075. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
1076. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
1077. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001 % to about 1% by weight.
1078. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
1079. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
1080. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
1081. The method of claim 966, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
1082. The method of claim 966, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
1083. The method of claim 966, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
1084. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with treatment for obesity.
1085. The method of claim 1084 wherein the agent promotes regeneration.
1086. The method of claim 1084 wherein the agent promotes angiogenesis.
1087. The method of claim 1084 wherein the agent promotes fibroblast migration.
1088. The method of claim 1084 wherein the agent promotes fibroblast proliferation.
1089. The method of claim 1084 wherein the agent promotes deposition of extracellular matrix (ECM).
1090. The method of claim 1084 wherein the agent promotes tissue remodeling.
1091. The method of claim 1084 wherein the agent is an arterial vessel wall irritant.
1092. The method of claim 1084 wherein the fibrosing agent is or comprises silk.
1093. The method of claim 1084 wherein the fibrosing agent is in the form of tufts.
1094. The method of claim 1084 wherein the fibrosing agent is or comprises mineral particles.
1095. The method of claim 1084 wherein the fibrosing agent is or comprises chitosan.
1096. The method of claim 1084 wherein the fibrosing agent is or comprises polylysine.
1097. The method of claim 1084 wherein the fibrosing agent is or comprises fibronectin.
1098. The method of claim 1084 wherein the fibrosing agent is or comprises bleomycin.
1099. The method of claim 1084 wherein the fibrosing agent is or comprises CTGF.
1100. The method of claim 1084 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
1101. The method of claim 1084 wherein the fibrosing agent is in the form of a particulate.
1102. The method of claim 1084, wherein the composition comprises a polymer.
1103. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
1104. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
1105. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
1106. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
1107. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
1108. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
1109. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
1110. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
1111. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
1112. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
1113. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
1114. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
1115. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
1116. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
1117. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
1118. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
1119. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
1120. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
1121. The method of claim 1084, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
1122. The method of claim 1084, wherein the composition further comprises a second pharmaceutically active agent.
1123. The method of claim 1084, wherein the composition further comprises an anti-inflammatory agent.
1124. The method of claim 1084, wherein the composition further comprises an agent that inhibits infection.
1125. The method of claim 1084, wherein the composition further comprises an anthracycline.
1126. The method of claim 1084, wherein the composition further comprises doxorubicin.
1127. The method of claim 1084 wherein the composition further comprises mitoxantrone.
1128. The method of claim 1084 wherein the composition further comprises a fluoropyrimidine.
1129. The method of claim 1084, wherein the composition further comprises 5-fluorouracil (5-FU).
1130. The method of claim 1084, wherein the composition further comprises a folic acid antagonist.
1131. The method of claim 1084, wherein the composition further comprises methotrexate.
1132. The method of claim 1084, wherein the composition further comprises a podophylotoxin.
1133. The method of claim 1084, wherein the composition further comprises etoposide.
1134. The method of claim 1084, wherein the composition further comprises camptothecin.
1135. The method of claim 1084, wherein the composition further comprises a hydroxyurea.
1136. The method of claim 1084, wherein the composition further comprises a platinum complex.
1137. The method of claim 1084, wherein the composition further comprises cisplatin.
1138. The method of claim 1084 wherein the composition further comprises an anti-thrombotic agent.
1139. The method of claim 1084, wherein the composition further comprises a visualization agent.
1140. The method of claim 1084, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
1141. The method of claim 1084, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
1142. The method of claim 1084, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
1143. The method of claim 1084, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
1144. The method of claim 1084, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
1145. The method of claim 1084, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
1146. The method of claim 1084, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
1147. The method of claim 1084 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
1148. The method of claim 1084 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
1149. The method of claim 1084 wherein the composition further comprises an inflammatory cytokine.
1150. The method of claim 1084 wherein the composition further comprises an agent that stimulates cell proliferation.
1151. The method of claim 1084 wherein the composition further comprises a polymeric carrier.
1152. The method of claim 1084 wherein the composition is in the form of a gel, paste, or spray.
1153. The method of claim 1084 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
1154. The method of claim 1084 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
1155. The method of claim 1084 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
1156. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
1157. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
1158. The method of claim 1084 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
1159. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
1160. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
1161. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
1162. The method of claim 1084 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
1163. The method of claim 1084 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
1164. The method of claim 1084 wherein the agent is delivered from a device, wherein the device is sterile.
1165. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
1166. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
1167. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
1168. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
1169. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
1170. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
1171. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
1172. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
1173. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
1174. The method of claim 1084 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
1175. The method of claim 1084 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
1176. The method of claim 1084 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
1177. The method of claim 1084 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
1178. The method of claim 1084 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
1179. The method of claim 1084 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
1180. The method of claim 1084 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
1181. The method of claim 1084 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1182. The method of claim 1084 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1183. The method of claim 1084 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1184. The method of claim 1084 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1185. The method of claim 1084 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1186. The method of claim 1084 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1187. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
1188. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
1189. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
1190. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
1191. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
1192. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
1193. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
1194. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
1195. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
1196. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
1197. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
1198. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
1199. The method of claim 1084, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
1200. The method of claim 1084, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
1201. The method of claim 1084, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
1202. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with treatment for GERD.
1203. The method of claim 1202 wherein the agent promotes regeneration.
1204. The method of claim 1202 wherein the agent promotes angiogenesis.
1205. The method of claim 1202 wherein the agent promotes fibroblast migration.
1206. The method of claim 1202 wherein the agent promotes fibroblast proliferation.
1207. The method of claim 1202 wherein the agent promotes deposition of extracellular matrix (ECM).
1208. The method of claim 1202 wherein the agent promotes tissue remodeling.
1209. The method of claim 1202 wherein the agent is an arterial vessel wall irritant.
1210. The method of claim 1202 wherein the fibrosing agent is or comprises silk.
1211. The method of claim 1202 wherein the fibrosing agent is in the form of tufts.
1212. The method of claim 1202 wherein the fibrosing agent is or comprises mineral particles.
1213. The method of claim 1202 wherein the fibrosing agent is or comprises chitosan.
1214. The method of claim 1202 wherein the fibrosing agent is or comprises polylysine.
1215. The method of claim 1202 wherein the fibrosing agent is or comprises fibronectin.
1216. The method of claim 1202 wherein the fibrosing agent is or comprises bleomycin.
1217. The method of claim 1202 wherein the fibrosing agent is or comprises CTGF.
1218. The method of claim 1202 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
1219. The method of claim 1202 wherein the fibrosing agent is in the form of a particulate.
1220. The method of claim 1202, wherein the composition comprises a polymer.
1221. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
1222. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
1223. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
1224. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
1225. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
1226. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
1227. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
1228. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
1229. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
1230. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
1231. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
1232. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
1233. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
1234. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
1235. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
1236. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
1237. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
1238. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
1239. The method of claim 1202, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
1240. The method of claim 1202, wherein the composition further comprises a second pharmaceutically active agent.
1241. The method of claim 1202, wherein the composition further comprises an anti-inflammatory agent.
1242. The method of claim 1202, wherein the composition further comprises an agent that inhibits infection.
1243. The method of claim 1202, wherein the composition further comprises an anthracycline.
1244. The method of claim 1202, wherein the composition further comprises doxorubicin.
1245. The method of claim 1202 wherein the composition further comprises mitoxantrone.
1246. The method of claim 1202 wherein the composition further comprises a fluoropyrimidine.
1247. The method of claim 1202, wherein the composition further comprises 5-fluorouracil (5-FU).
1248. The method of claim 1202, wherein the composition further comprises a folic acid antagonist.
1249. The method of claim 1202, wherein the composition further comprises methotrexate.
1250. The method of claim 1202, wherein the composition further comprises a podophylotoxin.
1251. The method of claim 1202, wherein the composition further comprises etoposide.
1252. The method of claim 1202, wherein the composition further comprises camptothecin.
1253. The method of claim 1202, wherein the composition further comprises a hydroxyurea.
1254. The method of claim 1202, wherein the composition further comprises a platinum complex.
1255. The method of claim 1202, wherein the composition further comprises cisplatin.
1256. The method of claim 1202 wherein the composition further comprises an anti-thrombotic agent.
1257. The method of claim 1202, wherein the composition further comprises a visualization agent.
1253. The method of claim 1202, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
1259. The method of claim 1202, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
1260. The method of claim 1202, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
1261. The method of claim 1202, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
1262. The method of claim 1202, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
1263. The method of claim 1202, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
1264. The method of claim 1202, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
1265. The method of claim 1202 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration'to about 90 days.
1266. The method of claim 1202 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
1267. The method of claim 1202 wherein the composition further comprises an inflammatory cytokine.
1268. The method of claim 1202 wherein the composition further comprises an agent that stimulates cell proliferation.
1269. The method of claim 1202 wherein the composition further comprises a polymeric carrier.
1270. The method of claim 1202 wherein the composition is in the form of a gel, paste, or spray.
1271. The method of claim 1202 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
1272. The method of claim 1202 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
1273. The method of claim 1202 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
1274. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
1275. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
1276. The method of claim 1202 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
1277. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
1278. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
1279. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
1280. The method of claim 1202 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
1281. The method of claim 1202 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
1282. The method of claim 1202 wherein the agent is delivered from a device, wherein the device is sterile.
1283. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
1284. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
1285. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
1286. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
1287. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
1288. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
1289. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
1290. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
1291. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
1292. The method of claim 1202 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
1293. The method of claim 1202 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
1294. The method of claim 1202 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
1295. The method of claim 1202 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
1296. The method of claim 1202 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
1297. The method of claim 1202 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
1298. The method of claim 1202 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
1299. The method of claim 1202 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1300. The method of claim 1202 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1301. The method of claim 1202 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1302. The method of claim 1202 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1303. The method of claim 1202 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1304. The method of claim 1202 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1305. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
1306. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
1307. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
1308. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
1309. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
1310. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
1311. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
1312. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
1313. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
1314. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
1315. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
1316. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
1317. The method of claim 1202, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
1318. The method of claim 1202, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
1319. The method of claim 1202, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
1320. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with treatment or prevention of fecal incontinence.
1321. The method of claim 1320 wherein the agent promotes regeneration.
1322. The method of claim 1320 wherein the agent promotes angiogenesis.
1323. The method of claim 1320 wherein the agent promotes fibroblast migration.
1324. The method of claim 1320 wherein the agent promotes fibroblast proliferation.
1325. The method of claim 1320 wherein the agent promotes deposition of extracellular matrix (ECM).
1326. The method of claim 7320 wherein the agent promotes tissue remodeling.
1327. The method of claim 1320 wherein the agent is an arterial vessel wall irritant.
1323. The method of claim 1320 wherein the fibrosing agent is or comprises silk.
1329. The method of claim 1320 wherein the fibrosing agent is in the form of tufts.
1330. The method of claim 1320 wherein the fibrosing agent is or comprises mineral particles.
1331. The method of claim 1320 wherein the fibrosing agent is or comprises chitosan.
1332. The method of claim 1320 wherein the fibrosing agent is or comprises polylysine.
1333. The method of claim 1320 wherein the fibrosing agent is or comprises fibronectin.
1334. The method of claim 1320 wherein the fibrosing agent is or comprises bleomycin.
1335. The method of claim 1320 wherein the fibrosing agent is or comprises CTGF.
1336. The method of claim 1320 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
1337. The method of claim 1320 wherein the fibrosing agent is in the form of a particulate.
1338. The method of claim 1320, wherein the composition comprises a polymer.
1339. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
1340. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
1341. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
1342. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
1343. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
1344. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
1345. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
1346. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
1347. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
1343. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
1349. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
1350. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
1351. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
1352. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
1353. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
1354. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
1355. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
1356. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
1357. The method of claim 1320, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
1358. The method of claim 1320, wherein the composition further comprises a second pharmaceutically active agent.
1359. The method of claim 1320, wherein the composition further comprises an anti-inflammatory agent.
1360. The method of claim 1320, wherein the composition further comprises an agent that inhibits infection.
1361. The method of claim 1320, wherein the composition further comprises an anthracycline.
1362. The method of claim 1320, wherein the composition further comprises doxorubicin.
1363. The method of claim 1320 wherein the composition further comprises mitoxantrone.
1364. The method of claim 1320 wherein the composition further comprises a fluoropyrimidine.
1365. The method of claim 1320, wherein the composition further comprises 5-fluorouracil (5-FU).
1366. The method of claim 1320, wherein the composition further comprises a folic acid antagonist.
1367. The method of claim 1320, wherein the composition further comprises methotrexate.
1368. The method of claim 1320, wherein the composition further comprises a podophylotoxin.
1369. The method of claim 1320, wherein the composition further comprises etoposide.
1370. The method of claim 1320, wherein the composition further comprises camptothecin.
1371. The method of claim 1320, wherein the composition further comprises a hydroxyurea.
1372. The method of claim 1320, wherein the composition further comprises a platinum complex.
1373. The method of claim 1320, wherein the composition further comprises cisplatin.
1374. The method of claim 1320 wherein the composition further comprises an anti-thrombotic agent.
1375. The method of claim 1320, wherein the composition further comprises a visualization agent.
1376. The method of claim 1320, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
1377. The method of claim 1320, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
1378. The method of claim 1320, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
1379. The method of claim 1320, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
1380. The method of claim 1320, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
1381. The method of claim 1320, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
1382. The method of claim 1320, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
1383. The method of claim 1320 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
1384. The method of claim 1320 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
1385. The method of claim 1320 wherein the composition further comprises an inflammatory cytokine.
1386. The method of claim 1320 wherein the composition further comprises an agent that stimulates cell proliferation.
1387. The method of claim 1320 wherein the composition further comprises a polymeric carrier.
1388. The method of claim 1320 wherein the composition is in the form of a gel, paste, or spray.
1389. The method of claim 1320 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
1390. The method of claim 1320 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
1391. The method of claim 1320 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
1392. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
1393. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
1394. The method of claim 1320 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
1395. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
1396. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
1397. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
1398. The method of °claim 1320 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
1399. The method of claim 1320 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
1400. The method of claim 1320 wherein the agent is delivered from a device, wherein the device is sterile.
1401. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
1402. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
1403. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
1404. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
1405. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
1406. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
1407. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
1408. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
1409. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
1410. The method of claim 1320 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
1411. The method of claim 1320 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
1412. The method of claim 1320 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
1413. The method of claim 1320 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
1414. The method of claim 1320 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
1415. The method of claim 1320 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
1416. The method of claim 1320 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
1417. The method of claim 1320 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1418. The method of claim 1320 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1419. The method of claim 1320 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1420. The method of claim 1320 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1421. The method of claim 1320 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1422. The method of claim 1320 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1423. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
1424. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
1425. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
1426. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
1427. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
1428. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
1429. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
1430. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
1431. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
1432. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
1433. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
1434. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
1435. The method of claim 1320, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
1436. The method of claim 1320, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
1437. The method of claim 1320, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
1438. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with treatment or prevention of varicose veins.
1439. The method of claim 1438 wherein the agent promotes regeneration.
1440. The method of claim 1438 wherein the agent promotes angiogenesis.
1441. The method of claim 1438 wherein the agent promotes fibroblast migration.
1442. The method of claim 1438 wherein the agent promotes fibroblast proliferation.
1443. The method of claim 1438 wherein the agent promotes deposition of extracellular matrix (ECM).
1444. The method of claim 1438 wherein the agent promotes tissue remodeling.
1445. The method of claim 1438 wherein the agent is an arterial vessel wall irritant.
1446. The method of claim 1438 wherein the fibrosing agent is or comprises silk.
1447. The method of claim 1438 wherein the fibrosing agent is in the form of tufts.
1448. The method of claim 1438 wherein the fibrosing agent is or comprises mineral particles.
1449. The method of claim 1438 wherein the fibrosing agent is or comprises chitosan.
1450. The method of claim 1438 wherein the fibrosing agent is or comprises polylysine.
1451. The method of claim 1438 wherein the fibrosing agent is or comprises fibronectin.
1452. The method of claim 1438 wherein the fibrosing agent is or comprises bleomycin.
1453. The method of claim 1438 wherein the fibrosing agent is or comprises CTGF.
1454. The method of claim 1438 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
1455. The method of claim 1438 wherein the fibrosing agent is in the form of a particulate.
1456. The method of claim 1438, wherein the composition comprises a polymer.
1457. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
1458. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
1459. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
1460. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
1461. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
1462. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
1463. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
1464. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
1465. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
1466. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
1467. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
1468. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
1469. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
1470. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
1471. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
1472. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
1473. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
1474. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
1475. The method of claim 1438, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
1476. The method of claim 1438, wherein the composition further comprises a second pharmaceutically active agent.
1477. The method of claim 1438, wherein the composition further comprises an anti-inflammatory agent.
1478. The method of claim 1438, wherein the composition further comprises an agent that inhibits infection.
1479. The method of claim 1438, wherein the composition further comprises an anthracycline.
1480. The method of claim 1438, wherein the composition further comprises doxorubicin.
1481. The method of claim 1438 wherein the composition further comprises mitoxantrone.
1482. The method of claim 1438 wherein the composition further comprises a fluoropyrimidine.
1483. The method of claim 1438, wherein the composition further comprises 5-fluorouracil (5-FU).
1484. The method of claim 1438, wherein the composition further comprises a folic acid antagonist.
1485. The method of claim 1438, wherein the composition further comprises methotrexate.
1486. The method of claim 1438, wherein the composition further comprises a podophylotoxin.
1487. The method of claim 1438, wherein the composition further comprises etoposide.
1488. The method of claim 1438, wherein the composition further comprises camptothecin.
1489. The method of claim 1438, wherein the composition further comprises a hydroxyurea.
1490. The method of claim 1438, wherein the composition further comprises a platinum complex.
1491. The method of claim 1438, wherein the composition further comprises cisplatin.
1492. The method of claim 1438 wherein the composition further comprises an anti-thrombotic agent.
1493. The method of claim 1438, wherein the composition further comprises a visualization agent.
1494. The method of claim 1438, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
1495. The method of claim 1438, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
1496. The method of claim 1438, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
1497. The method of claim 1438, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
1498. The method of claim 1438, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
1499. The method of claim 1438, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
1500. The method of claim 1438, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
1501. The method of claim 1438 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
1502. The method of claim 1438 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
1503. The method of claim 1438 wherein the composition further comprises an inflammatory cytokine.
1504. The method of claim 1438 wherein the composition further comprises an agent that stimulates cell proliferation.
1505. The method of claim 1438 wherein the composition further comprises a polymeric carrier.
1506. The method of claim 1438 wherein the composition is in the form of a gel, paste, or spray.
1507. The method of claim 1438 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
1508. The method of claim 1438 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
1509. The method of claim 1438 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
1510. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
1511. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
1512. The method of claim 1438 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
1513. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
1514. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
1515. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
1516. The method of claim 1438 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
1517. The method of claim 1438 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
1518. The method of claim 1438 wherein the agent is delivered from a device, wherein the device is sterile.
1519. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
1520. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
1521. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
1522. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
1523. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
1524. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
1525. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
1526. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
1527. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
1528. The method of claim 1438 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
1529. The method of claim 1438 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
1530. The method of claim 1438 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
1531. The method of claim 1438 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
1532. The method of claim 1438 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
1533. The method of claim 1438 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
1534. The method of claim 1438 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
1535. The method of claim 1438 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1536. The method of claim 1438 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1537. The method of claim 1438 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1538. The method of claim 1438 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1539. The method of claim 1438 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1540. The method of claim 1438 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1541. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
1542. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
1543. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
1544. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
1545. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
1546. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
1547. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
1548. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
1549. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
1550. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
1551. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
1552. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
1553. The method of claim 1438, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
1554. The method of claim 1438, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
1555. The method of claim 1438, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
1556. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with treatment for urinary incontinence.
1557. The method of claim 1556 wherein the agent promotes regeneration.
1558. The method of claim 1556 wherein the agent promotes angiogenesis.
1559. The method of claim 1556 wherein the agent promotes fibroblast migration.
1560. The method of claim 1556 wherein the agent promotes fibroblast proliferation.
1561. The method of claim 1556 wherein the agent promotes deposition of extracellular matrix (ECM).
1562. The method of claim 1556 wherein the agent promotes tissue remodeling.
1563. The method of claim 1556 wherein the agent is an arterial vessel wall irritant.
1564. The method of claim 1556 wherein the fibrosing agent is or comprises silk.
1565. The method of claim 1556 wherein the fibrosing agent is in the form of tufts.
1566. The method of claim 1556 wherein the fibrosing agent is or comprises mineral particles.
1567. The method of claim 1556 wherein the fibrosing agent is or comprises chitosan.
1568. The method of claim 1556 wherein the fibrosing agent is or comprises polylysine.
1569. The method of claim 1556 wherein the fibrosing agent is or comprises fibronectin.
1570. The method of claim 1556 wherein the fibrosing agent is or comprises bleomycin.
1571. The method of claim 1556 wherein the fibrosing agent is or comprises CTGF.
1572. The method of claim 1556 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
1573. The method of claim 1556 wherein the fibrosing agent is in the form of a particulate.
1574. The method of claim 1556, wherein the composition comprises a polymer.
1575. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
1576. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
1577. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
1578. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
1579. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
1580. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
1581. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
1582. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
1583. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
1584. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
1585. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
1586. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
1587. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
1588. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
1589. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
1590. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
1591. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
1592. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
1593. The method of claim 1556, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
1594. The method of claim 1556, wherein the composition further comprises a second pharmaceutically active agent.
1595. The method of claim 1556, wherein the composition further comprises an anti-inflammatory agent.
1596. The method of claim 1556, wherein the composition further comprises an agent that inhibits infection.
1597. The method of claim 1556, wherein the composition further comprises an anthracycline.
1598. The method of claim 1556, wherein the composition further comprises doxorubicin.
1599. The method of claim 1556 wherein the composition further comprises mitoxantrone.
1600. The method of claim 1556 wherein the composition further comprises a fluoropyrimidine.
1601. The method of claim 1556, wherein the composition further comprises 5-fluorouracil (5-FU).
1602. The method of claim 1556, wherein the composition further comprises a folic acid antagonist.
1603. The method of claim 1556, wherein the composition further comprises methotrexate.
1604. The method of claim 1556, wherein the composition further comprises a podophylotoxin.
1605. The method of claim 1556, wherein the composition further comprises etoposide.
1606. The method of claim 1556, wherein the composition further comprises camptothecin.
1607. The method of claim 1556, wherein the composition further comprises a hydroxyurea.
1608. The method of claim 1556, wherein the composition further comprises a platinum complex.
1609. The method of claim 1556, wherein the composition further comprises cisplatin.
1610. The method of claim 1556 wherein the composition further comprises an anti-thrombotic agent.
1611. The method of claim 1556, wherein the composition further comprises a visualization agent.
1612. The method of claim 1556, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
1613. The method of claim 1556, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
1614. The method of claim 1556, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
1615. The method of claim 1556, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
1616. The method of claim 1556, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
1617. The method of claim 1556, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
1618. The method of claim 1556, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
1619. The method of claim 1556 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
1620. The method of claim 1556 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
1621. The method of claim 1556 wherein the composition further comprises an inflammatory cytokine.
1622. The method of claim 1556 wherein the composition further comprises an agent that stimulates cell proliferation.
1623. The method of claim 1556 wherein the composition further comprises a polymeric carrier.
1624. The method of claim 1556 wherein the composition is in the form of a gel, paste, or spray.
1625. The method of claim 1556 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
1626. The method of claim 1556 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
1627. The method of claim 1556 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
1628. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
1629. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
1630. The method of claim 1556 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
1631. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
1632. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
1633. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
1634. The method of claim 1556 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
1635. The method of claim 1556 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
1636. The method of claim 1556 wherein the agent is delivered from a device, wherein the device is sterile.
1637. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
1638. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
1639. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
1640. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
1641. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
1642. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
1643. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
1644. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
1645. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
1646. The method of claim 1556 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
1647. The method of claim 1556 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
1648. The method of claim 1556 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
1649. The method of claim 1556 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
1650. The method of claim 1556 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
1651. The method of claim 1556 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
1652. The method of claim 1556 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
1653. The method of claim 1556 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1654. The method of claim 1556 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1655. The method of claim 1556 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1656. The method of claim 1556 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1657. The method of claim 1556 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1658. The method of claim 1556 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1659. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
1660. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
1661. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
1662. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises, a coating, and the coating is a patterned coating.
1663. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
1664. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a,thickness of 10 µm or less.
1665. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
1666. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
1667. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
1668. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
1669. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
1670. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
1671. The method of claim 1556, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
1672. The method of claim 1556, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
1673. The method of claim 1556, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
1674. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with contraception.
1675. The method of claim 1674 wherein the agent promotes regeneration.
1676. The method of claim 1674 wherein the agent promotes angiogenesis.
1677. The method of claim 1674 wherein the agent promotes fibroblast migration.
1678. The method of claim 1674 wherein the agent promotes fibroblast proliferation.
1679. The method of claim 1674 wherein the agent promotes deposition of extracellular matrix (ECM).
1680. The method of claim 1674 wherein the agent promotes tissue remodeling.
1681. The method of claim 1674 wherein the agent is an arterial vessel wall irritant.
1682. The method of claim 1674 wherein the fibrosing agent is or comprises silk.
1683. The method of claim 1674 wherein the fibrosing agent is in the form of tufts.
1684. The method of claim 1674 wherein the fibrosing agent is or comprises mineral particles.
1685. The method of claim 1674 wherein the fibrosing agent is or comprises chitosan.
1686. The method of claim 1674 wherein the fibrosing agent is or comprises polylysine.
1687. The method of claim 1674 wherein the fibrosing agent is or comprises fibronectin.
1688. The method of claim 1674 wherein the fibrosing agent is or comprises bleomycin.
1689. The method of claim 1674 wherein the fibrosing agent is or comprises CTGF.
1690. The method of claim 1674 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
1691. The method of claim 1674 wherein the fibrosing agent is in the form of a particulate.
1692. The method of claim 1674, wherein the composition comprises a polymer.
1693. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
1694. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
1695. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
1696. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
1697. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
1698. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
1699. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
1700. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
1701. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
1702. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
1703. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
1704. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
1705. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
1706. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
1707. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
1708. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
1709. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
1710. The method of claim 1674, wherein the composition , comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
1711. The method of claim 1674, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
1712. The method of claim 1674, wherein the composition further comprises a second pharmaceutically active agent.
1713. The method of claim 1674, wherein the composition further comprises an anti-inflammatory agent.
1714. The method of claim 1674, wherein the composition further comprises an agent that inhibits infection.
1715. The method of claim 1674, wherein the composition further comprises an anthracycline.
1716. The method of claim 1674, wherein the composition further comprises doxorubicin.
1717. The method of claim 1674 wherein the composition further comprises mitoxantrone.
1718. The method of claim 1674 wherein the composition further comprises a fluoropyrimidine.
1719. The method of claim 1674, wherein the composition further comprises 5-fluorouracil (5-FU).
1720. The method of claim 1674, wherein the composition further comprises a folic acid antagonist.
1721. The method of claim 1674, wherein the composition further comprises methotrexate.
1722. The method of claim 1674, wherein the composition further comprises a podophylotoxin.
1723. The method of claim 1674, wherein the composition further comprises etoposide.
1724. The method of claim 1674, wherein the composition further comprises camptothecin.
1725. The method of claim 1674, wherein the composition further comprises a hydroxyurea.
1726. The method of claim 1674, wherein the composition further comprises a platinum complex.
1727. The method of claim 1674, wherein the composition further comprises cisplatin.
1728. The method of claim 1674 wherein, the composition further comprises an anti-thrombotic agent.
1729. The method of claim 1674, wherein the composition further comprises a visualization agent.
1730. The method of claim 1674, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
1731. The method of claim 1674, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
1732. The method of claim 1674, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
1733. The method of claim 1674, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
1734. The method of claim 1674, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
1735. The method of claim 1674, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
1736. The method of claim 1674, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
1737. The method of claim 1674 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
1738. The method of claim 1674 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
1739. The method of claim 1674 wherein the composition further comprises an inflammatory cytokine.
1740. The method of claim 1674 wherein the composition further comprises an agent that stimulates cell proliferation.
1741. The method of claim 1674 wherein the composition further comprises a polymeric carrier.
1742. The method of claim 1674 wherein the composition is in the form of a gel, paste, or spray.
1743. The method of claim 1674 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
1744. The method of claim 1674 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
1745. The method of claim 1674 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
1746. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
1747. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
1748. The method of claim 1674 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
1749. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
1750. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
1751. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
1752. The method of claim 1674 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
1753. The method of claim 1674 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
1754. The method of claim 1674 wherein the agent is delivered from a device, wherein the device is sterile.
1755. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
1756. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
1757. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
1758. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
1759. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
1760. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
1761. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
1762. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
1763. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
1764. The method of claim 1674 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
1765. The method of claim 1674 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
1766. The method of claim 1674 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
1767. The method of claim 1674 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
1768. The method of claim 1674 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
1769. The method of claim 1674 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
1770. The method of claim 1674 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
1771. The method of claim 1674 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1772. The method of claim 1674 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1773. The method of claim 1674 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1774. The method of claim 1674 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1775. The method of claim 1674 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1776. The method of claim 1674 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1777. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
1778. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
1779. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
1780. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
1781. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
1782. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
1783. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
1784. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
1785. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
1786. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
1787. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
1788. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
1789. The method of claim 1674, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
1790. The method of claim 1674, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
1791. The method of claim 1674, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
1792. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with treatment for an orthopedic condition.
1793. The method of claim 1792 wherein the agent promotes regeneration.
1794. The method of claim 1792 wherein the agent promotes angiogenesis.
1795. The method of claim 1792 wherein the agent promotes fibroblast migration.
1796. The method of claim 1792 wherein the agent promotes fibroblast proliferation.
1797. The method of claim 1792 wherein the agent promotes deposition of extracellular matrix (ECM).
1798. The method of claim 1792 wherein the agent promotes tissue remodeling.
1799. The method of claim 1792 wherein the agent is an arterial vessel wall irritant.
1800. The method of claim 1792 wherein the fibrosing agent is or comprises silk.
1801. The method of claim 1792 wherein the fibrosing agent is in the form of tufts.
1802. The method of claim 1792 wherein the fibrosing agent is or comprises mineral particles.
1803. The method of claim 1792 wherein the fibrosing agent is or comprises chitosan.
1804. The method of claim 1792 wherein the fibrosing agent is or comprises polylysine.
1805. The method of claim 1792 wherein the fibrosing agent is or comprises fibronectin.
1806. The method of claim 1792 wherein the fibrosing agent is or comprises bleomycin.
1807. The method of claim 1792 wherein the fibrosing agent is or comprises CTGF.
1808. The method of claim 1792 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
1809. The method of claim 1792 wherein the fibrosing agent is in the form of a particulate.
1810. The method of claim 1792, wherein the composition comprises a polymer.
1811. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
1812. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
1813. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
1814. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
1815. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
1816. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
1817. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
1818. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
1819. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
1820. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
1821. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
1822. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
1823. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
1824. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
1825. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
1826. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
1827. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
1828. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
1829. The method of claim 1792, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
1830. The method of claim 1792, wherein the composition further comprises a second pharmaceutically active agent.
1831. The method of claim 1792, wherein the composition further comprises an anti-inflammatory agent.
1832. The method of claim 1792, wherein the composition further comprises an agent that inhibits infection.
1833. The method of claim 1792, wherein the composition further comprises an anthracycline.
1834. The method of claim 1792, wherein the composition further comprises doxorubicin.
1835. The method of claim 1792 wherein the composition further comprises mitoxantrone.
1836. The method of claim 1792 wherein the composition further comprises a fluoropyrimidine.
1837. The method of claim 1792, wherein the composition further comprises 5-fluorouracil (5-FU).
1838. The method of claim 1792, wherein the composition further comprises a folic acid antagonist.
1839. The method of claim 1792, wherein the composition further comprises methotrexate.
1840. The method of claim 1792, wherein the composition further comprises a podophylotoxin.
1841. The method of claim 1792, wherein the composition further comprises etoposide.
1842. The method of claim 1792, wherein the composition further comprises camptothecin.
1843. The method of claim 1792, wherein the composition further comprises a hydroxyurea.
1844. The method of claim 1792, wherein the composition further comprises a platinum complex.
1845. The method of claim 1792, wherein the composition further comprises cisplatin.
1846. The method of claim 1792 wherein the composition further comprises an anti-thrombotic agent.
1847. The method of claim 1792, wherein the composition further comprises a visualization agent.
1848. The method of claim 1792, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
1849. The method of claim 1792, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
1850. The method of claim 1792, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
1851. The method of claim 1792, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
1852. The method of claim 1792, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
1853. The method of claim 1792, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
1854. The method of claim 1792, wherein the composition further comprises a- visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
1855. The method of claim 1792 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
1856. The method of claim 1792 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
1857. The method of claim 1792 wherein the composition further comprises an inflammatory cytokine.
1858. The method of claim 1792 wherein the composition further comprises an agent that stimulates cell proliferation.
1859. The method of claim 1792 wherein the composition further comprises a polymeric carrier.
1860. The method of claim 1792 wherein the composition is in the form of a gel, paste, or spray.
1861. The method of claim 1792 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
1862. The method of claim 1792 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
1863. The method of claim 1792 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
1864. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
1865. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
1866. The method of claim 1792 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
1867. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
1868. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
1869. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
1870. The method of claim 1792 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
1871. The method of claim 1792 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
1872. The method of claim 1792 wherein the agent is delivered from a device, wherein the device is sterile.
1873. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
1874. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
1875. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
1876. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
1877. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
1878. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
1879. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
1880. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
1881. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
1882. The method of claim 1792 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
1883. The method of claim 1792 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
1884. The method of claim 1792 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
1885. The method of claim 1792 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
1886. The method of claim 1792 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
1887. The method of claim 1792 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
1888. The method of claim 1792 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
1889. The method of claim 1792 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1890. The method of claim 1792 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1891. The method of claim 1792 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1892. The method of claim 1792 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1893. The method of claim 1792 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1894. The method of claim 1792 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
1895. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
1896. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
1897. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
1898. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
1899. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
1900. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
1901. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
1902. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
1903. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
1904. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
1905. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
1906. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
1907. The method of claim 1792, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
1908. The method of claim 1792, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
1909. The method of claim 1792, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
1910. A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with treatment for a dental condition.
1911. The method of claim 1910 wherein the agent promotes regeneration.
1912. The method of claim 1910 wherein the agent promotes angiogenesis.
1913. The method of claim 1910 wherein the agent promotes fibroblast migration.
1914. The method of claim 1910 wherein the agent promotes fibroblast proliferation.
1915. The method of claim 1910 wherein the agent promotes deposition of extracellular matrix (ECM).
1916. The method of claim 1910 wherein the agent promotes tissue remodeling.
1917. The method of claim 1910 wherein the agent is an arterial vessel wall irritant.
1918. The method of claim 1910 wherein the fibrosing agent is or comprises silk.
1919. The method of claim 1910 wherein the fibrosing agent is in the form of tufts.
1920. The method of claim 1910 wherein the fibrosing agent is or comprises mineral particles.
1921. The method of claim 1910 wherein the fibrosing agent is or comprises chitosan.
1922. The method of claim 1910 wherein the fibrosing agent is or comprises polylysine.
1923. The method of claim 1910 wherein the fibrosing agent is or comprises fibronectin.
1924. The method of claim 1910 wherein the fiibrosing agent is or comprises bleomycin.
1925. The method of claim 1910 wherein the fibrosing agent is or comprises CTGF.
1926. The method of claim 1910 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
1927. The method of claim 1910 wherein the fibrosing agent is in the form of a particulate.
1928. The method of claim 1910, wherein the composition comprises a polymer.
1929. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a copolymer.
1930. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a block copolymer.
1931. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a random copolymer.
1932. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a biodegradable polymer.
1933. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-biodegradable polymer.
1934. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophilic polymer.
1935. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrophobic polymer.
1936. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophilic domains.
1937. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a polymer having hydrophobic domains.
1938. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a non-conductive polymer.
1939. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, an elastomer.
1940. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrogel.
1941. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a silicone polymer.
1942. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a hydrocarbon polymer.
1943. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a styrene-derived polymer.
1944. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a butadiene-derived polymer.
1945. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a macromer.
1946. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, a poly(ethylene glycol) polymer.
1947. The method of claim 1910, wherein the composition comprises a polymer, and the polymer is, or comprises, an amorphous polymer.
1948. The method of claim 1910, wherein the composition further comprises a second pharmaceutically active agent.
1949. The method of claim 1910, wherein the composition further comprises an anti-inflammatory agent.
1950. The method of claim 1910, wherein the composition further comprises an agent that inhibits infection.
1951. The method of claim 1910, wherein the composition further comprises an anthracycline.
1952. The method of claim 1910, wherein the composition further comprises doxorubicin.
1953. The method of claim 1910 wherein the composition further comprises mitoxantrone.
1954. The method of claim 1910 wherein the composition further comprises a fluoropyrimidine.
1955. The method of claim 1910, wherein the composition further comprises 5-fluorouracil (5-FU).
1956. The method of claim 1910, wherein the composition further comprises a folic acid antagonist.
1957. The method of claim 1910, wherein the composition further comprises methotrexate.
1958. The method of claim 1910, wherein the composition further comprises a podophylotoxin.
1959. The method of claim 1910, wherein the composition further comprises etoposide.
1960. The method of claim 1910, wherein the composition further comprises camptothecin.
1961. The method of claim 1910, wherein the composition further comprises a hydroxyurea.
1962. The method of claim 1910, wherein the composition further comprises a platinum complex.
1963. The method of claim 1910, wherein the composition further comprises cisplatin.
1964. The method of claim 1910 wherein the composition further comprises an anti-thrombotic agent.
1965. The method of claim 1910, wherein the composition further comprises a visualization agent.
1966. The method of claim 1910, wherein the composition further comprises a visualization agent, and the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
1967. The method of claim 1910, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, barium, tantalum, or technetium.
1968. The method of claim 1910, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, an MRI responsive material.
1969. The method of claim 1910, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a gadolinium chelate.
1970. The method of claim 1910, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron, magnesium, manganese, copper, or chromium.
1971. The method of claim 1910, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, iron oxide compound.
1972. The method of claim 1910, wherein the composition further comprises a visualization agent, and the visualization agent is, or comprises, a dye, pigment, or colorant.
1973. The method of claim 1910 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of administration to about 90 days.
1974. The method of claim 1910 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of administration to about 90 days.
1975. The method of claim 1910 wherein the composition further comprises an inflammatory cytokine.
1976. The method of claim 1910 wherein the composition further comprises an agent that stimulates cell proliferation.
1977. The method of claim 1910 wherein the composition further comprises a polymeric carrier.
1978. The method of claim 1910 wherein the composition is in the form of a gel, paste, or spray.
1979. The method of claim 1910 wherein the agent is delivered from a device, and the device delivers the fibrosing agent locally to tissue proximate to the device.
1980. The method of claim 1910 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises the fibrosing agent.
1981. The method of claim 1910 wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is disposed on a surface of the device.
1982. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating directly contacts the device.
1983. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating indirectly contacts the device.
1984. The method of claim 1910 wherein the agent is delivered from a device, wherein the device further comprises a coating, wherein the coating partially covers the device.
1985. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating completely covers the device.
1986. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is located within pores or holes of the device.
1987. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
1988. The method of claim 1910 wherein the agent is delivered from a device, wherein the device further comprising an echogenic material.
1989. The method of claim 1910 wherein the agent is delivered from a device, wherein the device further comprises an echogenic material, wherein the echogenic material is in the form of a coating.
1990. The method of claim 1910 wherein the agent is delivered from a device, wherein the device is sterile.
1991. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
1992. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
1993. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
1994. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
1995. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
1996. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
1997. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
1998. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
1999. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
2000. The method of claim 1910 wherein the fibrosing agent is released in efFective concentrations from the device at an increasing rate.
2001. The method of claim 1910 wherein the agent is delivered from a device, wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
2002. The method of claim 1910 wherein the agent is delivered from a device, wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
2003. The method of claim 1910 wherein the agent is delivered from a device, wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
2004. The method of claim 1910 wherein the agent is delivered from a device, wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
2005. The method of claim 1910 wherein the agent is delivered from a device, wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
2006. The method of claim 1910 wherein the agent is delivered from a device, wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
2007. The method of claim 1910 wherein the agent is delivered from a device, wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2008. The method of claim 1910 wherein the agent is delivered from a device, wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2009. The method of claim 1910 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1 µg to about µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2010. The method of claim 1910 wherein the agent is delivered from a device, wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2011. The method of claim 1910 wherein the agent is delivered from a device, wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2012. The method of claim 1910 wherein the agent is delivered from a device, wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2013. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a uniform coating.
2014. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a non-uniform coating.
2015. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a discontinuous coating.
2016. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is a patterned coating.
2017. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 100 µm or less.
2018. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating has a thickness of 10 µm or less.
2019. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating adheres to the surface of the device upon deployment of the device.
2020. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating is stable at room temperature for a period of at least 1 year.
2021. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
2022. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
2023. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
2024. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
2025. The method of claim 1910, wherein the agent is delivered from a device, wherein the device further comprises a coating, and the coating comprises a polymer.
2026. The method of claim 1910, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition.
2027. The method of claim 1910, wherein the agent is delivered from a device, wherein the device comprises a first coating having a first composition and a second coating having a second composition, wherein the first composition and the second composition are different.
2028. A medical device comprising an orthopedic implant and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
2029. The device of claim 2028 wherein the fibrosing agent promotes regeneration.
2030. The device of claim 2028 wherein the fibrosing agent promotes angiogenesis.
2031. The device of claim 2028 wherein the fibrosing agent promotes fibroblast migration.
2032. The device of claim 2028 wherein the fibrosing agent promotes fibroblast proliferation.
2033. The device of claim 2028 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
2034. The device of claim 2028 wherein the fibrosing agent promotes tissue remodeling.
2035. The device of claim 2028 wherein the fibrosing agent is an arterial vessel wall irritant.
2036. The device of claim 2028 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2037. The device of claim 2028 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2038. The device of claim 2028 wherein the fibrosing agent is or comprises silk.
2039. The device of claim 2028 wherein the fibrosing agent is or comprises mineral particles.
2040. The device of claim 2028 wherein the fibrosing agent is or comprises chitosan.
2041. The device of claim 2028 wherein the fibrosing agent is or comprises polylysine.
2042. The device of claim 2028 wherein the fibrosing agent is or comprises fibronectin.
2043. The device of claim 2028 wherein the fibrosing agent is or comprises bleomycin.
2044. The device of claim 2028 wherein the fibrosing agent is or comprises CTGF.
2045. The device of claim 2028 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
2046. The device of claim 2028 wherein the fibrosing agent is in the form of a particulate.
2047. The device of claim 2028 wherein the device further comprises an inflammatory cytokine.
2048. The device of claim 2028 wherein the device further comprises an agent that stimulates cell proliferation.
2049. The device of claim 2028 wherein the fibrosing agent is in the form of a gel, paste, or spray.
2050. The device of claim 2028 wherein the fibrosing agent is in the form of tufts.
2051. The device of claim 2028, further comprising a polymer.
2052. The device of claim 2028, further comprising a polymeric carrier.
2053. The device of claim 2028 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2054. The device of claim 2028 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2055. The device of claim 2028, further comprising a coating, wherein the coating comprises the fibrosing agent.
2056. The device of claim 2028, further comprising a coating, wherein the coating is disposed on a surface of the device.
2057. The device of claim 2028, further comprising a coating, wherein the coating directly contacts the device.
2058. The device of claim 2028, further comprising a coating, wherein the coating indirectly contacts the device.
2059. The device of claim 2028, further comprising a coating, wherein the coating partially covers the device.
2060. The device of claim 2028, further comprising a coating, wherein the coating completely covers the device.
2061. The device of claim 2028, further comprising a coating, wherein the coating is a uniform coating.
2062. The device of claim 2028, further comprising a coating, wherein the coating is a non-uniform coating.
2063. The device of claim 2028, further comprising a coating, wherein the coating is a discontinuous coating.
2064. The device of claim 2028, further comprising a coating, wherein the coating is a patterned coating.
2065. The device of claim 2028, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
2066. The device of claim 2028, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
2067. The device of claim 2028, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
2068. The device of claim 2028, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
2069. The device of claim 2028, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
2070. The device of claim 2028, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
2071. The device of claim 2028, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
2072. The device of claim 2028, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
2073. The device of claim 2028, further comprising a coating, wherein the coating further comprises a polymer.
2074. The device of claim 2028, further comprising a first coating having a first composition and the second coating having a second composition.
2075. The device of claim 2028, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
2076. The device of claim 2028, further comprising a polymer.
2077. The device of claim 2028, further comprising a polymeric carrier.
2078. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
2079. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
2080. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
2081. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
2082. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
2083. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
2084. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
2085. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
2086. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
2087. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
2088. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
2089. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
2090. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
2091. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
2092. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
2093. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
2094. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
2095. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
2096. The device of claim 2028, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
2097. The device of claim 2028, further comprising a lubricious coating.
2098. The device of claim 2028 wherein the fibrosing agent is located within pores or holes of the device.
2099. The device of claim 2028 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
2100. The device of claim 2028, further comprising a second pharmaceutically active agent.
2101. The device of claim 2028, further comprising an anti-inflammatory agent.
2102. The device of claim 2028, further comprising an agent that inhibits infection.
2103. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
2104. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
2105. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
2106. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
2107. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
2108. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
2109. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
2110. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
2111. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is etoposide.
2112. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
2113. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
2114. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
2115. The device of claim 2028, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
2116. The device of claim 2028, further comprising an anti-thrombotic agent.
2117. The device of claim 2028, further comprising a visualization agent.
2118. The device of claim 2028, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
2119. The device of claim 2028, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
2120. The device of claim 2028, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
2121. The device of claim 2028, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
2122. The device of claim 2028, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
2123. The device of claim 2028, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
2124. The device of claim 2028, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
2125. The device of claim 2028, further comprising an echogenic material.
2126. The device of claim 2028, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
2127. The device of claim 2028 wherein the device is sterile.
2128. The device of claim 2028 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
2129. The device of claim 2028 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
2130. The device of claim 2028 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
2131. The device of claim 2028 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
2132. The device of claim 2028 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
2133. The device of claim 2028 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
2134. The device of claim 2028 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
2135. The device of claim 2028 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
2136. The device of claim 2028 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
2137. The device of claim 2028 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
2138. The device of claim 2028 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
2139. The device of claim 2028 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
2140. The device of claim 2028 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
2141. The device of claim 2028 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
2142. The device of claim 2028 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
2143. The device of claim 2028 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
2144. The device of claim 2028 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
2145. The device of claim 2028 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
2146. The device of claim 2028 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2147. The device of claim 2028 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2148. The device of claim 2028 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2149. The device of claim 2028 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2150. The device of claim 2028 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2151. The device of claim 2028 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2152. The device of claim 2028 wherein the orthopedic implant is used as a substitute for a bone graft.
2153. The device of claim 2028 wherein the orthopedic implant is an orthopedic pin implant.
2154. The device of claim 2028 wherein the orthopedic implant is an orthopedic nail implant.
2155. A medical device comprising an orthopedic prosthesis and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
2156. The device of claim 2155 wherein the fibrosing agent promotes regeneration.
2157. The device of claim 2155 wherein the fibrosing agent promotes angiogenesis.
2158. The device of claim 2155 wherein the fibrosing agent promotes fibroblast migration.
2159. The device of claim 2155 wherein the fibrosing agent promotes fibroblast proliferation.
2160. The device of claim 2155 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
2161. The device of claim 2155 wherein the fibrosing agent promotes tissue remodeling.
2162. The device of claim 2155 wherein the fibrosing agent is an arterial vessel wall irritant.
2163. The device of claim 2155 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2164. The device of claim 2155 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2165. The device of claim 2155 wherein the fibrosing agent is or comprises silk.
2166. The device of claim 2155 wherein the fibrosing agent is or comprises mineral particles.
2167. The device of claim 2155 wherein the fibrosing agent is or comprises chitosan.
2168. The device of claim 2155 wherein the fibrosing agent is or comprises polylysine.
2169. The device of claim 2155 wherein the fibrosing agent is or comprises fibronectin.
2170. The device of claim 2155 wherein the fibrosing agent is or comprises bleomycin.
2171. The device of claim 2155 wherein the fibrosing agent is or comprises CTGF.
2172. The device of claim 2155 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
2173. The device of claim 2155 wherein the fibrosing agent is in the form of a particulate.
2174. The device of claim 2155 wherein the composition further comprises an inflammatory cytokine.
2175. The device of claim 2155 wherein the composition further comprises an agent that stimulates cell proliferation.
2176. The device of claim 2155 wherein the composition is in the form of a gel, paste, or spray.
2177. The device of claim 2155 wherein the fibrosing agent is in the form of tufts.
2178. The device of claim 2155, further comprising a polymer.
2179. The device of claim 2155, further comprising a polymeric carrier.
2180. The device of claim 2155 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2181. The device of claim 2155 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2182. The device of claim 2155, further comprising a coating, wherein the coating comprises the fibrosing agent.
2183. The device of claim 2155, further comprising a coating, wherein the coating is disposed on a surface of the device.
2184. The device of claim 2155, further comprising a coating, wherein the coating directly contacts the device.
2185. The device of claim 2155, further comprising a coating, wherein the coating indirectly contacts the device.
2186. The device of claim 2155, further comprising a coating, wherein the coating partially covers the device.
2187. The device of claim 2155, further comprising a coating, wherein the coating completely covers the device.
2188. The device of claim 2155, further comprising a coating, wherein the coating is a uniform coating.
2189. The device of claim 2155, further comprising a coating, wherein the coating is a non-uniform coating.
2190. The device of claim 2155, further comprising a coating, wherein the coating is a discontinuous coating.
2191. The device of claim 2155, further comprising a coating, wherein the coating is a patterned coating.
2192. The device of claim 2155, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
2193. The device of claim 2155, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
2194. The device of claim 2155, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
2195. The device of claim 2155, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
2196. The device of claim 2155, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
2197. The device of claim 2155, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
2198. The device of claim 2155, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
2199. The device of claim 2155, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
2200. The device of claim 2155, further comprising a coating, wherein the coating further comprises a polymer.
2201. The device of claim 2155, further comprising a first coating having a first composition and the second coating having a second composition.
2202. The device of claim 2155, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
2203. The device of claim 2155, further comprising a polymer.
2204. The device of claim 2155, further comprising a polymeric carrier.
2205. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
2206. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
2207. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
2208. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
2209. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
2210. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
2211. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
2212. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
2213. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
2214. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
2215. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
2216. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
2217. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
2218. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
2219. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
2220. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
2221. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
2222. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
2223. The device of claim 2155, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
2224. The device of claim 2155, further comprising a lubricious coating.
2225. The device of claim 2155 wherein the fibrosing agent is located within pores or holes of the device.
2226. The device of claim 2155 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
2227. The device of claim 2155, further comprising a second pharmaceutically active agent.
2228. The device of claim 2155, further comprising an anti-inflammatory agent.
2229. The device of claim 2155, further comprising an agent that inhibits infection.
2230. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
2231. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
2232. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
2233. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
2234. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
2235. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
2236. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
2237. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
2238. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is etoposide.
2239, The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
2240. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
2241. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
2242. The device of claim 2155, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
2243. The device of claim 2155, further comprising an anti-thrombotic agent.
2244. The device of claim 2155, further comprising a visualization agent.
2245. The device of claim 2155, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
2246. The device of claim 2155, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
2247. The device of claim 2155, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
2248. The device of claim 2155, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
2249. The device of claim 2155, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
2250. The device of claim 2155, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
2251. The device of claim 2155, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
2252. The device of claim 2155, further comprising an echogenic material.
2253. The device of claim 2155, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
2254. The device of claim 2155 wherein the device is sterile.
2255. The device of claim 2155 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
2256. The device of claim 2155 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
2257. The device of claim 2155 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
2258. The device of claim 2155 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
2259. The device of claim 2155 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
2260. The device of claim 2155 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
2261. The device of claim 2155 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
2262. The device of claim 2155 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
2263. The device of claim 2155 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
2264. The device of claim 2155 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
2265. The device of claim 2155 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
2266. The device of claim 2155 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
2267. The device of claim 2155 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
2268. The device of claim 2155 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
2269. The device of claim 2155 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
2270. The device of claim 2155 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
2271. The device of claim 2155 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
2272. The device of claim 2155 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
2273. The device of claim 2155 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2274. The device of claim 2155 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2275. The device of claim 2155 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2276. The device of claim 2155 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2277. The device of claim 2155 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2278. The device of claim 2155 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2279. A medical device comprising a modular implant and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
2280. The device of claim 2279 wherein the fibrosing agent promotes regeneration.
2281. The device of claim 2279 wherein the fibrosing agent promotes angiogenesis.
2282. The device of claim 2279 wherein the fibrosing agent promotes fibroblast migration.
2283. The device of claim 2279 wherein the fibrosing agent promotes fibroblast proliferation.
2284. The device of claim 2279 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
2285. The device of claim 2279 wherein the fibrosing agent promotes tissue remodeling.
2286. The device of claim 2279 wherein the fibrosing agent is an arterial vessel wall irritant.
2287. The device of claim 2279 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2288. The device of claim 2279 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2289. The device of claim 2279 wherein the fibrosing agent is or comprises silk.
2290. The device of claim 2279 wherein the fibrosing agent is or comprises mineral particles.
2291. The device of claim 2279 wherein the fibrosing agent is or comprises chitosan.
2292. The device of claim 2279 wherein the fibrosing agent is or comprises polylysine.
2293. The device of claim 2279 wherein the fibrosing agent is or comprises fibronectin.
2294. The device of claim 2279 wherein the fibrosing agent is or comprises bleomycin.
2295. The device of claim 2279 wherein the fibrosing agent is or comprises CTGF.
2296. The device of claim 2279 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
2297. The device of claim 2279 wherein the fibrosing agent is in the form of a particulate.
2298. The device of claim 2279 wherein the composition further comprises an inflammatory cytokine.
2299. The device of claim 2279 wherein the composition further comprises an agent that stimulates cell proliferation.
2300. The device of claim 2279 wherein the composition is in the form of a gel, paste, or spray.
2301. The device of claim 2279 wherein the fibrosing agent is in the form of tufts.
2302. The device of claim 2279, further comprising a polymer.
2303. The device of claim 2279, further comprising a polymeric carrier.
2304. The device of claim 2279 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2305. The device of claim 2279 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2306. The device of claim 2279, further comprising a coating, wherein the coating comprises the fibrosing agent.
2307. The device of claim 2279, further comprising a coating, wherein the coating is disposed on a surface of the device.
2308. The device of claim 2279, further comprising a coating, wherein the coating directly contacts the device.
2309. The device of claim 2279, further comprising a coating, wherein the coating indirectly contacts the device.
2310. The device of claim 2279, further comprising a coating, wherein the coating partially covers the device.
2311. The device of claim 2279, further comprising a coating, wherein the coating completely covers the device.
2312. The device of claim 2279, further comprising a coating, wherein the coating is a uniform coating.
2313. The device of claim 2279, further comprising a coating, wherein the coating is a non-uniform coating.
2314. The device of claim 2279, further comprising a coating, wherein the coating is a discontinuous coating.
2315. The device of claim 2279, further comprising a coating, wherein the coating is a patterned coating.
2316. The device of claim 2279, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
2317. The device of claim 2279, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
2318. The device of claim 2279, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
2319. The device of claim 2279, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
2320. The device of claim 2279, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
2321. The device of claim 2279, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
2322. The device of claim 2279, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
2323. The device of claim 2279, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
2324. The device of claim 2279, further comprising a coating, wherein the coating further comprises a polymer.
2325. The device of claim 2279, further comprising a first coating having a first composition and the second coating having a second composition.
2326. The device of claim 2279, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
2327. The device of claim 2279, further comprising a polymer.
2328. The device of claim 2279, further comprising a polymeric carrier.
2329. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
2330. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
2331. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
2332. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
2333. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
2334. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
2335. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
2336. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
2337. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
2338. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
2339. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
2340. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
2341. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
2342. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
2343. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
2344. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
2345. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
2346. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
2347. The device of claim 2279, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
2348. The device of claim 2279, further comprising a lubricious coating.
2349. The device of claim 2279 wherein the fibrosing agent is located within pores or holes of the device.
2350. The device of claim 2279 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
2351. The device of claim 2279, further comprising a second pharmaceutically active agent.
2352. The device of claim 2279, further comprising an anti-inflammatory agent.
2353. The device of claim 2279, further comprising an agent that inhibits infection.
2354. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
2355. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
2356. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
2357. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
2358. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
2359. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
2360. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
2361. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
2362. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is etoposide.
2363. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
2364. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
2365. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
2366. The device of claim 2279, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
2367. The device of claim 2279, further comprising an anti-thrombotic agent.
2368. The device of claim 2279, further comprising a visualization agent.
2369. The device of claim 2279, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
2370. The device of claim 2279, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
2371. The device of claim 2279, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
2372. The device of claim 2279, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
2373. The device of claim 2279, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
2374. The device of claim 2279, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
2375. The device of claim 2279, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
2376. The device of claim 2279, further comprising an echogenic material.
2377. The device of claim 2279, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
2378. The device of claim 2279 wherein the device is sterile.
2379. The device of claim 2279 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
2380. The device of claim 2279 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
2381. The device of claim 2279 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
2382. The device of claim 2279 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
2383. The device of claim 2279 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
2384. The device of claim 2279 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
2385. The device of claim 2279 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
2386. The device of claim 2279 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
2387. The device of claim 2279 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
2388. The device of claim 2279 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
2389. The device of claim 2279 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
2390. The device of claim 2279 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
2391. The device of claim 2279 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
2392. The device of claim 2279 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
2393. The device of claim 2279 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
2394. The device of claim 2279 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
2395. The device of claim 2279 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
2396. The device of claim 2279 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
2397. The device of claim 2279 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2398. The device of claim 2279 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2399. The device of claim 2279 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2400. The device of claim 2279 wherein a surface of the device comprises about 10 µg to about 250 µ.g of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2401. The device of claim 2279 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2402. The device of claim 2279 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2403. A medical device comprising a urinary sling and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
2404. The device of claim 2403 wherein the fibrosing agent promotes regeneration.
2405. The device of claim 2403 wherein the fibrosing agent promotes angiogenesis.
2406. The device of claim 2403 wherein the fibrosing agent promotes fibroblast migration.
2407. The device of claim 2403 wherein the fibrosing agent promotes fibroblast proliferation.
2408. The device of claim 2403 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
2409. The device of claim 2403 wherein the fibrosing agent promotes tissue remodeling.
2410. The device of claim 2403 wherein the fibrosing agent is an arterial vessel wall irritant.
2411. The device of claim 2403 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2412. The device of claim 2403 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2413. The device of claim 2403 wherein the fibrosing agent is or comprises silk.
2414. The device of claim 2403 wherein the fibrosing agent is or comprises mineral particles.
2415. The device of claim 2403 wherein the fibrosing agent is or comprises chitosan.
2416. The device of claim 2403 wherein the fibrosing agent is or comprises polylysine.
2417. The device of claim 2403 wherein the fibrosing agent is or comprises fibronectin.
2418. The device of claim 2403 wherein the fibrosing agent is or comprises bleomycin.
2419. The device of claim 2403 wherein the fibrosing agent is or comprises CTGF.
2420. The device of claim 2403 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
2421. The device of claim 2403 wherein the fibrosing agent is in the form of a particulate.
2422. The device of claim 2403 wherein the composition further comprises an inflammatory cytokine.
2423. The device of claim 2403 wherein the composition further comprises an agent that stimulates cell proliferation.
2424. The device of claim 2403 wherein the composition is in the form of a gel, paste, or spray.
2425. The device of claim 2403 wherein the fibrosing agent is in the form of tufts.
2426. The device of claim 2403, further comprising a polymer.
2427. The device of claim 2403, further comprising a polymeric carrier.
2428. The device of claim 2403 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2429. The device of claim 2403 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2430. The device of claim 2403, further comprising a coating, wherein the coating comprises the fibrosing agent.
2431. The device of claim 2403, further comprising a coating, wherein the coating is disposed on a surface of the device.
2432. The device of claim 2403, further comprising a coating, wherein the coating directly contacts the device.
2433. The device of claim 2403, further comprising a coating, wherein the coating indirectly contacts the device.
2434. The device of claim 2403, further comprising a coating, wherein the coating partially covers the device.
2435. The device of claim 2403, further comprising a coating, wherein the coating completely covers the device.
2436. The device of claim 2403, further comprising a coating, wherein the coating is a uniform coating.
2437. The device of claim 2403, further comprising a coating, wherein the coating is a non-uniform coating.
2438. The device of claim 2403, further comprising a coating, wherein the coating is a discontinuous coating.
2439. The device of claim 2403, further comprising a coating, wherein the coating is a patterned coating.
2440. The device of claim 2403, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
2441. The device of claim 2403, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
2442. The device of claim 2403, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
2443. The device of claim 2403, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
2444. The device of claim 2403, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
2445. The device of claim 2403, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
2446. The device of claim 2403, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
2447. The device of claim 2403, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
2448. The device of claim 2403, further comprising a coating, wherein the coating further comprises a polymer.
2449. The device of claim 2403, further comprising a first coating having a first composition and the second coating having a second composition.
2450. The device of claim 2403, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
2451. The device of claim 2403, further comprising a polymer.
2452. The device of claim 2403, further comprising a polymeric carrier.
2453. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
2454. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
2455. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
2456. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
2457. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
2458. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
2459. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
2460. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
2461. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
2462. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
2463. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
2464. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
2465. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
2466. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
2467. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
2468. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
2469. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
2470. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
2471. The device of claim 2403, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
2472. The device of claim 2403, further comprising a lubricious coating.
2473. The device of claim 2403 wherein the fibrosing agent is located within pores or holes of the device.
2474. The device of claim 2403 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
2475. The device of claim 2403, further comprising a second pharmaceutically active agent.
2476. The device of claim 2403, further comprising an anti-inflammatory agent.
2477. The device of claim 2403, further comprising an agent that inhibits infection.
2478. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
2479. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
2480. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
2481. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
2482. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
2483. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
2484. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
2485. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
2486. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is etoposide.
2487. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
2488. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
1369 2439. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
2490. The device of claim 2403, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
2491. The device of claim 2403, further comprising an anti-thrombotic agent.
2492. The device of claim 2403, further comprising a visualization agent.
2493. The device of claim 2403, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
2494. The device of claim 2403, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
2495. The device of claim 2403, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
2496. The device of claim 2403, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
2497. The device of claim 2403, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
2498. The device of claim 2403, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
2499. The device of claim 2403, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
2500. The device of claim 2403, further comprising an echogenic material.
2501. The device of claim 2403, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
2502. The device of claim 2403 wherein the device is sterile.
2503. The device of claim 2403 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
2504. The device of claim 2403 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
2505. The device of claim 2403 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
2506. The device of claim 2403 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
2507. The device of claim 2403 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
2508. The device of claim 2403 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
2509. The device of claim 2403 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
2510. The device of claim 2403 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
2511. The device of claim 2403 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
2512. The device of claim 2403 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
2513. The device of claim 2403 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
2514. The device of claim 2403 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
2515. The device of claim 2403 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
2516. The device of claim 2403 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
2517. The device of claim 2403 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
2518. The device of claim 2403 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
2519. The device of claim 2403 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
2520. The device of claim 2403 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
2521. The device of claim 2403 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2522. The device of claim 2403 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2523. The device of claim 2403 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2524. The device of claim 2403 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2525. The device of claim 2403 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2526. The device of claim 2403 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2527. A medical device comprising a prosthetic joint and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
2528. The device of claim 2527 wherein the fibrosing agent promotes regeneration.
2529. The device of claim 2527 wherein the fibrosing agent promotes angiogenesis.
2530. The device of claim 2527 wherein the fibrosing agent promotes fibroblast migration.
2531. The device of claim 2527 wherein the fibrosing agent promotes fibroblast proliferation.
2532. The device of claim 2527 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
2533. The device of claim 2527 wherein the fibrosing agent promotes tissue remodeling.
2534. The device of claim 2527 wherein the fibrosing agent is an arterial vessel wall irritant.
2535. The device of claim 2527 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2536. The device of claim 2527 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2537. The device of claim 2527 wherein the fibrosing agent is or comprises silk.
2533. The device of claim 2527 wherein the fibrosing agent is or comprises mineral particles.
2539. The device of claim 2527 wherein the fibrosing agent is or comprises chitosan.
2540. The device of claim 2527 wherein the fibrosing agent is or comprises polylysine.
2541. The device of claim 2527 wherein the fibrosing agent is or comprises fibronectin.
2542. The device of claim 2527 wherein the fibrosing agent is or comprises bleomycin.
2543. The device of claim 2527 wherein the fibrosing agent is or comprises CTGF.
2544. The device of claim 2527 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
2545. The device of claim 2527 wherein the fibrosing agent is in the form of a particulate.
2546. The device of claim 2527 wherein the composition further comprises an inflammatory cytokine.
2547. The device of claim 2527 wherein the composition further comprises an agent that stimulates cell proliferation.
2548. The device of claim 2527 wherein the composition is in the form of a gel, paste, or spray.
2549. The device of claim 2527 wherein the fibrosing agent is in the form of tufts.
2550. The device of claim 2527, further comprising a polymer.
2551. The device of claim 2527, further comprising a polymeric carrier.
2552. The device of claim 2527 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2553. The device of claim 2527 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2554. The device of claim 2527, further comprising a coating, wherein the coating comprises the fibrosing agent.
2555. The device of claim 2527, further comprising a coating, wherein the coating is disposed on a surface of the device.
2556. The device of claim 2527, further comprising a coating, wherein the coating directly contacts the device.
2557. The device of claim 2527, further comprising a coating, wherein the coating indirectly contacts the device.
2558. The device of claim 2527, further comprising a coating, wherein the coating partially covers the device.
2559. The device of claim 2527, further comprising a coating, wherein the coating completely covers the device.
2560. The device of claim 2527, further comprising a coating, wherein the coating is a uniform coating.
2561. The device of claim 2527, further comprising a coating, wherein the coating is a non-uniform coating.
2562. The device of claim 2527, further comprising a coating, wherein the coating is a discontinuous coating.
2563. The device of claim 2527, further comprising a coating, wherein the coating is a patterned coating.
2564. The device of claim 2527, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
2565. The device of claim 2527, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
2566. The device of claim 2527, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
2567. The device of claim 2527, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
256. The device of claim 2527, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
2569. The device of claim 2527, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
2570. The device of claim 2527, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
2571. The device of claim 2527, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
2572. The device of claim 2527, further comprising a coating, wherein the coating further comprises a polymer.
2573. The device of claim 2527, further comprising a first coating having a first composition and the second coating having a second composition.
2574. The device of claim 2527, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
2575. The device of claim 2527, further comprising a polymer.
2576. The device of claim 2527, further comprising a polymeric carrier.
2577. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
2578. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
2579. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
2580. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
2581. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
2582. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
2583. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
2584. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
2585. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
2586. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
2587. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
2588. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
2589. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
2590. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
2591. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
2592. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
2593. The device of claim 2527, further comprising a. polymeric carrier, wherein the polymeric carrier comprises a macromer.
2594. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
2595. The device of claim 2527, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
2596. The device of claim 2527, further comprising a lubricious coating.
2597. The device of claim 2527 wherein the fibrosing agent is located within pores or holes of the device.
2598. The device of claim 2527 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
2599. The device of claim 2527, further comprising a second pharmaceutically active agent.
2600. The device of claim 2527, further comprising an anti-inflammatory agent.
2601. The device of claim 2527, further comprising an agent that inhibits infection.
2602. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
2603. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
2604. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
2605. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
2606. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
2607. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
2608. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
2609. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
2610. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is etoposide.
2611. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
2612. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
2613. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
2614. The device of claim 2527, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
2615. The device of claim 2527, further comprising an anti-thrombotic agent.
2616. The device of claim 2527, further comprising a visualization agent.
2617. The device of claim 2527, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
2618. The device of claim 2527, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
2619. The device of claim 2527, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
2620. The device of claim 2527, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
2621. The device of claim 2527, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
2622. The device of claim 2527, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
2623. The device of claim 2527, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
2624. The device of claim 2527, further comprising an echogenic material.
2625. The device of claim 2527, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
2626. The device of claim 2527 wherein the device is sterile.
2627. The device of claim 2527 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
2628. The device of claim 2527 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
2629. The device of claim 2527 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
2630. The device of claim 2527 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
2631. The device of claim 2527 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
2632. The device of claim 2527 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
2633. The device of claim 2527 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
2634. The device of claim 2527 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
2635. The device of claim 2527 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
2636. The device of claim 2527 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
2637. The device of claim 2527 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
2638. The device of claim 2527 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
2639. The device of claim 2527 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
2640. The device of claim 2527 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
2641. The device of claim 2527 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
2642. The device of claim 2527 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
2643. The device of claim 2527 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
2644. The device of claim 2527 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
2645. The device of claim 2527 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2646. The device of claim 2527 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2647. The device of claim 2527 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2648. The device of claim 2527 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2649. The device of claim 2527 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2650. The device of claim 2527 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2651. A medical device comprising a modular prosthesis and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
2652. The device of claim 2651 wherein the fibrosing agent promotes regeneration.
2653. The device of claim 2651 wherein the fibrosing agent promotes angiogenesis.
2654. The device of claim 2651 wherein the fibrosing agent promotes fibroblast migration.
2655. The device of claim 2651 wherein the fibrosing agent promotes fibroblast proliferation.
2656. The device of claim 2651 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
2657. The device of claim 2651 wherein the fibrosing agent promotes tissue remodeling.
2658. The device of claim 2651 wherein the fibrosing agent is an arterial vessel wall irritant.
2659. The device of claim 2651 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2660. The device of claim 2651 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2661. The device of claim 2651 wherein the fibrosing agent is or comprises silk.
2662. The device of claim 2651 wherein the fibrosing agent is or comprises mineral particles.
2663. The device of claim 2651 wherein the fibrosing agent is or comprises chitosan.
2664. The device of claim 2651 wherein the fibrosing agent is or comprises polylysine.
2665. The device of claim 2651 wherein the fibrosing agent is or comprises fibronectin.
2666. The device of claim 2651 wherein the fibrosing agent is or comprises bleomycin.
2667. The device of claim 2651 wherein the fibrosing agent is or comprises CTGF.
2668. The device of claim 2651 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
2669. The device of claim 2651 wherein the fibrosing agent is in the form of a particulate.
2670. The device of claim 2651 wherein the composition further comprises an inflammatory cytokine.
2671. The device of claim 2651 wherein the composition further comprises an agent that stimulates cell proliferation.
2672. The device of claim 2651 wherein the composition is in the form of a gel, paste, or spray.
2673. The device of claim 2651 wherein the fibrosing agent is in the form of tufts.
2674. The device of claim 2651, further comprising a polymer.
2675. The device of claim 2651, further comprising a polymeric carrier.
2676. The device of claim 2651 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2677. The device of claim 2651 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2678. The device of claim 2651, further comprising a coating, wherein the coating comprises the fibrosing agent.
2679. The device of claim 2651, further comprising a coating, wherein the coating is disposed on a surface of the device.
2680. The device of claim 2651, further comprising a coating, wherein the coating directly contacts the device.
2681. The device of claim 2651, further comprising a coating, wherein the coating indirectly contacts the device.
2682. The device of claim 2651, further comprising a coating, wherein the coating partially covers the device.
2683. The device of claim 2651, further comprising a coating, wherein the coating completely covers the device.
2684. The device of claim 2651, further comprising a coating, wherein the coating is a uniform coating.
2685. The device of claim 2651, further comprising a coating, wherein the coating is a non-uniform coating.
2686. The device of claim 2651, further comprising a coating, wherein the coating is a discontinuous coating.
2687. The device of claim 2651, further comprising a coating, wherein the coating is a patterned coating.
2688. The device of claim 2651, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
2689. The device of claim 2651, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
2690. The device of claim 2651, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
2691. The device of claim 2651, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
2692. The device of claim 2651, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
2693. The device of claim 2651, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
2694. The device of claim 2651, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
2695. The device of claim 2651, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
2696. The device of claim 2651, further comprising a coating, wherein the coating further comprises a polymer.
2697. The device of claim 2651, further comprising a first coating having a first composition and the second coating having a second composition.
2698. The device of claim 2651, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
2699. The device of claim 2651, further comprising a polymer.
2700. The device of claim 2651, further comprising a polymeric carrier.
2701. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
2702. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
2703. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
2704. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
2705. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
2706. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
2707. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
2708. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
2709. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
2710. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
2711. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
2712. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
2713. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
2714. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
2715. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
2716. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
2717. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
2718. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
2719. The device of claim 2651, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
2720. The device of claim 2651, further comprising a lubricious coating.
2721. The device of claim 2651 wherein the fibrosing agent is located within pores or holes of the device.
2722. The device of claim 2651 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
2723. The device of claim 2651, further comprising a second pharmaceutically active agent.
2724. The device of claim 2651, further comprising an anti-inflammatory agent.
2725. The device of claim 2651, further comprising an agent that inhibits infection.
2726. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
2727. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
2728. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
2729. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
2730. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
2731. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
2732. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
2733. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
2734. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is etoposide.
2735. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
2736. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
2737. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
2738. The device of claim 2651, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
2739. The device of claim 2651, further comprising an anti-thrombotic agent.
2740. The device of claim 2651, further comprising a visualization agent.
2741. The device of claim 2651, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
2742. The device of claim 2651, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
2743. The device of claim 2651, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
2744. The device of claim 2651, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
2745. The device of claim 2651, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
2746. The device of claim 2651, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
2747. The device of claim 2651, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
2748. The device of claim 2651, further comprising an echogenic material.
2749. The device of claim 2651, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
2750. The device of claim 2651 wherein the device is sterile.
2751. The device of claim 2651 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
2752. The device of claim 2651 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
2753. The device of claim 2651 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
2754. The device of claim 2651 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
2755. The device of claim 2651 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
2756. The device of claim 2651 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
2757. The device of claim 2651 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
2758. The device of claim 2651 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
2759. The device of claim 2651 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
2760. The device of claim 2651 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
2761. The device of claim 2651 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
2762. The device of claim 2651 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
2763. The device of claim 2651 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
2764. The device of claim 2651 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
2765. The device of claim 2651 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
2766. The device of claim 2651 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
2767. The device of claim 2651 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
2768. The device of claim 2651 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
2769. The device of claim 2651 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2770. The device of claim 2651 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2771. The device of claim 2651 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2772. The device of claim 2651 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2773. The device of claim 2651 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2774. The device of claim 2651 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2775. A medical device comprising a joint prosthesis and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
2776. The device of claim 2775 wherein the fibrosing agent promotes regeneration.
2777. The device of claim 2775 wherein the fibrosing agent promotes angiogenesis.
2778. The device of claim 2775 wherein the fibrosing agent promotes fibroblast migration.
2779. The device of claim 2775 wherein the fibrosing agent promotes fibroblast proliferation.
2780. The device of claim 2775 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
2781. The device of claim 2775 wherein the fibrosing agent promotes tissue remodeling.
2782. The device of claim 2775 wherein the fibrosing agent is an arterial vessel wall irritant.
2783. The device of claim 2775 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2784. The device of claim 2775 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2785. The device of claim 2775 wherein the fibrosing agent is or comprises silk.
2786. The device of claim 2775 wherein the fibrosing agent is or comprises mineral particles.
2787. The device of claim 2775 wherein the fibrosing agent is or comprises chitosan.
2788. The device of claim 2775 wherein the fibrosing agent is or comprises polylysine.
2789. The device of claim 2775 wherein the fibrosing agent is or comprises fibronectin.
2790. The device of claim 2775 wherein the fibrosing agent is or comprises bleomycin.
2791. The device of claim 2775 wherein the fibrosing agent is or comprises CTGF.
2792. The device of claim 2775 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
2793. The device of claim 2775 wherein the fibrosing agent is in the form of a particulate.
2794. The device of claim 2775 wherein the composition further comprises an inflammatory cytokine.
2795. The device of claim 2775 wherein the composition further comprises an agent that stimulates cell proliferation.
2796. The device of claim 2775 wherein the composition is in the form of a gel, paste, or spray.
2797. The device of claim 2775 wherein the fibrosing agent is in the form of tufts.
2798. The device of claim 2775, further comprising a polymer.
2799. The device of claim 2775, further comprising a polymeric carrier.
2800. The device of claim 2775 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2801. The device of claim 2775 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2802. The device of claim 2775, further comprising a coating, wherein the coating comprises the fibrosing agent.
2803. The device of claim 2775, further comprising a coating, wherein the coating is disposed on a surface of the device.
2804. The device of claim 2775, further comprising a coating, wherein the coating directly contacts the device.
2805. The device of claim 2775, further comprising a coating, wherein the coating indirectly contacts the device.
2806. The device of claim 2775, further comprising a coating, wherein the coating partially covers the device.
2807. The device of claim 2775, further comprising a coating, wherein the coating completely covers the device.
2808. The device of claim 2775, further comprising a coating, wherein the coating is a uniform coating.
2809. The device of claim 2775, further comprising a coating, wherein the coating is a non-uniform coating.
2810. The device of claim 2775, further comprising a coating, wherein the coating is a discontinuous coating.
2811. The device of claim 2775, further comprising a coating, wherein the coating is a patterned coating.
2812. The device of claim 2775, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
2813. The device of claim 2775, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
2814. The device of claim 2775, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
2815. The device of claim 2775, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
2816. The device of claim 2775, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
2817. The device of claim 2775, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
2818. The device of claim 2775, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
2819. The device of claim 2775, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
2820. The device of claim 2775, further comprising a coating, wherein the coating further comprises a polymer.
2821. The device of claim 2775, further comprising a first coating having a first composition and the second coating having a second composition.
2822. The device of claim 2775, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
2823. The device of claim 2775, further comprising a polymer.
2824. The device of claim 2775, further comprising a polymeric carrier.
2825. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
2826. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
2827. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
2828. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
2829. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
2830. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
2831. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
2832. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
2833. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
2834. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
2835. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
2836. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
2837. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
2838. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
2839. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
2840. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
2841. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
2842. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
2843. The device of claim 2775, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
2844. The device of claim 2775, further comprising a lubricious coating.
2845. The device of claim 2775 wherein the fibrosing agent is located within pores or holes of the device.
2846. The device of claim 2775 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
2847. The device of claim 2775, further comprising a second pharmaceutically active agent.
2848. The device of claim 2775, further comprising an anti-inflammatory agent.
2849. The device of claim 2775, further comprising an agent that inhibits infection.
2850. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
2851. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
2852. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
2853. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
2854. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
2855. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
2856. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
2857. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
2858. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is etoposide.
2859. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
2860. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
2861. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
2862. The device of claim 2775, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
2863. The device of claim 2775, further comprising an anti-thrombotic agent.
2864. The device of claim 2775, further comprising a visualization agent.
2865. The device of claim 2775, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
2866. The device of claim 2775, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
2867. The device of claim 2775, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
2868. The device of claim 2775, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
2869. The device of claim 2775, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
2870. The device of claim 2775, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
2871. The device of claim 2775, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
2872. The device of claim 2775, further comprising an echogenic material.
2873. The device of claim 2775, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
2874. The device of claim 2775 wherein the device is sterile.
2875. The device of claim 2775 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
2876. The device of claim 2775 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
2877. The device of claim 2775 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
2878. The device of claim 2775 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
2879. The device of claim 2775 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
2880. The device of claim 2775 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
2881. The device of claim 2775 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
2882. The device of claim 2775 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
2883. The device of claim 2775 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
2884. The device of claim 2775 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
2885. The device of claim 2775 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
2886. The device of claim 2775 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
2887. The device of claim 2775 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
2888. The device of claim 2775 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
2889. The device of claim 2775 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
2890. The device of claim 2775 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
2891. The device of claim 2775 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
2892. The device of claim 2775 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
2893. The device of claim 2775 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2894. The device of claim 2775 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2895. The device of claim 2775 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2896. The device of claim 2775 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2897. The device of claim 2775 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2898. The device of claim 2775 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
2899. A medical device comprising a partial prosthesis and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
2900. The device of claim 2899 wherein the fibrosing agent promotes regeneration.
2901. The device of claim 2899 wherein the fibrosing agent promotes angiogenesis.
2902. The device of claim 2899 wherein the fibrosing agent promotes fibroblast migration.
2903. The device of claim 2899 wherein the fibrosing agent promotes fibroblast proliferation.
2904. The device of claim 2899 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
2905. The device of claim 2899 wherein the fibrosing agent promotes tissue remodeling.
2906. The device of claim 2899 wherein the fibrosing agent is an arterial vessel wall irritant.
2907. The device of claim 2899 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2908. The device of claim 2899 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2909. The device of claim 2899 wherein the fibrosing agent is or comprises silk.
2910. The device of claim 2899 wherein the fibrosing agent is or comprises mineral particles.
2911. The device of claim 2899 wherein the fibrosing agent is or comprises chitosan.
2912. The device of claim 2899 wherein the fibrosing agent is or comprises polylysine.
2913. The device of claim 2899 wherein the fibrosing agent is or comprises fibronectin.
2914. The device of claim 2899 wherein the fibrosing agent is or comprises bleomycin.
2915. The device of claim 2899 wherein the fibrosing agent is or comprises CTGF.
2916. The device of claim 2899 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
2917. The device of claim 2899 wherein the fibrosing agent is in the form of a particulate.
2918. The device of claim 2899 wherein the composition further comprises an inflammatory cytokine.
2919. The device of claim 2899 wherein the composition further comprises an agent that stimulates cell proliferation.
2920. The device of claim 2899 wherein the composition is in the form of a gel, paste, or spray.
2921. The device of claim 2899 wherein the fibrosing agent is in the form of tufts.
2922. The device of claim 2899, further comprising a polymer.
2923. The device of claim 2899, further comprising a polymeric carrier.
2924. The device of claim 2899 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
2925. The device of claim 2899 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
2926. The device of claim 2899, further comprising a coating, wherein the coating comprises the fibrosing agent.
2927. The device of claim 2899, further comprising a coating, wherein the coating is disposed on a surface of the device.
2928. The device of claim 2899, further comprising a coating, wherein the coating directly contacts the device.
2929. The device of claim 2899, further comprising a coating, wherein the coating indirectly contacts the device.
2930. The device of claim 2899, further comprising a coating, wherein the coating partially covers the device.
2931. The device of claim 2899, further comprising a coating, wherein the coating completely covers the device.
2932. The device of claim 2899, further comprising a coating, wherein the coating is a uniform coating.
2933. The device of claim 2899, further comprising a coating, wherein the coating is a non-uniform coating.
2934. The device of claim 2899, further comprising a coating, wherein the coating is a discontinuous coating.
2935. The device of claim 2899, further comprising a coating, wherein the coating is a patterned coating.
2936. The device of claim 2899, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
2937. The device of claim 2899, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
2938. The device of claim 2899, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
2939. The device of claim 2899, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
2940. The device of claim 2899, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001 % to about 1 % by weight.
2941. The device of claim 2899, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1 % to about 10% by weight.
2942. The device of claim 2899, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
2943. The device of claim 2899, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
2944. The device of claim 2899, further comprising a coating, wherein the coating further comprises a polymer.
2945. The device of claim 2899, further comprising a first coating having a first composition and the second coating having a second composition.
2946. The device of claim 2899, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
2947. The device of claim 2899, further comprising a polymer.
2948. The device of claim 2899, further comprising a polymeric carrier.
2949. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
2950. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
2951. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
2952. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
2953. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
2954. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
2955. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
2956. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
2957. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
2958. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
2959. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
2960. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
2961. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
2962. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
2963. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
2964. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
2965. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
2966. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
2967. The device of claim 2899, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
2968. The device of claim 2899, further comprising a lubricious coating.
2969. The device of claim 2899 wherein the fibrosing agent is located within pores or holes of the device.
2970. The device of claim 2899 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
2971. The device of claim 2899, further comprising a second pharmaceutically active agent.
2972. The device of claim 2899, further comprising an anti-inflammatory agent.
2973. The device of claim 2899, further comprising an agent that inhibits infection.
2974. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
2975. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
2976. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
2977. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
2978. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
2979. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
2980. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
2981. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
2982. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is etoposide.
2983. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
2984. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
2985. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
2986. The device of claim 2899, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
2987. The device of claim 2899, further comprising an anti-thrombotic agent.
2988. The device of claim 2899, further comprising a visualization agent.
2989. The device of claim 2899, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
2990. The device of claim 2899, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
2991. The device of claim 2899, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
2992. The device of claim 2899, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
2993. The device of claim 2899, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
2994. The device of claim 2899, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
2995. The device of claim 2899, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
2996. The device of claim 2899, further comprising an echogenic material.
2997. The device of claim 2899, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
2998. The device of claim 2899 wherein the device is sterile.
2999. The device of claim 2899 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
3000. The device of claim 2899 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
3001. The device of claim 2899 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
3002. The device of claim 2899 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
3003. The device of claim 2899 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
3004. The device of claim 2899 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
3005. The device of claim 2899 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
3006. The device of claim 2899 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
3007. The device of claim 2899 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
3008. The device of claim 2899 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
3009. The device of claim 2899 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
3010. The device of claim 2899 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
3011. The device of claim 2899 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
3012. The device of claim 2899 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
3013. The device of claim 2899 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
3014. The device of claim 2899 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
3015. The device of claim 2899 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
3016. The device of claim 2899 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
3017. The device of claim 2899 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3018. The device of claim 2899 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3019. The device of claim 2899 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3020. The device of claim 2899 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3021. The device of claim 2899 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3022. The device of claim 2899 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3023. A medical device comprising a hip implant and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
3024. The device of claim 3023 wherein the fibrosing agent promotes regeneration.
3025. The device of claim 3023 wherein the fibrosing agent promotes angiogenesis.
3026. The device of claim 3023 wherein the fibrosing agent promotes fibroblast migration.
3027. The device of claim 3023 wherein the fibrosing agent promotes fibroblast proliferation.
3028. The device of claim 3023 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
3029. The device of claim 3023 wherein the fibrosing agent promotes tissue remodeling.
3030. The device of claim 3023 wherein the fibrosing agent is an arterial vessel wall irritant.
3031. The device of claim 3023 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3032. The device of claim 3023 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3033. The device of claim 3023 wherein the fibrosing agent is or comprises silk.
3034. The device of claim 3023 wherein the fibrosing agent is or comprises mineral particles.
3035. The device of claim 3023 wherein the fibrosing agent is or comprises chitosan.
3036. The device of claim 3023 wherein the fibrosing agent is or comprises polylysine.
3037. The device of claim 3023 wherein the fibrosing agent is or comprises fibronectin.
3038. The device of claim 3023 wherein the fibrosing agent is or comprises bleomycin.
3039. The device of claim 3023 wherein the fibrosing agent is or comprises CTGF.
3040. The device of claim 3023 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
3041. The device of claim 3023 wherein the fibrosing agent is in the form of a particulate.
3042. The device of claim 3023 wherein the composition further comprises an inflammatory cytokine.
3043. The device of claim 3023 wherein the composition further comprises an agent that stimulates cell proliferation.
3044. The device of claim 3023 wherein the composition is in the form of a gel, paste, or spray.
3045. The device of claim 3023 wherein the fibrosing agent is in the form of tufts.
3046. The device of claim 3023, further comprising a polymer.
3047. The device of claim 3023, further comprising a polymeric carrier.
3048. The device of claim 3023 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3049. The device of claim 3023 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3050. The device of claim 3023, further comprising a coating, wherein the coating comprises the fibrosing agent.
3051. The device of claim 3023, further comprising a coating, wherein the coating is disposed on a surface of the device.
3052. The device of claim 3023, further comprising a coating, wherein the coating directly contacts the device.
3053. The device of claim 3023, further comprising a coating, wherein the coating indirectly contacts the device.
3054. The device of claim 3023, further comprising a coating, wherein the coating partially covers the device.
3055. The device of claim 3023, further comprising a coating, wherein the coating completely covers the device.
3056. The device of claim 3023, further comprising a coating, wherein the coating is a uniform coating.
3057. The device of claim 3023, further comprising a coating, wherein the coating is a non-uniform coating.
3058. The device of claim 3023, further comprising a coating, wherein the coating is a discontinuous coating.
3059. The device of claim 3023, further comprising a coating, wherein the coating is a patterned coating.
3060. The device of claim 3023, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
3061. The device of claim 3023, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
3062. The device of claim 3023, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
3063. The device of claim 3023, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
3064. The device of claim 3023, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001 % to about 1 % by weight.
3065. The device of claim 3023, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1 % to about 10% by weight.
3066. The device of claim 3023, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
3067. The device of claim 3023, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
3068. The device of claim 3023, further comprising a coating, wherein the coating further comprises a polymer.
3069. The device of claim 3023, further comprising a first coating having a first composition and the second coating having a second composition.
3070. The device of claim 3023, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
3071. The device of claim 3023, further comprising a polymer.
3072. The device of claim 3023, further comprising a polymeric carrier.
3073. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
3074. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
3075. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
3076. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
3077. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
3078. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
3079. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
3080. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
3081. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
3082. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
3083. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
3084. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
3085. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
3086. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
3087. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
3088. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
3089. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
3090. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
3091. The device of claim 3023, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
3092. The device of claim 3023, further comprising a lubricious coating.
3093. The device of claim 3023 wherein the fibrosing agent is located within pores or holes of the device.
3094. The device of claim 3023 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
3095. The device of claim 3023, further comprising a second pharmaceutically active agent.
3096. The device of claim 3023, further comprising an anti-inflammatory agent.
3097. The device of claim 3023, further comprising an agent that inhibits infection.
3098. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
3099. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
3100. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
3101. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
3102. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
3103. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
3104. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
3105. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
3106. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is etoposide.
3107. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
3108. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
3109. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
3110. The device of claim 3023, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
3111. The device of claim 3023, further comprising an anti-thrombotic agent.
3112. The device of claim 3023, further comprising a visualization agent.
3113. The device of claim 3023, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
3114. The device of claim 3023, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
3115. The device of claim 3023, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
3116. The device of claim 3023, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
3117. The device of claim 3023, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
3113. The device of claim 3023, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
3119. The device of claim 3023, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
3120. The device of claim 3023, further comprising an echogenic material.
3121. The device of claim 3023, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
3122. The device of claim 3023 wherein the device is sterile.
3123. The device of claim 3023 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
3124. The device of claim 3023 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
3125. The device of claim 3023 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
3126. The device of claim 3023 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
3127. The device of claim 3023 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
3128. The device of claim 3023 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
3129. The device of claim 3023 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
3130. The device of claim 3023 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
3131. The device of claim 3023 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
3132. The device of claim 3023 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
3133. The device of claim 3023 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
3134. The device of claim 3023 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
3135. The device of claim 3023 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
3136. The device of claim 3023 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
3137. The device of claim 3023 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
3138. The device of claim 3023 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
3139. The device of claim 3023 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
3140. The device of claim 3023 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
3141. The device of claim 3023 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3142. The device of claim 3023 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3143. The device of claim 3023 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm~ of device surface to which the fibrosing agent is applied.
3144. The device of claim 3023 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3145. The device of claim 3023 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3146. The device of claim 3023 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3147. The device of claim 3023 wherein the hip implant is a full hip replacement.
3148. The device of claim 3023 wherein the hip implant is a partial hip replacement.
3149. The device of claim 3023 wherein the hip implant is modular
3150. A medical device comprising a knee implant and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
3151. The device of claim 3150 wherein the fibrosing agent promotes regeneration.
3152. The device of claim 3150 wherein the fibrosing agent promotes angiogenesis.
3153. The device of claim 3150 wherein the fibrosing agent promotes fibroblast migration.
3154. The device of claim 3150 wherein the fibrosing agent promotes fibroblast proliferation.
3155. The device of claim 3150 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
3156. The device of claim 3150 wherein the fibrosing agent promotes tissue remodeling.
3157. The device of claim 3150 wherein the fibrosing agent is an arterial vessel wall irritant.
3158. The device of claim 3150 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3159. The device of claim 3150 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3160. The device of claim 3150 wherein the fibrosing agent is or comprises silk.
3161. The device of claim 3150 wherein the fibrosing agent is or comprises mineral particles.
3162. The device of claim 3150 wherein the fibrosing agent is or comprises chitosan.
3163. The device of claim 3150 wherein the fibrosing agent is or comprises polylysine.
3164. The device of claim 3150 wherein the fibrosing agent is or comprises fibronectin.
3165. The device of claim 3150 wherein the fibrosing agent is or comprises bleomycin.
3166. The device of claim 3150 wherein the fibrosing agent is or comprises CTGF.
3167. The device of claim 3150 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
3168. The device of claim 3150 wherein the fibrosing agent is in the form of a particulate.
3169. The device of claim 3150 wherein the composition further comprises an inflammatory cytokine.
3170. The device of claim 3150 wherein the composition further comprises an agent that stimulates cell proliferation.
3171. The device of claim 31,50 wherein the composition is in the form of a gel, paste, or spray.
3172. The device of claim 3150 wherein the fibrosing agent is in the form of tufts.
3173. The device of claim 3150, further comprising a polymer.
3174. The device of claim 3150, further comprising a polymeric carrier.
3175. The device of claim 3150 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3176. The device of claim 3150 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3177. The device of claim 3150, further comprising a coating, wherein the coating comprises the fibrosing agent.
3178. The device of claim 3150, further comprising a coating, wherein the coating is disposed on a surface of the device.
3179. The device of claim 3150, further comprising a coating, wherein the coating directly contacts the device.
3180. The device of claim 3150, further comprising a coating, wherein the coating indirectly contacts the device.
3181. The device of claim 3150, further comprising a coating, wherein the coating partially covers the device.
3182. The device of claim 3150, further comprising a coating, wherein the coating completely covers the device.
3183. The device of claim 3150, further comprising a coating, wherein the coating is a uniform coating.
3184. The device of claim 3150, further comprising a coating, wherein the coating is a non-uniform coating.
3185. The device of claim 3150, further comprising a coating, wherein the coating is a discontinuous coating.
3186. The device of claim 3150, further comprising a coating, wherein the coating is a patterned coating.
3187. The device of claim 3150, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
3188. The device of claim 3150, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
3189. The device of claim 3150, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
3190. The device of claim 3150, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
3191. The device of claim 3150, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001 % to about 1 % by weight.
3192. The device of claim 3150, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1 % to about 10% by weight.
3193. The device of claim 3150, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
3194. The device of claim 3150, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
3195. The device of claim 3150, further comprising a coating, wherein the coating further comprises a polymer.
3196. The device of claim 3150, further comprising a first coating having a first composition and the second coating having a second composition.
3197. The device of claim 3150, further comprising a first coating having a first composition and the second coating having a second composition, wherein-the first composition and the second composition are different.
3198. The device of claim 3150, further comprising a polymer.
3199. The device of claim 3150, further comprising a polymeric carrier.
3200. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
3201. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
3202. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
3203. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
3204. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
3205. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
3206. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
3207. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
3208. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
3209. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
3210. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
3211. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
3212. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
3213. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
3214. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
3215. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
3216. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
3217. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
3218. The device of claim 3150, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
3219. The device of claim 3150, further comprising a lubricious coating.
3220. The device of claim 3150 wherein the fibrosing agent is located within pores or holes of the device.
3221. The device of claim 3150 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
3222. The device of claim 3150, further comprising a second pharmaceutically active agent.
3223. The device of claim 3150, further comprising an anti-inflammatory agent.
3224. The device of claim 3150, further comprising an agent that inhibits infection.
3225. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
3226. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
3227. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
3228. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
3229. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
3230. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
3231. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
3232. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
3233. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is etoposide.
3234. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
3235. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
3236. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
3237. The device of claim 3150, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
3233. The device of claim 3150, further comprising an anti-thrombotic agent.
3239. The device of claim 3150, further comprising a visualization agent.
3240. The device of claim 3150, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
3241. The device of claim 3150, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
3242. The device of claim 3150, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
3243. The device of claim 3150, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
3244. The device of, claim 3150, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
3245. The device of claim 3150, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
3246. The device of claim 3150, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
3247. The device of claim 3150, further comprising an echogenic material.
3248. The device of claim 3150, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
3249. The device of claim 3150 wherein the device is sterile.
3250. The device of claim 3150 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
3251. The device of claim 3150 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
3252. The device of claim 3150 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
3253. The device of claim 3150 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
3254. The device of claim 3150 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
3255. The device of claim 3150 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
3256. The device of claim 3150 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
3257. The device of claim 3150 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
3258. The device of claim 3150 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
3259. The device of claim 3150 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
3260. The device of claim 3150 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
3261. The device of claim 3150 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
3262. The device of claim 3150 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
3263. The device of claim 3150 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
3264. The device of claim 3150 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
3265. The device of claim 3150 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
3266. The device of claim 3150 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
3267. The device of claim 3150 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
3268. The device of claim 3150 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3269. The device of claim 3150 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3270. The device of claim 3150 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3271. The device of claim 3150 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3272. The device of claim 3150 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3273. The device of claim 3150 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3274. A medical device comprising a shoulder implant and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
3275. The device of claim 3274 wherein the fibrosing agent promotes regeneration.
3276. The device of claim 3274 wherein the fibrosing agent promotes angiogenesis.
3277. The device of claim 3274 wherein the fibrosing agent promotes fibroblast migration.
3278. The device of claim 3274 wherein the fibrosing agent promotes fibroblast proliferation.
3279. The device of claim 3274 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
3280. The device of claim 3274 wherein the fibrosing agent promotes tissue remodeling.
3281. The device of claim 3274 wherein the fibrosing agent is an arterial vessel wall irritant.
3282. The device of claim 3274 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3283. The device of claim 3274 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3284. The device of claim 3274 wherein the fibrosing agent is or comprises silk.
3285. The device of claim 3274 wherein the fibrosing agent is or comprises mineral particles.
3286. The device of claim 3274 wherein the fibrosing agent is or comprises chitosan.
3287. The device of claim 3274 wherein the fibrosing agent is or comprises polylysine.
3288. The device of claim 3274 wherein the fibrosing agent is or comprises fibronectin.
3289. The device of claim 3274 wherein the fibrosing agent is or comprises bleomycin.
3290. The device of claim 3274 wherein the fibrosing agent is or comprises CTGF.
3291. The device of claim 3274 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
3292. The device of claim 3274 wherein the fibrosing agent is in the form of a particulate.
3293. The device of claim 3274 wherein the composition further comprises an inflammatory cytokine.
3294. The device of claim 3274 wherein the composition further comprises an agent that stimulates cell proliferation.
3295. The device of claim 3274 wherein the composition is in the form of a gel, paste, or spray.
3296. The device of claim 3274 wherein the fibrosing agent is in the form of tufts.
3297. The device of claim 3274, further comprising a polymer.
3298. The device of claim 3274, further comprising a polymeric carrier.
3299. The device of claim 3274 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3300. The device of claim 3274 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3301. The device of claim 3274, further comprising a coating, wherein the coating comprises the fibrosing agent.
3302. The device of claim 3274, further comprising a coating, wherein the coating is disposed on a surface of the device.
3303. The device of claim 3274, further comprising a coating, wherein the coating directly contacts the device.
3304. The device of claim 3274, further comprising a coating, wherein the coating indirectly contacts the device.
3305. The device of claim 3274, further comprising a coating, wherein the coating partially covers the device.
3306. The device of claim 3274, further comprising a coating, wherein the coating completely covers the device.
3307. The device of claim 3274, further comprising a coating, wherein the coating is a uniform coating.
3308. The device of claim 3274, further comprising a coating, wherein the coating is a non-uniform coating.
3309. The device of claim 3274, further comprising a coating, wherein the coating is a discontinuous coating.
3310. The device of claim 3274, further comprising a coating, wherein the coating is a patterned coating.
3311. The device of claim 3274, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
3312. The device of claim 3274, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
3313. The device of claim 3274, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
3314. The device of claim 3274, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
3315. The device of claim 3274, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
3316. The device of claim 3274, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
3317. The device of claim 3274, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
3318. The device of claim 3274, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
3319. The device of claim 3274, further comprising a coating, wherein the coating further comprises a polymer.
3320. The device of claim 3274, further comprising a first coating having a first composition and the second coating having a second composition.
3321. The device of claim 3274, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
3322. The device of claim 3274, further comprising a polymer.
3323. The device of claim 3274, further comprising a polymeric carrier.
3324. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
3325. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
3326. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
3327. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
3328. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
3329. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
3330. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
3331. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
3332. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
3333. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
3334. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
3335. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
3336. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
3337. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
3338. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
3339. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
3340. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
3341. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
3342. The device of claim 3274, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
3343. The device of claim 3274, further comprising a lubricious coating.
3344. The device of claim 3274 wherein the fibrosing agent is located within pores or holes of the device.
3345. The device of claim 3274 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
3346. The device of claim 3274, further comprising a second pharmaceutically active agent.
3347. The device of claim 3274, further comprising an anti-inflammatory agent.
3348. The device of claim 3274, further comprising an agent that inhibits infection.
3349. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
3350. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
3351. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
3352. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
3353. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
3354. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
3355. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
3356. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
3357. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is etoposide.
3358. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
3359. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
3360. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
3361. The device of claim 3274, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
3362. The device of claim 3274, further comprising an anti-thrombotic agent.
3363. The device of claim 3274, further comprising a visualization agent.
3364. The device of claim 3274, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
3365. The device of claim 3274, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
3366. The device of claim 3274, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
3367. The device of claim 3274, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
3368. The device of claim 3274, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
3369. The device of claim 3274, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
3370. The device of claim 3274, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
3371. The device of claim 3274, further comprising an echogenic material.
3372. The device of claim 3274, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
3373. The device of claim 3274 wherein the device is sterile.
3374. The device of claim 3274 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
3375. The device of claim 3274 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
3376. The device of claim 3274 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
3377. The device of claim 3274 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
3378. The device of claim 3274 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
3379. The device of claim 3274 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
3380. The device of claim 3274 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
3381. The device of claim 3274 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1-90 days.
3382. The device of claim 3274 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
3383. The device of claim 3274 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
3384. The device of claim 3274 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
3385. The device of claim 3274 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
3386. The device of claim 3274 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
3387. The device of claim 3274 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
3388. The device of claim 3274 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
3389. The device of claim 3274 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
3390. The device of claim 3274 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
3391. The device of claim 3274 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
3392. The device of claim 3274 wherein a surface of the device comprises less than 0.01 p.g of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3393. The device of claim 3274 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3394. The device of claim 3274 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3395. The device of claim 3274 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3396. The device of claim 3274 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3397. The device of claim 3274 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3398. The device of claim 3274 wherein the shoulder implant is a hemiarthroplasty.
3399. The device of claim 3274 wherein the shoulder implant is a total shoulder replacement.
3400. A medical device comprising a digit implant and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
3401. The device of claim 3400 wherein the fibrosing agent promotes regeneration.
3402. The device of claim 3400 wherein the fibrosing agent promotes angiogenesis.
3403. The device of claim 3400 wherein the fibrosing agent promotes fibroblast migration.
3404. The device of claim 3400 wherein the fibrosing agent promotes fibroblast proliferation.
3405. The device of claim 3400 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
3406. The device of claim 3400 wherein the fibrosing agent promotes tissue remodeling.
3407. The device of claim 3400 wherein the fibrosing agent is an arterial vessel wall irritant.
3408. The device of claim 3400 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3409. The device of claim 3400 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3410. The device of claim 3400 wherein the fibrosing agent is or comprises silk.
3411. The device of claim 3400 wherein the fibrosing agent is or comprises mineral particles.
3412. The device of claim 3400 wherein the fibrosing agent is or comprises chitosan.
3413. The device of claim 3400 wherein the fibrosing agent is or comprises polylysine.
3414. The device of claim 3400 wherein the fibrosing agent is or comprises fibronectin.
3415. The device of claim 3400 wherein the fibrosing agent is or comprises bleomycin.
3416. The device of claim 3400 wherein the fibrosing agent is or comprises CTGF.
3417. The device of claim 3400 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
3418. The device of claim 3400 wherein the fibrosing agent is in the form of a particulate.
3419. The device of claim 3400 wherein the composition further comprises an inflammatory cytokine.
3420. The device of claim 3400 wherein the composition further comprises an agent that stimulates cell proliferation.
3421. The device of claim 3400 wherein the composition is in the form of a gel, paste, or spray.
3422. The device of claim 3400 wherein the fibrosing agent is in the form of tufts.
3423. The device of claim 3400, further comprising a polymer.
3424. The device of claim 3400, further comprising a polymeric carrier.
3425. The device of claim 3400 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3426. The device of claim 3400 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3427. The device of claim 3400, further comprising a coating, wherein the coating comprises the fibrosing agent.
3423. The device of claim 3400, further comprising a coating, wherein the coating is disposed on a surface of the device.
3429. The device of claim 3400, further comprising a coating, wherein the coating directly contacts the device.
3430. The device of claim 3400, further comprising a coating, wherein the coating indirectly contacts the device.
3431. The device of claim 3400, further comprising a coating, wherein the coating partially covers the device.
3432. The device of claim 3400, further comprising a coating, wherein the coating completely covers the device.
3433. The device of claim 3400, further comprising a coating, wherein the coating is a uniform coating.
3434. The device of claim 3400, further comprising a coating, wherein the coating is a non-uniform coating.
3435. The device of claim 3400, further comprising a coating, wherein the coating is a discontinuous coating.
3436. The device of claim 3400, further comprising a coating, wherein the coating is a patterned coating.
3437. The device of claim 3400, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
3438. The device of claim 3400, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
3439. The device of claim 3400, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
3440. The device of claim 3400, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
3441. The device of claim 3400, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
3442. The device of claim 3400, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
3443. The device of claim 3400, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
3444. The device of claim 3400, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
3445. The device of claim 3400, further comprising a coating, wherein the coating further comprises a polymer.
3446. The device of claim 3400, further comprising a first coating having a first composition and the second coating having a second composition.
3447. The device of claim 3400, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
3448. The device of claim 3400, further comprising a polymer.
3449. The device of claim 3400, further comprising a polymeric carrier.
3450. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
3451. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
3452. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
3453. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
3454. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
3455. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
3456. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
3457. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
3458. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
3459. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
3460. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
3461. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
3462. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
3463. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
3464. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
3465. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
3466. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
3467. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polyethylene glycol) polymer.
3468. The device of claim 3400, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
3469. The device of claim 3400, further comprising a lubricious coating.
3470. The device of claim 3400 wherein the fibrosing agent is located within pores or holes of the device.
3471. The device of claim 3400 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
3472. The device of claim 3400, further comprising a second pharmaceutically active agent.
3473. The device of claim 3400, further comprising an anti-inflammatory agent.
3474. The device of claim 3400, further comprising an agent that inhibits infection.
3475. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
3476. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
3477. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
3478. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
3479. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
3480. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
3481. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
3482. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
3483. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is etoposide.
3484. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
3485. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
3486. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
3487. The device of claim 3400, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
3488. The device of claim 3400, further comprising an anti-thrombotic agent.
3489. The device of claim 3400, further comprising a visualization agent.
3490. The device of claim 3400, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
3491. The device of claim 3400, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
3492. The device of claim 3400, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
3493. The device of claim 3400, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
3494. The device of claim 3400, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
3495. The device of claim 3400, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
3496. The device of claim 3400, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
3497. The device of claim 3400, further comprising an echogenic material.
3498. The device of claim 3400, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
3499. The device of claim 3400 wherein the device is sterile.
3500. The device of claim 3400 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
3501. The device of claim 3400 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
3502. The device of claim 3400 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
3503. The device of claim 3400 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
3504. The device of claim 3400 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
3505. The device of claim 3400 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
3506. The device of claim 3400 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
3507. The device of claim 3400 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
3508. The device of claim 3400 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
3509. The device of claim 3400 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
3510. The device of claim 3400 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
3511. The device of claim 3400 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
3512. The device of claim 3400 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
3513. The device of claim 3400 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
3514. The device of claim 3400 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
3515. The device of claim 3400 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
3516. The device of claim 3400 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
3517. The device of claim 3400 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
3518. The device of claim 3400 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3519. The device of claim 3400 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3520. The device of claim 3400 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3521. The device of claim 3400 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3522. The device of claim 3400 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3523. The device of claim 3400 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3524. A medical device comprising a titanium fixture for replacement of the root portion of a missing natural tooth and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
3525. The device of claim 3524 wherein the fibrosing agent promotes regeneration.
3526. The device of claim 3524 wherein the fibrosing agent promotes angiogenesis.
3527. The device of claim 3524 wherein the fibrosing agent promotes fibroblast migration.
3528. The device of claim 3524 wherein the fibrosing agent promotes fibroblast proliferation.
3529. The device of claim 3524 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
3530. The device of claim 3524 wherein the fibrosing agent promotes tissue remodeling.
3531. The device of claim 3524 wherein the fibrosing agent is an arterial vessel wall irritant.
3532. The device of claim 3524 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3533. The device of claim 3524 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3534. The device of claim 3524 wherein the fibrosing agent is or comprises silk.
3535. The device of claim 3524 wherein the fibrosing agent is or comprises mineral particles.
3536. The device of claim 3524 wherein the fibrosing agent is or comprises chitosan.
3537. The device of claim 3524 wherein the fibrosing agent is or comprises polylysine.
3538. The device of claim 3524 wherein the fibrosing agent is or comprises fibronectin.
3539. The device of claim 3524 wherein the fibrosing agent is or comprises bleomycin.
3540. The device of claim 3524 wherein the fibrosing agent is or comprises CTGF.
3541. The device of claim 3524 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
3542. The device of claim 3524 wherein the fibrosing agent is in the form of a particulate.
3543. The device of claim 3524 wherein the composition further comprises an inflammatory cytokine.
3544. The device of claim 3524 wherein the composition further comprises an agent that stimulates cell proliferation.
3545. The device of claim 3524 wherein the composition is in the form of a gel, paste, or spray.
3546. The device of claim 3524 wherein the fibrosing agent is in the form of tufts.
3547. The device of claim 3524, further comprising a polymer.
3548. The device of claim 3524, further comprising a polymeric carrier.
3549. The device of claim 3524 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3550. The device of claim 3524 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3551. The device of claim 3524, further comprising a coating, wherein the coating comprises the fibrosing agent.
3552. The device of claim 3524, further comprising a coating, wherein the coating is disposed on a surface of the device.
3553. The device of claim 3524, further comprising a coating, wherein the coating directly contacts the device.
3554. The device of claim 3524, further comprising a coating, wherein the coating indirectly contacts the device.
3555. The device of claim 3524, further comprising a coating, wherein the coating partially covers the device.
3556. The device of claim 3524, further comprising a coating, wherein the coating completely covers the device.
3557. The device of claim 3524, further comprising a coating, wherein the coating is a uniform coating.
3558. The device of claim 3524, further comprising a coating, wherein the coating is a non-uniform coating.
3559. The device of claim 3524, further comprising a coating, wherein the coating is a discontinuous coating.
3560. The device of claim 3524, further comprising a coating, wherein the coating is a patterned coating.
3561. The device of claim 3524, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
3562. The device of claim 3524, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
3563. The device of claim 3524, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
3564. The device of claim 3524, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
3565. The device of claim 3524, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
3566. The device of claim 3524, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
3567. The device of claim 3524, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
3568. The device of claim 3524, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
3569. The device of claim 3524, further comprising a coating, wherein the coating further comprises a polymer.
3570. The device of claim 3524, further comprising a first coating having a first composition and the second coating having a second composition.
3571. The device of claim 3524, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
3572. The device of claim 3524, further comprising a polymer.
3573. The device of claim 3524, further comprising a polymeric carrier.
3574. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
3575. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
3576. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
3577. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
3578. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
3579. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
3580. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
3581. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
3582. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
3583. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
3584. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
3585. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
3586. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
3587. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
3588. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
3589. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
3590. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
3591. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
3592. The device of claim 3524, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
3593. The device of claim 3524, further comprising a lubricious coating.
3594. The device of claim 3524 wherein the fibrosing agent is located within pores or holes of the device.
3595. The device of claim 3524 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
3596. The device of claim 3524, further comprising a second pharmaceutically active agent.
3597. The device of claim 3524, further comprising an anti-inflammatory agent.
3598. The device of claim 3524, further comprising an agent that inhibits infection.
3599. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
3600. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
3601. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
3602. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
3603. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
3604. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
3605. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
3606. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
3607. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is etoposide.
3608. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
3609. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
3610. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
3611. The device of claim 3524, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
3612. The device of claim 3524, further comprising an anti-thrombotic agent.
3613. The device of claim 3524, further comprising a visualization agent.
3614. The device of claim 3524, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
3615. The device of claim 3524, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
3616. The device of claim 3524, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
3617. The device of claim 3524, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
3618. The device of claim 3524, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
3619. The device of claim 3524, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
3620. The device of claim 3524, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
3621. The device of claim 3524, further comprising an echogenic material.
3622. The device of claim 3524, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
3623. The device of claim 3524 wherein the device is sterile.
3624. The device of claim 3524 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
3625. The device of claim 3524 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
3626. The device of claim 3524 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
3627. The device of claim 3524 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
3628. The device of claim 3524 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
3629. The device of claim 3524 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
3630. The device of claim 3524 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
3631. The device of claim 3524 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
3632. The device of claim 3524 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
3633. The device of claim 3524 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
3634. The device of claim 3524 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
3635. The device of claim 3524 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
3636. The device of claim 3524 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
3637. The device of claim 3524 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
3638. The device of claim 3524 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
3639. The device of claim 3524 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
3640. The device of claim 3524 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
3641. The device of claim 3524 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
3642. The device of claim 3524 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3643. The device of claim 3524 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3644. The device of claim 3524 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3645. The device of claim 3524 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3646. The device of claim 3524 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3647. The device of claim 3524 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3648. A medical device comprising an endosteal implant and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
3649. The device of claim 3648 wherein the fibrosing agent promotes regeneration.
3650. The device of claim 3648 wherein the fibrosing agent promotes angiogenesis.
3651. The device of claim 3648 wherein the fibrosing agent promotes fibroblast migration.
3652. The device of claim 3648 wherein the fibrosing agent promotes fibroblast proliferation.
3653. The device of claim 3648 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
3654. The device of claim 3648 wherein the fibrosing agent promotes tissue remodeling.
3655. The device of claim 3648 wherein the fibrosing agent is an arterial vessel wall irritant.
3656. The device of claim 3648 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3657. The device of claim 3648 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3658. The device of claim 3648 wherein the fibrosing agent is or comprises silk.
3659. The device of claim 3648 wherein the fibrosing agent is or comprises mineral particles.
3660. The device of claim 3648 wherein the fibrosing agent is or comprises chitosan.
3661. The device of claim 3648 wherein the fibrosing agent is or comprises polylysine.
3662. The device of claim 3648 wherein the fibrosing agent is or comprises fibronectin.
3663. The device of claim 3648 wherein the fibrosing agent is or comprises bleomycin.
3664. The device of claim 3648 wherein the fibrosing agent is or comprises CTGF.
3665. The device of claim 3648 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
3666. The device of claim 3648 wherein the fibrosing agent is in the form of a particulate.
3667. The device of claim 3648 wherein the composition further comprises an inflammatory cytokine.
3668. The device of claim 3648 wherein the composition further comprises an agent that stimulates cell proliferation.
3669. The device of claim 3648 wherein the composition is in the form of a gel, paste, or spray.
3670. The device of claim 3648 wherein the fibrosing agent is in the form of tufts.
3671. The device of claim 3648, further comprising a polymer.
3672. The device of claim 3648, further comprising a polymeric carrier.
3673. The device of claim 3648 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3674. The device of claim 3648 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3675. The device of claim 3648, further comprising a coating, wherein the coating comprises the fibrosing agent.
3676. The device of claim 3648, further comprising a coating, wherein the coating is disposed on a surface of the device.
3677. The device of claim 3648, further comprising a coating, wherein the coating directly contacts the device.
3678. The device of claim 3648, further comprising a coating, wherein the coating indirectly contacts the device.
3679. The device of claim 3648, further comprising a coating, wherein the coating partially covers the device.
3680. The device of claim 3648, further comprising a coating, wherein the coating completely covers the device.
3681. The device of claim 3648, further comprising a coating, wherein the coating is a uniform coating.
3682. The device of claim 3648, further comprising a coating, wherein the coating is a non-uniform coating.
3683. The device of claim 3648, further comprising a coating, wherein the coating is a discontinuous coating.
3684. The device of claim 3648, further comprising a coating, wherein the coating is a patterned coating.
3685. The device of claim 3648, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
3686. The device of claim 3648, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
3687. The device of claim 3648, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
3688. The device of claim 3648, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
3689. The device of claim 3648, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
3690. The device of claim 3648, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
3691. The device of claim 3648, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
3692. The device of claim 3648, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
3693. The device of claim 3648, further comprising a coating, wherein the coating further comprises a polymer.
3694. The device of claim 3648, further comprising a first coating having a first composition and the second coating having a second composition.
3695. The device of claim 3648, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
3696. The device of claim 3648, further comprising a polymer.
3697. The device of claim 3648, further comprising a polymeric carrier.
3698. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
3699. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
3700. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
3701. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
3702. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
3703. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
3704. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
3705. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
3706. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
3707. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
3708. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
3709. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
3710. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
3711. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
3712. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
3713. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
3714. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
3715. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
3716. The device of claim 3648, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
3717. The device of claim 3648, further comprising a lubricious coating.
3718. The device of claim 3648 wherein the fibrosing agent is located within pores or holes of the device.
3719. The device of claim 3648 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
3720. The device of claim 3648, further comprising a second pharmaceutically active agent.
3721. The device of claim 3648, further comprising an anti-inflammatory agent.
3722. The device of claim 3648, further comprising an agent that inhibits infection.
3723. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
3724. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
3725. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
3726. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
3727. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
3728. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
3729. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
3730. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
3731. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is etoposide.
3732. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
3733. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
3734. The.device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
3735. The device of claim 3648, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
3736. The device of claim 3648, further comprising an anti-thrombotic agent.
3737. The device of claim 3648, further comprising a visualization agent.
3738. The device of claim 3648, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
3739. The device of claim 3648, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
3740. The device of claim 3648, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
3741. The device of claim 3648, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
3742. The device of claim 3648, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
3743. The device of claim 3648, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
3744. The device of claim 3648, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
3745. The device of claim 3648, further comprising an echogenic material.
3746. The device of claim 3648, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
3747. The device of claim 3648 wherein the device is sterile.
3748. The device of claim 3648 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
3749. The device of claim 3648 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
3750. The device of claim 3648 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
3751. The device of claim 3648 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
3752. The device of claim 3648 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
3753. The device of claim 3648 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
3754. The device of claim 3648 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
3755. The device of claim 3648 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
3756. The device of claim 3648 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
3757. The device of claim 3648 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
3758. The device of claim 3648 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
3759. The device of claim 3648 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
3760. The device of claim 3648 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
3761. The device of claim 3648 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
3762. The device of claim 3648 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
3763. The device of claim 3648 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
3764. The device of claim 3648 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
3765. The device of claim 3648 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
3766. The device of claim 3648 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3767. The device of claim 3648 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3768. The device of claim 3648 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3769. The device of claim 3648 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3770. The device of claim 3648 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3771. The device of claim 3648 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3772. A medical device comprising a subperiosteal implant and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
3773. The device of claim 3772 wherein the fibrosing agent promotes regeneration.
3774. The device of claim 3772 wherein the fibrosing agent promotes angiogenesis.
3775. The device of claim 3772 wherein the fibrosing agent promotes fibroblast migration.
3776. The device of claim 3772 wherein the fibrosing agent promotes fibroblast proliferation.
3777. The device of claim 3772 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
3778. The device of claim 3772 wherein the fibrosing agent promotes tissue remodeling.
3779. The device of claim 3772 wherein the fibrosing agent is an arterial vessel wall irritant.
3780. The device of claim 3772 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3781. The device of claim 3772 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3782. The device of claim 3772 wherein the fibrosing agent is or comprises silk.
3783. The device of claim 3772 wherein the fibrosing agent is or comprises mineral particles.
3784. The device of claim 3772 wherein the fibrosing agent is or comprises chitosan.
3785. The device of claim 3772 wherein the fibrosing agent is or comprises polylysine.
3786. The device of claim 3772 wherein the fibrosing agent is or comprises fibronectin.
3787. The device of claim 3772 wherein the fibrosing agent is or comprises bleomycin.
3788. The device of claim 3772 wherein the fibrosing agent is or comprises CTGF.
3789. The device of claim 3772 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
3790. The device of claim 3772 wherein the fibrosing agent is in the form of a particulate.
3791. The device of claim 3772 wherein the composition further comprises an inflammatory cytokine.
3792. The device of claim 3772 wherein the composition further comprises an agent that stimulates cell proliferation.
3793. The device of claim 3772 wherein the composition is in the form of a gel, paste, or spray.
3794. The device of claim 3772 wherein the fibrosing agent is in the form of tufts.
3795. The device of claim 3772, further comprising a polymer.
3796. The device of claim 3772, further comprising a polymeric carrier.
3797. The device of claim 3772 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3798. The device of claim 3772 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3799. The device of claim 3772, further comprising a coating, wherein the coating comprises the fibrosing agent.
3800. The device of claim 3772, further comprising a coating, wherein the coating is disposed on a surface of the device.
3801. The device of claim 3772, further comprising a coating, wherein the coating directly contacts the device.
3802. The device of claim 3772, further comprising a coating, wherein the coating indirectly contacts the device.
3803. The device of claim 3772, further comprising a coating, wherein the coating partially covers the device.
3804. The device of claim 3772, further comprising a coating, wherein the coating completely covers the device.
3805. The device of claim 3772, further comprising a coating, wherein the coating is a uniform coating.
3806. The device of claim 3772, further comprising a coating, wherein the coating is a non-uniform coating.
3807. The device of claim 3772, further comprising a coating, wherein the coating is a discontinuous coating.
3808. The device of claim 3772, further comprising a coating, wherein the coating is a patterned coating.
3809. The device of claim 3772, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
3810. The device of claim 3772, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
3811. The device of claim 3772, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
3812. The device of claim 3772, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
3813. The device of claim 3772, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
3814. The device of claim 3772, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
3815. The device of claim 3772, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
3816. The device of claim 3772, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
3817. The device of claim 3772, further comprising a coating, wherein the coating further comprises a polymer.
3818. The device of claim 3772, further comprising a first coating having a first composition and the second coating having a second composition.
3819. The device of claim 3772, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
3820. The device of claim 3772, further comprising a polymer.
3821. The device of claim 3772, further comprising a polymeric carrier.
3822. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
3823. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
3824. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
3825. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
3826. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
3827. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
3828. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
3829. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
3830. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
3831. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
3832. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
3833. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
3834. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
3835. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
3836. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
3837. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
3838. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
3839. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
3840. The device of claim 3772, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
3841. The device of claim 3772, further comprising a lubricious coating.
3842. The device of claim 3772 wherein the fibrosing agent is located within pores or holes of the device.
3843. The device of claim 3772 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
3844. The device of claim 3772, further comprising a second pharmaceutically active agent.
3845. The device of claim 3772, further comprising an anti-inflammatory agent.
3846. The device of claim 3772, further comprising an agent that inhibits infection.
3847. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
3848. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
3849. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
3850. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
3851. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
3852. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
3853. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
3854. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
3855. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is etoposide.
3856. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
3857. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
3858. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
3859. The device of claim 3772, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
3860. The device of claim 3772, further comprising an anti-thrombotic agent.
3861. The device of claim 3772, further comprising a visualization agent.
3862. The device of claim 3772, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
3863. The device of claim 3772, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
3864. The device of claim 3772, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
3865. The device of claim 3772, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
3866. The device of claim 3772, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
3867. The device of claim 3772, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
3868. The device of claim 3772, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
3869. The device of claim 3772, further comprising an echogenic material.
3870. The device of claim 3772, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
3871. The device of claim 3772 wherein the device is sterile.
3872. The device of claim 3772 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
3873. The device of claim 3772 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
3874. The device of claim 3772 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
3875. The device of claim 3772 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
3876. The device of claim 3772 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
3877. The device of claim 3772 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
3878. The device of claim 3772 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
3879. The device of claim 3772 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
3880. The device of claim 3772 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
3881. The device of claim 3772 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
3882. The device of claim 3772 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
3883. The device of claim 3772 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
3884. The device of claim 3772 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
3885. The device of claim 3772 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
3886. The device of claim 3772 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
3887. The device of claim 3772 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
3888. The device of claim 3772 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
3889. The device of claim 3772 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
3890. The device of claim 3772 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3891. The device of claim 3772 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3892. The device of claim 3772 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3893. The device of claim 3772 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3894. The device of claim 3772 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3895. The device of claim 3772 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
3896. A medical device comprising a guided bone regeneration (GBR) implant and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
3897. The device of claim 3896 wherein the fibrosing agent promotes regeneration.
3898. The device of claim 3896 wherein the fibrosing agent promotes angiogenesis.
3899. The device of claim 3896 wherein the fibrosing agent promotes fibroblast migration.
3900. The device of claim 3896 wherein the fibrosing agent promotes fibroblast proliferation.
3901. The device of claim 3896 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
3902. The device of claim 3896 wherein the fibrosing agent promotes tissue remodeling.
3903. The device of claim 3896 wherein the fibrosing agent is an arterial vessel wall irritant.
3904. The device of claim 3896 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3905. The device of claim 3896 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3906. The device of claim 3896 wherein the fibrosing agent is or comprises silk.
3907. The device of claim 3896 wherein the fibrosing agent is or comprises mineral particles.
3908. The device of claim 3896 wherein the fibrosing agent is or comprises chitosan.
3909. The device of claim 3896 wherein the fibrosing agent is or comprises polylysine.
3910. The device of claim 3896 wherein the fibrosing agent is or comprises fibronectin.
3911. The device of claim 3896 wherein the fibrosing agent is or comprises bleomycin.
3912. The device of claim 3896 wherein the fibrosing agent is or comprises CTGF.
3913. The device of claim 3896 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
3914. The device of claim 3896 wherein the fibrosing agent is in the form of a particulate.
3915. The device of claim 3896 wherein the composition further comprises an inflammatory cytokine.
3916. The device of claim 3896 wherein the composition further comprises an agent that stimulates cell proliferation.
3917. The device of claim 3896 wherein the composition is in the form of a gel, paste, or spray.
3918. The device of claim 3896 wherein the fibrosing agent is in the form of tufts.
3919. The device of claim 3896, further comprising a polymer.
3920. The device of claim 3896, further comprising a polymeric carrier.
3921. The device of claim 3896 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
3922. The device of claim 3896 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
3923. The device of claim 3896, further comprising a coating, wherein the coating comprises the fibrosing agent.
3924. The device of claim 3896, further comprising a coating, wherein the coating is disposed on a surface of the device.
3925. The device of claim 3896, further comprising a coating, wherein the coating directly contacts the device.
3926. The device of claim 3896, further comprising a coating, wherein the coating indirectly contacts the device.
3927. The device of claim 3896, further comprising a coating, wherein the coating partially covers the device.
3928. The device of claim 3896, further comprising a coating, wherein the coating completely covers the device.
3929. The device of claim 3896, further comprising a coating, wherein the coating is a uniform coating.
3930. The device of claim 3896, further comprising a coating, wherein the coating is a non-uniform coating.
3931. The device of claim 3896, further comprising a coating, wherein the coating is a discontinuous coating.
3932. The device of claim 3896, further comprising a coating, wherein the coating is a patterned coating.
3933. The device of claim 3896, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
3934. The device of claim 3896, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
3935. The device of claim 3896, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
3936. The device of claim 3896, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
3937. The device of claim 3896, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
3938. The device of claim 3896, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
3939. The device of claim 3896, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
3940. The device of claim 3896, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
3941. The device of claim 3896, further comprising a coating, wherein the coating further comprises a polymer.
3942. The device of claim 3896, further comprising a first coating having a first composition and the second coating having a second composition.
3943. The device of claim 3896, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
3944. The device of claim 3896, further comprising a polymer.
3945. The device of claim 3896, further comprising a polymeric carrier.
3946. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
3947. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
3948. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
3949. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
3950. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
3951. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
3952. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
3953. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
3954. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
3955. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
3956. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
3957. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
3958. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
3959. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
3960. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
3961. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
3962. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
3963. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
3964. The device of claim 3896, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
3965. The device of claim 3896, further comprising a lubricious coating.
3966. The device of claim 3896 wherein the fibrosing agent is located within pores or holes of the device.
3967. The device of claim 3896 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
3968. The device of claim 3896, further comprising a second pharmaceutically active agent.
3969. The device of claim 3896, further comprising an anti-inflammatory agent.
3970. The device of claim 3896, further comprising an agent that inhibits infection.
3971. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
3972. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
3973. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
3974. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
3975. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
3976. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
3977. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
3978. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
3979. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is etoposide.
3980. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
3981. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
3982. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
3983. The device of claim 3896, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
3984. The device of claim 3896, further comprising an anti-thrombotic agent.
3985. The device of claim 3896, further comprising a visualization agent.
3986. The device of claim 3896, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
3987. The device of claim 3896, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
3988. The device of claim 3896, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
3989. The device of claim 3896, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
3990. The device of claim 3896, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
3991. The device of claim 3896, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
3992. The device of claim 3896, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
3993. The device of claim 3896, further comprising an echogenic material.
3994. The device of claim 3896, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
3995. The device of claim 3896 wherein the device is sterile.
3996. The device of claim 3896 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
3997. The device of claim 3896 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
3998. The device of claim 3896 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
3999. The device of claim 3896 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
4000. The device of claim 3896 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
4001. The device of claim 3896 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
4002. The device of claim 3896 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
4003. The device of claim 3896 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
4004. The device of claim 3896 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
4005. The device of claim 3896 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
4006. The device of claim 3896 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
4007. The device of claim 3896 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
4008. The device of claim 3896 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
4009. The device of claim 3896 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
4010. The device of claim 3896 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
4011. The device of claim 3896 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
4012. The device of claim 3896 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
4013. The device of claim 3896 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
4014. The device of claim 3896 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4015. The device of claim 3896 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4016. The device of claim 3896 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4017. The device of claim 3896 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4018. The device of claim 3896 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4019. The device of claim 3896 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4020. The medical device of claqim 3896 wherein the GBR is resorbable bone substitutes for filing bony defects.
4021. A medical device comprising a dental implant to control the healing process subsequent to periodontal disease and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
4022. The device of claim 4021 wherein the fibrosing agent promotes regeneration.
4023. The device of claim 4021 wherein the fibrosing agent promotes angiogenesis.
4024. The device of claim 4021 wherein the fibrosing agent promotes fibroblast migration.
4025. The device of claim 4021 wherein the fibrosing agent promotes fibroblast proliferation.
4026. The device of claim 4021 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
4027. The device of claim 4021 wherein the fibrosing agent promotes tissue remodeling.
4028. The device of claim 4021 wherein the fibrosing agent is an arterial vessel wall irritant.
4029. The device of claim 4021 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
4030. The device of claim 4021 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
4031. The device of claim 4021 wherein the fibrosing agent is or comprises silk.
4032. The device of claim 4021 wherein the fibrosing agent is or comprises mineral particles.
4033. The device of claim 4021 wherein the fibrosing agent is or comprises chitosan.
4034. The device of claim 4021 wherein the fibrosing agent is or comprises polylysine.
4035. The device of claim 4021 wherein the fibrosing agent is or comprises fibronectin.
4036. The device of claim 4021 wherein the fibrosing agent is or comprises bleomycin.
4037. The device of claim 4021 wherein the fibrosing agent is or comprises CTGF.
4038. The device of claim 4021 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
4039. The device of claim 4021 wherein the fibrosing agent is in the form of a particulate.
4040. The device of claim 4021 wherein the composition further comprises an inflammatory cytokine.
4041. The device of claim 4021 wherein the composition further comprises an agent that stimulates cell proliferation.
4042. The device of claim 4021 wherein the composition is in the form of a gel, paste, or spray.
4043. The device of claim 4021 wherein the fibrosing agent is in the form of tufts.
4044. The device of claim 4021, further comprising a polymer.
4045. The device of claim 4021, further comprising a polymeric carrier.
4046. The device of claim 4021 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
4047. The device of claim 4021 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
4048. The device of claim 4021, further comprising a coating, wherein the coating comprises the fibrosing agent.
4049. The device of claim 4021, further comprising a coating, wherein the coating is disposed on a surface of the device.
4050. The device of claim 4021, further comprising a coating, wherein the coating directly contacts the device.
4051. The device of claim 4021, further comprising a coating, wherein the coating indirectly contacts the device.
4052. The device of claim 4021, further comprising a coating, wherein the coating partially covers the device.
4053. The device of claim 4021, further comprising a coating, wherein the coating completely covers the device.
4054. The device of claim 4021, further comprising a coating, wherein the coating is a uniform coating.
4055. The device of claim 4021, further comprising a coating, wherein the coating is a non-uniform coating.
4056. The device of claim 4021, further comprising a coating, wherein the coating is a discontinuous coating.
4057. The device of claim 4021, further comprising a coating, wherein the coating is a patterned coating.
4058. The device of claim 4021, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
4059. The device of claim 4021, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
4060. The device of claim 4021, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
4061. The device of claim 4021, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
4062. The device of claim 4021, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001 % to about 1 % by weight.
4063. The device of claim 4021, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1 % to about 10% by weight.
4064. The device of claim 4021, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
4065. The device of claim 4021, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
4066. The device of claim 4021, further comprising a coating, wherein the coating further comprises a polymer.
4067. The device of claim 4021, further comprising a first coating having a first composition and the second coating having a second composition.
4063. The device of claim 4021, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
4069. The device of claim 4021, further comprising a polymer.
4070. The device of claim 4021, further comprising a polymeric carrier.
4071. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
4072. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
4073. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
4074. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
4075. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
4076. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
4077. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
4078. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
4079. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
4080. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
4081. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
4082. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
4083. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
4084. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
4085. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
4086. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
4087. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
4088. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
4089. The device of claim 4021, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
4090. The device of claim 4021, further comprising a lubricious coating.
4091. The device of claim 4021 wherein the fibrosing agent is located within pores or holes of the device.
4092. The device of claim 4021 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
4093. The device of claim 4021, further comprising a second pharmaceutically active agent.
4094. The device of claim 4021, further comprising an anti-inflammatory agent.
4095. The device of claim 4021, further comprising an agent that inhibits infection.
4096. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
4097. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
4098: The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
4099. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
4100. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
4101. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
4102. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
4103. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
4104. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is etoposide.
4105. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is a camptothecin.
4106. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is a hydroxyurea.
4107. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is a platinum complex.
4108. The device of claim 4021, further comprising an agent that inhibits infection, wherein the agent is cisplatin.
4109. The device of claim 4021, further comprising an anti-thrombotic agent.
4110. The device of claim 4021, further comprising a visualization agent.
4111. The device of claim 4021, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises a metal, a halogenated compound, or a barium containing compound.
4112. The device of claim 4021, further comprising a visualization agent, wherein the visualization agent is a radiopaque material, wherein the radiopaque material comprises barium, tantalum, or technetium.
4113. The device of claim 4021, further comprising a visualization agent, wherein the visualization agent is a MRI responsive material.
4114. The device of claim 4021, further comprising a visualization agent, wherein the visualization agent comprises a gadolinium chelate.
4115. The device of claim 4021, further comprising a visualization agent, wherein the visualization agent comprises iron, magnesium, manganese, copper, or chromium.
4116. The device of claim 4021, further comprising a visualization agent, wherein the visualization agent comprises an iron oxide compound.
4117. The device of claim 4021, further comprising a visualization agent, wherein the visualization agent comprises a dye, pigment, or colorant.
1516 4918. The device of claim 4021, further comprising an echogenic material.
4119. The device of claim 4021, further comprising an echogenic material, wherein the echogenic material is in the form of a coating.
4120. The device of claim 4021 wherein the device is sterile.
4121. The device of claim 4021 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device.
4122. The device of claim 4021 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is connective tissue.
4123. The device of claim 4021 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is muscle tissue.
4124. The device of claim 4021 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is nerve tissue.
4125. The device of claim 4021 wherein the fibrosing agent is released into tissue in the vicinity of the device after deployment of the device, wherein the tissue is epithelium tissue.
4126. The device of claim 4021 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 1 year.
4127. The device of claim 4021 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 month to 6 months.
4128. The device of claim 4021 wherein the fibrosing agent is released in effective concentrations from the device over a period ranging from about 1 - 90 days.
4129. The device of claim 4021 wherein the fibrosing agent is released in effective concentrations from the device at a constant rate.
4130. The device of claim 4021 wherein the fibrosing agent is released in effective concentrations from the device at an increasing rate.
4131. The device of claim 4021 wherein the fibrosing agent is released in effective concentrations from the device at a decreasing rate.
4132. The device of claim 4021 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by diffusion over a period ranging from the time of deployment of the device to about 90 days.
4133. The device of claim 4021 wherein the fibrosing agent is released in effective concentrations from the composition comprising the fibrosing agent by erosion of the composition over a period ranging from the time of deployment of the device to about 90 days.
4134. The device of claim 4021 wherein the device comprises about 0.01 µg to about 10 µg of the fibrosing agent.
4135. The device of claim 4021 wherein the device comprises about 10 µg to about 10 mg of the fibrosing agent.
4136. The device of claim 4021 wherein the device comprises about 10 mg to about 250 mg of the fibrosing agent.
4137. The device of claim 4021 wherein the device comprises about 250 mg to about 1000 mg of the fibrosing agent.
4138. The device of claim 4021 wherein the device comprises about 1000 mg to about 2500 mg of the fibrosing agent.
4139. The device of claim 4021 wherein a surface of the device comprises less than 0.01 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4140. The device of claim 4021 wherein a surface of the device comprises about 0.01 µg to about 1 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4141. The device of claim 4021 wherein a surface of the device comprises about 1 µg to about 10 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4142. The device of claim 4021 wherein a surface of the device comprises about 10 µg to about 250 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4143. The device of claim 4021 wherein a surface of the device comprises about 250 µg to about 1000 µg of the fibrosing agent of fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4144. The device of claim 4021 wherein a surface of the device comprises about 1000 µg to about 2500 µg of the fibrosing agent per mm2 of device surface to which the fibrosing agent is applied.
4145. A medical device comprising an internal fixation implant and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
4146. The device of claim 4145 wherein the fibrosing agent promotes regeneration.
4147. The device of claim 4145 wherein the fibrosing agent promotes angiogenesis.
4148. The device of claim 4145 wherein the fibrosing agent promotes fibroblast migration.
4149. The device of claim 4145 wherein the fibrosing agent promotes fibroblast proliferation.
4150. The device of claim 4145 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
4151. The device of claim 4145 wherein the fibrosing agent promotes tissue remodeling.
4152. The device of claim 4145 wherein the fibrosing agent is an arterial vessel wall irritant.
4153. The device of claim 4145 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
4154. The device of claim 4145 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
4155. The device of claim 4145 wherein the fibrosing agent is or comprises silk.
4156. The device of claim 4145 wherein the fibrosing agent is or comprises mineral particles.
4157. The device of claim 4145 wherein the fibrosing agent is or comprises chitosan.
4158. The device of claim 4145 wherein the fibrosing agent is or comprises polylysine.
4159. The device of claim 4145 wherein the fibrosing agent is or comprises fibronectin.
4160. The device of claim 4145 wherein the fibrosing agent is or comprises bleomycin.
4161. The device of claim 4145 wherein the fibrosing agent is or comprises CTGF.
4162. The device of claim 4145 wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.
4163. The device of claim 4145 wherein the fibrosing agent is in the form of a particulate.
4164. The device of claim 4145 wherein the composition further comprises an inflammatory cytokine.
4165. The device of claim 4145 wherein the composition further comprises an agent that stimulates cell proliferation.
4166. The device of claim 4145 wherein the composition is in the form of a gel, paste, or spray.
4167. The device of claim 4145 wherein the fibrosing agent is in the form of tufts.
4163. The device of claim 4145, further comprising a polymer.
4169. The device of claim 4145, further comprising a polymeric carrier.
4170. The device of claim 4145 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.
4171. The device of claim 4145 wherein the device delivers the fibrosing agent locally to tissue proximate to the device.
4172. The device of claim 4145, further comprising a coating, wherein the coating comprises the fibrosing agent.
4173. The device of claim 4145, further comprising a coating, wherein the coating is disposed on a surface of the device.
4174. The device of claim 4145, further comprising a coating, wherein the coating directly contacts the device.
4175. The device of claim 4145, further comprising a coating, wherein the coating indirectly contacts the device.
4176. The device of claim 4145, further comprising a coating, wherein the coating partially covers the device.
4177. The device of claim 4145, further comprising a coating, wherein the coating completely covers the device.
4178. The device of claim 4145, further comprising a coating, wherein the coating is a uniform coating.
4179. The device of claim 4145, further comprising a coating, wherein the coating is a non-uniform coating.
4180. The device of claim 4145, further comprising a coating, wherein the coating is a discontinuous coating.
4181. The device of claim 4145, further comprising a coating, wherein the coating is a patterned coating.
4182. The device of claim 4145, further comprising a coating, wherein the coating has a thickness of 100 µm or less.
4183. The device of claim 4145, further comprising a coating, wherein the coating has a thickness of 10 µm or less.
4184. The device of claim 4145, further comprising a coating, wherein the coating adheres to the surface of the device upon deployment of the device.
4185. The device of claim 4145, further comprising a coating, wherein the coating is stable at room temperature for a period of 1 year.
4186. The device of claim 4145, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 0.0001% to about 1% by weight.
4187. The device of claim 4145, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 1% to about 10% by weight.
4188. The device of claim 4145, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 10% to about 25% by weight.
4189. The device of claim 4145, further comprising a coating, wherein the fibrosing agent is present in the coating in an amount ranging between about 25% to about 70% by weight.
4190. The device of claim 4145, further comprising a coating, wherein the coating further comprises a polymer.
4191. The device of claim 4145, further comprising a first coating having a first composition and the second coating having a second composition.
4192. The device of claim 4145, further comprising a first coating having a first composition and the second coating having a second composition, wherein the first composition and the second composition are different.
4193. The device of claim 4145, further comprising a polymer.
4194. The device of claim 4145, further comprising a polymeric carrier.
4195. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a copolymer.
4196. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a block copolymer.
4197. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a random copolymer.
4198. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a biodegradable polymer.
4199. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-biodegradable polymer.
4200. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophilic polymer.
4201. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrophobic polymer.
4202. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophilic domains.
4203. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a polymer having hydrophobic domains.
4204. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a non-conductive polymer.
4205. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises an elastomer.
4206. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrogel.
4207. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a silicone polymer.
4208. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a hydrocarbon polymer.
4209. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a styrene-derived polymer.
4210. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a butadiene polymer.
4211. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a macromer.
4212. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises a poly(ethylene glycol) polymer.
4213. The device of claim 4145, further comprising a polymeric carrier, wherein the polymeric carrier comprises an amorphous polymer.
4214. The device of claim 4145, further comprising a lubricious coating.
4215. The device of claim 4145 wherein the fibrosing agent is located within pores or holes of the device.
4216. The device of claim 4145 wherein the fibrosing agent is located within a channel, lumen, or divet of the device.
4217. The device of claim 4145, further comprising a second pharmaceutically active agent.
4218. The device of claim 4145, further comprising an anti-inflammatory agent.
4219. The device of claim 4145, further comprising an agent that inhibits infection.
4220. The device of claim 4145, further comprising an agent that inhibits infection, wherein the agent is an anthracycline.
4221. The device of claim 4145, further comprising an agent that inhibits infection, wherein the agent is doxorubicin.
4222. The device of claim 4145, further comprising an agent that inhibits infection, wherein the agent is mitoxantrone.
4223. The device of claim 4145, further comprising an agent that inhibits infection, wherein the agent is a fluoropyrimidine.
4224. The device of claim 4145, further comprising an agent that inhibits infection, wherein the agent is 5-fluorouracil (5-FU).
4225. The device of claim 4145, further comprising an agent that inhibits infection, wherein the agent is a folic acid antagonist.
4226. The device of claim 4145, further comprising an agent that inhibits infection, wherein the agent is methotrexate.
4227. The device of claim 4145, further comprising an agent that inhibits infection, wherein the agent is a podophylotoxin.
4228. The device of claim 4145, further comprising an agent that inhibits infection, wherein the agent is etoposide.
CA002536041A 2003-11-10 2004-11-10 Medical implants and fibrosis-inducing agents Abandoned CA2536041A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US51878503P 2003-11-10 2003-11-10
US60/518,785 2003-11-10
US52402303P 2003-11-20 2003-11-20
US52390803P 2003-11-20 2003-11-20
US60/523,908 2003-11-20
US60/524,023 2003-11-20
US57847104P 2004-06-09 2004-06-09
US60/578,471 2004-06-09
US58686104P 2004-07-09 2004-07-09
US60/586,861 2004-07-09
PCT/US2004/037335 WO2005046746A2 (en) 2003-11-10 2004-11-10 Medical implants and fibrosis-inducing agents

Publications (1)

Publication Number Publication Date
CA2536041A1 true CA2536041A1 (en) 2005-05-26

Family

ID=34596199

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002536041A Abandoned CA2536041A1 (en) 2003-11-10 2004-11-10 Medical implants and fibrosis-inducing agents

Country Status (7)

Country Link
US (13) US20050148512A1 (en)
EP (1) EP1691852A2 (en)
JP (1) JP2007513083A (en)
AU (1) AU2004289287A1 (en)
CA (1) CA2536041A1 (en)
IL (1) IL174637A0 (en)
WO (2) WO2005065079A2 (en)

Families Citing this family (822)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241747B1 (en) * 1993-05-03 2001-06-05 Quill Medical, Inc. Barbed Bodily tissue connector
US8795332B2 (en) 2002-09-30 2014-08-05 Ethicon, Inc. Barbed sutures
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US7867275B2 (en) * 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
US7846202B2 (en) * 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
US6302875B1 (en) 1996-10-11 2001-10-16 Transvascular, Inc. Catheters and related devices for forming passageways between blood vessels or other anatomical structures
US5931855A (en) 1997-05-21 1999-08-03 Frank Hoffman Surgical methods using one-way suture
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US6200312B1 (en) * 1997-09-11 2001-03-13 Vnus Medical Technologies, Inc. Expandable vein ligator catheter having multiple electrode leads
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US8288745B2 (en) 1997-10-10 2012-10-16 Senorx, Inc. Method of utilizing an implant for targeting external beam radiation
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US20090030309A1 (en) 2007-07-26 2009-01-29 Senorx, Inc. Deployment of polysaccharide markers
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
US20040097996A1 (en) 1999-10-05 2004-05-20 Omnisonics Medical Technologies, Inc. Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode
US8241274B2 (en) 2000-01-19 2012-08-14 Medtronic, Inc. Method for guiding a medical device
AUPQ573300A0 (en) * 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
US20050271701A1 (en) * 2000-03-15 2005-12-08 Orbus Medical Technologies, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) * 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) * 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20160287708A9 (en) * 2000-03-15 2016-10-06 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
AU2001261625B2 (en) 2000-05-16 2006-04-06 Regents Of The University Of Minnesota High mass throughput particle generation using multiple nozzle spraying
US7204851B2 (en) 2000-08-30 2007-04-17 Sdgi Holdings, Inc. Method and apparatus for delivering an intervertebral disc implant
ATE390899T1 (en) * 2000-08-30 2008-04-15 Warsaw Orthopedic Inc DISC IMPLANTS
US7503936B2 (en) * 2000-08-30 2009-03-17 Warsaw Orthopedic, Inc. Methods for forming and retaining intervertebral disc implants
US20020026244A1 (en) * 2000-08-30 2002-02-28 Trieu Hai H. Intervertebral disc nucleus implants and methods
WO2002041786A2 (en) 2000-11-20 2002-05-30 Senorx, Inc. Tissue site markers for in vivo imaging
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7056331B2 (en) * 2001-06-29 2006-06-06 Quill Medical, Inc. Suture method
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US6848152B2 (en) 2001-08-31 2005-02-01 Quill Medical, Inc. Method of forming barbs on a suture and apparatus for performing same
US6902932B2 (en) * 2001-11-16 2005-06-07 Tissue Regeneration, Inc. Helically organized silk fibroin fiber bundles for matrices in tissue engineering
US8308797B2 (en) 2002-01-04 2012-11-13 Colibri Heart Valve, LLC Percutaneously implantable replacement heart valve device and method of making same
US7022063B2 (en) 2002-01-07 2006-04-04 Paracor Medical, Inc. Cardiac harness
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US6773450B2 (en) 2002-08-09 2004-08-10 Quill Medical, Inc. Suture anchor and method
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US20040088003A1 (en) 2002-09-30 2004-05-06 Leung Jeffrey C. Barbed suture in combination with surgical needle
US8100940B2 (en) 2002-09-30 2012-01-24 Quill Medical, Inc. Barb configurations for barbed sutures
GB0224986D0 (en) 2002-10-28 2002-12-04 Smith & Nephew Apparatus
US6923754B2 (en) 2002-11-06 2005-08-02 Senorx, Inc. Vacuum device and method for treating tissue adjacent a body cavity
US8328710B2 (en) 2002-11-06 2012-12-11 Senorx, Inc. Temporary catheter for biopsy site tissue fixation
US7229405B2 (en) * 2002-11-15 2007-06-12 Paracor Medical, Inc. Cardiac harness delivery device and method of use
EP1560541A2 (en) * 2002-11-15 2005-08-10 Paracor Medical, Inc. Cardiac harness delivery device
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
US7468210B1 (en) * 2002-12-10 2008-12-23 Biosurface Engineering Technologies, Inc. Cross-linked heparin coatings and methods
US7883500B2 (en) * 2003-03-26 2011-02-08 G&L Consulting, Llc Method and system to treat and prevent myocardial infarct expansion
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
US7624487B2 (en) 2003-05-13 2009-12-01 Quill Medical, Inc. Apparatus and method for forming barbs on a suture
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US7169405B2 (en) 2003-08-06 2007-01-30 Warsaw Orthopedic, Inc. Methods and devices for the treatment of intervertebral discs
US8393328B2 (en) 2003-08-22 2013-03-12 BiO2 Medical, Inc. Airway assembly and methods of using an airway assembly
DE202004021943U1 (en) 2003-09-12 2013-05-13 Vessix Vascular, Inc. Selectable eccentric remodeling and / or ablation of atherosclerotic material
GB0325129D0 (en) 2003-10-28 2003-12-03 Smith & Nephew Apparatus in situ
WO2005046747A2 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Intravascular devices and fibrosis-inducing agents
EP1691852A2 (en) * 2003-11-10 2006-08-23 Angiotech International AG Medical implants and fibrosis-inducing agents
US20050107867A1 (en) * 2003-11-17 2005-05-19 Taheri Syde A. Temporary absorbable venous occlusive stent and superficial vein treatment method
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
ATE515245T1 (en) 2003-12-11 2011-07-15 Isto Technologies Inc PARTICLE CARTILAGE SYSTEM
WO2005061023A1 (en) * 2003-12-12 2005-07-07 C. R. Bard, Inc. Implantable medical devices with fluorinated polymer coatings, and methods of coating thereof
CA2550431A1 (en) * 2003-12-19 2005-07-14 Osteotech, Inc. Tissue-derived mesh for orthopedic regeneration
DE10360898A1 (en) * 2003-12-23 2005-07-21 BSH Bosch und Siemens Hausgeräte GmbH clothes dryer
US7794414B2 (en) 2004-02-09 2010-09-14 Emigrant Bank, N.A. Apparatus and method for an ultrasonic medical device operating in torsional and transverse modes
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
WO2005079339A2 (en) * 2004-02-12 2005-09-01 The University Of Akron Improved stent for use in arteries
JP4895826B2 (en) * 2004-02-20 2012-03-14 バイオサーフェス エンジニアリング テクノロジーズ,インク. Bone morphogenetic protein-2 positive modulator
US8048086B2 (en) * 2004-02-25 2011-11-01 Femasys Inc. Methods and devices for conduit occlusion
US10058642B2 (en) 2004-04-05 2018-08-28 Bluesky Medical Group Incorporated Reduced pressure treatment system
US7909805B2 (en) 2004-04-05 2011-03-22 Bluesky Medical Group Incorporated Flexible reduced pressure treatment appliance
US8062272B2 (en) 2004-05-21 2011-11-22 Bluesky Medical Group Incorporated Flexible reduced pressure treatment appliance
MXPA06013177A (en) 2004-05-14 2007-02-14 Quill Medical Inc Suture methods and devices.
MXPA04005080A (en) * 2004-05-27 2005-11-30 Aspid S A De C V Chronic articular inflammation-modulating composition based on collagen-polyvinylpyrrolidone.
US20060019096A1 (en) * 2004-06-01 2006-01-26 Hatton T A Field-responsive superparamagnetic composite nanofibers and methods of use thereof
US20070196457A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070196293A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for treating photo damaged skin
US20070189980A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for treating alopecia
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
US20080019927A1 (en) * 2004-06-07 2008-01-24 Jie Zhang Compositions and methods for dermally treating neuropathy with minoxidil
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070189978A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for dermally treating musculoskeletal pain
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070196323A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Polyvinyl alcohol-containing compositions and methods for dermal delivery of drugs
US20070189977A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Spray-on formulations and methods for dermal delivery of drugs
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20070190124A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
JP4949241B2 (en) * 2004-07-12 2012-06-06 イスト・テクノロジーズ・インコーポレイテッド Tissue matrix system
US8512730B2 (en) 2004-07-12 2013-08-20 Isto Technologies, Inc. Methods of tissue repair and compositions therefor
US8980300B2 (en) 2004-08-05 2015-03-17 Advanced Cardiovascular Systems, Inc. Plasticizers for coating compositions
WO2006026731A1 (en) 2004-08-30 2006-03-09 Spineovations, Inc. Method of treating spinal internal disk derangement
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US8396548B2 (en) 2008-11-14 2013-03-12 Vessix Vascular, Inc. Selective drug delivery in a lumen
US20060058881A1 (en) * 2004-09-16 2006-03-16 Trieu Hai H Intervertebral disc nucleus implants and methods
US20070144535A1 (en) * 2004-09-21 2007-06-28 Hegde Anant V Implant for treatment of sleep disorders
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US20210299056A9 (en) 2004-10-25 2021-09-30 Varian Medical Systems, Inc. Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods
US9114162B2 (en) 2004-10-25 2015-08-25 Celonova Biosciences, Inc. Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
US9107850B2 (en) 2004-10-25 2015-08-18 Celonova Biosciences, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
AU2005298344B2 (en) 2004-10-25 2011-02-10 Varian Medical Systems, Inc. Loadable polyphosphazene-comprising particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US7662082B2 (en) 2004-11-05 2010-02-16 Theragenics Corporation Expandable brachytherapy device
GB0424560D0 (en) * 2004-11-08 2004-12-08 Leuven K U Res & Dev Heart valve tissue engineering
US20080108969A1 (en) * 2005-11-28 2008-05-08 Andrew Kerr Dialysis Catheter
US20070233047A1 (en) * 2005-11-28 2007-10-04 Andrew Kerr Dialysis catheter
WO2006062518A2 (en) 2004-12-08 2006-06-15 Interpore Spine Ltd. Continuous phase composite for musculoskeletal repair
EP1819304B1 (en) 2004-12-09 2023-01-25 Twelve, Inc. Aortic valve repair
WO2012050591A1 (en) * 2010-10-15 2012-04-19 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
EP1841368B1 (en) 2005-01-25 2015-06-10 Covidien LP Structures for permanent occlusion of a hollow anatomical structure
US9452001B2 (en) * 2005-02-22 2016-09-27 Tecres S.P.A. Disposable device for treatment of infections of human limbs
EP1852135B1 (en) * 2005-02-23 2018-04-11 HI-LEX Corporation Medical material, artificial tooth root and method of producing material for clinical use
EP1865970A4 (en) * 2005-03-23 2010-11-10 Childrens Medical Center Minimally invasive clinical treatment method for closure of umbilical hernias
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
US7931681B2 (en) * 2005-04-14 2011-04-26 Warsaw Orthopedic, Inc. Anti-backout mechanism for an implant fastener
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
US8263109B2 (en) 2005-05-09 2012-09-11 Boston Scientific Scimed, Inc. Injectable bulking compositions
US8814567B2 (en) 2005-05-26 2014-08-26 Zimmer Dental, Inc. Dental implant prosthetic device with improved osseointegration and esthetic features
US20070005049A1 (en) * 2005-06-30 2007-01-04 Comben Richard H Apparatus and Method of Treating Urinary Incontinence by Heating Urethra
ATE526378T1 (en) * 2005-08-02 2011-10-15 Tufts College METHOD FOR THE STEP-BY-STEP DEPOSITION OF SILK FIBROIN COATINGS
DE102005038381A1 (en) * 2005-08-13 2007-02-15 Amedo Gmbh Spongy implant
DE202006006920U1 (en) * 2006-04-25 2007-08-30 Biomed Est. Orthopedic anchoring system, for fixation of long bone e.g. tibia, fracture, has two lateral implants, where each implant includes base and post that are arranged orthogonally and coated with active substances
US20070100199A1 (en) * 2005-11-03 2007-05-03 Lilip Lau Apparatus and method of delivering biomaterial to the heart
US20070049941A1 (en) * 2005-08-25 2007-03-01 Lanx, Llc Plate with stabilization
WO2007025290A2 (en) 2005-08-26 2007-03-01 Isto Technologies, Inc. Implants and methods for repair, replacement and treatment of joint disease
US8562346B2 (en) 2005-08-30 2013-10-22 Zimmer Dental, Inc. Dental implant for a jaw with reduced bone volume and improved osseointegration features
JP5438967B2 (en) 2005-08-30 2014-03-12 ジマー デンタル, インコーポレイテッド Dental implant with improved osseointegration features
US20070055147A1 (en) * 2005-09-06 2007-03-08 Honeywell International Inc. Medical devices incorporating radio-opaque and biocompatible coatings
WO2007030601A2 (en) * 2005-09-06 2007-03-15 Tyco Healthcare Group Lp Self contained wound dressing with micropump
JP2009509570A (en) 2005-09-07 2009-03-12 タイコ ヘルスケア グループ リミテッド パートナーシップ Self-contained wound care device
CN101257938A (en) 2005-09-07 2008-09-03 泰科保健集团有限合伙公司 Wound dressing with vacuum reservoir
WO2007033375A2 (en) * 2005-09-14 2007-03-22 Robert Rosen Methods and devices for drug eluding embolization
EP1926459B1 (en) 2005-09-19 2015-01-07 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US20070073218A1 (en) * 2005-09-26 2007-03-29 Lilip Lau Inflatable cardiac device for treating and preventing ventricular remodeling
ITMI20051854A1 (en) * 2005-10-03 2007-04-04 Sambusseti Antonio PATCH FOR THE REPLACEMENT OF A VESCICAL WALL PORTION FOLLOWED BY PARTIAL VESCITECTOMY
CA2562580C (en) 2005-10-07 2014-04-29 Inrad, Inc. Drug-eluting tissue marker
DE102005051342A1 (en) * 2005-10-25 2007-04-26 Goldschmidt Gmbh Encapsulation and controlled release of biologically active drugs with enzymatically degradable hyperbranched carrier polymers
AU2006312092A1 (en) * 2005-11-02 2007-05-18 Aeris Therapeutics, Inc. Polycation-polyanion complexes, compositions and methods of use thereof
WO2007056384A2 (en) * 2005-11-07 2007-05-18 The Board Of Regents Of The University Of Texas System Mesh anchoring system
CN1962155A (en) * 2005-11-10 2007-05-16 鸿富锦精密工业(深圳)有限公司 CO2 laser welding apparatus
US20080215076A1 (en) * 2005-11-14 2008-09-04 Sentinel Group, Llc Gastro-intestinal therapeutic device and method
US7465268B2 (en) 2005-11-18 2008-12-16 Senorx, Inc. Methods for asymmetrical irradiation of a body cavity
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
US9370370B2 (en) * 2005-11-22 2016-06-21 Boston Scientific Scimed, Inc. Shape memory hemostasis band
WO2007064908A2 (en) * 2005-11-30 2007-06-07 The Board Of Trustees Of The Leland Stanford Junior University A system to prevent airway obstruction
WO2007067637A2 (en) * 2005-12-07 2007-06-14 Isto Technologies, Inc. Cartilage repair methods
US7723422B2 (en) 2005-12-23 2010-05-25 Boston Scientific Scimed, Inc. Functionalized block copolymers
US20080243068A1 (en) * 2005-12-29 2008-10-02 Kamal Ramzipoor Methods and apparatus for treatment of venous insufficiency
US9474652B2 (en) * 2006-01-09 2016-10-25 Jack Mentkow Hemostatic agent delivery system
US8609129B2 (en) * 2006-01-09 2013-12-17 Jack Mentkow Hemostatic agent composition, delivery system and method
CA2636957A1 (en) * 2006-01-12 2007-07-19 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
US20070163601A1 (en) * 2006-01-17 2007-07-19 Neil Pollock Apparatus and method for reversible male and female contraceptive implants
US20070185009A1 (en) * 2006-01-20 2007-08-09 Imarx Therapeutics, Inc. Coated catheters
CA2632871A1 (en) * 2006-01-30 2007-08-09 Angiotech Pharmaceuticals, Inc. Sutures and fibrosing agents
CA2641117C (en) 2006-01-31 2018-01-02 Nanocopoeia, Inc. Nanoparticle coating of surfaces
WO2007089881A2 (en) 2006-01-31 2007-08-09 Regents Of The University Of Minnesota Electrospray coating of objects
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
EP1991284A4 (en) * 2006-02-01 2012-07-04 Jake Barralet Bioimplants for use in tissue growth
JP5367692B2 (en) 2006-02-08 2013-12-11 タイレックス・インコーポレイテッド Temporary stiffening mesh prosthesis
US8591531B2 (en) * 2006-02-08 2013-11-26 Tyrx, Inc. Mesh pouches for implantable medical devices
CA2641860C (en) 2006-02-09 2015-07-14 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
US20070233219A1 (en) * 2006-02-16 2007-10-04 Bilal Shafi Polymeric heart restraint
US7598219B2 (en) * 2006-02-24 2009-10-06 Warsaw Orthopedic, Inc. Implants comprising an osteoinductive factor and a contrast agent compatible therewith
US20070264613A1 (en) * 2006-03-07 2007-11-15 Biomed Est. Dental implant
US20070270970A1 (en) * 2006-03-14 2007-11-22 Sdgi Holdings, Inc. Spinal implants with improved wear resistance
US20070270971A1 (en) * 2006-03-14 2007-11-22 Sdgi Holdings, Inc. Intervertebral prosthetic disc with improved wear resistance
US20070233246A1 (en) * 2006-03-31 2007-10-04 Sdgi Holdings, Inc. Spinal implants with improved mechanical response
WO2007115174A2 (en) * 2006-03-31 2007-10-11 Traxtal Inc. System, methods, and instrumentation for image guided prostate treatment
US9017361B2 (en) * 2006-04-20 2015-04-28 Covidien Lp Occlusive implant and methods for hollow anatomical structure
US7879027B2 (en) 2006-04-24 2011-02-01 Warsaw Orthopedic, Inc. Controlled release devices for fusion of osteal structures
US7771414B2 (en) 2006-04-24 2010-08-10 Warsaw Orthopedic, Inc. Controlled release devices for therapeutic treatments of spinal discs
US8642060B2 (en) 2006-04-24 2014-02-04 Warsaw Orthopedic, Inc. Controlled release systems and methods for osteal growth
US8642059B2 (en) 2006-04-24 2014-02-04 Warsaw Orthopedic, Inc. Controlled release systems and methods for intervertebral discs
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US9789161B2 (en) * 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
US7689291B2 (en) * 2006-05-01 2010-03-30 Cardiac Pacemakers, Inc. Lead with fibrous matrix coating and methods related thereto
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
US20070258941A1 (en) * 2006-05-02 2007-11-08 Pfister Brian E Methods and compositions for remediation of disc herniation by modifying structure
US20080262633A1 (en) 2006-05-08 2008-10-23 Williams Michelle Leroux Cancellous bone treated with collagenase and essentially free of blood cells
WO2007133451A1 (en) 2006-05-08 2007-11-22 Nuvasive, Inc. Cancellous bone treated with collegenase and essentially free of blood cells
US7570986B2 (en) * 2006-05-17 2009-08-04 The United States Of America As Represented By The Secretary Of Health And Human Services Teniae coli guided navigation and registration for virtual colonoscopy
AU2016204897B2 (en) * 2006-05-19 2018-11-01 Boston Scientific Scimed, Inc. Method and articles for treatment of stress urinary incontinence
WO2007140331A2 (en) 2006-05-25 2007-12-06 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
JP2009541358A (en) * 2006-06-22 2009-11-26 バイオサーフェス エンジニアリング テクノロジーズ,インク. Compositions and methods for delivering a BMP-2 amplification factor / co-activator to enhance bone formation
US8617046B2 (en) * 2006-06-26 2013-12-31 Ams Research Corporation Floating sling for treatment of incontinence
US7833284B2 (en) * 2006-06-28 2010-11-16 The Cleveland Clinic Foundation Anti-adhesion membrane
US9642891B2 (en) 2006-06-30 2017-05-09 Biomimetic Therapeutics, Llc Compositions and methods for treating rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US7722665B2 (en) 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
US9028859B2 (en) * 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
EP3047860A1 (en) 2006-07-20 2016-07-27 OrbusNeich Medical, Inc. Bioabsorbable polymeric composition for a medical device
US20110276147A1 (en) * 2006-07-20 2011-11-10 Nuvasive, Inc. Bone Graft Substitutes and Methods Thereof
US20080021557A1 (en) * 2006-07-24 2008-01-24 Warsaw Orthopedic, Inc. Spinal motion-preserving implants
US20080021462A1 (en) * 2006-07-24 2008-01-24 Warsaw Orthopedic Inc. Spinal stabilization implants
EP2068622A4 (en) * 2006-07-28 2012-10-10 Ceramoptec Gmbh Method and mixture for in-vivo photochemical cross-linking of collagen
US20080027554A1 (en) * 2006-07-31 2008-01-31 Talmadge Karen D Kit and methods of treatment of an intervertebral disc
US20080051830A1 (en) * 2006-08-24 2008-02-28 Boston Scientific Scimed, Inc. Occluding device and method
US20080050436A1 (en) * 2006-08-25 2008-02-28 Chu Jack F Methods and compounds for obliteration of vessels
EP2062604A4 (en) * 2006-08-28 2011-08-10 Univ Nagoya Nat Univ Corp Bone filling material and kit for the preparation of the same
WO2008033728A2 (en) * 2006-09-11 2008-03-20 Pluromed, Inc. Atraumatic occlusion balloons and skirts, and methods of use thereof
US7544213B2 (en) * 2006-09-12 2009-06-09 Adams Jason P Inflatable hernia patch
US20080097380A1 (en) * 2006-09-21 2008-04-24 Li Kasey K Method and apparatus for creating variable stiffness and/or reduction of soft tissue
US20080075788A1 (en) * 2006-09-21 2008-03-27 Samuel Lee Diammonium phosphate and other ammonium salts and their use in preventing clotting
US20080082177A1 (en) * 2006-09-29 2008-04-03 Chunlin Yang Device for tissue reinforcement having microporous and macroporous structures
US20080082170A1 (en) * 2006-09-29 2008-04-03 Peterman Marc M Apparatus and methods for surgical repair
US20080078411A1 (en) * 2006-10-03 2008-04-03 Restore Medical, Inc. Tongue implant for sleep apnea
US20080078412A1 (en) * 2006-10-03 2008-04-03 Restore Medical, Inc. Tongue implant
US8066750B2 (en) 2006-10-06 2011-11-29 Warsaw Orthopedic, Inc Port structures for non-rigid bone plates
WO2008049082A2 (en) 2006-10-18 2008-04-24 Minnow Medical, Inc. Inducing desirable temperature effects on body tissue
WO2008049087A2 (en) 2006-10-18 2008-04-24 Minnow Medical, Inc. System for inducing desirable temperature effects on body tissue
EP2954868A1 (en) 2006-10-18 2015-12-16 Vessix Vascular, Inc. Tuned rf energy and electrical tissue characterization for selective treatment of target tissues
EP2073754A4 (en) 2006-10-20 2012-09-26 Orbusneich Medical Inc Bioabsorbable polymeric composition and medical device background
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
ES2443526T3 (en) 2006-10-23 2014-02-19 C.R. Bard, Inc. Breast marker
US8579939B2 (en) * 2006-10-30 2013-11-12 Poly-Med, Inc. Silk / absorbable polyester hybrid medical devices and applications thereof
US9439948B2 (en) 2006-10-30 2016-09-13 The Regents Of The University Of Michigan Degradable cage coated with mineral layers for spinal interbody fusion
US8275594B2 (en) * 2006-10-30 2012-09-25 The Regents Of The University Of Michigan Engineered scaffolds for intervertebral disc repair and regeneration and for articulating joint repair and regeneration
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
US8142805B1 (en) * 2006-11-06 2012-03-27 Clemson University Research Foundation Implantable devices including fixed tissues
US20080107711A1 (en) * 2006-11-08 2008-05-08 Alexis Paul Shelokov Bioabsorbable Implantable Material Fortified with Antibiotics for Localized Delivery of Drugs
EP2097513A4 (en) * 2006-11-17 2012-11-28 Cytograft Tissue Engineering Inc Preparation and use of cell-synthesized threads
US20080255550A1 (en) * 2006-11-30 2008-10-16 Minos Medical Systems and methods for less invasive neutralization by ablation of tissue including the appendix and gall bladder
US20080140002A1 (en) * 2006-12-06 2008-06-12 Kamal Ramzipoor System for delivery of biologically active substances with actuating three dimensional surface
US7998313B2 (en) * 2006-12-07 2011-08-16 Georgia-Pacific Consumer Products Lp Inflated fibers of regenerated cellulose formed from ionic liquid/cellulose dope and related products
US9040816B2 (en) 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
WO2008073965A2 (en) 2006-12-12 2008-06-19 C.R. Bard Inc. Multiple imaging mode tissue marker
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
WO2008076973A2 (en) 2006-12-18 2008-06-26 C.R.Bard Inc. Biopsy marker with in situ-generated imaging properties
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
WO2008079983A1 (en) * 2006-12-21 2008-07-03 Vanderbilt University Protein release from tissue graft materials
US7980000B2 (en) 2006-12-29 2011-07-19 Applied Materials, Inc. Vapor dryer having hydrophilic end effector
US20080161890A1 (en) * 2007-01-03 2008-07-03 Boston Scientific Scimed, Inc. Methods, systems, and apparatuses for protecting esophageal tissue during ablation
WO2008081463A2 (en) * 2007-01-04 2008-07-10 Hepacore Ltd. Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
US8383586B2 (en) 2007-01-18 2013-02-26 Warsaw Orthopedic, Inc. Compositions and methods for soft tissue repair
US8105375B2 (en) * 2007-01-19 2012-01-31 The Cleveland Clinic Foundation Method for implanting a cardiovascular valve
US20090287309A1 (en) * 2007-01-30 2009-11-19 Tornier Sas Intra-articular joint replacement
FR2911773B1 (en) 2007-01-30 2009-03-27 Tornier Sas METHOD AND ASSEMBLY OF SURGICAL INSTRUMENTATION FOR POSITIONING A TOTAL REVERSE SHOULDER PROSTHESIS, AND CORRESPONDING PROSTHESIS
US20080188892A1 (en) * 2007-02-01 2008-08-07 Cook Incorporated Vascular occlusion device
WO2008093342A2 (en) 2007-02-01 2008-08-07 Technion Research & Development Foundation Ltd. Albumin fibers and fabrics and methods of generating and using same
US20080188936A1 (en) * 2007-02-02 2008-08-07 Tornier, Inc. System and method for repairing tendons and ligaments
EP2125058B1 (en) 2007-02-07 2014-12-03 Cook Medical Technologies LLC Medical device coatings for releasing a therapeutic agent at multiple rates
US20100233137A1 (en) * 2007-02-27 2010-09-16 Lanx, Inc. Compositions and Methods for Modification of Target Cells and to Their Uses Thereof
WO2008107484A2 (en) * 2007-03-07 2008-09-12 Coloplast A/S Fistula plug comprising ecm
US8287442B2 (en) 2007-03-12 2012-10-16 Senorx, Inc. Radiation catheter with multilayered balloon
US20080228023A1 (en) * 2007-03-15 2008-09-18 Senorx, Inc. Soft body catheter with low friction lumen
US20080233203A1 (en) 2007-03-21 2008-09-25 Jennifer Woodell-May Porous orthapedic materials coated with demineralized bone matrix
US20080234727A1 (en) * 2007-03-22 2008-09-25 Venkat Garigapati Novel Carriers For Coating Growth Factors Onto Sutures
WO2008118896A1 (en) * 2007-03-26 2008-10-02 Dynamic Flowform Corp. Proximally self-locking long bone prosthesis
CN101687384A (en) * 2007-03-26 2010-03-31 康涅狄格大学 electrospun apatite/polymer nano-composite scaffolds
WO2008128075A1 (en) 2007-04-12 2008-10-23 Isto Technologies, Inc. Compositions and methods for tissue repair
US20080255612A1 (en) * 2007-04-13 2008-10-16 Angiotech Pharmaceuticals, Inc. Self-retaining systems for surgical procedures
US7897168B2 (en) * 2007-04-13 2011-03-01 Medtronic Vascular, Inc. Degradable polymers incorporating gamma-butyrolactone
US8239007B2 (en) * 2007-04-13 2012-08-07 Ethicon Endo-Surgert, Inc. Biocompatible nanoparticle compositions and methods
US8430852B2 (en) * 2007-04-17 2013-04-30 Medtronic, Inc. Therapeutic sleeve for implantable medical device
US20080269897A1 (en) * 2007-04-26 2008-10-30 Abhijeet Joshi Implantable device and methods for repairing articulating joints for using the same
US20080268056A1 (en) * 2007-04-26 2008-10-30 Abhijeet Joshi Injectable copolymer hydrogel useful for repairing vertebral compression fractures
US8062364B1 (en) 2007-04-27 2011-11-22 Knee Creations, Llc Osteoarthritis treatment and device
US20080287986A1 (en) * 2007-05-18 2008-11-20 Possis Medical, Inc. Closure device
BRPI0811784A2 (en) * 2007-05-23 2011-05-10 Allergan Inc cross-linked collagen and use thereof
SE531177C2 (en) 2007-05-24 2009-01-13 Cochlear Ltd Distance for implants
US9511076B2 (en) * 2008-05-30 2016-12-06 Clarion Research Group Formulations and methods for recovery from dental surgery
US20080300684A1 (en) * 2007-05-31 2008-12-04 Shelokov Alexis P System and method for controlled delivery of bone morphogenic protein and other bone graft substitutes for bone formation, repair and healing
WO2008151119A2 (en) * 2007-06-01 2008-12-11 Lanx, Llc Compositions and methods for use of scar tissue in repair of weight bearing surfaces
US20090028921A1 (en) * 2007-06-18 2009-01-29 New Jersey Institute Of Technology Electrospun Ceramic-Polymer Composite As A Scaffold For Tissue Repair
US8133553B2 (en) 2007-06-18 2012-03-13 Zimmer, Inc. Process for forming a ceramic layer
US8309521B2 (en) * 2007-06-19 2012-11-13 Zimmer, Inc. Spacer with a coating thereon for use with an implant device
WO2010008822A2 (en) 2008-06-23 2010-01-21 Adhezion Biomedical, Llc Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
US8729121B2 (en) 2007-06-25 2014-05-20 Adhezion Biomedical, Llc Curing accelerator and method of making
WO2009005790A2 (en) * 2007-06-29 2009-01-08 Carbylan Biosurgery, Inc. Sterile thiol-derivatized hyaluronic acid polymer compositions and uses thereof
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
US7790946B2 (en) * 2007-07-06 2010-09-07 Tyco Healthcare Group Lp Subatmospheric pressure wound therapy dressing
US20080082168A1 (en) * 2007-07-31 2008-04-03 Marc Peterman Surgical scaffold to enhance fibrous tissue response
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
US8192351B2 (en) 2007-08-13 2012-06-05 Paracor Medical, Inc. Medical device delivery system having integrated introducer
EP2192907B1 (en) 2007-08-16 2018-04-18 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for therapeutic applications
EP2034010A1 (en) 2007-08-30 2009-03-11 Omrix Biopharmaceuticals Ltd. Compositions suitable for repair and/or treatment of injured spinal tissue
US20090061389A1 (en) 2007-08-30 2009-03-05 Matthew Lomicka Dental implant prosthetic device with improved osseointegration and shape for resisting rotation
US10376685B2 (en) 2007-08-31 2019-08-13 Mermaid Medical Vascular Aps Thrombus detection device and method
US9687333B2 (en) 2007-08-31 2017-06-27 BiO2 Medical, Inc. Reduced profile central venous access catheter with vena cava filter and method
US8668712B2 (en) 2007-08-31 2014-03-11 BiO2 Medical, Inc. Multi-lumen central access vena cava filter apparatus and method of using same
US8613753B2 (en) 2007-08-31 2013-12-24 BiO2 Medical, Inc. Multi-lumen central access vena cava filter apparatus and method of using same
US9039728B2 (en) 2007-08-31 2015-05-26 BiO2 Medical, Inc. IVC filter catheter with imaging modality
US8641774B2 (en) * 2007-09-14 2014-02-04 The Curators Of The University Of Missouri Synthetic osteochondral composite and method of fabrication thereof
US20100234948A1 (en) * 2009-03-11 2010-09-16 Exogenesis Corporation Methods for improving the bioactivity characteristics of a surface and objects with surfaces improved thereby
EP2550978B1 (en) 2007-09-27 2014-04-30 Ethicon, LLC A system for cutting a retainer in a suture
WO2009042829A1 (en) * 2007-09-27 2009-04-02 Stephen Massia Bioactive hydrogel fibers
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
US8608049B2 (en) 2007-10-10 2013-12-17 Zimmer, Inc. Method for bonding a tantalum structure to a cobalt-alloy substrate
WO2009051945A1 (en) * 2007-10-15 2009-04-23 Cardiac Pacemakers, Inc. Conductive composite electrode material
WO2009055186A2 (en) * 2007-10-19 2009-04-30 Cardiac Pacemakers, Inc. Fibrous electrode material
US20090112332A1 (en) * 2007-10-31 2009-04-30 Alexis Paul Shelokov Bone graft and bone graft substitutes with antibiotics for sustained, localized release of antibiotics for reducing postoperative surgical wound infection in spinal and other bone surgery
US20090149958A1 (en) * 2007-11-01 2009-06-11 Ann Prewett Structurally reinforced spinal nucleus implants
EP2742875B1 (en) * 2007-11-14 2016-02-24 Adhezion Biomedical, LLC Cyanoacrylate tissue adhesives
US8506982B2 (en) * 2007-11-14 2013-08-13 Osteosphere, Llc Development of a human colloidal bone graft material
US20110091862A1 (en) * 2007-11-14 2011-04-21 Osteosphere, Llc Generation of an hla-negative osteogenic precursor cell line
JP5670196B2 (en) 2007-11-16 2015-02-18 バイセプト セラピューティクス、インク. Compositions and methods for treating purpura
US9345809B2 (en) * 2007-11-28 2016-05-24 Fziomed, Inc. Carboxymethylcellulose polyethylene glycol compositions for medical uses
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8394784B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
EP2227212A1 (en) * 2007-12-07 2010-09-15 BioCure, Inc. Bone substitute
US8629314B2 (en) * 2007-12-18 2014-01-14 Ethicon, Inc. Surgical barriers having adhesion inhibiting properties
US8299316B2 (en) * 2007-12-18 2012-10-30 Ethicon, Inc. Hemostatic device
US20090163919A1 (en) * 2007-12-19 2009-06-25 Peter Tarcha Devices, systems, and methods for delivery of a pharmaceutical to a subject's spine
JP5518737B2 (en) 2007-12-19 2014-06-11 エシコン・エルエルシー Indwelling suture with thermal contact mediator retainer
US8916077B1 (en) 2007-12-19 2014-12-23 Ethicon, Inc. Self-retaining sutures with retainers formed from molten material
US8118834B1 (en) 2007-12-20 2012-02-21 Angiotech Pharmaceuticals, Inc. Composite self-retaining sutures and method
SE532467C2 (en) * 2007-12-27 2010-01-26 Numat As Implant cleaning tool for cleaning a metallic implant
CA2781407A1 (en) 2008-01-14 2009-07-23 Michael P. Brenzel Apparatus and methods for fracture repair
US8172908B2 (en) * 2008-01-17 2012-05-08 The University Of Hong Kong Implant for tissue engineering
US9072810B2 (en) 2008-01-17 2015-07-07 The University Of Hong Kong Implant for tissue engineering
US8360950B2 (en) 2008-01-24 2013-01-29 Senorx, Inc. Multilumen brachytherapy balloon catheter
CA2712843A1 (en) * 2008-01-24 2009-07-30 University Of Utah Research Foundation Adhesive complex coacervates and methods of making and using thereof
JP5829400B2 (en) * 2008-01-24 2015-12-09 レメドー バイオメッド リミテッド Erythropoietin and fibronectin composition for bone regeneration
US8283384B2 (en) 2008-01-24 2012-10-09 University Of Utah Research Foundation Adhesive complex coacervates and methods of making and using thereof
EP3970664A1 (en) * 2008-01-28 2022-03-23 Implantica Patent Ltd. A fluid movement device
US20090192528A1 (en) * 2008-01-29 2009-07-30 Biomet Biologics, Inc. Method and device for hernia repair
US8875607B2 (en) * 2008-01-30 2014-11-04 Ethicon, Inc. Apparatus and method for forming self-retaining sutures
US8615856B1 (en) 2008-01-30 2013-12-31 Ethicon, Inc. Apparatus and method for forming self-retaining sutures
WO2009099767A2 (en) 2008-01-31 2009-08-13 C.R. Bard, Inc. Biopsy tissue marker
JP2011511668A (en) * 2008-02-07 2011-04-14 トラスティーズ オブ タフツ カレッジ Three-dimensional silk hydroxyapatite composition
US8808314B2 (en) 2008-02-18 2014-08-19 Covidien Lp Device and method for deploying and attaching an implant to a biological tissue
US8317808B2 (en) 2008-02-18 2012-11-27 Covidien Lp Device and method for rolling and inserting a prosthetic patch into a body cavity
US8758373B2 (en) 2008-02-18 2014-06-24 Covidien Lp Means and method for reversibly connecting a patch to a patch deployment device
US9833240B2 (en) 2008-02-18 2017-12-05 Covidien Lp Lock bar spring and clip for implant deployment device
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device
US9301826B2 (en) 2008-02-18 2016-04-05 Covidien Lp Lock bar spring and clip for implant deployment device
CA2715740C (en) 2008-02-18 2014-05-27 Polytouch Medical Ltd. A device and method for deploying and attaching a patch to a biological tissue
US9393002B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device
US9034002B2 (en) 2008-02-18 2015-05-19 Covidien Lp Lock bar spring and clip for implant deployment device
US9398944B2 (en) 2008-02-18 2016-07-26 Covidien Lp Lock bar spring and clip for implant deployment device
US9044235B2 (en) 2008-02-18 2015-06-02 Covidien Lp Magnetic clip for implant deployment device
WO2009105579A2 (en) * 2008-02-19 2009-08-27 Garahan Patrick J Portable holder for beverage containers
WO2009105606A1 (en) * 2008-02-21 2009-08-27 Lanx, Llc Compositions and methods for use of scar tissue in repair of weight bearing surfaces
ES2706295T3 (en) 2008-02-21 2019-03-28 Ethicon Llc Method and apparatus for raising retainers in self-retaining sutures
US8216273B1 (en) 2008-02-25 2012-07-10 Ethicon, Inc. Self-retainers with supporting structures on a suture
US8641732B1 (en) 2008-02-26 2014-02-04 Ethicon, Inc. Self-retaining suture with variable dimension filament and method
US8469961B2 (en) 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
US8293813B2 (en) * 2008-03-05 2012-10-23 Biomet Manufacturing Corporation Cohesive and compression resistant demineralized bone carrier matrix
US8298200B2 (en) 2009-06-01 2012-10-30 Tyco Healthcare Group Lp System for providing continual drainage in negative pressure wound therapy
US8021347B2 (en) 2008-07-21 2011-09-20 Tyco Healthcare Group Lp Thin film wound dressing
JP2011513034A (en) 2008-03-10 2011-04-28 マーフライ・2・リミテッド・パートナーシップ Bone cement composition
US20090325296A1 (en) 2008-03-25 2009-12-31 New Jersey Institute Of Technology Electrospun electroactive polymers for regenerative medicine applications
US20090248066A1 (en) * 2008-03-28 2009-10-01 David Hjalmar Wilkie Elastic barbed suture and tissue support system
FR2929502B1 (en) * 2008-04-04 2011-04-08 Clariance NUCLEIC IMPLANT.
WO2009144708A1 (en) * 2008-04-14 2009-12-03 Ganot, Arie Augmentation and treatment of gingival defects
CN102026619A (en) * 2008-04-14 2011-04-20 先进科技及再生医学有限责任公司 Liquid buffered GDF-5 formulations
EP3530196A1 (en) 2008-04-15 2019-08-28 Ethicon, LLC Self-retaining sutures with bi-directional retainers or uni-directional retainers
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US9289409B2 (en) * 2008-04-18 2016-03-22 Warsaw Orthopedic, Inc. Sulindac formulations in a biodegradable material
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US8846068B2 (en) 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US20090270787A1 (en) * 2008-04-23 2009-10-29 Abbott Cardiovascular Systems Inc. Systems and methods for creating enlarged migration channels for therapeutic agents within the endothelium
US11464518B2 (en) 2008-05-01 2022-10-11 Aneuclose Llc Proximal concave neck bridge with central lumen and distal net for occluding cerebral aneurysms
US11484322B2 (en) 2018-01-03 2022-11-01 Aneuclose Llc Aneurysm neck bridge with a closeable opening or lumen through which embolic material is inserted into the aneurysm sac
US11471163B2 (en) 2008-05-01 2022-10-18 Aneuclose Llc Intrasaccular aneurysm occlusion device with net or mesh expanded by string-of-pearls embolies
US20160374690A9 (en) * 2010-10-21 2016-12-29 Robert A. Connor Devices and Methods for Occluding a Cerebral Aneurysm
WO2009136941A1 (en) 2008-05-09 2009-11-12 Nbr Pathfinder Llc Composition and methods of treatment of bacterial meningitis
EP2299951B1 (en) 2008-05-16 2012-03-07 Conceptus, Inc. Occlusion device and system for occluding a reproductive body lumen
US20090297603A1 (en) * 2008-05-29 2009-12-03 Abhijeet Joshi Interspinous dynamic stabilization system with anisotropic hydrogels
US8293838B2 (en) * 2008-06-20 2012-10-23 Adhezion Biomedical, Llc Stable and sterile tissue adhesive composition with a controlled high viscosity
US8198344B2 (en) 2008-06-20 2012-06-12 Adhezion Biomedical, Llc Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator
US8257326B2 (en) 2008-06-30 2012-09-04 Tyco Healthcare Group Lp Apparatus for enhancing wound healing
US9095396B2 (en) 2008-07-02 2015-08-04 Zimmer Dental, Inc. Porous implant with non-porous threads
US8231387B2 (en) 2008-07-02 2012-07-31 Zimmer, Inc. Porous implant with non-porous threads
US8562348B2 (en) 2008-07-02 2013-10-22 Zimmer Dental, Inc. Modular implant with secured porous portion
US8899982B2 (en) 2008-07-02 2014-12-02 Zimmer Dental, Inc. Implant with structure for securing a porous portion
CA2729308C (en) 2008-07-08 2016-11-22 Tyco Healthcare Group Lp Portable negative pressure wound therapy device
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US8557271B2 (en) * 2008-07-16 2013-10-15 Warsaw Orthopedic, Inc. Drug depot implantable within a joint
US8202531B2 (en) * 2008-07-23 2012-06-19 Warsaw Orthopedic, Inc. Drug depots having one or more anchoring members
US9492375B2 (en) 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
US8968373B2 (en) * 2008-07-24 2015-03-03 Warsaw Orthopedic, Inc. Cortical tenting screw
IT1391734B1 (en) * 2008-07-29 2012-01-27 Anika Therapeutics Srl NEW BIOMATERIALS, THEIR PREPARATION FOR ELECTROSPINNING AND THEIR USE IN BIOMEDICAL AND SURGICAL FIELDS.
US8678008B2 (en) * 2008-07-30 2014-03-25 Ethicon, Inc Methods and devices for forming an auxiliary airway for treating obstructive sleep apnea
US8556797B2 (en) * 2008-07-31 2013-10-15 Ethicon, Inc. Magnetic implants for treating obstructive sleep apnea and methods therefor
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
RU2457855C2 (en) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Antiviral and antimicrobial composition
WO2010017451A2 (en) * 2008-08-07 2010-02-11 Exogenesis Corporation Medical device for bone implant and method for producing such a device
DK2309961T3 (en) 2008-08-08 2018-03-12 Smith & Nephew Inc Wound dressing of continuous fibers
US8413661B2 (en) 2008-08-14 2013-04-09 Ethicon, Inc. Methods and devices for treatment of obstructive sleep apnea
US8039433B2 (en) * 2008-08-19 2011-10-18 Warsaw Orthopedic, Inc. Osteogenic compositions containing a coloring agent
US10010500B2 (en) * 2008-08-21 2018-07-03 Biomet Manufacturing, Llc Ceramic implants affording controlled release of active materials
US8642063B2 (en) * 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
JP5722217B2 (en) 2008-09-02 2015-05-20 アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエAllergan Holdings France S.A.S. Yarn of hyaluronic acid and / or its derivative, method for its preparation and use thereof
US9414968B2 (en) 2008-09-05 2016-08-16 Smith & Nephew, Inc. Three-dimensional porous film contact layer with improved wound healing
MX2011002555A (en) 2008-09-09 2011-08-03 Biomimetic Therapeutics Inc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries.
MX2011002593A (en) * 2008-09-11 2011-09-06 Bacterin Int Inc Elastomeric article having a broad spectrum antimicrobial agent and method of making.
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US9149319B2 (en) * 2008-09-23 2015-10-06 Lanx, Llc Methods and compositions for stabilization of a vertebra
US20100080791A1 (en) * 2008-09-26 2010-04-01 Rousseau Robert A Composition and Method For Treating Tissue Defects
US20100082064A1 (en) * 2008-09-30 2010-04-01 Iksoo Chun Method for coating metallic surfaces of medical devices with an anti-infective agent
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
AU2009305958B9 (en) 2008-10-20 2013-07-11 Covidien Lp A device for attaching a patch to a biological tissue
US8343088B2 (en) * 2008-10-21 2013-01-01 Douglas Bates Apparatus and method for treating occluded infection collections of the digestive tract
US8561616B2 (en) 2008-10-24 2013-10-22 Ethicon, Inc. Methods and devices for the indirect displacement of the hyoid bone for treating obstructive sleep apnea
US9623222B2 (en) * 2008-10-30 2017-04-18 Warsaw Orthopedic, Inc. Drug depot with anchor
US8561617B2 (en) 2008-10-30 2013-10-22 Ethicon, Inc. Implant systems and methods for treating obstructive sleep apnea
US9161903B2 (en) * 2008-10-31 2015-10-20 Warsaw Orthopedic, Inc. Flowable composition that hardens on delivery to a target tissue site beneath the skin
US8609128B2 (en) * 2008-10-31 2013-12-17 Adhezion Biomedical, Llc Cyanoacrylate-based liquid microbial sealant drape
US8652510B2 (en) 2008-10-31 2014-02-18 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US9254133B2 (en) 2008-10-31 2016-02-09 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
SG196767A1 (en) 2008-11-03 2014-02-13 Ethicon Llc Length of self-retaining suture and method and device for using the same
US20100114314A1 (en) 2008-11-06 2010-05-06 Matthew Lomicka Expandable bone implant
EP2355737B1 (en) 2008-11-17 2021-08-11 Boston Scientific Scimed, Inc. Selective accumulation of energy without knowledge of tissue topography
US8580240B1 (en) 2008-11-19 2013-11-12 University Of Kentucky Research Foundation Compounds and methods for reducing the occurrence of post-surgical adhesions
DE102008059201A1 (en) * 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ precipitating drug solutions
US20100137908A1 (en) * 2008-12-01 2010-06-03 Zimmer Spine, Inc. Dynamic Stabilization System Components Including Readily Visualized Polymeric Compositions
US8800567B2 (en) * 2008-12-01 2014-08-12 Ethicon, Inc. Implant systems and methods for treating obstructive sleep apnea
US8783258B2 (en) 2008-12-01 2014-07-22 Ethicon, Inc. Implant systems and methods for treating obstructive sleep apnea
US9204954B2 (en) * 2008-12-15 2015-12-08 Allergan, Inc. Knitted scaffold with diagonal yarn
US9326840B2 (en) 2008-12-15 2016-05-03 Allergan, Inc. Prosthetic device and method of manufacturing the same
US9308070B2 (en) * 2008-12-15 2016-04-12 Allergan, Inc. Pliable silk medical device
US9204953B2 (en) 2008-12-15 2015-12-08 Allergan, Inc. Biocompatible surgical scaffold with varying stretch
CN105063875A (en) 2008-12-15 2015-11-18 阿勒根公司 Manufacturing method for knitted mesh of prosthetic device
US20100151114A1 (en) * 2008-12-17 2010-06-17 Zimmer, Inc. In-line treatment of yarn prior to creating a fabric
US20100160731A1 (en) * 2008-12-22 2010-06-24 Marc Giovannini Ultrasound-visualizable endoscopic access system
US8980317B2 (en) * 2008-12-23 2015-03-17 Warsaw Orthopedic, Inc. Methods and compositions for treating infections comprising a local anesthetic
NZ593892A (en) 2008-12-23 2013-11-29 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
JP5453453B2 (en) 2008-12-30 2014-03-26 シー・アール・バード・インコーポレーテッド Marker transmission device for placement of tissue markers
US9579524B2 (en) 2009-02-11 2017-02-28 Hologic, Inc. Flexible multi-lumen brachytherapy device
US9248311B2 (en) 2009-02-11 2016-02-02 Hologic, Inc. System and method for modifying a flexibility of a brachythereapy catheter
CN102316823B (en) * 2009-02-11 2016-06-08 新加坡南洋理工大学 Multi-layered surgical prosthesis
US8371308B2 (en) 2009-02-17 2013-02-12 Ethicon, Inc. Magnetic implants and methods for treating an oropharyngeal condition
KR101781653B1 (en) 2009-02-20 2017-09-25 코비디엔 엘피 Methods and devices for venous occlusion for the treatment of venous insufficiency
US10143455B2 (en) 2011-07-20 2018-12-04 Covidien LLP Enhanced ultrasound visualization of intravascular devices
US7964208B2 (en) 2009-02-25 2011-06-21 Warsaw Orthopedic, Inc. System and methods of maintaining space for augmentation of the alveolar ridge
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100226959A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Matrix that prolongs growth factor release
JP5988588B2 (en) * 2009-03-10 2016-09-07 ザ ジョーンズ ホプキンズ ユニバーシティThe Johns Hopkins University Biological tissue bonding and repair device and method of use thereof
US9192655B2 (en) 2009-03-12 2015-11-24 New Jersey Institute Of Technology System and method for a hydrogel and hydrogel composite for cartilage repair applications
US9334476B2 (en) 2009-03-12 2016-05-10 New Jersey Institute Of Technology Method for nerve growth and repair using a piezoelectric scaffold
US9476026B2 (en) 2009-03-12 2016-10-25 New Jersey Institute Of Technology Method of tissue repair using a piezoelectric scaffold
US9771557B2 (en) 2009-03-12 2017-09-26 New Jersey Institute Of Technology Piezoelectric scaffold for nerve growth and repair
US8307831B2 (en) 2009-03-16 2012-11-13 Ethicon, Inc. Implant systems and methods for treating obstructive sleep apnea
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
WO2010118298A2 (en) * 2009-04-09 2010-10-14 University Of Virginia Patent Foundation Compositions and methods for bioactive coatings to improve allograft incorporation
US10207126B2 (en) 2009-05-11 2019-02-19 Cytyc Corporation Lumen visualization and identification system for multi-lumen balloon catheter
US20110196321A1 (en) 2009-06-10 2011-08-11 Tyco Healthcare Group Lp Fluid Collection Canister Including Canister Top with Filter Membrane and Negative Pressure Wound Therapy Systems Including Same
US8556957B2 (en) * 2009-06-18 2013-10-15 Medtronic Vascular, Inc. Biodegradable medical device with hydroxyapatite filaments and biodegradable polymer fibers
US20100324516A1 (en) 2009-06-18 2010-12-23 Tyco Healthcare Group Lp Apparatus for Vacuum Bridging and/or Exudate Collection
US9707058B2 (en) 2009-07-10 2017-07-18 Zimmer Dental, Inc. Patient-specific implants with improved osseointegration
US20110014587A1 (en) * 2009-07-16 2011-01-20 Warsaw Orthopedic, Inc. System and methods of preserving an oral socket
US8617583B2 (en) 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US9539068B2 (en) * 2009-07-24 2017-01-10 Warsaw Orthopedic, Inc. Implantable screw and system for socket preservation
US20110021869A1 (en) * 2009-07-24 2011-01-27 Hilary John Cholhan Single-incision minimally-invasive surgical repair of pelvic organ/vaginal prolapse conditions
WO2011017031A2 (en) * 2009-07-27 2011-02-10 The Regents Of The University Of California Prohealing endovascular devices
FR2948584B1 (en) * 2009-07-30 2012-08-03 Prod Dentaires Pierre Rolland APPLICATION TIP
US8653029B2 (en) 2009-07-30 2014-02-18 Warsaw Orthopedic, Inc. Flowable paste and putty bone void filler
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US8906045B2 (en) 2009-08-17 2014-12-09 Covidien Lp Articulating patch deployment device and method of use
WO2011021082A1 (en) 2009-08-17 2011-02-24 PolyTouch Medical, Inc. Means and method for reversibly connecting an implant to a deployment device
JP5789799B2 (en) * 2009-08-21 2015-10-07 国立研究開発法人農業生物資源研究所 Porous body manufacturing method, cell or tissue supply support manufacturing method, and tissue supply body manufacturing method
EP2475330A1 (en) * 2009-09-11 2012-07-18 Allergan, Inc. Prosthetic device and method of manufacturing the same
US9271925B2 (en) 2013-03-11 2016-03-01 Bioinspire Technologies, Inc. Multi-layer biodegradable device having adjustable drug release profile
EP2477617B1 (en) 2009-09-18 2018-01-31 Bioinspire Technologies Inc. Free-standing biodegradable patch
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
US9877862B2 (en) * 2009-10-29 2018-01-30 Ethicon, Inc. Tongue suspension system with hyoid-extender for treating obstructive sleep apnea
US9326886B2 (en) 2009-10-29 2016-05-03 Ethicon, Inc. Fluid filled implants for treating obstructive sleep apnea
US8597192B2 (en) 2009-10-30 2013-12-03 Warsaw Orthopedic, Inc. Ultrasonic devices and methods to diagnose pain generators
US9974683B2 (en) * 2009-10-30 2018-05-22 Ethicon, Inc. Flexible implants having internal volume shifting capabilities for treating obstructive sleep apnea
WO2011060079A1 (en) * 2009-11-10 2011-05-19 The Trustees Of Columbia University In The City Of New York Compositions and methods for wound treatment
US20130226234A1 (en) 2009-11-16 2013-08-29 Angiotech Pharmaceuticals, Inc. Braided self-retaining sutures and methods
US8602782B2 (en) 2009-11-24 2013-12-10 Zimmer Dental, Inc. Porous implant device with improved core
EP2504039A4 (en) 2009-11-25 2014-07-02 Univ Loma Linda Med Chitosan-based hemostatic textile
US8632488B2 (en) 2009-12-15 2014-01-21 Ethicon, Inc. Fluid filled implants for treating medical conditions
US20110152896A1 (en) * 2009-12-21 2011-06-23 Purvis Jr Jerry G Patch Plug for Extended Coverage During and After Hernia Surgery and Method of Anchoring Patch Plug
WO2011090628A2 (en) 2009-12-29 2011-07-28 Angiotech Pharmaceuticals, Inc. Bidirectional self-retaining sutures with laser-marked and/or non-laser marked indicia and methods
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US20110171311A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives
FR2955032B1 (en) * 2010-01-14 2012-03-02 Urgo Lab NEW DRESSING COMPRISING PARTICULATE AGGLOMERATES CAPABLE OF GELIFIER OR RAPIDLY SOLUBULIZE
FR2955033B1 (en) * 2010-01-14 2012-03-02 Urgo Lab NEW DRESSING COMPRISING A MICROFIBRE OR NANOFIBRE SAIL CAPABLE OF GELIFIER OR SOLUBILIZE
WO2011088172A1 (en) 2010-01-15 2011-07-21 Brenzel Michael P Rotary-rigid orthopaedic rod
AU2011207550B2 (en) 2010-01-20 2016-03-10 Conventus Orthopaedics, Inc. Apparatus and methods for bone access and cavity preparation
US8475824B2 (en) 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
US8758791B2 (en) 2010-01-26 2014-06-24 Warsaw Orthopedic, Inc. Highly compression resistant matrix with porous skeleton
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US9125902B2 (en) * 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
SG182621A1 (en) * 2010-02-04 2012-08-30 Novabay Pharmaceuticals Inc Polysaccharide based antimicrobial formulations
US8492335B2 (en) 2010-02-22 2013-07-23 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US8361144B2 (en) 2010-03-01 2013-01-29 Colibri Heart Valve Llc Percutaneously deliverable heart valve and methods associated therewith
CN103002824B (en) * 2010-03-08 2015-07-29 康文图斯整形外科公司 For the device and method of fixing bone implant
US20110218559A1 (en) * 2010-03-08 2011-09-08 Tropsha Yelena G Oxidized polypropylene mesh materials for tissue in growth
US9180166B2 (en) 2010-03-12 2015-11-10 New Jersey Institute Of Technology Cartilage repair systems and applications utilizing a glycosaminoglycan mimic
KR101764451B1 (en) * 2010-03-12 2017-08-02 알러간 인더스트리 에스에이에스 A Fluid Composition Comprising A Hyaluronan Polymer and Mannitol For Improving Skin Condition
EP2550027B2 (en) 2010-03-22 2019-03-20 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
ES2672622T3 (en) * 2010-03-25 2018-06-15 Lifecell Corporation Preparation of regenerative tissue frames
SA111320355B1 (en) * 2010-04-07 2015-01-08 Baxter Heathcare S A Hemostatic sponge
JP2013523318A (en) 2010-04-09 2013-06-17 べシックス・バスキュラー・インコーポレイテッド Power generation and control equipment for tissue treatment
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US9408652B2 (en) 2010-04-27 2016-08-09 Tornier Sas Intra-articular joint replacement and method
US8501690B2 (en) 2010-04-30 2013-08-06 John G. Stark Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
KR20170121318A (en) 2010-05-04 2017-11-01 에티컨, 엘엘씨 Self-retaining systems having laser-cut retainers
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US20110277777A1 (en) * 2010-05-14 2011-11-17 Tyco Healthcare Group Lp System and Method for Diverticulitis Treatment
US8858577B2 (en) 2010-05-19 2014-10-14 University Of Utah Research Foundation Tissue stabilization system
US8945156B2 (en) 2010-05-19 2015-02-03 University Of Utah Research Foundation Tissue fixation
US9309019B2 (en) 2010-05-21 2016-04-12 Adhezion Biomedical, Llc Low dose gamma sterilization of liquid adhesives
WO2011149907A1 (en) 2010-05-24 2011-12-01 University Of Utah Research Foundation Reinforced adhesive complex coacervates and methods of making and using thereof
CN104873237B (en) 2010-06-11 2017-08-08 伊西康有限责任公司 For endoscope type and the suture means of delivery of robot assisted formula surgical operation
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US20110306820A1 (en) * 2010-06-14 2011-12-15 Coloplast A/S Method of treating incontinence
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
JP5936610B2 (en) 2010-06-28 2016-06-22 コリブリ ハート バルブ エルエルシーColibri Heart Valve Llc Device for intracavity delivery of an intravascular injection device
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8246571B2 (en) 2010-08-24 2012-08-21 Warsaw Orthopedic, Inc. Drug storage and delivery device having a retaining member
US9352172B2 (en) 2010-09-30 2016-05-31 Hologic, Inc. Using a guide member to facilitate brachytherapy device swap
US9022914B2 (en) 2010-10-01 2015-05-05 Varian Medical Systems Inc. Laser accelerator driven particle brachytherapy devices, systems, and methods
US8664463B2 (en) 2010-10-06 2014-03-04 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Reversible adhesives
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US11207109B2 (en) 2010-10-20 2021-12-28 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
WO2014190289A2 (en) 2013-05-23 2014-11-27 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants
US10525169B2 (en) 2010-10-20 2020-01-07 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US11291483B2 (en) 2010-10-20 2022-04-05 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants
US11484627B2 (en) 2010-10-20 2022-11-01 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US10525168B2 (en) 2010-10-20 2020-01-07 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US20120101593A1 (en) 2010-10-20 2012-04-26 BIOS2 Medical, Inc. Implantable polymer for bone and vascular lesions
US11058796B2 (en) 2010-10-20 2021-07-13 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US20120109301A1 (en) 2010-11-03 2012-05-03 Zimmer, Inc. Modified Polymeric Materials And Methods Of Modifying Polymeric Materials
US11007296B2 (en) 2010-11-03 2021-05-18 Ethicon, Inc. Drug-eluting self-retaining sutures and methods relating thereto
NZ704801A (en) 2010-11-09 2015-10-30 Ethicon Llc Emergency self-retaining sutures and packaging
EP2637708A2 (en) 2010-11-12 2013-09-18 University of Utah Research Foundation Simple adhesive coacervates and methods of making and using thereof
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
WO2012075451A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Clonidine and gaba compounds in a biodegradable polymer carrier
WO2012075447A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Compositions and methods for delivering clonidine and bupivacaine to a target tissue site
ES2764117T3 (en) * 2010-12-13 2020-06-02 Theradep Tech Inc Implantable medical devices
SG10201601962WA (en) 2010-12-14 2016-04-28 Colibri Heart Valve Llc Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
US10342992B2 (en) 2011-01-06 2019-07-09 Hologic, Inc. Orienting a brachytherapy applicator
WO2012100095A1 (en) 2011-01-19 2012-07-26 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
US8852214B2 (en) 2011-02-04 2014-10-07 University Of Utah Research Foundation System for tissue fixation to bone
RU2746457C2 (en) 2011-03-23 2021-04-14 ЭТИКОН ЭлЭлСи Self-retaining suture with an adjustable loop
US9302034B2 (en) 2011-04-04 2016-04-05 Smith & Nephew, Inc. Negative pressure wound therapy dressing
KR20130131471A (en) 2011-04-08 2013-12-03 코비디엔 엘피 Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
JP6189827B2 (en) 2011-04-13 2017-08-30 ニュー ジャージー インスティテューツ オブ テクノロジー Systems and methods for electrospinning biodegradable scaffolds for bone repair
WO2012145594A2 (en) * 2011-04-20 2012-10-26 Trustees Of Tufts College Molded regenerated silk geometries using temperature control and mechanical processing
US9492383B2 (en) 2011-04-20 2016-11-15 Carbylan Therapeutics, Inc. Rapid in-situ gel forming compositions prepared via reaction of vinyl sulfone derivatized hyaluronic acid with thiol derivatized polyethylene glycol at alkaline pH
EP2701623B1 (en) 2011-04-25 2016-08-17 Medtronic Ardian Luxembourg S.à.r.l. Apparatus related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
CN107412002A (en) 2011-06-03 2017-12-01 阿勒根公司 Dermal filler composition including antioxidant
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US20130172931A1 (en) 2011-06-06 2013-07-04 Jeffrey M. Gross Methods and devices for soft palate tissue elevation procedures
WO2012168678A1 (en) 2011-06-07 2012-12-13 Smith & Nephew Plc Wound contacting members and methods
US9205241B2 (en) 2011-07-12 2015-12-08 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive material
US9132194B2 (en) 2011-07-12 2015-09-15 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive sheet containing a drug depot
US9579030B2 (en) 2011-07-20 2017-02-28 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
CN103813829B (en) 2011-07-22 2016-05-18 波士顿科学西美德公司 There is the neuromodulation system of the neuromodulation element that can be positioned in spiral guiding piece
JP5689765B2 (en) * 2011-07-29 2015-03-25 富士フイルム株式会社 Carbon dioxide separation member, method for producing the same, and carbon dioxide separation module
US9315798B2 (en) 2011-08-22 2016-04-19 Exogenesis Corporation Methods for improving the bioactivity characteristics of a surface and objects with surfaces improved thereby
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
DE102011082960A1 (en) * 2011-09-19 2013-03-21 Resorba Wundversorgung Gmbh & Co. Kg Shaped body with collagen-containing composite material for insertion into a bone defect site
KR101349667B1 (en) * 2011-09-20 2014-01-20 차의과학대학교 산학협력단 Medical wound dressing using hydrolysate from silkworm gland and manufacturing method thereof
WO2013042869A1 (en) * 2011-09-20 2013-03-28 Republic Of Korea (Management : Rural Development Administration) Medical dressing using silkworm gland-derived hydrolysate and method of manufacturing the same
US8905033B2 (en) 2011-09-28 2014-12-09 Ethicon, Inc. Modular tissue securement systems
US9186210B2 (en) 2011-10-10 2015-11-17 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US10085799B2 (en) 2011-10-11 2018-10-02 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
US9162046B2 (en) 2011-10-18 2015-10-20 Boston Scientific Scimed, Inc. Deflectable medical devices
ES2694586T3 (en) * 2011-10-18 2018-12-21 Anaxiom Corporation Apparatus for the treatment of a patient by intentional occlusion of a blood vessel
WO2013059202A1 (en) 2011-10-18 2013-04-25 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
US9161855B2 (en) 2011-10-24 2015-10-20 Ethicon, Inc. Tissue supporting device and method
KR101330397B1 (en) * 2011-11-01 2013-11-15 재단법인 아산사회복지재단 A device for blood vessel anastomosis using the self-expandable material or structure and a method for blood vessel anastomosis using the same
EP3366250A1 (en) 2011-11-08 2018-08-29 Boston Scientific Scimed, Inc. Ostial renal nerve ablation
US9119600B2 (en) 2011-11-15 2015-09-01 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US10064960B2 (en) * 2011-11-25 2018-09-04 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
US8973582B2 (en) 2011-11-30 2015-03-10 Ethicon, Inc. Tongue suspension device and method
US10470760B2 (en) 2011-12-08 2019-11-12 Ethicon, Inc. Modified tissue securement fibers
US9113879B2 (en) 2011-12-15 2015-08-25 Ethicon Endo-Surgery, Inc. Devices and methods for endoluminal plication
US9119615B2 (en) 2011-12-15 2015-09-01 Ethicon Endo-Surgery, Inc. Devices and methods for endoluminal plication
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
JP6130397B2 (en) 2011-12-23 2017-05-17 べシックス・バスキュラー・インコーポレイテッド Device for remodeling tissue in or adjacent to a body passage
WO2013101452A1 (en) 2011-12-28 2013-07-04 Boston Scientific Scimed, Inc. Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US8758806B2 (en) 2012-01-23 2014-06-24 Warsaw Orthopedic, Inc. Human lubrication gel
US8956157B2 (en) 2012-01-31 2015-02-17 Alexander Philippovich Rutberg Apparatus and method for treatment of periodontal disease
US20130226061A1 (en) * 2012-02-29 2013-08-29 Richard M. Dickson Multi-layer bandages and methods for dressing a wound
EP2819620A4 (en) 2012-02-29 2015-11-04 206 Ortho Inc Method and apparatus for treating bone fractures, including the use of composite implants
US8992547B2 (en) 2012-03-21 2015-03-31 Ethicon Endo-Surgery, Inc. Methods and devices for creating tissue plications
US9511018B2 (en) 2012-04-05 2016-12-06 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable matrix
EP3842580B1 (en) 2012-04-06 2023-10-18 Poly-Med Inc. Polymeric mesh products and method of making thereof
PL231639B1 (en) 2012-04-17 2019-03-29 Politechnika Lodzka Medical material for the reconstruction of blood vessels, a method for producing the medical material and medical material applied to the reconstruction of blood vessels
US8735504B2 (en) 2012-05-02 2014-05-27 Warsaw Orthopedic, Inc. Methods for preparing polymers having low residual monomer content
WO2013169927A1 (en) 2012-05-08 2013-11-14 Boston Scientific Scimed, Inc. Renal nerve modulation devices
US9173766B2 (en) 2012-06-01 2015-11-03 Ethicon, Inc. Systems and methods to treat upper pharyngeal airway of obstructive sleep apnea patients
US8906108B2 (en) 2012-06-18 2014-12-09 DePuy Synthes Products, LLC Dual modulus hip stem and method of making the same
US10390935B2 (en) 2012-07-30 2019-08-27 Conextions, Inc. Soft tissue to bone repair devices, systems, and methods
US10835241B2 (en) 2012-07-30 2020-11-17 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
US10219804B2 (en) 2012-07-30 2019-03-05 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
US11253252B2 (en) 2012-07-30 2022-02-22 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
US9629632B2 (en) 2012-07-30 2017-04-25 Conextions, Inc. Soft tissue repair devices, systems, and methods
US9427309B2 (en) 2012-07-30 2016-08-30 Conextions, Inc. Soft tissue repair devices, systems, and methods
WO2014032016A1 (en) 2012-08-24 2014-02-27 Boston Scientific Scimed, Inc. Intravascular catheter with a balloon comprising separate microporous regions
WO2014043687A2 (en) 2012-09-17 2014-03-20 Boston Scientific Scimed, Inc. Self-positioning electrode system and method for renal nerve modulation
SE537633C2 (en) * 2012-09-18 2015-08-25 Corticalis As Hydrogel coated titanium dioxide scaffold and method of making this scaffold
WO2014047454A2 (en) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
US10398464B2 (en) 2012-09-21 2019-09-03 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
EP2906135A2 (en) 2012-10-10 2015-08-19 Boston Scientific Scimed, Inc. Renal nerve modulation devices and methods
US9272072B1 (en) 2012-10-19 2016-03-01 Nuvasive, Inc. Osteoinductive bone graft substitute
EP2912121B1 (en) 2012-10-29 2019-09-25 Ariste Medical, LLC Polymer coating compositions and coated products
US10780197B1 (en) 2012-10-29 2020-09-22 Nuvasive, Inc. Malleable, cryopreserved osteogenic compositions with viable cells
US9925355B2 (en) 2012-11-12 2018-03-27 Hollister Incorporated Intermittent catheter assembly and kit
EP3441092B1 (en) 2012-11-14 2020-03-04 Hollister Incorporated Disposable catheter with selectively degradable inner core
US10245306B2 (en) 2012-11-16 2019-04-02 Isto Technologies Ii, Llc Flexible tissue matrix and methods for joint repair
WO2014081940A1 (en) * 2012-11-21 2014-05-30 Trustees Of Boston University Tissue markers and uses thereof
US20140200395A1 (en) * 2012-12-11 2014-07-17 Bilal Shafi Apparatuses and methods for preventing or reversing heart dilation
KR101454363B1 (en) * 2012-12-20 2014-11-03 한남대학교 산학협력단 Therapeutic product for the arthritis, and method for preparing thereof
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
WO2014123665A1 (en) 2013-02-06 2014-08-14 Kci Licensing, Inc. Polymers, preparation and use thereof
EP2964395B1 (en) * 2013-03-07 2019-05-08 Allergan, Inc. Double-cartridge syringe for mixing and dispensing adipose tissue with additive
US9693821B2 (en) 2013-03-11 2017-07-04 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
WO2014163987A1 (en) 2013-03-11 2014-10-09 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9867939B2 (en) 2013-03-12 2018-01-16 Allergan, Inc. Adipose tissue combinations, devices, and uses thereof
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
US9040093B2 (en) 2013-03-13 2015-05-26 Orthovita, Inc. Bone graft materials containing calcium phosphate and chitosan
US9427272B2 (en) * 2013-03-14 2016-08-30 Kyphon SÀRL Device for performing a surgical procedure and method
US9271839B2 (en) 2013-03-14 2016-03-01 DePuy Synthes Products, Inc. Femoral component for an implantable hip prosthesis
JP6220044B2 (en) 2013-03-15 2017-10-25 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. Medical device for renal nerve ablation
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
WO2014149690A2 (en) 2013-03-15 2014-09-25 Boston Scientific Scimed, Inc. Medical devices and methods for treatment of hypertension that utilize impedance compensation
US20160151296A1 (en) * 2013-05-22 2016-06-02 Empire Technology Development Llc Long delayed release laxative
US20140350516A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Mechanical syringe accessory
JP6340415B2 (en) 2013-05-31 2018-06-06 クック・メディカル・テクノロジーズ・リミテッド・ライアビリティ・カンパニーCook Medical Technologies Llc Access needle and stylet assembly
CN105473091B (en) 2013-06-21 2020-01-21 波士顿科学国际有限公司 Renal denervation balloon catheter with co-movable electrode supports
US10022182B2 (en) 2013-06-21 2018-07-17 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation having rotatable shafts
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
EP2818162A1 (en) 2013-06-28 2014-12-31 Encubator AB A composition for use in the treatment of intervertebral disc-related pain
WO2015002787A1 (en) 2013-07-01 2015-01-08 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
WO2015006573A1 (en) 2013-07-11 2015-01-15 Boston Scientific Scimed, Inc. Medical device with stretchable electrode assemblies
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
US9925001B2 (en) 2013-07-19 2018-03-27 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
CN105392435B (en) 2013-07-22 2018-11-09 波士顿科学国际有限公司 Renal nerve ablation catheter with twisting sacculus
US10342609B2 (en) 2013-07-22 2019-07-09 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
EP4049605A1 (en) 2013-08-22 2022-08-31 Boston Scientific Scimed Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
WO2015035047A1 (en) 2013-09-04 2015-03-12 Boston Scientific Scimed, Inc. Radio frequency (rf) balloon catheter having flushing and cooling capability
EP3043733A1 (en) 2013-09-13 2016-07-20 Boston Scientific Scimed, Inc. Ablation balloon with vapor deposited cover layer
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
US9248384B2 (en) 2013-10-02 2016-02-02 Allergan, Inc. Fat processing system
US9687166B2 (en) 2013-10-14 2017-06-27 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
WO2015057584A1 (en) 2013-10-15 2015-04-23 Boston Scientific Scimed, Inc. Medical device balloon
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
EP3057521B1 (en) 2013-10-18 2020-03-25 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires
EP3060153A1 (en) 2013-10-25 2016-08-31 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
HUE054872T2 (en) 2013-11-08 2021-10-28 Hollister Inc Oleophilic lubricated catheters
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
AU2014363933B2 (en) 2013-12-12 2019-10-10 Hollister Incorporated Flushable disintegration catheter
CA2933525C (en) 2013-12-12 2020-11-17 Hollister Incorporated Flushable catheters
ES2762743T3 (en) 2013-12-12 2020-05-25 Hollister Inc Downloadable catheters
CA2969316A1 (en) 2013-12-12 2015-06-18 Conventus Orthopaedics, Inc. Tissue displacement tools and methods
AU2014362360B2 (en) 2013-12-12 2020-01-02 Hollister Incorporated Flushable catheters
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
CN105899157B (en) 2014-01-06 2019-08-09 波士顿科学国际有限公司 Tear-proof flexible circuit assembly
CA2876720C (en) 2014-01-09 2018-04-10 Covidien Lp Systems and methods for treatment of perforator veins for venous insufficiency
JP6663858B2 (en) 2014-01-30 2020-03-13 ポリ−メッド インコーポレイテッド Time-dependent synthetic biological barrier materials
WO2015116912A1 (en) 2014-01-30 2015-08-06 Poly-Med. Inc. Thermally and dimensionally stabilized electrospun compositions and methods of making same
EP3102136B1 (en) 2014-02-04 2018-06-27 Boston Scientific Scimed, Inc. Alternative placement of thermal sensors on bipolar electrode
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
US11583384B2 (en) 2014-03-12 2023-02-21 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
SI3119386T1 (en) 2014-03-20 2019-11-29 Stayble Therapeutics Ab A composition for use in the treatment of intervertebral disc-related pain
US9919075B2 (en) * 2014-03-20 2018-03-20 Anexis, Llc Cohesive materials including derivatized collagens and methods of making and using them
JP6783143B2 (en) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド Passive replenishment of medium
US9421297B2 (en) 2014-04-02 2016-08-23 Adhezion Biomedical, Llc Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
US20150290362A1 (en) * 2014-04-10 2015-10-15 Georgia Tech Research Corporation Hybrid fibrin-microgel constructs for tissue repair and regeneration
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
GB2537770B (en) * 2014-04-22 2017-09-13 Ariste Medical Llc Methods and processes for application of drug delivery polymeric coatings
US8899318B1 (en) 2014-04-24 2014-12-02 Ronald C. Parsons Applying an aggregate to expandable tubular
US10709490B2 (en) 2014-05-07 2020-07-14 Medtronic Ardian Luxembourg S.A.R.L. Catheter assemblies comprising a direct heating element for renal neuromodulation and associated systems and methods
EP3139972B1 (en) * 2014-05-08 2020-04-29 The Secant Group, LLC Composite lumen with reinforcing textile and matrix
EP4218618A3 (en) * 2014-05-12 2023-08-23 Jeffrey E. Thomas Photon-activatable gel coated intracranial stent and embolic coil
US10029048B2 (en) 2014-05-13 2018-07-24 Allergan, Inc. High force injection devices
WO2016004222A1 (en) 2014-07-01 2016-01-07 Georgia Regents University Bio-compatible radiopaque dental fillers for imaging
EP3169374B1 (en) 2014-07-14 2022-01-05 University of Utah Research Foundation In situ solidifying complex coacervates and methods of making and using thereof
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
US11058521B2 (en) 2014-08-18 2021-07-13 University of Central Oklahoma Method and apparatus for improving osseointegration, functional load, and overall strength of intraosseous implants
US10932910B2 (en) 2014-08-18 2021-03-02 University of Central Oklahoma Nanofiber coating to improve biological and mechanical performance of joint prosthesis
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
EP3620184A1 (en) 2014-09-30 2020-03-11 Allergan Industrie, SAS Stable hydrogel compositions including additives
US10179191B2 (en) 2014-10-09 2019-01-15 Isto Technologies Ii, Llc Flexible tissue matrix and methods for joint repair
US9149346B1 (en) * 2014-10-17 2015-10-06 Kelly Walter Lee Caldiero Method for synthetic polymer tooth replacement
US20170304501A1 (en) * 2014-10-23 2017-10-26 Biotronik Se & Co. Kg Method for treating a medical implant
KR101582202B1 (en) * 2014-11-05 2016-01-05 대한민국 Vascular Patch using Cocoon and Method for manufacturing thereof
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
US10156427B2 (en) * 2014-12-11 2018-12-18 Stanislaw Litwin Multi-spectral camouflage device and method
EP3137058B1 (en) 2015-01-16 2018-09-05 SpineOvations, Inc. Method of treating spinal disk
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
JP6708200B2 (en) * 2015-03-03 2020-06-10 株式会社カネカメディックス Vascular embolization device and method for manufacturing the same
BR112017019272A2 (en) 2015-03-10 2018-05-02 Allergan Pharmaceuticals Holdings Ireland Unlimited Company multiple needle injector
US11684358B2 (en) 2015-04-20 2023-06-27 Boston Scientific Scimed, Inc. Fusible biodegradable sutures utilizing tissue soldering technology
US11752242B2 (en) * 2015-06-11 2023-09-12 Ath Therapeutics Inc. Medical devices, systems, and methods utilizing antithrombin-heparin composition
EP3310404A1 (en) 2015-06-17 2018-04-25 Hollister Incorporated Selectively water disintegrable materials and catheters made of such materials
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
KR101784863B1 (en) 2015-09-03 2017-10-13 (주)진우바이오 Preparation Method of High Functional Suture coated with Hyaluronate and High Functional Suture Prepared Thereof
RU2731405C2 (en) 2015-09-14 2020-09-02 Стайбле Терапеутикс Аб Composition for use in treating intervertebral disk-related pain
US11045441B2 (en) * 2015-10-13 2021-06-29 Wisconsin Alumni Research Foundation Use of retinoic acid and analogs thereof to treat central neural apneas
WO2017083753A1 (en) * 2015-11-12 2017-05-18 Herr John C Compositions and methods for vas-occlusive contraception and reversal thereof
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
EP3420020B1 (en) 2016-02-25 2020-07-22 The Secant Group, LLC Composite containing poly(glycerol sebacate) filler
CA3055171C (en) * 2016-03-23 2021-07-27 University of Central Oklahoma Method and apparatus to coat a metal implant with electrospun nanofiber matrix
EP3223181B1 (en) * 2016-03-24 2019-12-18 Sofradim Production System and method of generating a model and simulating an effect on a surgical repair site
JP2019510589A (en) 2016-04-08 2019-04-18 アラーガン、インコーポレイテッドAllergan,Incorporated Suction and injection device
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
USD802756S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
AU2017204355B2 (en) 2016-07-08 2021-09-09 Mako Surgical Corp. Scaffold for alloprosthetic composite implant
EP3512937A4 (en) 2016-09-13 2020-04-15 Angiocrine Bioscience, Inc. Blood-brain barrier comprising engineered endothelial cells
US11696822B2 (en) 2016-09-28 2023-07-11 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
US11344573B2 (en) * 2016-10-28 2022-05-31 Merz Pharma Gmbh & Co. Kgaa Treatment of gynoid lipodystrophy
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
WO2018129369A1 (en) 2017-01-05 2018-07-12 Contraline, Inc. Methods for implanting and reversing stimuli-responsive implants
US11439728B2 (en) * 2017-03-23 2022-09-13 Council Of Scientific & Industrial Research Process for coating a biomedical implant with a biocompatible polymer and a biomedical implant therefrom
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7216007B2 (en) 2017-03-31 2023-01-31 ザ・セカント・グループ・エルエルシー Hardened biodegradable microparticles and scaffolding materials, and methods of making and using them
EP3656841A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
CA3063847A1 (en) 2017-05-16 2018-11-22 Embody Inc. Biopolymer compositions, scaffolds and devices
US10918426B2 (en) 2017-07-04 2021-02-16 Conventus Orthopaedics, Inc. Apparatus and methods for treatment of a bone
TR201710921A2 (en) * 2017-07-26 2019-02-21 Rd Global Arastirma Gelistirme Saglik Ilac Insaat Yatirimlari Sanayi Ve Ticaret Anonim Sirketi INTERNAL COMPRESSION TREATMENT (ICT)
WO2019051476A1 (en) 2017-09-11 2019-03-14 Incubar, LLC Conduit vascular implant sealing device for reducing endoleak
WO2019071156A1 (en) 2017-10-06 2019-04-11 The Secant Group, Llc Flexible hollow lumen composite
WO2019084209A1 (en) * 2017-10-24 2019-05-02 Embody Llc Biopolymer scaffold implants and methods for their production
CA3083170A1 (en) * 2017-11-21 2019-05-31 The University Of Akron Amino acid-based poly(ester urea) polymer mesh for hernia and other soft tissue applications
US11547397B2 (en) 2017-12-20 2023-01-10 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
WO2019126819A1 (en) * 2017-12-23 2019-06-27 Matregenix, Inc. Novel electrospun synthetic dental barrier membranes for guided tissue regeneration and guided bone regeneration applications
US11116561B2 (en) 2018-01-24 2021-09-14 Medtronic Ardian Luxembourg S.A.R.L. Devices, agents, and associated methods for selective modulation of renal nerves
US11896234B2 (en) 2018-01-26 2024-02-13 Fluidx Medical Technology, Llc Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion
EP3755236A4 (en) 2018-02-20 2021-11-17 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
WO2019204061A1 (en) 2018-04-19 2019-10-24 Poly-Med, Inc. Macromers and compositions for photocuring processes
WO2019217199A1 (en) * 2018-05-09 2019-11-14 President And Fellows Of Harvard College Luminescent devices
WO2019221200A1 (en) * 2018-05-16 2019-11-21 日産化学株式会社 Gas separation membrane manufacturing method
JP2022506078A (en) 2018-11-13 2022-01-17 コントラライン,インコーポレイテッド Systems and methods for delivering biomaterials
WO2020150332A1 (en) * 2019-01-15 2020-07-23 University Of Massachusetts Eggshell particle containing hydrogels and prepolymer compositions for biomedical applications
WO2020158833A1 (en) 2019-01-31 2020-08-06 セルメディシン株式会社 Inorganic salt-protein composite medical instrument
EP3924008A4 (en) * 2019-02-15 2022-10-26 William Marsh Rice University Vascularizing devices and methods for implanted diagnostics and therapeutics
EP4021369A4 (en) 2019-08-26 2023-12-27 Mervyn B. Forman Medical devices for continuous delivery of therapeutic agents
US20210060316A1 (en) * 2019-08-30 2021-03-04 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CA3169482A1 (en) * 2020-02-26 2021-09-02 Krzysztof Palczewski Compositions and methods for treating misfolded protein ocular disorders
JP2023526244A (en) * 2020-05-13 2023-06-21 スパイラル・セラピューティクス・インコーポレイテッド Gelling solution for administering compounds to the inner ear
WO2021240539A1 (en) * 2020-05-25 2021-12-02 SHREY, Dhawan Ion-substituted bovine hydroxyapatite for bone regeneration
EP4185343A1 (en) * 2020-07-21 2023-05-31 Shankar Rajeswaran M.D. LLC System and method for treatment of bone
EP4216968A1 (en) * 2020-09-25 2023-08-02 University of Cincinnati Method for pleurodesis and delivery of drugs to the lung and pleural space
US20220354680A1 (en) * 2021-05-10 2022-11-10 Boston Scientific Scimed, Inc. Systems and methods to enable pyloric closure
US11872105B1 (en) 2022-12-01 2024-01-16 Robert Parker Dental implant device for regeneration of dental pulp and dentin
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3124136A (en) * 1964-03-10 Method of repairing body tissue
US2671444A (en) * 1951-12-08 1954-03-09 Jr Benjamin F Pease Nonmetallic mesh surgical insert for hernia repair
US3054406A (en) * 1958-10-17 1962-09-18 Phillips Petroleum Co Surgical mesh
US4193137A (en) * 1977-05-06 1980-03-18 Meadox Medicals, Inc. Warp-knitted double-velour prosthesis
US6410697B1 (en) * 1979-04-20 2002-06-25 Schering Corporation Process for purifying human leukocyte interferon
US4452245A (en) * 1980-06-06 1984-06-05 Usher Francis C Surgical mesh and method
US4347847A (en) * 1980-06-06 1982-09-07 Usher Francis C Method of hernia repair
DE3211263A1 (en) * 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo HUMAN INTERFERON RELATED PEPTIDES, ANTIGENS AND ANTIBODIES, AND METHOD FOR THE PRODUCTION THEREOF
US4520821A (en) * 1982-04-30 1985-06-04 The Regents Of The University Of California Growing of long-term biological tissue correction structures in vivo
US4461298A (en) * 1982-07-26 1984-07-24 Ethicon, Inc. Composite sutures of silk and hydrophobic thermoplastic elastomers
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US4633873A (en) * 1984-04-26 1987-01-06 American Cyanamid Company Surgical repair mesh
DE3423234A1 (en) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim SYNERGISTIC MIXTURES OF INTERFERON AND TUMOR-NECROSE FACTOR
RU2130493C1 (en) * 1984-07-06 1999-05-20 Новартис Аг Method of preparing protein exhibiting gm-csf activity of pimates
FR2569565B1 (en) * 1984-08-31 1987-06-19 Russier Jean Jacques SEALED PHYSIOLOGICAL SEAL FOR ENDO-EXTRACORPOREAL IMPLANTS
UA29377C2 (en) * 1984-09-19 2000-11-15 Новартіс Аг Method for preparing protein with activity of granulocyte macrophage-colony stimulating factor (gm-csf) of primates
US4652264A (en) * 1985-04-25 1987-03-24 American Cyanamid Company Prosthetic tubular article
US4655221A (en) * 1985-05-06 1987-04-07 American Cyanamid Company Method of using a surgical repair mesh
IL76079A (en) * 1985-08-13 1991-03-10 Univ Ramot Collagen implants
US5002551A (en) * 1985-08-22 1991-03-26 Johnson & Johnson Medical, Inc. Method and material for prevention of surgical adhesions
US4769038A (en) * 1986-03-18 1988-09-06 C. R. Bard, Inc. Prostheses and techniques and repair of inguinal and femoral hernias
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
CH673117A5 (en) * 1986-12-10 1990-02-15 Ajinomoto Kk
US5290552A (en) 1988-05-02 1994-03-01 Matrix Pharmaceutical, Inc./Project Hear Surgical adhesive material
US5213580A (en) 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5643464A (en) * 1988-11-21 1997-07-01 Collagen Corporation Process for preparing a sterile, dry crosslinking agent
US5304595A (en) * 1988-11-21 1994-04-19 Collagen Corporation Collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5264214A (en) * 1988-11-21 1993-11-23 Collagen Corporation Composition for bone repair
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
US5475052A (en) * 1988-11-21 1995-12-12 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5936035A (en) * 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US5800541A (en) * 1988-11-21 1998-09-01 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction
US5527856A (en) * 1988-11-21 1996-06-18 Collagen Corporation Method of preparing crosslinked biomaterial compositions for use in tissue augmentation
US5550187A (en) * 1988-11-21 1996-08-27 Collagen Corporation Method of preparing crosslinked biomaterial compositions for use in tissue augmentation
JPH02240165A (en) * 1989-03-13 1990-09-25 Kanebo Ltd Aqueous silk fibroin solution with excellent storage stability and preparation thereof
ES2034790T3 (en) * 1989-04-11 1993-04-01 Boehringer Ingelheim International Gmbh USE OF AT LEAST ONE CITROQUINE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE SYSTEMATIC TREATMENT OF PRENEOPLASTIC INJURIES.
US5022399A (en) 1989-05-10 1991-06-11 Biegeleisen Ken P Venoscope
US5061286A (en) * 1989-08-18 1991-10-29 Osteotech, Inc. Osteoprosthetic implant
US5278063A (en) * 1989-09-28 1994-01-11 Board Of Regents The University Of Texas System Chemical modification of promote animal cell adhesion on surfaces
US5214768A (en) * 1989-11-01 1993-05-25 E-Systems, Inc. Mass data storage library
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5197882A (en) * 1990-05-14 1993-03-30 Gary R. Jernberg Periodontal barrier and method for aiding periodontal tissue regeneration agents
US5141735A (en) * 1990-06-18 1992-08-25 Hoffman-La Roche, Inc. Substituted amino-benzodiazepines having anitviral activity
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6559119B1 (en) * 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US5300292A (en) * 1991-05-03 1994-04-05 The Regents Of The University Of California Composition and method for treating inflammation
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US5248499A (en) * 1991-10-07 1993-09-28 Genentech, Inc. Control of microbial infections in transplant patients
US5292328A (en) * 1991-10-18 1994-03-08 United States Surgical Corporation Polypropylene multifilament warp knitted mesh and its use in surgery
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US7060287B1 (en) * 1992-02-11 2006-06-13 Bioform Inc. Tissue augmentation material and method
US5204382A (en) 1992-02-28 1993-04-20 Collagen Corporation Injectable ceramic compositions and methods for their preparation and use
US5316476B1 (en) * 1992-06-19 1996-06-18 Jack T Krauser Dental implant with a longitudinally grooved cylindrical surface
IN181695B (en) * 1992-08-10 1998-09-05 Ranbaxy Lab Ltd
US5323278A (en) * 1992-09-17 1994-06-21 International Business Machines Corporation Low noise amplifier circuit for magnetoresistive sensors for fast read-write switching in low supply voltage applications
WO1994006460A1 (en) 1992-09-21 1994-03-31 Vitaphore Corporation Embolization plugs for blood vessels
US5690666A (en) * 1992-11-18 1997-11-25 Target Therapeutics, Inc. Ultrasoft embolism coils and process for using them
AU5847794A (en) * 1992-12-09 1994-07-04 Indiana University Foundation Suppression of myeloid cells
DE4242863A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5523291A (en) * 1993-09-07 1996-06-04 Datascope Investment Corp. Injectable compositions for soft tissue augmentation
FR2709947B1 (en) * 1993-09-13 1995-11-10 Bard Sa Laboratoires Curved prosthetic mesh and its manufacturing process.
WO1995008354A1 (en) * 1993-09-24 1995-03-30 Takiron Co., Ltd. Implantation material
US6419491B1 (en) * 1993-11-02 2002-07-16 Bio-Lok International, Inc. Dental implant system with repeating microgeometric surface patterns
US5759205A (en) * 1994-01-21 1998-06-02 Brown University Research Foundation Negatively charged polymeric electret implant
US5624895A (en) * 1994-02-18 1997-04-29 Georgetown University Medical Center Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
US6140452A (en) * 1994-05-06 2000-10-31 Advanced Bio Surfaces, Inc. Biomaterial for in situ tissue repair
US5583114A (en) * 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
US6280453B1 (en) * 1994-09-29 2001-08-28 Bard Asdi Inc. Hernia mesh patch with stiffener line segment
US5634931A (en) * 1994-09-29 1997-06-03 Surgical Sense, Inc. Hernia mesh patches and methods of their use
US6335383B1 (en) * 1994-10-18 2002-01-01 Ethicon, Inc. Microdispersions for coating surgical devices
PT789588E (en) * 1994-11-17 2005-05-31 Univ South Florida Process for the production of a medicament for the treatment of secondary immunodeficiency
US5709934A (en) * 1994-11-22 1998-01-20 Tissue Engineering, Inc. Bipolymer foams having extracellular matrix particulates
EP0721780A3 (en) * 1994-12-16 1997-12-17 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for promoting platelet and/or leukocyte production
US6051751A (en) * 1995-01-20 2000-04-18 Spire Corporation Arthroplasty process for securely anchoring prostheses to bone, and arthroplasty products therefor
US5693341A (en) * 1995-03-16 1997-12-02 Collagen Corporation Affinity bound collagen matrices for the delivery of biologically active agents
US5571191A (en) * 1995-03-16 1996-11-05 Fitz; William R. Artificial facet joint
US5900245A (en) * 1996-03-22 1999-05-04 Focal, Inc. Compliant tissue sealants
BR9607977A (en) * 1995-03-23 1998-01-13 Univ Texas Photoinitiated and redox preparation systems for improved gel adhesion to substrates
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5645558A (en) * 1995-04-20 1997-07-08 Medical University Of South Carolina Anatomically shaped vasoocclusive device and method of making the same
US6117456A (en) * 1995-05-19 2000-09-12 Etex Corporation Methods and products related to the physical conversion of reactive amorphous calcium phosphate
US6129761A (en) * 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5888546A (en) 1995-08-28 1999-03-30 The Regents Of The University Of California Embolic material for endovascular occlusion of abnormal vasculature and method for using the same
US5611358A (en) 1995-09-08 1997-03-18 Suval; William D. Method and apparatus for treating varicose veins
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US5752974A (en) * 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
EP2111876B1 (en) * 1995-12-18 2011-09-07 AngioDevice International GmbH Crosslinked polymer compositions and methods for their use
US6458889B1 (en) * 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US6033674A (en) * 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US5712252A (en) * 1996-03-08 1998-01-27 The University Of Tennessee Research Corporation Method of augmenting soft tissue in mammals
US5843072A (en) 1996-11-07 1998-12-01 Cynosure, Inc. Method for treatment of unwanted veins and device therefor
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
US5916585A (en) * 1996-06-03 1999-06-29 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto biodegradable polymers
US5976800A (en) * 1996-06-28 1999-11-02 The Regents Of The University Of California Enhancement of cancer cell death
US5702677A (en) * 1996-07-10 1997-12-30 Osteotech, Inc. Spherical hydroxyapatite particles and process for the production thereof
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
HUP0000210A3 (en) * 1996-08-28 2001-07-30 Procter And Gamble Co Cincinna Heterocyclic compounds as metalloprotease inhibitors and use of them for producing pharmaceutical compisitions
US6096052A (en) * 1998-07-08 2000-08-01 Ovion, Inc. Occluding device and method of use
US6371975B2 (en) * 1998-11-06 2002-04-16 Neomend, Inc. Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
US5879697A (en) * 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US6248763B1 (en) 1998-05-19 2001-06-19 Scivoletto Rosemarie Composition for treating skin conditions
US6149581A (en) * 1997-06-12 2000-11-21 Klingenstein; Ralph James Device and method for access to the colon and small bowel of a patient
US6306154B1 (en) * 1997-06-18 2001-10-23 Bhk Holding Hemostatic system for body cavities
AU7977298A (en) * 1997-06-18 1999-01-04 Cohesion Technologies, Inc. Compositions containing thrombin and microfibrillar collagen, and methods for preparation and use thereof
ATE249172T1 (en) 1997-06-18 2003-09-15 John Hudson MEDICAL DEVICE
GB2326344A (en) 1997-06-18 1998-12-23 John Overton Hudson Filling means for repairing an intestinal diverticulum
US5824082A (en) * 1997-07-14 1998-10-20 Brown; Roderick B. Patch for endoscopic repair of hernias
US6042592A (en) * 1997-08-04 2000-03-28 Meadox Medicals, Inc. Thin soft tissue support mesh
US6214049B1 (en) * 1999-01-14 2001-04-10 Comfort Biomedical, Inc. Method and apparatus for augmentating osteointegration of prosthetic implant devices
JP3066434B2 (en) * 1997-12-25 2000-07-17 農林水産省蚕糸・昆虫農業技術研究所長 Modified silk material, its manufacturing method
US6181960B1 (en) * 1998-01-15 2001-01-30 University Of Virginia Patent Foundation Biopsy marker device
US6660301B1 (en) * 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
DE69922352T2 (en) * 1998-03-06 2005-12-15 Biosphere Medical, Inc., Rockland IMPLANTABLE PARTICLES FOR INCREASING TISSUE VOLUME AND TREATING GASTROÖSOPHAGAL REFLUX, INCONTINENCE AND SKIN WRINKLES
US6179872B1 (en) * 1998-03-17 2001-01-30 Tissue Engineering Biopolymer matt for use in tissue repair and reconstruction
US6319264B1 (en) * 1998-04-03 2001-11-20 Bionx Implants Oy Hernia mesh
DE69921055T2 (en) * 1998-04-07 2005-10-20 Cook Inc., Bloomington OCCLUSION DEVICE WITH A VARIETY OF ASYMMETRIC FIBERS
MXPA00010110A (en) * 1998-04-17 2002-08-06 Angiogenix Inc Therapeutic angiogenic factors and methods for their use.
US20020022588A1 (en) * 1998-06-23 2002-02-21 James Wilkie Methods and compositions for sealing tissue leaks
US6428579B1 (en) * 1998-07-01 2002-08-06 Brown University Research Foundation Implantable prosthetic devices coated with bioactive molecules
US6818018B1 (en) * 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6605294B2 (en) * 1998-08-14 2003-08-12 Incept Llc Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US6458147B1 (en) * 1998-11-06 2002-10-01 Neomend, Inc. Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
US20030007991A1 (en) * 1998-09-25 2003-01-09 Masters David B. Devices including protein matrix materials and methods of making and using thereof
US6110484A (en) 1998-11-24 2000-08-29 Cohesion Technologies, Inc. Collagen-polymer matrices with differential biodegradability
US6310036B1 (en) * 1999-01-09 2001-10-30 Last Chance Tissue Adhesives Corporation High strength, Bio-compatible tissue adhesive and methods for treating vigorously bleeding surfaces
ATE297198T1 (en) 1999-02-23 2005-06-15 Angiotech Int Ag COMPOSITIONS AND METHODS FOR IMPROVING THE INTEGRITY OF ATTACKED BODY PASSAGES AND CAVIES
JP3151665B2 (en) * 1999-03-23 2001-04-03 農林水産省蚕糸・昆虫農業技術研究所長 Biopolymer / polyallylamine complex and method for producing the same
US6312725B1 (en) * 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
US6383201B1 (en) * 1999-05-14 2002-05-07 Tennison S. Dong Surgical prosthesis for repairing a hernia
WO2001000792A1 (en) * 1999-06-29 2001-01-04 Marchosky J Alexander Compositions and methods for forming and strengthening bone
EP1206254A1 (en) * 1999-08-06 2002-05-22 The Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US6610043B1 (en) * 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
DK1218437T3 (en) * 1999-08-27 2009-10-19 Angiodevice Internat Gmbh Preparations forming interpenetrating polymer networks for use as high-strength medical sealants
US20030158302A1 (en) * 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
JP2001163899A (en) * 1999-12-09 2001-06-19 Natl Inst Of Sericultural & Entomological Science Method for producing functional silk fibroin and its use
US6436061B1 (en) 1999-12-29 2002-08-20 Peter D. Costantino Ultrasound treatment of varicose veins
US6368859B1 (en) * 1999-12-29 2002-04-09 Children's Medical Center Corporation Methods and compositions for producing a fascial sling
US6436030B2 (en) * 2000-01-31 2002-08-20 Om P. Rehil Hiatal hernia repair patch and method for using the same
CA2398668C (en) * 2000-02-17 2010-06-15 3M Innovative Properties Company Delivery systems using preformed biodegradable polymer compositions and methods
US6652883B2 (en) * 2000-03-13 2003-11-25 Biocure, Inc. Tissue bulking and coating compositions
US6638408B1 (en) * 2000-04-03 2003-10-28 The Wistar Institute Method and device for separation of charged molecules by solution isoelectric focusing
EP1142596A1 (en) * 2000-04-03 2001-10-10 Universiteit Gent Compositions of crosslinkable prepolymers for use in therapeutically active biodegradable implants
DK1272204T3 (en) 2000-04-14 2007-09-10 Univ Pittsburgh Enhancement and bulking of soft tissue and bone tissue using muscle derived progenitor cells, preparations thereof and treatment thereof
US6524598B2 (en) 2000-07-10 2003-02-25 The Procter & Gamble Company Cosmetic compositions
US6475500B2 (en) 2000-07-10 2002-11-05 The Procter & Gamble Company Anhydrous cosmetic compositions
US7077836B2 (en) 2000-07-21 2006-07-18 Vein Rx, Inc. Methods and apparatus for sclerosing the wall of a varicose vein
US20050107738A1 (en) 2000-07-21 2005-05-19 Slater Charles R. Occludable intravascular catheter for drug delivery and method of using the same
US6610006B1 (en) * 2000-07-25 2003-08-26 C. R. Bard, Inc. Implantable prosthesis
ES2169681B1 (en) * 2000-08-10 2003-10-01 Osfarma S L PRODUCTION METHOD OF QUITOSAN FILMS WITH A HIGH CAPACITY OF CELLULAR ADHERENCE, OBRENIDO PRODUCT AND APPLICATIONS.
CA2425206A1 (en) 2000-08-23 2002-02-28 Phairson Medical, Inc. Treatment of trauma, and other indications
US20020026244A1 (en) * 2000-08-30 2002-02-28 Trieu Hai H. Intervertebral disc nucleus implants and methods
US20020025340A1 (en) * 2000-08-30 2002-02-28 Dyer Wallace K. Methods and compositions for tissue augmentation
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
EP1318834A2 (en) * 2000-09-12 2003-06-18 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
GB2369996B (en) 2000-12-18 2004-06-23 S T D Pharmaceutical Products Method and apparatus for producing an injectable foam
US6733774B2 (en) * 2001-01-25 2004-05-11 Nycomed Pharma As Carrier with solid fibrinogen and solid thrombin
US20020176893A1 (en) * 2001-02-02 2002-11-28 Wironen John F. Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue
US6685626B2 (en) * 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
US6913762B2 (en) * 2001-04-25 2005-07-05 Mayo Foundation For Medical Education And Research Stent having non-woven framework containing cells
US20030003135A1 (en) * 2001-06-28 2003-01-02 Leung Jeffrey C. Article for drug delivery and methods of making and using same
IL159624A0 (en) * 2001-06-29 2004-06-01 Medgraft Microtech Inc Biodegradable injectable implants and related methods of manufacture and use
JP4602602B2 (en) * 2001-07-19 2010-12-22 オリンパス株式会社 Medical instruments
WO2003008006A1 (en) * 2001-07-19 2003-01-30 Dempsey, Donald, J. Bioactive surface for titanium implants
WO2003017826A2 (en) * 2001-08-27 2003-03-06 Regeneration Technologies, Inc. Processed soft tissue for topical or internal application
US6726674B2 (en) 2001-09-04 2004-04-27 Jomed Gmbh Methods for minimally invasive, localized delivery of sclerotherapeutic agents
ES2321915T3 (en) * 2001-10-25 2009-06-15 University Of Connecticut FIBROIN COMPOSITIONS AND METHODS TO PREPARE THE SAME.
US6902932B2 (en) * 2001-11-16 2005-06-07 Tissue Regeneration, Inc. Helically organized silk fibroin fiber bundles for matrices in tissue engineering
US20040068078A1 (en) * 2001-12-12 2004-04-08 Milbocker Michael T. In situ polymerizing medical compositions
US20030120201A1 (en) 2001-12-21 2003-06-26 Abergel R. Patrick Methods and devices for sclerotherapy
JP5105697B2 (en) * 2002-01-18 2012-12-26 シヴィダ・インコーポレイテッド Co-drug polymer delivery system for controlled delivery
EP1476202B1 (en) * 2002-02-21 2009-01-14 Encelle, Inc. Cross-linked bioactive hydrogel matrices
US20040131582A1 (en) * 2002-02-26 2004-07-08 Grinstaff Mark W. Novel dendritic polymers and their biomedical uses
US20030190336A1 (en) 2002-03-18 2003-10-09 Adams Christine Helga Personal care compositions comprising solid particles enterapped in a gel network
EP1490119A1 (en) * 2002-03-29 2004-12-29 Boston Scientific Limited Tissue treatment
US7131997B2 (en) * 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US6923833B2 (en) * 2002-04-09 2005-08-02 Ray C. Wasielewski Biologically reabsorbable acetabular constraining components and materials for use with a hip replacement prosthesis and bioreabsorbable materials to augment hip replacement stability and function
US20030212456A1 (en) * 2002-05-09 2003-11-13 John Lipchitz Implant for tissue repair
CN100341589C (en) * 2002-05-24 2007-10-10 血管技术国际股份公司 Compositions and methods for coating medical implants
US20040086474A1 (en) 2002-06-17 2004-05-06 The Procter & Gamble Company Multi-step cosmetic benefit foundation kit and associated methods
JP3772207B2 (en) * 2002-06-19 2006-05-10 独立行政法人農業生物資源研究所 Biodegradable biopolymer material, production method thereof, and functional material comprising the polymer material
US7091259B2 (en) * 2002-07-03 2006-08-15 3M Innovative Properties Company Dental fillers, pastes, and compositions prepared therefrom
US7588825B2 (en) 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US7309361B2 (en) * 2002-10-23 2007-12-18 Wasielewski Ray C Biologic modular tibial and femoral component augments for use with total knee arthroplasty
EP1572154B1 (en) 2002-11-18 2012-02-01 Rutgers, The State University of New Jersey Medical devices employing novel polymers
US20040199241A1 (en) 2002-12-30 2004-10-07 Angiotech International Ag Silk stent grafts
EP1583561A3 (en) 2002-12-30 2005-12-07 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US20040225077A1 (en) * 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040161435A1 (en) 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
KR20040077553A (en) * 2003-02-28 2004-09-04 독립행정법인농업생물자원연구소 Extraction and utilization of cell growth promoting peptides from silk protein
US20040228821A1 (en) 2003-05-16 2004-11-18 The Procter & Gamble Company Personal care products comprising active agents in a gel network
US7837742B2 (en) 2003-05-19 2010-11-23 The Procter & Gamble Company Cosmetic compositions comprising a polymer and a colorant
EP1691852A2 (en) * 2003-11-10 2006-08-23 Angiotech International AG Medical implants and fibrosis-inducing agents
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
CA2448541A1 (en) 2003-11-24 2005-05-24 Carlos Patrickson Pain-alleviating injection needle
WO2006023203A1 (en) 2004-08-19 2006-03-02 Vein Rx, Inc. An occludable intravascular catheter for drug delivery and method of using the same

Also Published As

Publication number Publication date
EP1691852A2 (en) 2006-08-23
US20060240064A9 (en) 2006-10-26
US20050158274A1 (en) 2005-07-21
US20050175657A1 (en) 2005-08-11
WO2005065079A2 (en) 2005-07-21
US20050148512A1 (en) 2005-07-07
US20070254833A1 (en) 2007-11-01
US20050147562A1 (en) 2005-07-07
US20050277577A1 (en) 2005-12-15
US20050147643A1 (en) 2005-07-07
US20050191248A1 (en) 2005-09-01
US7166570B2 (en) 2007-01-23
US20050142163A1 (en) 2005-06-30
WO2005046746A2 (en) 2005-05-26
US20050186247A1 (en) 2005-08-25
US20060240063A9 (en) 2006-10-26
US20050147599A1 (en) 2005-07-07
JP2007513083A (en) 2007-05-24
IL174637A0 (en) 2006-08-20
US20050169959A1 (en) 2005-08-04
AU2004289287A1 (en) 2005-05-26
US7241736B2 (en) 2007-07-10
US20050169958A1 (en) 2005-08-04
WO2005065079A3 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
CA2536041A1 (en) Medical implants and fibrosis-inducing agents
US20050149175A1 (en) Intravascular devices and fibrosis-inducing agents
CA2610948C (en) Compositions and methods for treating diverticular disease
US20110264139A1 (en) Sutures and fibrosing agents
CN101420923A (en) Intravascular devices and fibrosis-inducing agents
WO2006121521A2 (en) Soft tissue implants, anti-scarring agents, and therapeutic compositions

Legal Events

Date Code Title Description
FZDE Discontinued